<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001511.pub3" GROUP_ID="LIVER" ID="640999090214074359" MERGED_FROM="" MODIFIED="2017-11-02 15:06:56 +0000" MODIFIED_BY="Dimitrinka Nikolova" REVIEW_NO="01" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2017-11-02 15:31:03 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<TITLE MODIFIED="2015-05-22 10:11:09 +0200" MODIFIED_BY="Dimitrinka Nikolova">Glucocorticosteroids for people with alcoholic hepatitis</TITLE>
<CONTACT>
<PERSON ID="79143FAF82E26AA200C1C7C4F47593CE" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Chavdar</FIRST_NAME>
<MIDDLE_INITIALS>S</MIDDLE_INITIALS>
<LAST_NAME>Pavlov</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>chpavlov@mail.ru</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+79 16 68 29 954</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>The Cochrane Hepato-Biliary Group</DEPARTMENT>
<ORGANISATION>Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital</ORGANISATION>
<ADDRESS_1>Blegdamsvej 9</ADDRESS_1>
<ADDRESS_2/>
<CITY>Copenhagen</CITY>
<ZIP>DK-2100</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2017-11-02 15:31:03 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<PERSON ID="79143FAF82E26AA200C1C7C4F47593CE" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Chavdar</FIRST_NAME>
<MIDDLE_INITIALS>S</MIDDLE_INITIALS>
<LAST_NAME>Pavlov</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>chpavlov@mail.ru</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+79 16 68 29 954</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>The Cochrane Hepato-Biliary Group</DEPARTMENT>
<ORGANISATION>Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital</ORGANISATION>
<ADDRESS_1>Blegdamsvej 9</ADDRESS_1>
<ADDRESS_2/>
<CITY>Copenhagen</CITY>
<ZIP>DK-2100</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1602011521314034684192764688353" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Daria</FIRST_NAME>
<MIDDLE_INITIALS>L</MIDDLE_INITIALS>
<LAST_NAME>Varganova</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>datich@ya.ru</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Gastroenterology</DEPARTMENT>
<ORGANISATION>Ulyanovsk Regional Clinical Hospital</ORGANISATION>
<ADDRESS_1>International 3</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ulyanovsk</CITY>
<ZIP>432063</ZIP>
<REGION/>
<COUNTRY CODE="RU">Russian Federation</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="9708AA4382E26AA20165AC2EE764A66D" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Giovanni</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Casazza</LAST_NAME>
<SUFFIX/>
<POSITION>Statistician</POSITION>
<EMAIL_1>giovanni.casazza@unimi.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Dipartimento di Scienze Biomediche e Cliniche "L. Sacco"</DEPARTMENT>
<ORGANISATION>Università degli Studi di Milano</ORGANISATION>
<ADDRESS_1>via GB Grassi 74</ADDRESS_1>
<ADDRESS_2/>
<CITY>Milan</CITY>
<ZIP>20157</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 0250319653</PHONE_1>
<PHONE_2/>
<FAX_1>+39 0250319656</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6675B2B282E26AA20125F76BF955FE80" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Emmanuel</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Tsochatzis</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>mtsochatzis@hotmail.com</EMAIL_1>
<EMAIL_2>mtsochatzis@med.uoa.gr</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Sheila Sherlock Liver Centre</DEPARTMENT>
<ORGANISATION>Royal Free Hospital and the UCL Institute of Liver and Digestive Health</ORGANISATION>
<ADDRESS_1>Pond Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP>NW3 2QG</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6511" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Dimitrinka</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Nikolova</LAST_NAME>
<SUFFIX>M.A.</SUFFIX>
<POSITION>Managing Editor</POSITION>
<EMAIL_1>dimitrinka.nikolova@ctu.dk</EMAIL_1>
<EMAIL_2>mikolgig@yahoo.dk</EMAIL_2>
<URL>http://inet.uni2.dk/~ctucph/chbg</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>The Cochrane Hepato-Biliary Group</DEPARTMENT>
<ORGANISATION>Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital</ORGANISATION>
<ADDRESS_1>Blegdamsvej 9</ADDRESS_1>
<ADDRESS_2/>
<CITY>Copenhagen</CITY>
<ZIP>DK-2100</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1>+45 3545 7169</PHONE_1>
<PHONE_2/>
<FAX_1>+45 3545 7101</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6439" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Christian</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Gluud</LAST_NAME>
<SUFFIX>M.D, Dr. Med. Sci.</SUFFIX>
<POSITION>Head of Department</POSITION>
<EMAIL_1>cgluud@ctu.dk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>The Cochrane Hepato-Biliary Group</DEPARTMENT>
<ORGANISATION>Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital</ORGANISATION>
<ADDRESS_1>Blegdamsvej 9</ADDRESS_1>
<ADDRESS_2/>
<CITY>Copenhagen</CITY>
<ZIP>DK-2100</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1>+ 45 3545 7175</PHONE_1>
<PHONE_2/>
<FAX_1>+ 45 3545 7101</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2017-11-01 15:48:30 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<UP_TO_DATE>
<DATE DAY="10" MONTH="11" YEAR="2016"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="20" MONTH="10" YEAR="2016"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="22" MONTH="10" YEAR="2018"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="11" YEAR="2017"/>
<LAST_CITATION_ISSUE ISSUE="11" YEAR="2017"/>
</DATES>
<WHATS_NEW MODIFIED="2016-10-11 16:57:13 +0200" MODIFIED_BY="[Empty name]"/>
<HISTORY MODIFIED="2017-11-01 15:49:26 +0100" MODIFIED_BY="Dimitrinka Nikolova"/>
<SOURCES_OF_SUPPORT MODIFIED="2015-04-16 15:52:02 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<INTERNAL_SOURCES MODIFIED="2015-04-16 15:52:02 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<SOURCE MODIFIED="2015-04-16 15:52:02 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<NAME>The Cochrane Hepato-Biliary Group Editorial Team Office</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2017-11-02 15:31:59 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<SUMMARY MODIFIED="2017-11-01 15:37:08 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<TITLE MODIFIED="2017-02-22 16:30:55 +0100" MODIFIED_BY="Dimitrinka Nikolova">Glucocorticosteroids for people with alcoholic hepatitis</TITLE>
<SUMMARY_BODY MODIFIED="2017-11-01 15:37:08 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Review question</B>
<BR/>To assess the benefits and harms of glucocorticosteroids administered in any route, dose, and duration versus placebo or no intervention in people with alcoholic hepatitis in terms of death, health-related quality of life, and complications.</P>
<P>
<B>Background</B>
<BR/>Excessive alcoholic consumption may damage the liver, causing alcoholic hepatitis. The first stage of liver damage in alcoholic hepatitis is usually reversible if people abstain from drinking, but the risk of the disease developing further and getting more complications increases with resumed drinking. A heavy drinker is considered a person who consumes more than 60 g to 80 g (for men) or more than 20 g (for women) alcohol per day. Only 10 to 35 people out of 100 heavy drinkers with evidence of excessive fat in the liver would most probably develop alcoholic hepatitis. With time, alcoholic hepatitis will cause liver fibrosis (scarring of the liver) or liver cirrhosis with complications (bleeding, infections, liver cancer, etc).</P>
<P>Glucocorticosteroids are considered to have anti-inflammatory effects (relieving pain, oedema, fever). They are administered to people with alcoholic hepatitis in order to repair their liver injury. However, the benefits and harms of glucocorticosteroids are not well studied in randomised clinical trials, and therefore, it is uncertain if they should be used in clinical practice for people with alcoholic liver disease.</P>
<P>
<B>Search date</B>
</P>
<P>The date of the last search was 20 October 2016.</P>
<P>
<B>Study characteristics</B>
</P>
<P>Sixteen randomised clinical trials compared glucocorticosteroids with placebo or no intervention in people with alcoholic hepatitis. Fifteen trials provided data for analysis (927 participants received glucocorticosteroids and 934 participants received placebo or no intervention). Glucocorticosteroids were administered orally or as an injection for a median of 28 days (range 3 days to 12 weeks). The trial participants were between 25 and 70 years old (men: 65%) and had different stages of alcoholic liver disease. Trial participants were followed up to the moment of discharge from the hospital, or until they died (a median of 63 days), or for at least a year. Not all trials reported the follow-up of participants. The trials were conducted in France, India, UK, and USA. Two trials administered pentoxifylline to both glucocorticosteroids and placebo intervention groups.</P>
<P>
<B>Funding</B>
<BR/>Nine of the trials were industry-funded.</P>
<P>
<B>Quality of evidence</B>
</P>
<P>The overall quality of evidence was very low, low, or moderate, and all the trials were at high risk of bias, which means that there is possibility of drawing wrong conclusions, exaggerating benefits or underestimating harms of glucocorticosteroids because of the way that the trials were conducted and analysed.</P>
<P>
<B>Key results</B>
</P>
<P>Glucocorticosteroids did not benefit clinical outcomes of importance to people with alcoholic liver disease, such as mortality, no matter the cause, and health-related quality of life. In addition, glucocorticosteroids may increase the number of adverse events. We cannot exclude benefits and harms of glucocorticosteroids but researchers need to study further their effects in high-quality, placebo-controlled, randomised clinical trials. Such trials ought to be registered before they are launched and openly report depersonalised individual participant data so that individual participant data meta-analysis can be conducted.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2017-11-01 16:55:28 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<ABS_BACKGROUND MODIFIED="2017-10-16 15:22:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Alcoholic hepatitis is a form of alcoholic liver disease, characterised by steatosis, necroinflammation, fibrosis, and potential complications to the liver disease. Typically, alcoholic hepatitis presents in people between 40 and 50 years of age. Alcoholic hepatitis can be resolved if people abstain from drinking, but the risk of death will depend on the severity of the liver damage and abstinence from alcohol. Glucocorticosteroids are used as anti-inflammatory drugs for people with alcoholic hepatitis. Glucocorticosteroids have been studied extensively in randomised clinical trials in order to assess their benefits and harms. However, the results have been contradictory.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2016-10-11 16:57:01 +0200" MODIFIED_BY="[Empty name]">
<P>To assess the benefits and harms of glucocorticosteroids in people with alcoholic hepatitis.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2017-11-01 14:21:29 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We identified trials through electronic searches in Cochrane Hepato-Biliary's (CHB) Controlled Trials Register, CENTRAL, MEDLINE, Embase, LILACS, and Science Citation Index Expanded. We looked for ongoing or unpublished trials in clinical trials registers and pharmaceutical company sources. We also scanned reference lists of the studies retrieved. The last search was 20 October 2016.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2017-11-01 14:21:35 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Randomised clinical trials assessing glucocorticosteroids versus placebo or no intervention in people with alcoholic hepatitis, irrespective of year, language of publication, or format. We considered trials with adult participants diagnosed with alcoholic hepatitis, which could have been established through clinical or biochemical diagnostic criteria or both. We defined alcoholic hepatitis as mild (Maddrey's score less than 32) and severe (Maddrey's score 32 or more). We allowed co-interventions in the trial groups, provided they were similar.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2017-11-01 16:27:48 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We followed Cochrane and CHB methodology, performing the meta-analyses using Review Manager 5 and Trial Sequential Analysis. We presented the results of dichotomous outcomes as risk ratios (RR) and those of the continuous outcomes as mean difference (MD). We applied both the fixed-effect model and the random-effects model meta-analyses. Whenever there were significant discrepancies in the results, we reported the more conservative point estimate of the two. We considered a P value of 0.01 or less, two-tailed, as statistically significant if the required information size was reached due to our three primary outcomes (all-cause mortality, health-related quality of life, and serious adverse events during treatment) and our post hoc decision to include analyses of mortality at more time points. We presented heterogeneity using the I² statistic. If trialists used intention-to-treat analysis to deal with missing data, we used these data in our primary analysis; otherwise, we used the available data. We assessed the bias risk of the trials using bias risk domains and the quality of the evidence using GRADE.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2017-11-01 16:27:57 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Sixteen trials fulfilled the inclusion criteria. All trials were at high risk of bias. Fifteen trials provided data for analysis (927 participants received glucocorticosteroids and 934 participants received placebo or no intervention). The glucocorticosteroids were administered orally or parenterally for a median of 28 days (range 3 days to 12 weeks). The participants were between 25 and 70 years old, had different stages of alcoholic liver disease, and 65% were men. The follow-up of trial participants, when it was reported, was up to the moment of discharge from the hospital, until they died (a median of 63 days), or for at least a year. There was no evidence of effect of glucocorticosteroids on all-cause mortality up to three months following randomisation neither with traditional meta-analysis (random-effects RR 0.90, 95% CI 0.70 to 1.15; participants = 1861; trials = 15; I² = 45% (moderate heterogeneity) nor with Trial Sequential Analysis. Meta-analysis showed no evidence of effect on health-related quality of life up to three months (MD -0.04 points; 95% CI -0.11 to 0.03; participants = 377; trial = 1; low-quality evidence), measured with the European Quality of Life - 5 Dimensions-3 Levels (EQ- 5D-3L) scale. There was no evidence of effect on the occurrence of serious adverse events during treatment, neither with traditional meta-analysis (random-effects RR 1.05, 95% CI 0.85 to 1.29; participants = 1861; trials = 15; I² = 36% (moderate heterogeneity), liver-related mortality up to three months following randomisation (random-effects RR 0.89, 95% CI 0.69 to 1.14; participants = 1861; trials = 15; I² = 46% (moderate heterogeneity), frequency of any complications up to three months following randomisation (random-effects RR 1.04, 95% CI 0.86 to 1.27; participants = 1861; I² = 42% (moderate heterogeneity), and frequency of non-serious adverse events up to three months' follow-up after end of treatment (random-effects RR 1.99, 95% CI 0.72 to 5.48; participants = 160; trials = 4; I² = 0% (no heterogeneity) nor with Trial Sequential Analysis. Nine of the trials were industry-funded.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2017-11-01 16:55:28 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We found no evidence of a difference between glucocorticosteroids and placebo or no intervention on all-cause mortality, health-related quality of life, and serious adverse events during treatment. The risk of bias was high and the quality of evidence was very low or low. Therefore, we are very uncertain about this effect estimate. Due to inadequate reporting, we cannot exclude increases in adverse events. As the confidence intervals were wide, we cannot rule out significant benefits and harms of glucocorticosteroids. Therefore, we need placebo-controlled, randomised clinical trials, designed according to the SPIRIT guidelines and reported according to the CONSORT guidelines. Future trials ought to report depersonalised individual participant data, so that proper individual participant data meta-analyses of the effects of glucocorticosteroids in subgroups can be conducted.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2017-11-02 15:31:59 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<BACKGROUND MODIFIED="2017-11-02 15:31:21 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<CONDITION MODIFIED="2017-11-02 11:28:23 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>The term 'alcoholic hepatitis' was used for the first time in a paper by Beckett and colleagues in 1961 (<LINK REF="REF-Beckett-1961" TYPE="REFERENCE">Beckett 1961</LINK>), but clinical jaundice after excessive ethanol consumption was reported in the literature long before that (<LINK REF="REF-Gerber-1973" TYPE="REFERENCE">Gerber 1973</LINK>). Most probably, these reports represented people with alcoholic hepatitis (<LINK REF="STD-Mendenhall-1984" TYPE="STUDY">Mendenhall 1984</LINK>; <LINK REF="REF-Jensen-1994" TYPE="REFERENCE">Jensen 1994</LINK>).</P>
<P>Alcoholic hepatitis is a serious form of alcoholic liver disease (injury of the liver due to excessive alcohol consumption) (<LINK REF="REF-WHO-2010" TYPE="REFERENCE">WHO 2010</LINK>).</P>
<P>The first stage of liver damage in alcoholic hepatitis is usually reversible if people abstain from drinking, but the risk of progression to fibrosis and cirrhosis increases with resumed drinking (<LINK REF="REF-Ellis-2012" TYPE="REFERENCE">Ellis 2012</LINK>). The accumulation of fat in the hepatocytes causes disruption of the mitochondrial beta-oxidation of fatty acids, accumulation of lipotoxic metabolites, and release of reactive oxygen species (<LINK REF="REF-Lieber-1999" TYPE="REFERENCE">Lieber 1999</LINK>; <LINK REF="REF-Wu-1999" TYPE="REFERENCE">Wu 1999</LINK>; <LINK REF="REF-Petrasek-2013" TYPE="REFERENCE">Petrasek 2013</LINK>). Lipotoxic metabolites and reactive oxygen species lead to cell death and liver inflammation (<LINK REF="REF-Wu-1999" TYPE="REFERENCE">Wu 1999</LINK>; <LINK REF="REF-Petrasek-2013" TYPE="REFERENCE">Petrasek 2013;</LINK> <LINK REF="REF-WHO-2013" TYPE="REFERENCE">WHO 2013</LINK>). Alcoholic hepatitis is a histological form of alcoholic liver disease, characterised by steatosis (the earliest stage of alcoholic liver damage) and necroinflammation (EASL 2012b). Alcoholic hepatitis can be resolved if people abstain from drinking, but the risk of death will depend on the severity of the liver damage and drinking patterns. In 20% to 40% of persistent heavy drinkers (defined as alcohol consumption per day of more than 60 g to 80 g in men and more than 20 g in women), alcoholic hepatitis and other complications may develop (<LINK REF="REF-WHO-2013" TYPE="REFERENCE">WHO 2013</LINK>).</P>
<P>Severe alcoholic hepatitis may be characterised by clinically clear signs of jaundice, coagulopathy, liver decompensation with ascites, portal hypertension, variceal bleeding, hepatorenal syndrome, hepatic encephalopathy, systemic inflammatory response syndrome, or sepsis (<LINK REF="REF-Becker-1996" TYPE="REFERENCE">Becker 1996</LINK>; EASL 2012b). Typically, alcoholic hepatitis presents in people aged between 40 and 50 years. Among the risk factors of developing severe alcoholic hepatitis are being female, Hispanic ethnicity, various types of alcohol, binge drinking, poor nutrition, obesity, etc (<LINK REF="REF-WHO-2010" TYPE="REFERENCE">WHO 2010</LINK>). Several composite prognostic scores exist to distinguish people with poor prognosis from those who can become abstinent, instituting supportive care, until recovery is achieved. Some of these scores, designed to predict mortality, are Maddrey's discriminant function (<LINK REF="STD-Maddrey-1978" TYPE="STUDY">Maddrey 1978</LINK>), the model of end-stage liver disease (MELD) score (<LINK REF="REF-Dunn-2005" TYPE="REFERENCE">Dunn 2005</LINK>), the Glasgow alcoholic hepatitis score (<LINK REF="REF-Forrest-2005" TYPE="REFERENCE">Forrest 2005</LINK>), and the age, bilirubin, international normalised ratio, creatinine (ABIC) score (<LINK REF="REF-Dominguez-2008" TYPE="REFERENCE">Dominguez 2008</LINK>).</P>
<P>The Maddrey Discriminant Function is the most often used score in severe alcoholic hepatitis to identify people in potential need of glucocorticosteroids (also known as glucocorticosteroids, corticosteroids, or steroids). The one-month survival of people with alcoholic hepatitis and with Maddrey's score higher than 32 varied between 50% and 65% (<LINK REF="STD-Carithers-1989" TYPE="STUDY">Carithers 1989</LINK>; <LINK REF="REF-Phillips-2006" TYPE="REFERENCE">Phillips 2006</LINK>). The Lille Model (<A HREF="http://www.lillemodel.com">www.lillemodel.com</A>) is the only validated model so far to assess glucocorticosteroid response and is highly predictive of death at six months (P value &lt; 0.000001) in people with severe alcoholic hepatitis (<LINK REF="REF-Louvet-2007" TYPE="REFERENCE">Louvet 2007</LINK>). A Lille Model score greater than 0.45, calculated after seven days of treatment with prednisolone, means failure to respond to treatment and predicts a six-month mortality of about 75% (<LINK REF="REF-Lefkowitch-2005" TYPE="REFERENCE">Lefkowitch 2005</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2017-11-02 15:31:21 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Glucocorticosteroids are used as anti-inflammatory drugs. Glucocorticosteroid agents mimic the endogenous-produced glucocorticoid (cortisol) (<LINK REF="REF-Rhen-2005" TYPE="REFERENCE">Rhen 2005</LINK>). Glucocorticosteroids, primarily regulated by corticotropin, are considered to have anti-inflammatory effects as well as metabolic and immunogenic effects in our body (<LINK REF="REF-Rhen-2005" TYPE="REFERENCE">Rhen 2005</LINK>). It is agreed that the anti-inflammatory effects of glucocorticosteroids are mediated primarily through repression of gene transcription (<LINK REF="REF-Sch_x00e4_cke-2002" TYPE="REFERENCE">Schäcke 2002</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2017-11-02 15:31:21 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Glucocorticosteroids administered to people with alcoholic hepatitis repair the liver injury by decreasing the liver polymorphonuclear neutrophil (PMN) (effector cells) infiltrates and the level of pro-inflammatory mediators such as tumour necrosis factor-alpha (TNF-alpha), intercellular adhesion molecule 1, and interleukin (IL)-6 and IL-8 in the liver tissue (<LINK REF="REF-Ta_x00ef_eb-2000" TYPE="REFERENCE">Taïeb 2000</LINK>; <LINK REF="REF-Spahr-2001" TYPE="REFERENCE">Spahr 2001</LINK>). The benefits of corticosteroids ensue from short-term vascular changes (<LINK REF="REF-Sch_x00e4_cke-2002" TYPE="REFERENCE">Schäcke 2002</LINK>). However, adverse events have still been poorly reported (<LINK REF="REF-Christensen-1995" TYPE="REFERENCE">Christensen 1995</LINK>; <LINK REF="REF-Rambaldi-2008" TYPE="REFERENCE">Rambaldi 2008</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2017-11-01 14:23:55 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Over the years, a number of randomised clinical trials have studied the benefits and harms of corticosteroids for people with alcoholic hepatitis, in order to determine the best route of administration, dose, and duration. However, results have been contradictory. Some systematic reviews (<LINK REF="REF-Christensen-1995" TYPE="REFERENCE">Christensen 1995</LINK>; <LINK REF="REF-Rambaldi-2008" TYPE="REFERENCE">Rambaldi 2008</LINK>) and meta-analyses of randomised clinical trials (<LINK REF="STD-Reynolds-1989" TYPE="STUDY">Reynolds 1989</LINK>; <LINK REF="STD-Imperiale-1990" TYPE="STUDY">Imperiale 1990</LINK>; <LINK REF="STD-Daures-1991" TYPE="STUDY">Daures 1991</LINK>; <LINK REF="REF-Christensen-1999" TYPE="REFERENCE">Christensen 1999</LINK>; <LINK REF="REF-Mathurin-2011" TYPE="REFERENCE">Mathurin 2011</LINK>) have been published. The review authors explained their various conclusions regarding patient-orientated outcomes as being due to differences in glucocorticosteroid regimens, trial quality, participants' characteristics, and clinical spectrum of the disease. <LINK REF="STD-Reynolds-1989" TYPE="STUDY">Reynolds 1989</LINK> concluded that corticosteroid treatment could help only the most severely ill people with severe alcoholic hepatitis characterised by high levels of serum bilirubin, prolonged prothrombin times, and development of hepatic encephalopathy. <LINK REF="STD-Imperiale-1990" TYPE="STUDY">Imperiale 1990</LINK>
 concluded that glucocorticosteroids reduced short-term mortality in people with severe alcoholic hepatitis, provided that they also had hepatic encephalopathy but did not have severe gastrointestinal bleeding. <LINK REF="STD-Daures-1991" TYPE="STUDY">Daures 1991</LINK> concluded that further randomised clinical trials were needed to confirm the benefits and harms of glucocorticosteroids, especially in people with severe alcoholic hepatitis. 
<LINK REF="REF-Christensen-1995" TYPE="REFERENCE">Christensen 1995,</LINK> <LINK REF="REF-Christensen-1999" TYPE="REFERENCE">Christensen 1999</LINK>, and <LINK REF="REF-Rambaldi-2006" TYPE="REFERENCE">Rambaldi 2006</LINK> could not find sufficient proof supporting the routine use of glucocorticosteroids in people with alcoholic hepatitis, including those with hepatic encephalopathy. <LINK REF="REF-Rambaldi-2008" TYPE="REFERENCE">Rambaldi 2008</LINK>
 concluded that glucocorticosteroids did not improve overall survival in people with alcoholic hepatitis. Based on the Trial Sequential Analysis of the subgroup of people with Maddrey's score of at least 32 or spontaneous hepatic encephalopathy, the required information size of 2420 people for the outcome mortality was far from reached, with only 249 participants randomised in the six randomised trials (<LINK REF="REF-Rambaldi-2008" TYPE="REFERENCE">Rambaldi 2008</LINK>). Using the Lille model, <LINK REF="REF-Mathurin-2011" TYPE="REFERENCE">Mathurin 2011</LINK> concluded that glucocorticosteroids significantly improved 28-day survival in people with severe alcoholic hepatitis. The <LINK REF="REF-Mathurin-2011" TYPE="REFERENCE">Mathurin 2011</LINK> meta-analysis was based on individual data from five selected randomised clinical trials and is accordingly at risk of 'cherry picking'. This is why we decided to conduct this Cochrane systematic review in order to assess the efficacy of glucocorticosteroids in people with severe alcoholic hepatitis with or without complications.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2017-06-13 14:41:43 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>To assess the benefits and harms of glucocorticosteroids in people with alcoholic hepatitis. </P>
</OBJECTIVES>
<METHODS MODIFIED="2017-11-02 14:03:13 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<SELECTION_CRITERIA MODIFIED="2017-11-01 14:26:47 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<CRIT_STUDIES MODIFIED="2017-11-01 14:24:12 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We included randomised clinical trials in which glucocorticosteroids were assessed in people with alcoholic hepatitis, irrespective of year or language of publication or format.</P>
<P>We found no reports of quasi-randomised or observational studies retrieved with our searches for randomised clinical trials, in order to extract data on harm.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2017-11-01 14:24:12 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We included adult participants with alcoholic hepatitis, diagnosed according to the diagnostic work-up used in the individual randomised clinical trial. Alcoholic hepatitis could have been established through clinical or biochemical diagnostic criteria or both.</P>
<P>We considered alcoholic hepatitis as mild if a randomised participant had Maddrey's score less than 32 (Maddrey's score = 4.6 x (prothrombin time - control time)(s) + serum bilirubin (mg per dL)) (<LINK REF="STD-Maddrey-1978" TYPE="STUDY">Maddrey 1978</LINK>). Usually, people with mild alcoholic hepatitis do not have concomitant gastrointestinal bleeding.</P>
<P>We considered alcoholic hepatitis as severe at any stage of the alcoholic liver disease with the presence of spontaneous hepatic encephalopathy; or Maddrey's score equal to or higher than 32. We also examined whether there was a difference in terms of initiation of treatment with glucocorticosteroids in trials using the Maddrey's score where severe alcoholic hepatitis was defined as equal to or higher than 32.</P>
<P>Included trial participants diagnosed with severe alcoholic hepatitis could also manifest with hepatic encephalopathy, gastro-intestinal bleeding, cirrhosis (e.g. classified with Child-Pugh score - Child-Pugh type C (<LINK REF="REF-Pugh-1973" TYPE="REFERENCE">Pugh 1973</LINK>)), ascites, hepatorenal syndrome, hyponatraemia, or spontaneous bacterial peritonitis.</P>
<P>For studies not reporting the Maddrey's score, we used the classifications for mild and severe alcoholic hepatitis as provided by the trialists.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2016-11-03 11:36:57 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Glucocorticosteroids administered in any route, dose, and duration versus placebo or no intervention.</P>
<P>We allowed co-interventions in the trial groups, provided they were the same.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2017-11-01 14:26:47 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2017-11-01 14:26:35 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>All-cause mortality: up to three months' follow-up after randomisation (the primary time point for drawing our main conclusion); at the end of treatment (post hoc analysis); and one year following randomisation (post hoc analysis)</LI>
<LI>Health-related quality of life as defined by the trial authors</LI>
<LI>Serious adverse events during treatment. We used the International Conference on Harmonisation (ICH) Guidelines for Good Clinical Practice's definition of a serious adverse event (<LINK REF="REF-ICH_x002d_GCP-1997" TYPE="REFERENCE">ICH-GCP 1997</LINK>), that is, any untoward medical occurrence that results in death, is life threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a congenital anomaly or birth defect. We considered all other adverse events as non-serious (see below).</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2017-11-01 14:26:47 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>Liver-related mortality up to three months' follow-up after randomisation</LI>
<LI>Participants with any complication up to three months' follow-up after randomisation (i.e. ascites, hepatorenal syndrome, spontaneous bacterial peritonitis, gastrointestinal bleeding, hepatic encephalopathy, nonobstructive jaundice, systemic inflammatory response syndrome, sepsis, or hepatocellular carcinoma, or a combination of any of these)</LI>
<LI>Participants with non-serious adverse events up to three months' follow-up after randomisation</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="4">Exploratory analysis</HEADING>
<UL>
<LI>Participants with an increase of liver enzymes as defined by the trialists</LI>
<LI>Participants with a decrease of prothrombin index as defined by the trialists</LI>
<LI>Participants with a decrease of serum albumin as defined by the trialists</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2017-11-01 14:27:20 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<ELECTRONIC_SEARCHES MODIFIED="2017-11-01 14:27:14 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We searched Cochrane Hepato-Biliary's Controlled Trials Register (<LINK REF="REF-Gluud-2017" TYPE="REFERENCE">Gluud 2017</LINK>; September 2016), Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 8) in the Cochrane Library, MEDLINE Ovid (1946 to September 2016), Embase Ovid (1974 to September 2016), LILACS, and Science Citation Index Expanded (Web of Science; 1900 to September 2016) (<LINK REF="REF-Royle-2003" TYPE="REFERENCE">Royle 2003</LINK>). We applied no language or document-type restrictions. <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> shows the search strategies with the time spans of the searches.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2017-11-01 14:27:20 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We searched online trials registries such as ClinicalTrials.gov (<A HREF="http://clinicaltrials.gov">clinicaltrials.gov</A>), European Medicines Agency (EMA; <A HREF="http://www.ema.europa.eu">www.ema.europa.eu</A>), WHO International Clinical Trial Registry Platform <A HREF="http://www.who.int/ictrp">www.who.int/ictrp</A>), the Food and Drug Administration (FDA; <A HREF="http://www.fda.gov">www.fda.gov</A>), and pharmaceutical company sources for ongoing or unpublished trials (last search 20 October 2016).</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2017-11-02 14:03:13 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We followed the available guidelines provided in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>), and the Cochrane Hepato-Biliary Module (<LINK REF="REF-Gluud-2017" TYPE="REFERENCE">Gluud 2017</LINK>). We performed the analyses using Review Manager 5 (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>) and Trial Sequential Analysis (<LINK REF="REF-Thorlund-2011" TYPE="REFERENCE">Thorlund 2011</LINK>; <LINK REF="REF-TSA-2011" TYPE="REFERENCE">TSA 2011</LINK>; <LINK REF="REF-Wetterslev-2017" TYPE="REFERENCE">Wetterslev 2017</LINK>). We assessed the evidence according to Jakobsen and colleagues (<LINK REF="REF-Jakobsen-2014" TYPE="REFERENCE">Jakobsen 2014</LINK>).</P>
<STUDY_SELECTION MODIFIED="2017-11-01 14:27:37 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We retrieved the publications that we considered as potentially eligible for inclusion, after reading their titles and abstracts. Three review authors (CP, DV, GC) independently reviewed the full-text publications for eligibility. The review authors assessed each publication to determine if trial participants and the interventions administered met the inclusion criteria. We included abstracts if sufficient data were provided for analysis. We resolved disagreements by discussion or consulting any of the remaining review authors for arbitration.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2017-11-01 14:27:48 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Three review authors (CP, DV, GC) independently completed a data extraction form for all included trials. Authors extracted general information on the trial, such as publication title; place and year of publication; trial design; inclusion and exclusion criteria; preliminary sample size calculation reached or not; number of participants randomised in each trial and following treatment allocation; diagnostic work-up; age (mean or median); sex or sex ratio; race; co-infection; type, dose, and route of administration of glucocorticosteroids and their possible link with adverse events; concurrent medications used; length of trial; and length of follow-up. CP, DV and GC also extracted data on malnutrition whenever it was clearly defined by the trial authors.</P>
<P>The review authors resolved disagreements by discussion or asking the advice of the review arbitrator, CG.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2017-11-01 14:28:00 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Three review authors (CP, DV, and GC) independently assessed the risk of bias of each included trial according to the recommendations in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>), the Cochrane Hepato-Biliary Module (<LINK REF="REF-Gluud-2017" TYPE="REFERENCE">Gluud 2017</LINK>), and methodological studies (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>; <LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>; <LINK REF="REF-Kjaergard-2001" TYPE="REFERENCE">Kjaergard 2001</LINK>; <LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>; <LINK REF="REF-Savovi_x0107_-2012a" TYPE="REFERENCE">Savovi&#263; 2012a</LINK>; <LINK REF="REF-Savovi_x0107_-2012b" TYPE="REFERENCE">Savovi&#263; 2012b</LINK>; <LINK REF="REF-Lundh-2017" TYPE="REFERENCE">Lundh 2017</LINK>). We used the following definitions in the assessment of risk of bias.</P>
<SUBSECTION>
<HEADING LEVEL="4">Allocation sequence generation</HEADING>
<UL>
<LI>Low risk of bias: the study performed sequence generation using computer random number generation or a random number table. Drawing lots, tossing a coin, shuffling cards, and throwing dice were adequate if an independent person not otherwise involved in the study performed them.</LI>
<LI>Unclear risk of bias: the study authors did not specify the method of sequence generation.</LI>
<LI>High risk of bias: the sequence generation method was not random. We will only include such studies for assessment of harms.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<UL>
<LI>Low risk of bias: the participant allocations could not have been foreseen in advance of, or during, enrolment. A central and independent randomisation unit controlled allocation. The investigators were unaware of the allocation sequence (e.g. if the allocation sequence was hidden in sequentially numbered, opaque, and sealed envelopes).</LI>
<LI>Unclear risk of bias: the study authors did not describe the method used to conceal the allocation so the intervention allocations may have been foreseen before, or during, enrolment.</LI>
<LI>High risk of bias: it is likely that the investigators who assigned the participants knew the allocation sequence. We will only include such studies for assessment of harms.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding of participants and personnel</HEADING>
<UL>
<LI>Low risk of bias: any of the following: no blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding; or blinding of participants and key study personnel ensured, and it is unlikely that the blinding could have been broken.</LI>
<LI>Unclear risk of bias: any of the following: insufficient information to permit judgement of &#8216;low risk&#8217; or &#8216;high risk&#8217;; or the trial did not address this outcome.</LI>
<LI>High risk of bias: any of the following: no blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding; or blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinded outcome assessment</HEADING>
<UL>
<LI>Low risk of bias: any of the following: no blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding; or blinding of outcome assessment ensured, and unlikely that the blinding could have been broken.</LI>
<LI>Unclear risk of bias: any of the following: insufficient information to permit judgement of &#8216;low risk&#8217; or &#8216;high risk&#8217;; or the trial did not address this outcome.</LI>
<LI>High risk of bias: any of the following: no blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding; or blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Incomplete outcome data</HEADING>
<UL>
<LI>Low risk of bias: missing data were unlikely to make treatment effects depart from plausible values. The study used sufficient methods, such as multiple imputation, to handle missing data.</LI>
<LI>Unclear risk of bias: there was insufficient information to assess whether missing data in combination with the method used to handle missing data were likely to induce bias on the results.</LI>
<LI>High risk of bias: the results were likely to be biased due to missing data.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Selective outcome reporting</HEADING>
<UL>
<LI>Low risk: the trial reported the following pre-defined outcomes: all-cause mortality, serious adverse events, and liver-related mortality. If the original trial protocol was available, the outcomes should be those called for in that protocol. If the trial protocol was obtained from a trials registry (e.g. <A HREF="http://www.clinicaltrials.gov/">www.clinicaltrials.gov</A>), the outcomes sought should have been those enumerated in the original protocol if the trial protocol was registered before or at the time that the trial was begun. If the trial protocol was registered after the trial was begun, those outcomes will not be considered to be reliable.</LI>
<LI>Unclear risk: not all pre-defined outcomes were reported fully, or it was unclear whether data on these outcomes were recorded or not.</LI>
<LI>High risk: one or more pre-defined outcomes were not reported.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">For-profit bias</HEADING>
<UL>
<LI>Low risk of bias: the trial appeared to be free of industry sponsorship or other type of for-profit support that may manipulate the trial design, conduct, or analyses of results of the trial.</LI>
<LI>Unclear risk of bias: the trial may or may not be free of for-profit bias as no information on clinical trial support or sponsorship was provided.</LI>
<LI>High risk of bias: the trial was sponsored by industry or received other type of for-profit support.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other bias</HEADING>
<UL>
<LI>Low risk of bias: the trial appeared to be free of other factors that could put it at risk of bias.</LI>
<LI>Unclear risk of bias: the trial may or may not have been free of other factors that could put it at risk of bias.</LI>
<LI>High risk of bias: there were other factors in the trial that could put it at risk of bias.</LI>
</UL>
<P>We judged each trial as having a low, uncertain, or high risk of bias based on the definitions described above. We included a bias risk assessment combining all domains and judged the trials to be at low risk of bias if none of the trial domains was assessed as being with high or unclear risk of bias. Moreover, we considered trials with one or more domains with unclear or high risk of bias as trials at high risks of bias.</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2017-10-30 11:45:12 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Dichotomous outcomes</HEADING>
<P>We used risk ratio (RR) with 95% confidence interval (CI) and Trial Sequential Analysis-adjusted CI for dichotomous outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Continuous outcomes</HEADING>
<P>We used mean difference (MD) with 95% CI and Trial Sequential Analysis-adjusted CI for health-related quality of life. We planned to use the standardised mean difference (SMD) with 95% CI if trials used different measures for health-related quality of life.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2017-11-02 14:03:13 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Trial participants as randomised per intervention group. In case of multiple treatment groups, we considered only the trial group to which glucocorticosteroids were administered versus the group that received placebo or no intervention. If a trial consisted of more than two groups (either parallel or factorial design), we compared the participants from all the glucocorticosteroid groups versus all participants from the placebo group(s). Had we been able to include a cross-over trial from which we could extract data for analyses, we would have used the data from the first treatment period of the cross-over trial.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2017-11-01 14:28:11 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>If dichotomous or continuous data were missing in a published report, we, whenever possible, contacted the original investigators to request the missing data.</P>
<P>If trialists used intention-to-treat analysis to deal with missing data, we used these data in our primary analysis. Otherwise, we used the data that were available to us.</P>
<SUBSECTION>
<HEADING LEVEL="4">Dealing with missing data using sensitivity analysis</HEADING>
<P>As some trials reported only per-protocol analysis results, we included missing data by considering participants as treatment failures or treatment successes by imputing them according to the following two scenarios:</P>
<UL>
<LI>extreme case analysis favouring the experimental intervention ('best-worse' case scenario): none of the participants who dropped out from the experimental trial group experienced the outcome, but all of the participants who dropped out from the control trial group experienced the outcome; including all randomised participants in the denominator.</LI>
<LI>extreme case analysis favouring the control ('worst-best' case scenario): all participants who dropped out from the experimental trial group, but none from the control trial group experienced the outcome; including all randomised participants in the denominator.</LI>
</UL>
<P>For continuous outcomes, as in our case health-related quality of life, we planned to perform a &#8216;best-worst&#8217; case scenario analysis assuming that all participants lost to follow-up in the experimental group had an improved outcome (the group mean plus 1 standard deviation (SD)); and all those with missing outcomes in the control group had a worsened outcome (the group mean minus 1 SD) (<LINK REF="REF-Jakobsen-2014" TYPE="REFERENCE">Jakobsen 2014</LINK>). We also planned to perform 'worst-best' case scenario analysis assuming that all participants lost to follow-up in the experimental group had a worsened outcome (the group mean minus 1 SD); and all those with missing outcomes in the control group had an improved outcome (the group mean plus 1 SD) (<LINK REF="REF-Jakobsen-2014" TYPE="REFERENCE">Jakobsen 2014</LINK>).</P>
<P>We performed the two sensitivity scenario analyses only for our primary outcomes.</P>
</SUBSECTION>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2017-11-01 14:28:52 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We addressed the presence of heterogeneity in both clinical and statistical ways.</P>
<P>To assess heterogeneity between the trials, we specifically examined the degree of heterogeneity observed in the results using the I² statistic (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>). As thresholds for the interpretation of the I² statistic could be misleading, we used the following rough guide for interpretation of heterogeneity provided in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>):</P>
<UL>
<LI>0% to 40%: might not be important;</LI>
<LI>30% to 60%: may represent moderate heterogeneity*;</LI>
<LI>50% to 90%: may represent substantial heterogeneity*;</LI>
<LI>75% to 100%: considerable heterogeneity*.</LI>
</UL>
<P>*The importance of the observed value of the I² statistic depends on (i) the magnitude and direction of effects and (ii) the strength of evidence for heterogeneity (e.g. P value from the Chi² test, or a CI for I² statistic).</P>
<P>For the heterogeneity adjustment of the required information size in the Trial Sequential Analysis, we used diversity (D²) because the I² statistics used for this purpose underestimates the required information size (<LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>).</P>
<P>Depending on the number of eligible trials, we planned to add covariates to a meta-regression model to adjust for heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2017-11-01 14:28:58 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We drew funnel plots to assess reporting biases from the individual trials by plotting the RR on a logarithmic scale against its standard error (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>; <LINK REF="REF-Sterne-2011" TYPE="REFERENCE">Sterne 2011</LINK>).</P>
<P>For dichotomous outcomes, we tested asymmetry using the Harbord test in cases where Tau² was less than 0.1 (<LINK REF="REF-Harbord-2006" TYPE="REFERENCE">Harbord 2006</LINK>), and we planned to use <LINK REF="REF-R_x00fc_cker-2008" TYPE="REFERENCE">Rücker 2008</LINK> in cases where Tau² was more than 0.1. For continuous outcomes, we planned to use the regression asymmetry test (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>), and the adjusted rank correlation (<LINK REF="REF-Begg-1994" TYPE="REFERENCE">Begg 1994</LINK>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2017-11-02 13:15:59 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<SUBSECTION>
<HEADING LEVEL="4">Meta-analysis</HEADING>
<P>We performed the meta-analyses using Review Manager 5 (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>) and according to the recommendations stated in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>).</P>
<P>We presented the results of dichotomous outcomes of individual trials as risk ratios (RR) with 95% CI and the results of the continuous outcomes as mean difference (MD) with 95% CI and Trial Sequential Analysis-adjusted CI. We applied both the fixed-effect model (<LINK REF="REF-DeMets-1987" TYPE="REFERENCE">DeMets 1987</LINK>) and the random-effects model (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>) meta-analyses. If there were statistically significant discrepancies in the results (e.g. one giving a significant intervention effect and the other no significant intervention effect), we reported the more conservative point estimate of the two (<LINK REF="REF-Jakobsen-2014" TYPE="REFERENCE">Jakobsen 2014</LINK>). The more conservative point estimate is the estimate closest to zero effect. If the two point estimates were equal, we used the estimate with the widest CI as our main result of the two analyses. We considered a P value of 0.025 or less, two-tailed, as statistically significant if the required information size was reached due to the three primary outcomes (<LINK REF="REF-Jakobsen-2014" TYPE="REFERENCE">Jakobsen 2014</LINK>). Due to us expanding the number of analyses conducted, we post hoc made the alpha level even lower. We used the eight-step procedure to assess if the thresholds for significance were crossed (<LINK REF="REF-Jakobsen-2014" TYPE="REFERENCE">Jakobsen 2014</LINK>). We presented heterogeneity using the I<SUP>2 </SUP>statistic (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>). We presented the results of the individual trials and meta-analyses in the form of forest plots.</P>
<P>Where data were only available from one trial (in our case continuous data on health-related quality of life), we used Student's t-test (<LINK REF="REF-Student-1908" TYPE="REFERENCE">Student 1908</LINK>). We planned to use Fisher's exact test for dichotomous data in a single trial (<LINK REF="REF-Fisher-1922" TYPE="REFERENCE">Fisher 1922</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Trial Sequential Analysis</HEADING>
<P>We applied Trial Sequential Analysis for both dichotomous and continuous outcomes (<LINK REF="REF-Thorlund-2011" TYPE="REFERENCE">Thorlund 2011</LINK>; <LINK REF="REF-TSA-2011" TYPE="REFERENCE">TSA 2011</LINK>; <LINK REF="REF-Wetterslev-2017" TYPE="REFERENCE">Wetterslev 2017</LINK>), as cumulative meta-analyses are at risk of producing random errors due to sparse data and repetitive testing of the accumulating data (<LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>; <LINK REF="REF-Wetterslev-2017" TYPE="REFERENCE">Wetterslev 2017</LINK>). To control random errors, we calculated the diversity-adjusted required information size (DARIS) (i.e. the number of participants needed in a meta-analysis to detect or reject a certain intervention effect) (<LINK REF="REF-Brok-2008" TYPE="REFERENCE">Brok 2008</LINK>; <LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>; <LINK REF="REF-Brok-2009" TYPE="REFERENCE">Brok 2009</LINK>; <LINK REF="REF-Thorlund-2009" TYPE="REFERENCE">Thorlund 2009</LINK>, <LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>; <LINK REF="REF-Thorlund-2010" TYPE="REFERENCE">Thorlund 2010</LINK>).</P>
<P>In our meta-analysis, we based the DARIS for dichotomous outcomes on the event proportion in the control group; assumption of a plausible risk ratio reduction of 20% of the risk observed in the included trials; a risk of type I error of 1% due to more than three outcomes, as we decided to perform post hoc analyses on mortality at end of treatment and at one year following randomisation, a risk of type II error of 20%, and the diversity of the included trials in the meta-analysis. For health-related quality of life, we planned to: estimate DARIS using a minimal relevant difference of 10% of the mean response observed in the control group; the standard deviation; alpha of 1% (<LINK REF="REF-Jakobsen-2014" TYPE="REFERENCE">Jakobsen 2014</LINK>); beta of 20%; and the diversity as estimated from the trials in the meta-analysis (<LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>). However, we did not conduct Trial Sequential Analysis because only one trial provided data on health-related quality of life. We also calculated and reported the Trial Sequential Analysis-adjusted CI (<LINK REF="REF-Thorlund-2011" TYPE="REFERENCE">Thorlund 2011</LINK>).</P>
<P>The underlying assumption of Trial Sequential Analysis is that testing for statistical significance may be performed each time a new trial is added to the meta-analysis. We added the trials according to the year of publication, and, if more than one trial was published in a year, we added trials alphabetically according to the last name of the first author. On the basis of the DARIS, we constructed the trial sequential monitoring boundaries for benefit, harm, and futility (<LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>; <LINK REF="REF-Thorlund-2011" TYPE="REFERENCE">Thorlund 2011</LINK>). These boundaries determine the statistical inference one may draw regarding the cumulative meta-analysis that has not reached the DARIS; if the trial sequential monitoring boundary for benefit or harm is crossed before the DARIS is reached, firm evidence may be established and further trials may be superfluous. However, if the boundaries are not crossed, it is most probably necessary to continue doing trials in order to detect or reject a certain intervention effect. However, if the cumulative Z-curve crosses the trial sequential monitoring boundaries for futility, no more trials may be needed.</P>
<P>A more detailed description of Trial Sequential Analysis can be found at <A HREF="http://www.ctu.dk/tsa/">www.ctu.dk/tsa/</A> (<LINK REF="REF-Thorlund-2011" TYPE="REFERENCE">Thorlund 2011</LINK>).</P>
</SUBSECTION>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2017-11-01 14:29:18 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Whenever possible, we performed the following subgroup analyses for all-cause mortality up to three months after randomisation.</P>
<UL>
<LI>Trials at low risk of bias compared to trials at high risk of bias.</LI>
<LI>Trials with people with mild alcoholic hepatitis compared to trials with severe alcoholic hepatitis, following Maddrey's score lower than 32 or equal to or higher than 32 or presence of hepatic encephalopathy; or as provided by the trialists.</LI>
<LI>Trials with glucocorticosteroid dose equal to or less than 40 mg compared to trials with glucocorticosteroid dose more than 40 mg.</LI>
<LI>Trials with people with severe alcoholic hepatitis without cirrhosis compared to trials with people with severe alcoholic hepatitis with cirrhosis. If cirrhosis is classified by Child-Pugh score, then we may be able to perform additional subgroup analyses in order to adjust for the clinical spectrum of the disease.</LI>
<LI>Trials with people with severe alcoholic hepatitis without hepatorenal syndrome compared to trials with people with severe alcoholic hepatitis with hepatorenal syndrome.</LI>
<LI>Trials with people with severe alcoholic hepatitis without ascites compared to trials with people with severe alcoholic hepatitis with ascites.</LI>
</UL>
<P>We did not perform any additional subgroup analyses to those planned in advance.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2017-11-01 17:00:13 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We planned to undertake additional sensitivity analyses to those specified under <LINK TAG="MISSING_DATA" TYPE="SECTION">Dealing with missing data</LINK> should we have considered it necessary (e.g. trials published as full-paper articles, abstracts, and unpublished trials).</P>
<SUBSECTION>
<HEADING LEVEL="3">Summary of findings' tables</HEADING>
<P>We created 'Summary of findings' tables on all review outcomes using <LINK REF="REF-GRADEpro-GDT-2015" TYPE="REFERENCE">GRADEpro GDT 2015</LINK>. The GRADE approach appraises the quality of a body of evidence based on the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. The quality of a body of evidence considers within-study risk of bias, indirectness of the evidence (population, intervention, control, outcomes), unexplained inconsistency (heterogeneity) of results (including problems with subgroup analyses); imprecision of results (wide CIs as evaluated with our Trial Sequential Analyses) (<LINK REF="REF-Jakobsen-2014" TYPE="REFERENCE">Jakobsen 2014</LINK>), and risk of publication bias (<LINK REF="REF-Balshem-2011" TYPE="REFERENCE">Balshem 2011</LINK>; <LINK REF="REF-Guyatt-2011a" TYPE="REFERENCE">Guyatt 2011a</LINK>; <LINK REF="REF-Guyatt-2011b" TYPE="REFERENCE">Guyatt 2011b</LINK>; <LINK REF="REF-Guyatt-2011c" TYPE="REFERENCE">Guyatt 2011c</LINK>; <LINK REF="REF-Guyatt-2011d" TYPE="REFERENCE">Guyatt 2011d</LINK>; <LINK REF="REF-Guyatt-2011e" TYPE="REFERENCE">Guyatt 2011e</LINK>; <LINK REF="REF-Guyatt-2011f" TYPE="REFERENCE">Guyatt 2011f</LINK>; <LINK REF="REF-Guyatt-2011g" TYPE="REFERENCE">Guyatt 2011g</LINK>; <LINK REF="REF-Guyatt-2011h" TYPE="REFERENCE">Guyatt 2011h</LINK>; <LINK REF="REF-Guyatt-2013a" TYPE="REFERENCE">Guyatt 2013a</LINK>; <LINK REF="REF-Guyatt-2013b" TYPE="REFERENCE">Guyatt 2013b</LINK>; <LINK REF="REF-Guyatt-2013c" TYPE="REFERENCE">Guyatt 2013c</LINK>; <LINK REF="REF-Mustafa-2013" TYPE="REFERENCE">Mustafa 2013</LINK>; <LINK REF="REF-Guyatt-2017" TYPE="REFERENCE">Guyatt 2017</LINK>).</P>
<P>We defined the levels of evidence as 'high', 'moderate', 'low', or 'very low'. These grades are defined as follows:</P>
<UL>
<LI>High quality: this research provides a very good indication of the likely effect; the likelihood that the effect will be substantially different is low. </LI>
<LI>Moderate quality: this research provides a good indication of the likely effect; the likelihood that the effect will be substantially different is moderate. </LI>
<LI>Low quality: this research provides some indication of the likely effect; however, the likelihood that it will be substantially different is high. </LI>
<LI>Very low quality: this research does not provide a reliable indication of the likely effect; the likelihood that the effect will be substantially different is very high.</LI>
</UL>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2017-11-02 14:27:34 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<STUDY_DESCRIPTION MODIFIED="2017-11-02 14:27:34 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>See: <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
<SEARCH_RESULTS MODIFIED="2017-11-02 11:25:22 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We identified 932 potentially relevant records through the electronic searches (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Of these, 37 records that referred to 16 randomised clinical trials fulfilled our inclusion criteria. We found two trials published in abstract form (<LINK REF="STD-Mendenhall-1977" TYPE="STUDY">Mendenhall 1977</LINK>; <LINK REF="STD-Richardet-1993" TYPE="STUDY">Richardet 1993</LINK>), and fourteen trials described in full paper articles (<LINK REF="STD-Helman-1971" TYPE="STUDY">Helman 1971</LINK>; <LINK REF="STD-Porter-1971" TYPE="STUDY">Porter 1971</LINK>; <LINK REF="STD-Campra-1973" TYPE="STUDY">Campra 1973</LINK>; <LINK REF="STD-Blitzer-1977" TYPE="STUDY">Blitzer 1977</LINK>; <LINK REF="STD-Maddrey-1978" TYPE="STUDY">Maddrey 1978</LINK>; <LINK REF="STD-Shumaker-1978" TYPE="STUDY">Shumaker 1978</LINK>; <LINK REF="STD-Depew-1980" TYPE="STUDY">Depew 1980</LINK>; <LINK REF="STD-Theodossi-1982" TYPE="STUDY">Theodossi 1982</LINK>; <LINK REF="STD-Mendenhall-1984" TYPE="STUDY">Mendenhall 1984</LINK>; <LINK REF="STD-Bories-1987" TYPE="STUDY">Bories 1987</LINK>; <LINK REF="STD-Carithers-1989" TYPE="STUDY">Carithers 1989</LINK>; <LINK REF="STD-Ramond-1992" TYPE="STUDY">Ramond 1992</LINK>; <LINK REF="STD-De-2014" TYPE="STUDY">De 2014</LINK>; <LINK REF="STD-Thursz-2015" TYPE="STUDY">Thursz 2015</LINK>). Our searches retrieved no quasi-randomised trials or observational studies. We identified no additional references by handsearching the reference lists of articles, retrieved through the computerised databases.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2017-11-02 14:27:34 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Sixteen randomised clinical trials fulfilled our review protocol inclusion criteria (<LINK REF="STD-Helman-1971" TYPE="STUDY">Helman 1971</LINK>; <LINK REF="STD-Porter-1971" TYPE="STUDY">Porter 1971</LINK>; <LINK REF="STD-Campra-1973" TYPE="STUDY">Campra 1973</LINK>; <LINK REF="STD-Blitzer-1977" TYPE="STUDY">Blitzer 1977</LINK>; <LINK REF="STD-Mendenhall-1977" TYPE="STUDY">Mendenhall 1977</LINK>; <LINK REF="STD-Maddrey-1978" TYPE="STUDY">Maddrey 1978</LINK>; <LINK REF="STD-Shumaker-1978" TYPE="STUDY">Shumaker 1978</LINK>; <LINK REF="STD-Depew-1980" TYPE="STUDY">Depew 1980</LINK>; <LINK REF="STD-Theodossi-1982" TYPE="STUDY">Theodossi 1982</LINK>; <LINK REF="STD-Mendenhall-1984" TYPE="STUDY">Mendenhall 1984</LINK>; <LINK REF="STD-Bories-1987" TYPE="STUDY">Bories 1987</LINK>; <LINK REF="STD-Carithers-1989" TYPE="STUDY">Carithers 1989</LINK>; <LINK REF="STD-Ramond-1992" TYPE="STUDY">Ramond 1992</LINK>; <LINK REF="STD-Richardet-1993" TYPE="STUDY">Richardet 1993</LINK>; <LINK REF="STD-De-2014" TYPE="STUDY">De 2014</LINK>; <LINK REF="STD-Thursz-2015" TYPE="STUDY">Thursz 2015</LINK>). Two were three-armed trials (<LINK REF="STD-Mendenhall-1977" TYPE="STUDY">Mendenhall 1977</LINK>; <LINK REF="STD-Mendenhall-1984" TYPE="STUDY">Mendenhall 1984</LINK>), one trial was a randomised trial with a two-by-two factorial design (<LINK REF="STD-Thursz-2015" TYPE="STUDY">Thursz 2015</LINK>), one trial was a cross-over trial (<LINK REF="STD-Richardet-1993" TYPE="STUDY">Richardet 1993</LINK>), and the remaining were parallel, two-group design trials. There were 1884 participants randomised in all trials. Some participants from <LINK REF="STD-Mendenhall-1977" TYPE="STUDY">Mendenhall 1977</LINK> (pilot trial or feasibility trial) continued participation in <LINK REF="STD-Mendenhall-1984" TYPE="STUDY">Mendenhall 1984</LINK>. The trials were conducted in France (n = 3), India (n = 1), UK (n = 2), and USA (n = 10) (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). All the trials reported the sex (65% of the participants were men) and age of the participants (range 25 years to 70 years). Four trials excluded women (<LINK REF="STD-Blitzer-1977" TYPE="STUDY">Blitzer 1977</LINK>; <LINK REF="STD-Mendenhall-1977" TYPE="STUDY">Mendenhall 1977</LINK>; <LINK REF="STD-Mendenhall-1984" TYPE="STUDY">Mendenhall 1984</LINK>; <LINK REF="STD-De-2014" TYPE="STUDY">De 2014</LINK>). Eleven trials reported to have included trial participants at different stages of alcoholic liver disease due to hepatitis, fibrosis, or cirrhosis (<LINK REF="STD-Helman-1971" TYPE="STUDY">Helman 1971</LINK>; <LINK REF="STD-Porter-1971" TYPE="STUDY">Porter 1971</LINK>; <LINK REF="STD-Campra-1973" TYPE="STUDY">Campra 1973</LINK>; <LINK REF="STD-Blitzer-1977" TYPE="STUDY">Blitzer 1977</LINK>; <LINK REF="STD-Maddrey-1978" TYPE="STUDY">Maddrey 1978</LINK>; <LINK REF="STD-Depew-1980" TYPE="STUDY">Depew 1980</LINK>; <LINK REF="STD-Theodossi-1982" TYPE="STUDY">Theodossi 1982</LINK>; <LINK REF="STD-Mendenhall-1984" TYPE="STUDY">Mendenhall 1984</LINK> <LINK REF="STD-Bories-1987" TYPE="STUDY">Bories 1987</LINK>; <LINK REF="STD-Ramond-1992" TYPE="STUDY">Ramond 1992</LINK>; <LINK REF="STD-Thursz-2015" TYPE="STUDY">Thursz 2015</LINK>). Most trials established diagnosis primarily through liver biopsy. One trial included only participants with liver cirrhosis in addition to alcoholic hepatitis (<LINK REF="STD-De-2014" TYPE="STUDY">De 2014</LINK>). The remaining trials did not provide information on the stage of disease. All the trials included participants with recent history of alcohol consumption, increase of serum bilirubin, liver enzymes, prolonged prothrombin time, and participants without previous treatment with glucocorticosteroids within the last three months before the start of the trial. Ten trials performed liver biopsy whenever possible (<LINK REF="STD-Helman-1971" TYPE="STUDY">Helman 1971</LINK>; <LINK REF="STD-Porter-1971" TYPE="STUDY">Porter 1971</LINK>; <LINK REF="STD-Campra-1973" TYPE="STUDY">Campra 1973</LINK>; <LINK REF="STD-Blitzer-1977" TYPE="STUDY">Blitzer 1977</LINK>; <LINK REF="STD-Maddrey-1978" TYPE="STUDY">Maddrey 1978</LINK>; <LINK REF="STD-Shumaker-1978" TYPE="STUDY">Shumaker 1978</LINK>; <LINK REF="STD-Depew-1980" TYPE="STUDY">Depew 1980</LINK>; <LINK REF="STD-Bories-1987" TYPE="STUDY">Bories 1987</LINK>; <LINK REF="STD-Ramond-1992" TYPE="STUDY">Ramond 1992</LINK>; <LINK REF="STD-Thursz-2015" TYPE="STUDY">Thursz 2015</LINK>); however, it was an inclusion criterion in only one trial, performed at the admission and after treatment (<LINK REF="STD-Helman-1971" TYPE="STUDY">Helman 1971</LINK>).</P>
<P>Ten trials reported the period of trial enrolment (range of one year to five years, with the median of three years) (<LINK REF="STD-Campra-1973" TYPE="STUDY">Campra 1973</LINK>; <LINK REF="STD-Blitzer-1977" TYPE="STUDY">Blitzer 1977</LINK>; <LINK REF="STD-Mendenhall-1977" TYPE="STUDY">Mendenhall 1977</LINK>; <LINK REF="STD-Maddrey-1978" TYPE="STUDY">Maddrey 1978</LINK>; <LINK REF="STD-Depew-1980" TYPE="STUDY">Depew 1980</LINK>; <LINK REF="STD-Mendenhall-1984" TYPE="STUDY">Mendenhall 1984</LINK>; <LINK REF="STD-Bories-1987" TYPE="STUDY">Bories 1987</LINK>; <LINK REF="STD-Carithers-1989" TYPE="STUDY">Carithers 1989</LINK>; <LINK REF="STD-De-2014" TYPE="STUDY">De 2014</LINK>; <LINK REF="STD-Thursz-2015" TYPE="STUDY">Thursz 2015</LINK>). The earliest trial began participant recruitment in 1966 (<LINK REF="STD-Campra-1973" TYPE="STUDY">Campra 1973</LINK>), and the most recently published trial began recruitment in 2011 and completed it in 2014 (<LINK REF="STD-Thursz-2015" TYPE="STUDY">Thursz 2015</LINK>).</P>
<P>Three trials followed participants up to one year <LINK REF="STD-Mendenhall-1984" TYPE="STUDY">Mendenhall 1984</LINK>, <LINK REF="STD-De-2014" TYPE="STUDY">De 2014</LINK> and <LINK REF="STD-Thursz-2015" TYPE="STUDY">Thursz 2015</LINK>. The remaining trials followed their participants to the moment of discharge from the hospital or until death occurred, with a median duration of follow-up of 63 days (range 28 to 120).</P>
<P>We could extract data for analysis from all 16 trials but one (<LINK REF="STD-Richardet-1993" TYPE="STUDY">Richardet 1993</LINK>). We contacted Richardet in 2006, but we did not receive a reply. In the remaining 15 trials, 182 participants had mild alcoholic hepatitis and 1679 had severe alcoholic hepatitis. The analyses of the 15 trials accounted for 927 participants randomised to glucocorticosteroids, and 934 participants randomised to placebo or no intervention.</P>
<SUBSECTION>
<HEADING LEVEL="4">Experimental interventions</HEADING>
<P>Glucocorticosteroids (prednisolone or 6-methylprednisolone in equivalent dose of prednisolone) were administered orally or parenterally at different dose regimens and different durations. Twelve trials assessed oral glucocorticosteroids at a dose equal to or more than 40 mg prednisolone (<LINK REF="STD-Helman-1971" TYPE="STUDY">Helman 1971</LINK>; <LINK REF="STD-Mendenhall-1977" TYPE="STUDY">Mendenhall 1977</LINK>; <LINK REF="STD-Maddrey-1978" TYPE="STUDY">Maddrey 1978</LINK>; <LINK REF="STD-Shumaker-1978" TYPE="STUDY">Shumaker 1978</LINK>; <LINK REF="STD-Depew-1980" TYPE="STUDY">Depew 1980</LINK>; <LINK REF="STD-Mendenhall-1984" TYPE="STUDY">Mendenhall 1984</LINK>; <LINK REF="STD-Bories-1987" TYPE="STUDY">Bories 1987</LINK>; <LINK REF="STD-Carithers-1989" TYPE="STUDY">Carithers 1989</LINK>; <LINK REF="STD-Ramond-1992" TYPE="STUDY">Ramond 1992</LINK>; <LINK REF="STD-Richardet-1993" TYPE="STUDY">Richardet 1993</LINK>; <LINK REF="STD-De-2014" TYPE="STUDY">De 2014</LINK>; <LINK REF="STD-Thursz-2015" TYPE="STUDY">Thursz 2015</LINK>), but three trials also allowed parenteral administration to participants who were not able to swallow (<LINK REF="STD-Shumaker-1978" TYPE="STUDY">Shumaker 1978</LINK>; <LINK REF="STD-Carithers-1989" TYPE="STUDY">Carithers 1989</LINK>; <LINK REF="STD-Ramond-1992" TYPE="STUDY">Ramond 1992</LINK>). Two trials assessed oral glucocorticosteroids at a dose less than 40 mg prednisolone (<LINK REF="STD-Campra-1973" TYPE="STUDY">Campra 1973</LINK>; <LINK REF="STD-Blitzer-1977" TYPE="STUDY">Blitzer 1977</LINK>), and in one trial the initial therapy was parenteral and then it was administered orally (<LINK REF="STD-Porter-1971" TYPE="STUDY">Porter 1971</LINK>). One trial used only parenteral (intravenous) glucocorticosteroids (<LINK REF="STD-Theodossi-1982" TYPE="STUDY">Theodossi 1982</LINK>).</P>
<P>The median duration of glucocorticosteroid administration was 28 days with a range of three days (<LINK REF="STD-Theodossi-1982" TYPE="STUDY">Theodossi 1982</LINK>) to 11 weeks (<LINK REF="STD-De-2014" TYPE="STUDY">De 2014</LINK>): one week (<LINK REF="STD-Richardet-1993" TYPE="STUDY">Richardet 1993</LINK>), three weeks (<LINK REF="STD-Mendenhall-1977" TYPE="STUDY">Mendenhall 1977</LINK>), four weeks (<LINK REF="STD-Ramond-1992" TYPE="STUDY">Ramond 1992</LINK>; <LINK REF="STD-Thursz-2015" TYPE="STUDY">Thursz 2015</LINK>), 26 days (<LINK REF="STD-Blitzer-1977" TYPE="STUDY">Blitzer 1977</LINK>), one month (<LINK REF="STD-Maddrey-1978" TYPE="STUDY">Maddrey 1978</LINK>; <LINK REF="STD-Mendenhall-1984" TYPE="STUDY">Mendenhall 1984</LINK>; <LINK REF="STD-Bories-1987" TYPE="STUDY">Bories 1987</LINK>), five weeks (<LINK REF="STD-Shumaker-1978" TYPE="STUDY">Shumaker 1978</LINK>; <LINK REF="STD-Carithers-1989" TYPE="STUDY">Carithers 1989</LINK>), six weeks (<LINK REF="STD-Helman-1971" TYPE="STUDY">Helman 1971;</LINK> <LINK REF="STD-Campra-1973" TYPE="STUDY">Campra 1973</LINK>; <LINK REF="STD-Depew-1980" TYPE="STUDY">Depew 1980</LINK>), 45 days (<LINK REF="STD-Porter-1971" TYPE="STUDY">Porter 1971</LINK>). The dose of prednisolone was tapered until it was stopped in <LINK REF="STD-Helman-1971" TYPE="STUDY">Helman 1971</LINK>; <LINK REF="STD-Porter-1971" TYPE="STUDY">Porter 1971</LINK>; <LINK REF="STD-Campra-1973" TYPE="STUDY">Campra 1973</LINK>; <LINK REF="STD-Blitzer-1977" TYPE="STUDY">Blitzer 1977</LINK>; <LINK REF="STD-Mendenhall-1977" TYPE="STUDY">Mendenhall 1977</LINK>; <LINK REF="STD-Shumaker-1978" TYPE="STUDY">Shumaker 1978</LINK>; <LINK REF="STD-Depew-1980" TYPE="STUDY">Depew 1980</LINK>; <LINK REF="STD-Mendenhall-1984" TYPE="STUDY">Mendenhall 1984</LINK>; <LINK REF="STD-Carithers-1989" TYPE="STUDY">Carithers 1989</LINK>; and <LINK REF="STD-De-2014" TYPE="STUDY">De 2014</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Control interventions</HEADING>
<P>Twelve trials used identical placebos (<LINK REF="STD-Helman-1971" TYPE="STUDY">Helman 1971</LINK>; <LINK REF="STD-Porter-1971" TYPE="STUDY">Porter 1971</LINK>; <LINK REF="STD-Blitzer-1977" TYPE="STUDY">Blitzer 1977</LINK>; <LINK REF="STD-Mendenhall-1977" TYPE="STUDY">Mendenhall 1977</LINK>; <LINK REF="STD-Maddrey-1978" TYPE="STUDY">Maddrey 1978</LINK>; <LINK REF="STD-Shumaker-1978" TYPE="STUDY">Shumaker 1978</LINK>; <LINK REF="STD-Depew-1980" TYPE="STUDY">Depew 1980</LINK>; <LINK REF="STD-Mendenhall-1984" TYPE="STUDY">Mendenhall 1984</LINK>; <LINK REF="STD-Carithers-1989" TYPE="STUDY">Carithers 1989</LINK>; <LINK REF="STD-Ramond-1992" TYPE="STUDY">Ramond 1992</LINK>; <LINK REF="STD-De-2014" TYPE="STUDY">De 2014</LINK>; <LINK REF="STD-Thursz-2015" TYPE="STUDY">Thursz 2015</LINK>) and four trials used no intervention (<LINK REF="STD-Campra-1973" TYPE="STUDY">Campra 1973</LINK>; <LINK REF="STD-Theodossi-1982" TYPE="STUDY">Theodossi 1982</LINK>; <LINK REF="STD-Bories-1987" TYPE="STUDY">Bories 1987</LINK>; <LINK REF="STD-Richardet-1993" TYPE="STUDY">Richardet 1993</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Co-interventions</HEADING>
<P>Two trials administered pentoxifylline to both glucocorticosteroids and placebo intervention groups (<LINK REF="STD-De-2014" TYPE="STUDY">De 2014</LINK>; <LINK REF="STD-Thursz-2015" TYPE="STUDY">Thursz 2015</LINK>). There seemed to be no interaction between the intervention effects of pentoxifylline and glucocorticosteroids (<LINK REF="STD-De-2014" TYPE="STUDY">De 2014</LINK>; <LINK REF="STD-Thursz-2015" TYPE="STUDY">Thursz 2015</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>The <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> tables detail the outcomes reported in the individual trials. Five trials reported on outcomes with a follow-up period up to three months after randomisation (<LINK REF="STD-Helman-1971" TYPE="STUDY">Helman 1971</LINK>; <LINK REF="STD-Mendenhall-1977" TYPE="STUDY">Mendenhall 1977</LINK>; <LINK REF="STD-Bories-1987" TYPE="STUDY">Bories 1987</LINK>; <LINK REF="STD-De-2014" TYPE="STUDY">De 2014</LINK>; <LINK REF="STD-Thursz-2015" TYPE="STUDY">Thursz 2015</LINK>). Twelve trials reported on outcomes at the end of treatment or at the moment of discharge from the hospital (<LINK REF="STD-Helman-1971" TYPE="STUDY">Helman 1971</LINK>; <LINK REF="STD-Porter-1971" TYPE="STUDY">Porter 1971</LINK>; <LINK REF="STD-Campra-1973" TYPE="STUDY">Campra 1973</LINK>; <LINK REF="STD-Blitzer-1977" TYPE="STUDY">Blitzer 1977</LINK>; <LINK REF="STD-Maddrey-1978" TYPE="STUDY">Maddrey 1978</LINK>; <LINK REF="STD-Shumaker-1978" TYPE="STUDY">Shumaker 1978</LINK>; <LINK REF="STD-Depew-1980" TYPE="STUDY">Depew 1980</LINK>; <LINK REF="STD-Theodossi-1982" TYPE="STUDY">Theodossi 1982</LINK>; <LINK REF="STD-Bories-1987" TYPE="STUDY">Bories 1987</LINK>; <LINK REF="STD-Carithers-1989" TYPE="STUDY">Carithers 1989</LINK>; <LINK REF="STD-Ramond-1992" TYPE="STUDY">Ramond 1992</LINK>; <LINK REF="STD-Richardet-1993" TYPE="STUDY">Richardet 1993</LINK>). Three trials exceeded the 12-month follow-up period (<LINK REF="STD-Mendenhall-1984" TYPE="STUDY">Mendenhall 1984</LINK>; <LINK REF="STD-De-2014" TYPE="STUDY">De 2014</LINK>; <LINK REF="STD-Thursz-2015" TYPE="STUDY">Thursz 2015</LINK>).</P>
<P>Only one trial reported health-related quality of life, using the European quality of life-5 dimensions (EQ-5D) score registered to Eudra CT 2009- 013897-42 and ISRCTN 88782125 and it was reported in all the groups at three months' follow-up after randomisation, and at one year (<LINK REF="STD-Thursz-2015" TYPE="STUDY">Thursz 2015</LINK>; see Notes in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P>
<P>None of the trials provided usable data for meta-analyses of our exploratory outcomes.</P>
<P>For further details on trial characteristics, please see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2017-11-01 14:30:09 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We excluded 26 trials from the final assessment with the reasons for their exclusion provided in <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.<BR/>
<BR/>Among the excluded trials are two trials that used a nutritional intervention in the control group (<LINK REF="STD-Lesesne-1978" TYPE="STUDY">Lesesne 1978</LINK>; <LINK REF="STD-Cabr_x00e9_-2000" TYPE="STUDY">Cabré 2000</LINK>). Although nutritional intervention as an overall intervention does not seem to influence mortality or serious adverse events (<LINK REF="REF-Feinberg-2017" TYPE="REFERENCE">Feinberg 2017</LINK>), including the <LINK REF="STD-Cabr_x00e9_-2000" TYPE="STUDY">Cabré 2000</LINK> and <LINK REF="STD-Lesesne-1978" TYPE="STUDY">Lesesne 1978</LINK> trials in our review would not have affected our results noticeably because these trials were small and had very few events.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2017-11-02 11:25:22 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<ALLOCATION MODIFIED="2017-11-02 11:25:22 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<SUBSECTION>
<HEADING LEVEL="4">Allocation sequence generation</HEADING>
<P>Based on the information that we collected from the published reports and information from study authors, we assessed the allocation sequence generation as low risk of bias in eight trials (<LINK REF="STD-Porter-1971" TYPE="STUDY">Porter 1971</LINK>; <LINK REF="STD-Campra-1973" TYPE="STUDY">Campra 1973</LINK>; <LINK REF="STD-Blitzer-1977" TYPE="STUDY">Blitzer 1977</LINK>; <LINK REF="STD-Maddrey-1978" TYPE="STUDY">Maddrey 1978</LINK>; <LINK REF="STD-Carithers-1989" TYPE="STUDY">Carithers 1989</LINK>; <LINK REF="STD-Ramond-1992" TYPE="STUDY">Ramond 1992</LINK>; <LINK REF="STD-De-2014" TYPE="STUDY">De 2014</LINK>; <LINK REF="STD-Thursz-2015" TYPE="STUDY">Thursz 2015</LINK>) and as unclear in the remaining trials (<LINK REF="STD-Helman-1971" TYPE="STUDY">Helman 1971</LINK>; <LINK REF="STD-Mendenhall-1977" TYPE="STUDY">Mendenhall 1977</LINK>; <LINK REF="STD-Shumaker-1978" TYPE="STUDY">Shumaker 1978</LINK>; <LINK REF="STD-Depew-1980" TYPE="STUDY">Depew 1980</LINK>; <LINK REF="STD-Theodossi-1982" TYPE="STUDY">Theodossi 1982</LINK>; <LINK REF="STD-Mendenhall-1984" TYPE="STUDY">Mendenhall 1984</LINK>; <LINK REF="STD-Bories-1987" TYPE="STUDY">Bories 1987</LINK>; <LINK REF="STD-Richardet-1993" TYPE="STUDY">Richardet 1993</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<P>Based on the information that we collected from the published reports and information from study authors, we assessed the allocation concealment as low risk of bias in ten trials (<LINK REF="STD-Helman-1971" TYPE="STUDY">Helman 1971</LINK>; <LINK REF="STD-Porter-1971" TYPE="STUDY">Porter 1971</LINK>; <LINK REF="STD-Campra-1973" TYPE="STUDY">Campra 1973</LINK>; <LINK REF="STD-Blitzer-1977" TYPE="STUDY">Blitzer 1977</LINK>; <LINK REF="STD-Shumaker-1978" TYPE="STUDY">Shumaker 1978</LINK>; <LINK REF="STD-Theodossi-1982" TYPE="STUDY">Theodossi 1982</LINK>; <LINK REF="STD-Mendenhall-1984" TYPE="STUDY">Mendenhall 1984</LINK>; <LINK REF="STD-Carithers-1989" TYPE="STUDY">Carithers 1989</LINK>; <LINK REF="STD-Ramond-1992" TYPE="STUDY">Ramond 1992</LINK>; <LINK REF="STD-Thursz-2015" TYPE="STUDY">Thursz 2015</LINK>) and as unclear in the remaining trials (<LINK REF="STD-Mendenhall-1977" TYPE="STUDY">Mendenhall 1977</LINK>; <LINK REF="STD-Maddrey-1978" TYPE="STUDY">Maddrey 1978</LINK>; <LINK REF="STD-Depew-1980" TYPE="STUDY">Depew 1980</LINK>; <LINK REF="STD-Bories-1987" TYPE="STUDY">Bories 1987</LINK>; <LINK REF="STD-Richardet-1993" TYPE="STUDY">Richardet 1993</LINK>; <LINK REF="STD-De-2014" TYPE="STUDY">De 2014</LINK>).</P>
</SUBSECTION>
</ALLOCATION>
<BLINDING MODIFIED="2017-11-02 11:25:22 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Three trials were at high risk of performance bias as they were open-label trials, without blinding of participants or investigators (<LINK REF="STD-Campra-1973" TYPE="STUDY">Campra 1973</LINK>; <LINK REF="STD-Bories-1987" TYPE="STUDY">Bories 1987</LINK>; <LINK REF="STD-Theodossi-1982" TYPE="STUDY">Theodossi 1982</LINK>) and placebo was used in the <LINK REF="STD-Richardet-1993" TYPE="STUDY">Richardet 1993</LINK> trial, but there was no description of it and we judged the risk of bias as unclear. Twelve trials were blinded, using identical placebo (<LINK REF="STD-Helman-1971" TYPE="STUDY">Helman 1971</LINK>; <LINK REF="STD-Porter-1971" TYPE="STUDY">Porter 1971</LINK>; <LINK REF="STD-Blitzer-1977" TYPE="STUDY">Blitzer 1977</LINK>; <LINK REF="STD-Mendenhall-1977" TYPE="STUDY">Mendenhall 1977</LINK>; <LINK REF="STD-Maddrey-1978" TYPE="STUDY">Maddrey 1978</LINK>; <LINK REF="STD-Shumaker-1978" TYPE="STUDY">Shumaker 1978</LINK>; <LINK REF="STD-Depew-1980" TYPE="STUDY">Depew 1980</LINK>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1505221000455357620971906969558&amp;format=REVMAN#STD-Mendenhall-1984b">Mendenhall 1984b</A>: <LINK REF="STD-Carithers-1989" TYPE="STUDY">Carithers 1989</LINK>; <LINK REF="STD-Ramond-1992" TYPE="STUDY">Ramond 1992</LINK>; <LINK REF="STD-De-2014" TYPE="STUDY">De 2014</LINK>; <LINK REF="STD-Thursz-2015" TYPE="STUDY">Thursz 2015</LINK>), and hence, at low risk of bias.</P>
<P>We assessed five trials at low risk of detection bias (<LINK REF="STD-Porter-1971" TYPE="STUDY">Porter 1971</LINK>; <LINK REF="STD-Shumaker-1978" TYPE="STUDY">Shumaker 1978</LINK>; <LINK REF="STD-Carithers-1989" TYPE="STUDY">Carithers 1989</LINK>; <LINK REF="STD-De-2014" TYPE="STUDY">De 2014</LINK>; <LINK REF="STD-Thursz-2015" TYPE="STUDY">Thursz 2015</LINK>), and the remaining eleven trials as unclear risk of detection bias (<LINK REF="STD-Helman-1971" TYPE="STUDY">Helman 1971</LINK>; <LINK REF="STD-Campra-1973" TYPE="STUDY">Campra 1973</LINK>; <LINK REF="STD-Blitzer-1977" TYPE="STUDY">Blitzer 1977</LINK>; <LINK REF="STD-Mendenhall-1977" TYPE="STUDY">Mendenhall 1977</LINK>; <LINK REF="STD-Maddrey-1978" TYPE="STUDY">Maddrey 1978</LINK>; <LINK REF="STD-Depew-1980" TYPE="STUDY">Depew 1980</LINK>; <LINK REF="STD-Theodossi-1982" TYPE="STUDY">Theodossi 1982</LINK>; <LINK REF="STD-Mendenhall-1984" TYPE="STUDY">Mendenhall 1984</LINK>; <LINK REF="STD-Bories-1987" TYPE="STUDY">Bories 1987</LINK>; <LINK REF="STD-Ramond-1992" TYPE="STUDY">Ramond 1992</LINK>; <LINK REF="STD-Richardet-1993" TYPE="STUDY">Richardet 1993</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2017-11-02 11:25:22 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We classed four trials at high risk of attrition bias because they did not account for participants with missing outcomes (<LINK REF="STD-Porter-1971" TYPE="STUDY">Porter 1971</LINK>; <LINK REF="STD-Blitzer-1977" TYPE="STUDY">Blitzer 1977</LINK>; <LINK REF="STD-Theodossi-1982" TYPE="STUDY">Theodossi 1982</LINK>; <LINK REF="STD-Thursz-2015" TYPE="STUDY">Thursz 2015</LINK>). Eleven trials were assessed as having low risk of attrition bias (<LINK REF="STD-Helman-1971" TYPE="STUDY">Helman 1971</LINK>; <LINK REF="STD-Campra-1973" TYPE="STUDY">Campra 1973</LINK>; <LINK REF="STD-Mendenhall-1977" TYPE="STUDY">Mendenhall 1977</LINK>; <LINK REF="STD-Maddrey-1978" TYPE="STUDY">Maddrey 1978</LINK>; <LINK REF="STD-Shumaker-1978" TYPE="STUDY">Shumaker 1978</LINK>; <LINK REF="STD-Depew-1980" TYPE="STUDY">Depew 1980</LINK>; <LINK REF="STD-Mendenhall-1984" TYPE="STUDY">Mendenhall 1984</LINK>; <LINK REF="STD-Bories-1987" TYPE="STUDY">Bories 1987</LINK>; <LINK REF="STD-Carithers-1989" TYPE="STUDY">Carithers 1989</LINK>; <LINK REF="STD-Ramond-1992" TYPE="STUDY">Ramond 1992</LINK>; <LINK REF="STD-De-2014" TYPE="STUDY">De 2014</LINK>). We judged the risk of bias as unclear in <LINK REF="STD-Richardet-1993" TYPE="STUDY">Richardet 1993</LINK>. </P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2017-11-02 11:25:22 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>All trials but <LINK REF="STD-Richardet-1993" TYPE="STUDY">Richardet 1993</LINK> reported pre-defined outcomes in our review. We assessed the remaining 15 trials at low risk of reporting bias.</P>
<SUBSECTION>
<HEADING LEVEL="3">For-profit bias</HEADING>
<P>Based on the information that we collected from the published reports, we judged two trials to be at low risk of for-profit bias (<LINK REF="STD-Porter-1971" TYPE="STUDY">Porter 1971</LINK>; <LINK REF="STD-Thursz-2015" TYPE="STUDY">Thursz 2015</LINK>). We assessed the profit-bias as unclear in the remaining trials (<LINK REF="STD-Helman-1971" TYPE="STUDY">Helman 1971</LINK>; <LINK REF="STD-Campra-1973" TYPE="STUDY">Campra 1973</LINK>; <LINK REF="STD-Blitzer-1977" TYPE="STUDY">Blitzer 1977</LINK>; <LINK REF="STD-Mendenhall-1977" TYPE="STUDY">Mendenhall 1977</LINK>; <LINK REF="STD-Maddrey-1978" TYPE="STUDY">Maddrey 1978</LINK>; <LINK REF="STD-Shumaker-1978" TYPE="STUDY">Shumaker 1978</LINK>; <LINK REF="STD-Depew-1980" TYPE="STUDY">Depew 1980</LINK>; <LINK REF="STD-Theodossi-1982" TYPE="STUDY">Theodossi 1982</LINK>; <LINK REF="STD-Mendenhall-1984" TYPE="STUDY">Mendenhall 1984</LINK>; <LINK REF="STD-Bories-1987" TYPE="STUDY">Bories 1987</LINK>; <LINK REF="STD-Carithers-1989" TYPE="STUDY">Carithers 1989</LINK>; <LINK REF="STD-Ramond-1992" TYPE="STUDY">Ramond 1992</LINK>; <LINK REF="STD-Richardet-1993" TYPE="STUDY">Richardet 1993</LINK>; <LINK REF="STD-De-2014" TYPE="STUDY">De 2014</LINK>).</P>
</SUBSECTION>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2017-11-01 17:17:00 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We did not identify other biases for any of the included trials.</P>
<P>We judged all trials as high risk-of-bias trials. <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> show our assessment of risk of bias of the published trial reports (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2017-11-02 12:29:08 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">All-cause mortality</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Up to three months following randomisation</HEADING>
<P>In total, 258 of 927 (27.8%) participants in the group treated with glucocorticosteroids died versus 279 of 934 (29.9%) participants in the control group. There was no evidence of effect of glucocorticosteroids on all-cause mortality (random-effects RR 0.90, 95% CI 0.70 to 1.15; participants = 1861; trials = 15; I² = 45% (moderate heterogeneity; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). We observed a similar result with the Trial Sequential Analysis showing that the cumulative Z-curve did not cross the trial sequential monitoring boundaries for benefit or harm, nor enter the trial sequential monitoring area for futility in order to include an intervention effect of 20% risk ratio reduction (RRR) (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). The Trial Sequential analysis-adjusted CI was 0.36 to 2.32. We rated the quality of the evidence as very low (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>We constructed a funnel plot for publication bias, and using the <LINK REF="REF-Harbord-2006" TYPE="REFERENCE">Harbord 2006</LINK> test, we found no evidence of reporting bias (P = 0.31) (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="6">'Best-worst' case scenario analysis</HEADING>
<P>The 'best-worst' case scenario analysis on mortality up to three months after randomisation produced two different results. While there was no evidence of effect of glucocorticosteroids with the random-effects model (RR 0.82, 95% CI 0.64 to 1.05; I² = 47%), there was evidence of beneficial effect with the fixed-effect model (RR 0.74, 95% CI 0.65 to 0.84; participants = 1861; trials = 15; I² = 47%; <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). The heterogeneity in both analyses was moderate.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">'Worst-best' case scenario analysis</HEADING>
<P>The 'worst-best' case scenario analysis on mortality up to three months after randomisation produced two different results. While there was no evidence of effect of glucocorticosteroids with the random-effects model (RR 0.97, 95% CI 0.73 to 1.29; I² = 62%), there was evidence of harmful effect with the fixed-effect model (RR 1.21, 95% CI 1.06 to 1.37; I² = 62%); <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">At the end of treatment (post hoc analysis)</HEADING>
<P>The treatment lasted for a median of 28 days (range 3 days to 12 weeks). In total, 162 of 907 (17%) participants in the group treated with glucocorticosteroids died versus 202 of 917 (22%) participants in the control group. There was no evidence of effect of glucocorticosteroids on all-cause mortality (random-effects (RR 0.87, 95% CI 0.66 to 1.15; participants = 1824; trials = 14; I² = 42% (moderate heterogeneity); <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.1). We observed a similar result with the Trial Sequential Analysis showing that the cumulative Z-curve did not cross the trial sequential monitoring boundaries for benefit or harm, and did not enter the trial sequential monitoring area for futility in order to exclude an intervention effect of 20% RRR (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>). The Trial Sequential Analysis-adjusted CI was CI 0.29 to 2.68. We rated the quality of the evidence as very low (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>We constructed a funnel plot for publication bias, and using the <LINK REF="REF-Harbord-2006" TYPE="REFERENCE">Harbord 2006</LINK> test, we found no evidence of reporting bias (P = 0.84) (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">At one year following randomisation (post hoc analysis)</HEADING>
<P>Three of the included trials provided data on all-cause mortality one year following randomisation (<LINK REF="STD-Mendenhall-1984" TYPE="STUDY">Mendenhall 1984</LINK>; <LINK REF="STD-De-2014" TYPE="STUDY">De 2014</LINK>; <LINK REF="STD-Thursz-2015" TYPE="STUDY">Thursz 2015</LINK>). In total, 274 of 668 (41%) participants in the group treated with glucocorticosteroids died versus 265 of 664 (40%) participants in the control group. There was no evidence of effect of glucocorticosteroids on all-cause mortality (random-effects RR 1.03, 95% CI 0.91 to 1.17; participants = 1343; trials = 3; I² = 0% (no heterogeneity among the trials); <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.3). We observed a similar result with the Trial Sequential Analysis showing that the cumulative Z-curve entered the area of futility, which excludes an intervention effect of 20% RRR (<LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>). The Trial Sequential analysis-adjusted CI was CI 0.85 to 1.25. We rated the quality of the evidence as moderate (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Subgroup analysis and investigation of heterogeneity: all-cause mortality up to three months after randomisation</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Trials at low risk of bias compared to trials at high risk of bias</HEADING>
<P>As all the trials were at high risk of bias, we could not perform subgroup analysis on risk of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Trials with people with mild alcoholic hepatitis compared to trials with severe alcoholic hepatitis, following Maddrey's score lower than or equal to or higher than 32, or presence of hepatic encephalopathy; or as provided by the trialists</HEADING>
<P>There was no significant difference (P = 0.75) between the subgroups (mild alcoholic hepatitis RR 1.02, 95% CI 0.58 to 1.80; participants = 182; trials = 4; I² = 0%; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>.1) and severe alcoholic hepatitis (RR 0.92, 95% CI 0.73 to 1.16; participants = 1679; trials = 14; I² = 37%; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>.2).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Trials with glucocorticosteroid dose equal to or less than 40 mg compared to trials with glucocorticosteroid dose more than 40 mg</HEADING>
<P>There was no significant difference (P = 0.22) between the subgroups of the trials with glucocorticosteroid dose less than or equal to 40 mg (RR 0.75, 95% CI 0.50 to 1.14; participants = 1547; trials = 10; I² = 58%; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>.1) and trials with glucocorticosteroid dose more than 40 mg (RR 1.02, 95% CI 0.79 to 1.30; participants = 314; trials = 5; I² = 0%; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>.2).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Trials with people with severe alcoholic hepatitis without cirrhosis compared to trials with people with severe alcoholic hepatitis with cirrhosis</HEADING>
<P>There was no significant difference (P = 0.83) between the subgroups of the trials with severe alcoholic hepatitis without cirrhosis (RR 0.79, 95% CI 0.18 to 3.48; participants = 123; trials = 3; I² = 77%; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>.1) and trials with people with severe alcoholic hepatitis with cirrhosis (RR 0.92, 95% CI 0.74 to 1.16; participants = 1738; studies = 12; I<SUP>2</SUP> = 35%; ; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>.2).</P>
<P>As only two trials classified cirrhosis by Child-Pugh score (<LINK REF="STD-Bories-1987" TYPE="STUDY">Bories 1987</LINK>; <LINK REF="STD-De-2014" TYPE="STUDY">De 2014</LINK>) and we did not know what classification system the remaining trials had used, we could not perform a subgroup analysis in order to adjust for the clinical spectrum of the disease.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Trials with people with severe alcoholic hepatitis without hepatorenal syndrome compared to trials with people with severe alcoholic hepatitis with hepatorenal syndrome</HEADING>
<P>There was no significant difference (P = 0.64) between the subgroups of the trials with people with severe alcoholic hepatitis without hepatorenal syndrome (RR 1.00, 95% CI 0.85 to 1.17; participants = 1382; studies = 8; I<SUP>2</SUP> = 0%; <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>.1) compared to trials with people with severe alcoholic hepatitis with hepatorenal syndrome (RR 0.56, 95% CI 0.05 to 6.49; participants = 129; studies = 2; I<SUP>2</SUP> = 88%; <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>.2). The presence of hepatorenal syndrome was not clearly described in five trials (<LINK REF="STD-Blitzer-1977" TYPE="STUDY">Blitzer 1977</LINK>; <LINK REF="STD-Bories-1987" TYPE="STUDY">Bories 1987</LINK>; <LINK REF="STD-Mendenhall-1977" TYPE="STUDY">Mendenhall 1977</LINK>; <LINK REF="STD-Mendenhall-1984" TYPE="STUDY">Mendenhall 1984</LINK>; <LINK REF="STD-Ramond-1992" TYPE="STUDY">Ramond 1992</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Trials with people with severe alcoholic hepatitis without ascites compared to trials with people with severe alcoholic hepatitis with ascites</HEADING>
<P>As we did not have data on trials with participants not having ascites, we could analyse only the subgroup of trials including participants with ascites (RR 0.82, 95% CI 0.60 to 1.12; participants = 729; trials = 13; I² = 48%) (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>.1). In addition, the presence of ascites was not clearly described in two trials (<LINK REF="STD-Mendenhall-1977" TYPE="STUDY">Mendenhall 1977</LINK>; <LINK REF="STD-Thursz-2015" TYPE="STUDY">Thursz 2015</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Health-related quality of life</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Up to three months</HEADING>
<P>Only one trial reported on quality of life at follow-up period of up to three months, using responses to the European Quality of Life - 5 Dimensions-3 Levels (EQ-5D-3L) (<LINK REF="STD-Thursz-2015" TYPE="STUDY">Thursz 2015</LINK>). We applied the Student's t-test for the glucocorticosteroids versus the placebo group. We observed no difference between the two groups (MD -0.04 points; 95% CI -0.11 to 0.03; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). We rated the quality of the evidence as low (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). We did not perform Trial Sequential Analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Up to one year</HEADING>
<P>Only one trial reported on quality of life at follow-up period of up to one year, using responses to the European Quality of Life - 5 Dimensions-3 Levels (EQ-5D-3L) (<LINK REF="STD-Thursz-2015" TYPE="STUDY">Thursz 2015</LINK>). We applied the Student's t-test for the glucocorticosteroids versus the placebo group. We observed no difference between the two groups (MD 0.00 points; 95% CI -0.11 to 0.10; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). We rated the quality of the evidence as very low (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). We did not perform Trial Sequential Analysis.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Serious adverse events during treatment</HEADING>
<P>Fifteen trials reported number of participants with serious adverse events during treatment. In total, 361 of 927 (38%) participants in the group treated with glucocorticosteroids had serious adverse events during treatment versus 338 of 934 (36%) participants in the control group. There was no evidence of effect of glucocorticosteroids on the occurrence of serious adverse events (random-effects RR 1.05, 95% CI 0.85 to 1.29; participants = 1861; trials = 15; I² = 36% (moderate heterogeneity); <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). We observed a similar result with the Trial Sequential Analysis showing that the cumulative Z-curve entered the area of futility which excludes an intervention effect of 20% RRR (<LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>). The Trial Sequential analysis-adjusted CI was 0.60 to 1.82. We rated the quality of the evidence as low (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>
<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> shows the number of participants with the most often occurring serious adverse events in 14 included trials; mortality is not included. <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> presents the most often occurring serious adverse events in <LINK REF="STD-Thursz-2015" TYPE="STUDY">Thursz 2015</LINK> because this trial did not specify the individual number of participants with a serious adverse event.</P>
<P>We constructed a funnel plot for publication bias, and using the <LINK REF="REF-Harbord-2006" TYPE="REFERENCE">Harbord 2006</LINK> test, we found no evidence of reporting bias (P = 0.63).</P>
<SUBSECTION>
<HEADING LEVEL="6">'Best-worst' case scenario analysis</HEADING>
<P>There was no evidence of effect of glucocorticosteroids on serious adverse events during treatment, with neither of the models (random-effects model (RR 1.00, 95% CI 0.83 to 1.21; participants = 1861; studies = 15; I<SUP>2</SUP> = 28%) (not important heterogeneity) and fixed-effect model RR 0.99, 95% CI 0.89 to 1.11; participants = 1861; I² = 28% (not important heterogeneity); <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">'Worst-best' case scenario analysis</HEADING>
<P>While there was evidence of harmful effect of glucocorticosteroids with the fixed-effect model (RR 1.18, 95% CI 1.05 to 1.31; participants = 1861; I² = 38%), there was no evidence of effect of glucocorticosteroids with the random-effects model (RR 1.11, 95% CI 0.91 to 1.36; I² = 38%; <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Liver-related mortality up to three months following randomisation</HEADING>
<P>In total, 257 of 927 (27.7%) participants in the group treated with glucocorticosteroids died versus 279 of 934 (29.9%) participants in the control group.</P>
<P>There was no evidence of effect of glucocorticosteroids on liver-related mortality (random-effects RR 0.89, 95% CI 0.69 to 1.14; participants = 1861; trials = 15; I² = 46% (moderate heterogeneity); <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). The heterogeneity among the trials was moderate. We observed a similar result with the Trial Sequential Analysis showing that the cumulative Z-curve did not cross the trial sequential monitoring boundaries for benefit or harm, nor enter the trial sequential monitoring area for futility in order to include an intervention effect of 20% RRR (<LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>). The Trial Sequential analysis-adjusted CI was 0.32 to 2.45. We rated the quality of the evidence as low (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Number of participants with any complication up to three months' follow-up after randomisation</HEADING>
<P>In total, 440 of 927 (47%) participants in the group treated with glucocorticosteroids had one or more complications versus 414 of 934 (44%) participants in the control group. There was no evidence of effect of glucocorticosteroids on frequency of any complications (random-effects RR 1.04, 95% CI 0.86 to 1.27; participants = 1861; I² = 42% (moderate heterogeneity); <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). We observed a similar result with the Trial Sequential Analysis showing that the cumulative Z-curve did not cross the trial sequential monitoring boundaries for benefit or harm, nor enter the trial sequential monitoring area for futility in order to include an intervention effect of 20% RRR (<LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK>). The Trial Sequential analysis-adjusted CI was 0.67 to 1.63. We rated the quality of the evidence as very low, mainly due to within-study bias, inconsistency, and imprecision (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Number of people with non-serious adverse events up to three months following randomisation</HEADING>
<P>Only four trials reported non-serious adverse events such as Cushingoid symptoms, vertigo, and fungal lesions. There was no evidence of effect of glucocorticosteroids on frequency of non-serious adverse events (random-effects RR 1.99, 95% CI 0.72 to 5.48; participants = 160; trials = 4; I² = 0% (no heterogeneity); <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). We observed a similar result with the Trial Sequential Analysis showing that the cumulative Z-curve did not cross the trial sequential monitoring boundaries for benefit or harm, nor enter the trial sequential monitoring area for futility in order to include an intervention effect of 50% RRR (<LINK REF="FIG-11" TYPE="FIGURE">Figure 11</LINK>). The Trial Sequential Analysis-adjusted CI was 0.01 to 249.60. We rated the quality of the evidence as very low (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Exploratory outcomes at the end of treatment</HEADING>
<P>No trial reported on number of participants with change of level of liver enzymes, prothrombin index, or serum albumin at the end of treatment. This is why we could not perform the planned exploratory analyses. Instead, post hoc, we decided to present in a tabular way the extracted information on level of liver enzymes reported in the trials by <LINK REF="STD-Campra-1973" TYPE="STUDY">Campra 1973</LINK>; <LINK REF="STD-Maddrey-1978" TYPE="STUDY">Maddrey 1978</LINK>; <LINK REF="STD-Theodossi-1982" TYPE="STUDY">Theodossi 1982</LINK>; and <LINK REF="STD-Carithers-1989" TYPE="STUDY">Carithers 1989</LINK> (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>); prothrombin index or international normalised ratio reported in the trials by <LINK REF="STD-Campra-1973" TYPE="STUDY">Campra 1973</LINK>; <LINK REF="STD-Maddrey-1978" TYPE="STUDY">Maddrey 1978</LINK>; <LINK REF="STD-Theodossi-1982" TYPE="STUDY">Theodossi 1982</LINK>; <LINK REF="STD-Carithers-1989" TYPE="STUDY">Carithers 1989</LINK>; <LINK REF="STD-Ramond-1992" TYPE="STUDY">Ramond 1992</LINK> (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>); and level of serum albumin (and bilirubin - post hoc again) reported in the trials by <LINK REF="STD-Campra-1973" TYPE="STUDY">Campra 1973</LINK>; <LINK REF="STD-Maddrey-1978" TYPE="STUDY">Maddrey 1978</LINK>; <LINK REF="STD-Depew-1980" TYPE="STUDY">Depew 1980</LINK>; <LINK REF="STD-Theodossi-1982" TYPE="STUDY">Theodossi 1982</LINK>; <LINK REF="STD-Carithers-1989" TYPE="STUDY">Carithers 1989</LINK>; and <LINK REF="STD-Ramond-1992" TYPE="STUDY">Ramond 1992</LINK> ( <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>; <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">'Summary of findings' table</HEADING>
<P>We have presented the key results on the outcomes mortality, health-related quality of life, serious adverse events, liver-related mortality, all complications, and non-serious adverse events in <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>. We assessed the evidence as being very low to low.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2017-11-02 11:25:22 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<SUMMARY_OF_RESULTS MODIFIED="2017-11-01 14:38:14 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We included 16 randomised clinical trials comparing glucocorticosteroids versus placebo or no intervention in people with alcoholic hepatitis. Fifteen of the trials provided data for analyses. Our traditional meta-analyses showed no beneficial or detrimental effects of glucocorticosteroids on any of our outcomes. In general, serious and non-serious adverse events as well as complications were poorly reported or the information was unclear, and hence, these analyses may be subject to outcome reporting bias (<LINK REF="REF-Ioannidis-2009" TYPE="REFERENCE">Ioannidis 2009</LINK>). Trial Sequential Analyses showed similar results. Based on methodological concerns, we classified the strength of the evidence as very low to moderate. As the trials were at high risk of bias, it is more likely that we are overestimating benefits and overlooking harms.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2017-11-02 11:25:22 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial participants varied according to severity of alcoholic hepatitis and the trials were published between 1971 and 2014. However, only 1861 participants were included. During this time period, glucocorticosteroid interventions varied regarding dose and duration. The small number of trials and trial participants, except for the <LINK REF="STD-Thursz-2015" TYPE="STUDY">Thursz 2015</LINK> trial, the poor trial design and reporting, make the results of our review inconclusive. The high risk of bias of the trials undermines the precision of our meta-analyses results.</P>
<P>We were not able to assess if ethnicity had any influence on our results, as data were either lacking or insufficient. The same applied for the nutritional status of the participants, as only one trial reported on it (<LINK REF="STD-Mendenhall-1984" TYPE="STUDY">Mendenhall 1984</LINK>). Mathurin and coworkers have proposed that people with alcoholic hepatitis with Madderey's score of at least 32 should likely benefit from glucocorticosteroids (<LINK REF="REF-Mathurin-2011" TYPE="REFERENCE">Mathurin 2011</LINK>). However, we did not find a significant effect of glucocorticosteroids in this subgroup of trial participants.</P>
<P>This review is applicable in people with alcoholic hepatitis at different stages of the disease. Our meta-analyses and Trial Sequential Analyses seem to provide no evidence of benefit of glucocorticosteroids on all-cause mortality at one-year follow-up after randomisation. It is also unlikely that glucocorticosteroids may have a beneficial effect on mortality at end of treatment and three months following randomisation; however, due to mainly imprecision (the confidence interval crossed the clinical decision threshold between recommending and not recommending treatment and the required number of participants is far from reached), we cannot exclude the possibility of a short-term beneficial or harmful effect. We cannot say if glucocorticosteroids may influence infection and gastrointestinal bleeding as we had no data for meta-analysis. However, <LINK REF="STD-Thursz-2015" TYPE="STUDY">Thursz 2015</LINK> and colleagues' analysis shows an increase in the number of these complications in treated participants.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2017-11-01 14:38:26 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>The quality of the evidence reflects only the quality of the included trials so we cannot be certain of our conclusions. We judged the overall quality of evidence as very low to low for all outcomes except for all-cause mortality at one year after randomisation, for which the quality of the evidence was moderate. All trials were at high risk of bias, mainly because the randomisation procedures were insufficiently reported. In addition to downgrading the trials for within-study risk of bias, we also downgraded the trials for imprecision of effect estimates due to the number of participants included in the trials (all but one of the 14 trials had fewer than 400 participants), and for inconsistency of our results (there was wide variation in the effect estimates across the trials; there was little overlap of confidence intervals associated with the effect estimates; and we assessed heterogeneity of the data as moderate with I² of 36% to 46%, which could be explained with selection bias). We also found some evidence of publication bias or small study bias.</P>
<P>In spite of the quality of the evidence being mostly low to very low, we are pretty confident in our recommendations regarding implications for practice and for research. This ensues from our analysis results and is based on the knowledge that trials at high risk of bias overestimate benefits and underestimate harms. Therefore, we do not find supporting evidence for using glucocorticosteroids in clinical practice. There is definitely a need for more transparent reporting of individual participant data (<LINK REF="REF-NTAWG-2015" TYPE="REFERENCE">NTAWG 2015</LINK>; <LINK REF="REF-Garattini-2016" TYPE="REFERENCE">Garattini 2016</LINK>).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2017-11-01 14:38:34 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>The strengths of our review are that we have conducted our review following the recommendations of Cochrane Hepato-Biliary and the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>; <LINK REF="REF-Gluud-2017" TYPE="REFERENCE">Gluud 2017</LINK>). We included only randomised clinical trials in our review. This creates a bias towards benefits as short-term randomised trials often overlook harms. We attempted to minimise possible selection biases by using a comprehensive search strategy. We combined searches in electronic databases with extensive manual searches. In addition, we also searched conference proceedings and abstract books, irrespective of language. We think it is unlikely that we have missed any published trials, but we cannot exclude the possibility that we have missed unpublished trials. In fact, visual inspection of the funnel plots suggests publication bias or small trial bias on the outcomes, mortality at end of treatment and following three months after randomisation (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). We wrote to pharmaceutical companies as well as to regulatory authorities. We made extensive attempts to avoid risk of system and random errors. We assessed the evidence with GRADE approach.</P>
<P>Limitations of our review were the small number of trials and the small total number of participants. Having in mind that hepatitis C viral disease was discovered as late as 1989, we might have run the risk that the included trials initiated before 1989 did not include participants with only alcoholic hepatitis (<LINK REF="REF-Houghton-2009" TYPE="REFERENCE">Houghton 2009</LINK>). Furthermore, our results are hampered by the quality of the included trials as well as imprecision and severe inconsistency. Even though all trials provided data on mortality, data on other serious adverse events and complications were rarely reported, which calls into question the reliability of the two latter analyses. Moreover, by including primarily randomised clinical trials we have focused on potential beneficial effects and overlooked the many known harms connected with the administration of glucocorticosteroids. Again, these flaws in our review make us suspect that benefits are overestimated and harms are underestimated.</P>
<P>When conducting our Trial Sequential Analyses, we used plausible parameters to calculate our required information sizes. However, we only used 80% power (beta = 20%). Had we used 90% power (beta = 10%) or less, which is relevant in meta-analyses where one does not want to discharge a potentially relevant intervention, then we would have obtained larger required information sizes and wider Trial Sequential Analyses-adjusted Confidence Intervals (<LINK REF="REF-Garattini-2016" TYPE="REFERENCE">Garattini 2016</LINK>; <LINK REF="REF-Castellini-2017" TYPE="REFERENCE">Castellini 2017</LINK>). Accordingly, the imprecision may be worse than signalled by our analyses.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2017-11-01 18:19:47 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>The meta-analysis by <LINK REF="REF-Christensen-1995" TYPE="REFERENCE">Christensen 1995</LINK> and colleagues found no effect of glucocorticosteroids versus placebo on mortality. This review included data from 13 trials with 659 participants randomised. <LINK REF="REF-Rambaldi-2008" TYPE="REFERENCE">Rambaldi 2008</LINK> and colleagues updated the meta-analysis by <LINK REF="REF-Christensen-1995" TYPE="REFERENCE">Christensen 1995</LINK>, adding two more trials with 62 participants randomised. Hence, <LINK REF="REF-Rambaldi-2008" TYPE="REFERENCE">Rambaldi 2008</LINK> and colleagues concluded that depending on the estimation of the information size, their review lacked another 1000 to 2000 participants randomised to glucocorticosteroids versus placebo in order to be able to either demonstrate or reject a clinically relevant 20% mortality reduction.</P>
<P>We found two new trials for inclusion in our review (<LINK REF="STD-De-2014" TYPE="STUDY">De 2014</LINK>; <LINK REF="STD-Thursz-2015" TYPE="STUDY">Thursz 2015</LINK>). However, we excluded two of the trials from the Rambaldi and colleagues review (<LINK REF="REF-Rambaldi-2008" TYPE="REFERENCE">Rambaldi 2008</LINK>) as they assessed glucocorticosteroids versus nutrition (<LINK REF="STD-Lesesne-1978" TYPE="STUDY">Lesesne 1978</LINK>; <LINK REF="STD-Cabr_x00e9_-2000" TYPE="STUDY">Cabré 2000</LINK>). In addition, two trial reports turned out to be the same trial (<LINK REF="STD-Shumaker-1978" TYPE="STUDY">Shumaker 1978</LINK>; <LINK REF="STD-Galambos-1984" TYPE="STUDY">Galambos 1984</LINK>), and thus, we counted them as one trial.</P>
<P>Our systematic review of pair-wise comparison randomised clinical trials is in agreement with the recent meta-analysis by <LINK REF="REF-Buzzetti-2017" TYPE="REFERENCE">Buzzetti 2017</LINK>. In this network meta-analysis, the authors found no significant effects of glucocorticosteroids on mortality at maximal follow-up and up to 90 days of follow-up.</P>
<P>Due to the inclusion of the two new trials, our review now includes 1861 participants. The <LINK REF="STD-Thursz-2015" TYPE="STUDY">Thursz 2015</LINK> trial included 1103 participants and found "a reduction in the 28-day mortality in the prednisolone-treated group on logistic regression model analysis, but there was not clear evidence of benefit, sustained beyond this point". <LINK REF="REF-Mathurin-2011" TYPE="REFERENCE">Mathurin 2011</LINK> performed "analysis of individual data from five randomised clinical trials which showed that corticosteroids significantly improved 28-day survival in patients with severe alcoholic hepatitis". In our present aggregate meta-analysis, we cannot see an effect of glucocorticosteroids on mortality at 'end of treatment', which is quite close to 28 days.</P>
<P>Modern clinical guidelines recommend prescribing glucocorticosteroids: "Patients with severe disease (Maddrey's Discriminant Function (MDF) score of <U>&gt;</U> 32, with or without hepatic encephalopathy) and lacking contraindications to steroid use should be considered for a four-week course of prednisolone (40 mg/day for 28 days, typically followed by discontinuation or a 2-week taper) (Class I, level A)" (<LINK REF="REF-AASLD-2010" TYPE="REFERENCE">AASLD 2010</LINK>); and "First-line therapy in patients with severe alcoholic hepatitis includes corticosteroids or, in case of ongoing sepsis, pentoxifylline (Recommendation B1) (see original publication for Figure 2)" (<LINK REF="REF-EASL-2012" TYPE="REFERENCE">EASL 2012</LINK>). In our present aggregate meta-analysis, we cannot find a beneficial effect of glucocorticosteroids in people with severe alcoholic hepatitis.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2017-11-02 15:31:59 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<IMPLICATIONS_PRACTICE MODIFIED="2017-11-01 18:11:16 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We found no evidence of a difference between glucocorticosteroids and placebo or no intervention on all-cause mortality, health-related quality of life, and serious adverse events during treatment. The risk of bias was high and the quality of evidence was very low or low. Therefore, we are very uncertain about this effect estimate. Due to inadequate reporting, we cannot exclude increases in adverse events. As the confidence intervals were wide, we cannot rule out significant benefits and harms of glucocorticosteroids.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2017-11-02 15:31:59 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>As there could be some people with alcoholic hepatitis who could benefit from glucocorticosteroids, it could be of use for researchers to study further the effects of glucocorticosteroids in randomised clinical trials on short-term all-cause mortality. Additional evidence evaluating the effect on health-related quality of life may also be needed. Future trials ought to be designed according to the SPIRIT guidelines (<A HREF="http://www.spirit-statement.org/">http://www.spirit-statement.org/</A>) and reported according to the CONSORT guidelines (<A HREF="http://www.consort-statement.org">www.consort-statement.org</A>). Future trials ought to report individual participant data, so that proper individual participant data meta-analyses of the effects of glucocorticosteroids in subgroups can be conducted (<LINK REF="REF-NTAWG-2015" TYPE="REFERENCE">NTAWG 2015</LINK>; <LINK REF="REF-Garattini-2016" TYPE="REFERENCE">Garattini 2016</LINK>).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2017-11-01 14:40:35 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Cochrane Review Group funding acknowledgement: the Danish State is the largest single funder of Cochrane Hepato-Biliary through its investment in the Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark. Disclaimer: The views and opinions expressed in this review are those of the authors and do not necessarily reflect those of the Danish State or the Copenhagen Trial Unit.</P>
<P>Peer reviewers: Kurinchi S Gurusamy, UK; Michael Ronan Lucey, USA.<BR/>Contact editor: Dario Conte, Italy.<BR/>Sign-off editor: Mirella Fraquelli, Italy.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2017-11-01 14:40:42 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>CP: no financial, academic, or personal conflicts of interest.<BR/>DV: no financial, academic, or personal conflicts of interest.<BR/>GC: no financial, academic, or personal conflicts of interest.<BR/>ET: no financial, academic, or personal conflicts of interest.<BR/>DN: no financial, academic, or personal conflicts of interest.<BR/>CG: no financial, academic, or personal conflicts of interest.<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2017-11-02 12:34:56 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>CP, DV, and GC: drafted the review.<BR/>DN, ET, and CG: revised the review.<BR/>CP and DV are the guarantors of the review.<BR/>All authors approved the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2017-11-01 14:40:50 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>Review author team changed.</LI>
<LI>We removed the word 'alcohol' from the outcome "Alcohol liver-related mortality up to three months follow-up after end of treatment" as it was superfluous.</LI>
<LI>Outcomes</LI>
<UL>
<LI>All-cause mortality is now better defined. Duration of treatment varied across the trials and also mortality data for up to three-months' follow-up. This is why we have modified all-cause mortality to all-cause mortality at the end of treatment, up to three months' follow-up after randomisation, and one year following randomisation. Thus, our primary time point has become "all-cause mortality up to three months' follow-up after randomisation".</LI>
</UL>
<UL>
<LI>Trials also reported data on liver-related mortality, any complication, and non-serious adverse events up to three months' follow-up after randomisation. Thus, three months' follow-up after randomisation has also become our primary time point for the latter outcomes. However, serious adverse events were reported mostly during the treatment period.</LI>
<LI>Regarding exploratory outcomes, we created tables, as we did not have sufficient data for analysis.</LI>
</UL>
<LI>As we did not have trials with low risk of bias, we calculated the diversity-adjusted required information size (DARIS) for our Trial Sequential Analysis using data from all included trials.</LI>
<LI>We calculated and reported the Trial Sequential Analysis-adjusted CI as a supplement to the naive 95% CI.</LI>
<LI>We changed the risk of type I error from 2.5% (as originally planned based on the three primary outcomes) into type I error of 1%, as we performed Trial Sequential Analysis on all primary and secondary outcomes.</LI>
</UL>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2015-06-25 15:21:51 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Cochrane Reviews can be expected to have a high percentage of overlap in the methods section because of standardised methods. In addition, overlap may be observed across two of our protocols as they share at least four common authors.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-11-02 15:06:56 +0000" MODIFIED_BY="Dimitrinka Nikolova">
<STUDIES MODIFIED="2017-11-02 14:38:45 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<INCLUDED_STUDIES MODIFIED="2017-11-02 11:25:21 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<STUDY DATA_SOURCE="PUB" ID="STD-Blitzer-1977" MODIFIED="2017-06-21 14:39:46 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Blitzer 1977" YEAR="1977">
<REFERENCE MODIFIED="2017-03-01 15:24:50 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Blitzer BL, Mutchnick MG, Joshi PH, Phillips MM, Fessel JM, Conn HO</AU>
<TI>Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double-blind randomized study</TI>
<SO>Digestive Diseases</SO>
<YR>1977</YR>
<VL>22</VL>
<NO>6</NO>
<PG>477-84</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009495"/><IDENTIFIER TYPE="MEDLINE" VALUE="77199192"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-06-21 14:39:46 +0200" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blitzer BL, Mutchnick MG, Joshi PH, Phillips MM, Fessel JM, Conn HO</AU>
<TI>Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double-blind randomized study</TI>
<SO>Gastroenterology</SO>
<YR>1973</YR>
<VL>64</VL>
<PG>880</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009496"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009494"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bories-1987" MODIFIED="2016-02-11 09:58:48 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Bories 1987" YEAR="1987">
<REFERENCE MODIFIED="2016-02-11 09:55:33 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bories P, Guedj JY, Mirouze D, Yousfi A, Michel H</AU>
<TI>Prednisolone treatment of alcoholic hepatitis: forty-five patients</TI>
<TO>Traitement de l'hepatite alcoolique aigue par la prednisolone. Quarante-cinq malades</TO>
<SO>La Presse Medicale</SO>
<YR>1987</YR>
<VL>16</VL>
<PG>769-72</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009498"/><IDENTIFIER TYPE="MEDLINE" VALUE="87231696"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009497"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Campra-1973" MODIFIED="2016-02-11 09:59:09 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Campra 1973" YEAR="1973">
<REFERENCE MODIFIED="2016-02-11 09:55:33 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Campra JL, Hamlin EM Jr, Kirshbaum RJ, Olivier M, Redeker AG, Reynolds TB</AU>
<TI>Prednisone therapy of acute alcoholic hepatitis. Report of a controlled trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1973</YR>
<VL>79</VL>
<NO>5</NO>
<PG>625-31</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009500"/><IDENTIFIER TYPE="MEDLINE" VALUE="74028322"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009499"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carithers-1989" MODIFIED="2017-11-01 14:53:46 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Carithers 1989" YEAR="1989">
<REFERENCE MODIFIED="2016-02-11 09:55:33 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Carithers RL Jr, Herlong HF, Diehl AM, Shaw EW, Combes B, Fallon HJ, et al</AU>
<TI>Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1989</YR>
<VL>110</VL>
<PG>685-90</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009502"/><IDENTIFIER TYPE="MEDLINE" VALUE="89191875"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-11 10:01:54 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carithers RLJ, Herlong HF, Diehl AM, Shaw EW, Combes B, Fallon HJ, et al</AU>
<TI>Corticosteroid therapy of alcoholic hepatitis: how many studies will it take?</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>1990</YR>
<VL>12</VL>
<NO>3</NO>
<PG>619-20</PG>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="844269"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="6800100000024896"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009503"/><IDENTIFIER TYPE="OTHER" VALUE="CN-00844269"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-11-01 14:53:46 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="OTHER">
<TI>Erratum: Methylprednisolone therapy in patients with severe alcoholic hepatitis: Randomized multicenter trial (American Journal of Gastroenterology, Vol. 85, No. 4 (473))</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1990</YR>
<VL>85</VL>
<NO>6</NO>
<PG>776</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="6800131000045704"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009504"/><IDENTIFIER TYPE="EMBASE" VALUE="1990185566"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-06-21 14:40:52 +0200" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maddrey WC, Carithers R Jr, Herlong HF, Combes B, Diehl AM, Shaw E, et al</AU>
<TI>Prednisolone therapy in patients with severe alcoholic hepatitis: results of a multicenter trial</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>1986</YR>
<VL>6</VL>
<NO>5</NO>
<PG>1202</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009505"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009501"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-2014" MODIFIED="2016-02-10 20:43:25 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="De 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-02-10 20:43:25 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De BK, Mandal SK, Sau D, Mani S, Chatterjee S, Mondal SS, et al</AU>
<TI>Pentoxifylline plus prednisolone versus pentoxifylline only for severe alcoholic hepatitis: a randomised controlled clinical trial</TI>
<SO>Annals of Medical and Health Sciences Research</SO>
<YR>2014</YR>
<VL>4</VL>
<NO>5</NO>
<PG>810-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009507"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009506"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Depew-1980" MODIFIED="2017-06-21 14:41:47 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Depew 1980" YEAR="1980">
<REFERENCE MODIFIED="2017-03-01 15:25:31 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Depew W, Boyer T, Omata M, Redeker A, Reynolds T</AU>
<TI>Double-blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy</TI>
<SO>Gastroenterology</SO>
<YR>1980</YR>
<VL>78</VL>
<NO>3</NO>
<PG>524-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009509"/><IDENTIFIER TYPE="MEDLINE" VALUE="80092633"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-06-21 14:41:47 +0200" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Depew WT, Boyer TD, Omata M, Redeker AG, Reynolds TB</AU>
<TI>Double-blind controlled trial of corticosteroid-therapy in severe alcoholic hepatitis with encephalopathy</TI>
<SO>Clinical Research</SO>
<YR>1978</YR>
<VL>26</VL>
<NO>2</NO>
<PG>A150</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="6800131000045795"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009510"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009508"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Helman-1971" MODIFIED="2016-02-11 09:55:33 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Helman 1971" YEAR="1971">
<REFERENCE MODIFIED="2016-02-11 09:55:33 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Helman RA, Temko MH, Nye SW, Fallon HJ</AU>
<TI>Alcoholic hepatitis. Natural history and evaluation of prednisolone therapy</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1971</YR>
<VL>74</VL>
<NO>3</NO>
<PG>311-21</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009512"/><IDENTIFIER TYPE="MEDLINE" VALUE="71158944"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009511"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maddrey-1978" MODIFIED="2017-06-21 14:42:14 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Maddrey 1978" YEAR="1978">
<REFERENCE MODIFIED="2016-09-25 16:25:46 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr, Mezey E, White RI Jr</AU>
<TI>Corticosteroid therapy of alcoholic hepatitis</TI>
<SO>Gastroenterology</SO>
<YR>1978</YR>
<VL>75</VL>
<NO>2</NO>
<PG>193-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009514"/><IDENTIFIER TYPE="MEDLINE" VALUE="78215698"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-06-21 14:42:14 +0200" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maddrey WC, Boitnott JK, Bedine MS</AU>
<TI>Corticosteroid treatment of alcoholic liver disease: a controlled trial</TI>
<SO>Gastroenterology</SO>
<YR>1977</YR>
<VL>72</VL>
<NO>5 II</NO>
<PG>A-148</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="6800131000045726"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009515"/><IDENTIFIER TYPE="EMBASE" VALUE="0978117751"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009513"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mendenhall-1977" MODIFIED="2016-09-25 16:50:36 +0200" MODIFIED_BY="[Empty name]" NAME="Mendenhall 1977" YEAR="1977">
<REFERENCE MODIFIED="2016-02-11 10:43:36 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mendenhall CL, Goldberg S</AU>
<TI>Risk factors and therapy in alcoholic hepatitis (AH)</TI>
<SO>Gastroenterology</SO>
<YR>1977</YR>
<VL>72</VL>
<NO>5</NO>
<PG>1100</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009517"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009516"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mendenhall-1984" MODIFIED="2017-11-02 11:25:21 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Mendenhall 1984" YEAR="1984">
<REFERENCE MODIFIED="2017-11-01 14:53:56 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mendenhall C; The Cooperative Study on Alcoholic Hepatitis</AU>
<TI>Survival after steroid treatment (T) for alcoholic hepatitis (AH)</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>1983</YR>
<VL>3</VL>
<NO>5</NO>
<PG>850</PG>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="221691"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="6800100000005197"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009519"/><IDENTIFIER TYPE="OTHER" VALUE="CN-00221691"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-06-21 14:44:17 +0200" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mendenhall CL, Anderson S, Garcia-Pont P, Goldberg S, Kiernan T, Seeff LB, et al</AU>
<TI>Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone</TI>
<SO>New England Journal of Medicine</SO>
<YR>1984</YR>
<VL>311</VL>
<NO>23</NO>
<PG>1464-70</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009520"/><IDENTIFIER TYPE="MEDLINE" VALUE="85061344"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-11 09:55:33 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mendenhall CL, Roselle GA, Gartside P, Moritz T</AU>
<TI>Relationship of protein calorie malnutrition to alcoholic liver disease: a reexamination of data from two Veterans Administration Cooperative Studies</TI>
<SO>Alcoholism, Clinical and Experimental Research</SO>
<YR>1995</YR>
<VL>19</VL>
<NO>3</NO>
<PG>635-41</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009521"/><IDENTIFIER TYPE="MEDLINE" VALUE="96028371"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009518"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Porter-1971" MODIFIED="2017-06-21 14:44:33 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Porter 1971" YEAR="1971">
<REFERENCE MODIFIED="2017-06-21 14:44:33 +0200" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Porter HP, Simon FR, Pope CE II, Volwiler W, Fenster LF</AU>
<TI>Corticosteroid therapy in severe alcoholic hepatitis. A double-blind drug trial</TI>
<SO>New England Journal of Medicine</SO>
<YR>1971</YR>
<VL>284</VL>
<NO>24</NO>
<PG>1350-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009523"/><IDENTIFIER TYPE="MEDLINE" VALUE="71190888"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009522"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ramond-1992" MODIFIED="2017-11-01 14:54:31 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Ramond 1992" YEAR="1992">
<REFERENCE MODIFIED="2017-06-21 14:44:52 +0200" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mathurin P, Duchatelle V, Ramond MJ, Degott C, Bedossa P, Erlinger S, et al</AU>
<TI>Long term survival and prognostic factors in patients with severe biopsy-proved alcoholic hepatitis (AH) treated by prednisolone: randomized trial, new cohort and simulation</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>1994</YR>
<VL>20</VL>
<NO>4</NO>
<PG>319A</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009525"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-11 09:55:33 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mathurin P, Duchatelle V, Ramond MJ, Degott C, Bedossa P, Erlinger S, et al</AU>
<TI>Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone</TI>
<SO>Gastroenterology</SO>
<YR>1996</YR>
<VL>110</VL>
<NO>6</NO>
<PG>1847-53</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009526"/><IDENTIFIER TYPE="MEDLINE" VALUE="96239692"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-06-21 14:45:14 +0200" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ramond M-J, Poynard T, Rueff B, Carey WD</AU>
<TI>Steroids in alcoholic hepatitis: another salvo of data</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1992</YR>
<VL>87</VL>
<NO>9</NO>
<PG>1219-20</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="6800131000045543"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009527"/><IDENTIFIER TYPE="EMBASE" VALUE="1992277170"/><IDENTIFIER TYPE="OTHER" VALUE="CN-00196579"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-06-21 14:45:20 +0200" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ramond MJ, Poynard T, Rueff B, Horwitz RJ</AU>
<TI>Prednisolone for severe alcoholic hepatitis</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1992</YR>
<VL>117</VL>
<NO>Suppl 2</NO>
<PG>36</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="6800131000045702"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009528"/><IDENTIFIER TYPE="EMBASE" VALUE="1992360747"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-06-21 14:45:28 +0200" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ramond MJ, Poynard T, Rueff B, Mathurin P, Theodore C, Chaput JC, et al</AU>
<TI>A randomized trial of prednisolone in patients with severe alcoholic hepatitis</TI>
<SO>New England Journal of Medicine</SO>
<YR>1992</YR>
<VL>326</VL>
<NO>8</NO>
<PG>507-12</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009529"/><IDENTIFIER TYPE="MEDLINE" VALUE="92123307"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-11-01 14:54:31 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ramond MJ, Poynard T, Rueff B, Theodore C, Matthurin P, Chaput JC, et al</AU>
<TI>Prednisolone markedly improves short-term survival of patients with severe biopsy-proven alcoholic hepatitis A double blind randomized bicenter trial</TI>
<SO>Journal of Hepatology</SO>
<YR>1991</YR>
<VL>13</VL>
<NO>Suppl 2</NO>
<PG>S63</PG>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="222028"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="6800100000005449"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009530"/><IDENTIFIER TYPE="OTHER" VALUE="CN-00222028"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009524"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Richardet-1993" MODIFIED="2017-06-21 14:45:49 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Richardet 1993" YEAR="1993">
<REFERENCE MODIFIED="2017-06-21 14:45:49 +0200" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mal F, Pham Huu T, Richardet JP, Roulot D, Labadie H, Pol S, et al</AU>
<TI>Corticosteroids (Cs) does not influence plasma tumor necrosis factor-alpha (pTNF) and interleukin 6 (pIL6) concentrations in severe alcoholic hepatitis (AH): a cross over study</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>1992</YR>
<VL>16</VL>
<PG>234A</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009532"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-11 09:55:33 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Richardet JP, Dehoux M, Mal F, Roulot D, Labadie H, Pol S, et al</AU>
<TI>Influence of corticosteroids (CS) on plasma cytokines concentrations in patients with severe alcoholic hepatitis (HA): results of a randomized study</TI>
<SO>Journal of Hepatology</SO>
<YR>1993</YR>
<VL>18</VL>
<PG>S75</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009533"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009531"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shumaker-1978" MODIFIED="2017-06-21 14:46:13 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Shumaker 1978" YEAR="1978">
<REFERENCE MODIFIED="2016-10-02 09:17:37 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Conn HO</AU>
<TI>Steroid treatment of alcoholic hepatitis. The yeas and the nays</TI>
<SO>Gastroenterology</SO>
<YR>1978</YR>
<VL>74</VL>
<NO>2 (Pt 1)</NO>
<PG>319-22</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009535"/><IDENTIFIER TYPE="PUBMED" VALUE="620902"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-06-21 14:46:06 +0200" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galambos JT</AU>
<TI>Alcoholic liver disease, new aspects of an old problem</TI>
<SO>Schweizerische Medizinische Wochenschrift. Journal Suisse de Medecine</SO>
<YR>1978</YR>
<VL>108</VL>
<NO>28</NO>
<PG>1050-2</PG>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="221034"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="6800100000004689"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009536"/><IDENTIFIER TYPE="EMBASE" VALUE="0978366839"/><IDENTIFIER OTHERTYPE="JC--NLM" TYPE="OTHER" VALUE="Journal ID:uei, 0404401"/><IDENTIFIER TYPE="PUBMED" VALUE="78228296"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-06-21 14:46:13 +0200" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shumaker JB, Resnick RH, Galambos JT, Makopour H, Iber FL</AU>
<TI>A controlled trial of 6-methylprednisolone in acute alcoholic hepatitis. With a note on published results in encephalopathic patients</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1978</YR>
<VL>69</VL>
<NO>4</NO>
<PG>443-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009537"/><IDENTIFIER TYPE="MEDLINE" VALUE="78254157"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009534"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Theodossi-1982" MODIFIED="2016-02-11 10:46:56 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Theodossi 1982" YEAR="1982">
<REFERENCE MODIFIED="2016-02-11 10:46:22 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Theodossi A, Eddleston AL, Williams R</AU>
<TI>Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis</TI>
<SO>Gut</SO>
<YR>1982</YR>
<VL>23</VL>
<NO>1</NO>
<PG>75-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009539"/><IDENTIFIER TYPE="MEDLINE" VALUE="82118195"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009538"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thursz-2015" MODIFIED="2017-11-01 14:54:51 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Thursz 2015" YEAR="2013">
<REFERENCE MODIFIED="2017-06-21 14:46:22 +0200" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Forrest E, Mellor J, Stanton L, Bowers M, Ryder P, Austin A, et al</AU>
<TI>Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial</TI>
<SO>Trials</SO>
<YR>2013</YR>
<VL>14</VL>
<NO>1</NO>
<PG>262</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="6800131000045566"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009541"/><IDENTIFIER TYPE="EMBASE" VALUE="2013572163"/><IDENTIFIER TYPE="OTHER" VALUE="CN-00917636"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-06-21 14:50:44 +0200" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petts G, Lloyd K, Vergis N, Kudo H, Quaglia A, Forrest E, et al</AU>
<TI>The liver biopsy in alcoholic hepatitis: data from the steroids or pentoxifylline in alcoholic hepatitis (STOPAH) clinical trial</TI>
<SO>Gut</SO>
<YR>2015</YR>
<VL>64</VL>
<NO>Suppl 1</NO>
<PG>A262</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="6800131000059987"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009542"/><IDENTIFIER TYPE="EMBASE" VALUE="72009796"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-07-11 14:34:46 +0200" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petts G, Lloyd K, Vergis N, Kudo H, Quaglia A, Forrest E, et al</AU>
<TI>The liver biopsy in alcoholic hepatitis: data from the steroids or pentoxifylline in alcoholic hepatitis (STOPAH) clinical trial</TI>
<SO>Journal of Pathology</SO>
<YR>2015</YR>
<VL>237</VL>
<NO>Suppl 1</NO>
<PG>S23</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="6800131000075013"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009543"/><IDENTIFIER TYPE="EMBASE" VALUE="72082064"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-06-21 14:50:34 +0200" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petts G, Lloyd K, Vergis N, Kudo H, Quaglia A, Forrest E, et al</AU>
<TI>Utility of liver biopsy in alcoholic hepatitis: data from the steroids or pentoxyfilline in alcoholic hepatitis (STOPAH) clinical trial</TI>
<SO>Journal of Hepatology</SO>
<YR>2015</YR>
<VL>62</VL>
<NO>Suppl 2</NO>
<PG>S776-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="6800131000059992"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009544"/><IDENTIFIER TYPE="EMBASE" VALUE="71937847"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-11-01 14:54:51 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thursz M, Forrest E, Roderick P, Day C, Austin A, O'Grady J, et al</AU>
<TI>The clinical effectiveness and cost-effectiveness of steroids or pentoxifylline for alcoholic hepatitis (STOPAH): a 2 x 2 factorial randomised controlled trial</TI>
<SO>Health Technology Assessment</SO>
<YR>2015</YR>
<VL>19</VL>
<NO>102</NO>
<PG>1-138</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="6800131000075049"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009545"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-06-21 14:51:01 +0200" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Thursz MR, Richardson P, Allison M, Austin A, Bowers M, Day CP, et al</AU>
<TI>Prednisolone or pentoxifylline for alcoholic hepatitis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2015</YR>
<VL>372</VL>
<NO>17</NO>
<PG>1619-28</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="6800131000075005"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009546"/><IDENTIFIER OTHERTYPE="JC--NLM" TYPE="OTHER" VALUE="Journal ID:0255562, now"/><IDENTIFIER TYPE="PUBMED" VALUE="25901427"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009540"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2017-11-02 14:38:45 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<STUDY DATA_SOURCE="PUB" ID="STD-Alvarez-2004" MODIFIED="2016-02-11 10:47:48 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Alvarez 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-02-11 10:47:48 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alvarez MA, Cabre E, Lorenzo-Zuniga V, Montoliu S, Planas R, Gassull MA</AU>
<TI>Combining steroids with enteral nutrition: a better therapeutic strategy for severe alcoholic hepatitis? Results of a pilot study</TI>
<SO>European Journal of Gastroenterology &amp; Hepatology</SO>
<YR>2004</YR>
<VL>16</VL>
<PG>1375-80</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009548"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009547"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cabr_x00e9_-2000" MODIFIED="2017-11-01 14:55:27 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Cabré 2000" YEAR="2000">
<REFERENCE MODIFIED="2017-06-21 14:51:59 +0200" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cabré E, Rodríguez-Iglesias P, Caballería J, Quer JC, Sánchez-Lombraña JL, Parés A, et al</AU>
<TI>Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>2000</YR>
<VL>32</VL>
<PG>36-42</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009550"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-10-31 17:00:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cabré E; on behalf of the Spanish Group for the Study of Alcoholic Hepatitis</AU>
<TI>Treatment of severe alcoholic hepatitis with steroids or total enteral nutrition: interim results of a prospective, randomized, multicentric trial</TI>
<SO>Gastroenterology</SO>
<YR>1998</YR>
<VL>114</VL>
<PG>A868-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009551"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-11-01 14:55:27 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gassull M, Cabré E</AU>
<TI>Short and long-term outcome in severe alcoholic hepatitis (SAH) treated with steroids or total enteral nutrition (TEN). A multicentric randomized controlled trial by the Spanish Group for the Study of Alcoholic Hepatitis</TI>
<SO>Journal of Parenteral and Enteral Nutrition</SO>
<YR>2000</YR>
<VL>24</VL>
<PG>S5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009552"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009549"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Christensen-1981" MODIFIED="2016-02-11 10:47:48 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Christensen 1981" YEAR="1981">
<REFERENCE MODIFIED="2016-02-11 10:47:48 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christensen E, Fauerholdt L, Schlichting P, Juhl E, Poulsen H, Tygstrup N</AU>
<TI>Aspects of the natural history of gastrointestinal bleeding in cirrhosis and the effect of prednisone</TI>
<SO>Gastroenterology</SO>
<YR>1981</YR>
<VL>81</VL>
<NO>5</NO>
<PG>944-52</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009554"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009553"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Copenhagen-1969" MODIFIED="2017-11-01 14:55:10 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Copenhagen 1969" YEAR="1969">
<REFERENCE MODIFIED="2017-11-01 14:55:10 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Copenhagen Study Group for Liver Diseases</AU>
<TI>Effect of prednisone on the survival of patients with cirrhosis of the liver. A report from the Copenhagen Study Group for Liver Diseases</TI>
<SO>Lancet</SO>
<YR>1969</YR>
<VL>1</VL>
<NO>586</NO>
<PG>119-21</PG>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="844264"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="6800100000024872"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009556"/><IDENTIFIER TYPE="PUBMED" VALUE="69076529"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009555"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Daures-1991" MODIFIED="2016-02-11 10:47:48 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Daures 1991" YEAR="1991">
<REFERENCE MODIFIED="2016-02-11 10:47:48 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daures J-P, Peray P, Bories P, Blanc P, Yousfi A, Michel H, et al</AU>
<TI>Steroid therapy in acute alcoholic hepatitis: a pooled estimate based on published randomized controlled trials</TI>
<TO>Place de la corticotherapie dans le traitement des hépatites alcooliques aiguës. Résultants d'une méta-analyse</TO>
<SO>Gastroenterologie Clinique et Biologique</SO>
<YR>1991</YR>
<VL>51</VL>
<PG>223-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009558"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009557"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dhanda-2016" MODIFIED="2017-11-02 14:38:45 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Dhanda 2016" YEAR="2014">
<REFERENCE MODIFIED="2017-10-31 17:02:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dhanda A, Collins P</AU>
<TI>Infection is common in patients with severe alcoholic hepatitis treated with steroids but not associated with poor outcome</TI>
<SO>Journal of Hepatology</SO>
<YR>2016</YR>
<VL>64</VL>
<PG>S213&#8211;S424</PG>
<IDENTIFIERS MODIFIED="2017-10-31 17:02:51 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009560"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-10-31 17:03:05 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009559"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Galambos-1984" MODIFIED="2017-06-21 14:54:10 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Galambos 1984" YEAR="1984">
<REFERENCE MODIFIED="2017-06-21 14:54:10 +0200" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galambos JT, Riepe SP</AU>
<TI>Use of colchicine and steroids in the treatment of alcoholic liver disease</TI>
<SO>Recent Developments in Alcoholism</SO>
<YR>1984</YR>
<VL>2</VL>
<PG>181-94</PG>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="34655"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="6800100000000618"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009562"/><IDENTIFIER TYPE="EMBASE" VALUE="6374780"/><IDENTIFIER OTHERTYPE="JC--NLM" TYPE="OTHER" VALUE="Journal ID:rda, 8301996"/><IDENTIFIER TYPE="PUBMED" VALUE="84222884"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009561"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gill-1984" MODIFIED="2017-06-21 14:54:18 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Gill 1984" YEAR="1984">
<REFERENCE MODIFIED="2017-06-21 14:54:18 +0200" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gill R, Zieve L, Logan G</AU>
<TI>Severe alcoholic hepatitis improved by combined treatment with prednisolone, testosterone and an amino acid supplement</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>1984</YR>
<VL>4</VL>
<PG>2894</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009564"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009563"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goldis-2000" MODIFIED="2016-02-11 10:47:48 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Goldis 2000" YEAR="2000">
<REFERENCE MODIFIED="2016-02-11 10:47:48 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Goldis A, Matei R, Vernic C, Strain R</AU>
<TI>Treatment of acute alcoholic hepatitis with glucocorticosteroids-prognostic factors. Steatohepatitis (NASH and ASH)</TI>
<SO>Falk Symposium 121</SO>
<YR>2000</YR>
<VL>123</VL>
<PG>25</PG>
<CY>Den Haag (Netherlands)</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009566"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009565"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hozo-1996" MODIFIED="2016-02-11 10:47:48 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Hozo 1996" YEAR="1996">
<REFERENCE MODIFIED="2016-02-11 10:47:48 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hozo I, Mise S, Rumboldt Z, Bagatin J, Tonkic A</AU>
<TI>A controlled clinical trial of methylprednisolone in patients with the cholestatic form of alcoholic liver cirrhosis</TI>
<TO>Kontrolirano klinicko ispitivanje metilprednisolona u bolesnika sa kolestatskim oblikom alkoholne ciroze jetre</TO>
<SO>Medicinski Arhiv</SO>
<YR>1996</YR>
<VL>50</VL>
<PG>81-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009568"/><IDENTIFIER TYPE="OTHER" VALUE="PMID: 9601759"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-11 10:47:48 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hozo I, Mise S, Rumboldt Z, Bagatin J, Tonkic A</AU>
<TI>Controlled clinical trial of methylprednisolone in patients with the cholestatic form of alcoholic liver cirrhosis</TI>
<SO>Gastroenterology International</SO>
<YR>1997</YR>
<VL>10</VL>
<PG>137-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009569"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009567"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Imperiale-1990" MODIFIED="2016-02-11 10:47:48 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Imperiale 1990" YEAR="1990">
<REFERENCE MODIFIED="2016-02-11 10:47:48 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Imperiale TF, McCullough AJ</AU>
<TI>Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1990</YR>
<VL>113</VL>
<NO>4</NO>
<PG>299-307</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009571"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009570"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lesesne-1978" MODIFIED="2016-10-20 15:07:21 +0200" MODIFIED_BY="[Empty name]" NAME="Lesesne 1978" YEAR="1978">
<REFERENCE MODIFIED="2016-10-20 15:07:21 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lesesne HR, Bozymski EM, Fallon HJ</AU>
<TI>Treatment of alcoholic hepatitis with encephalopathy. Comparison of prednisolone with caloric supplements</TI>
<SO>Gastroenterology</SO>
<YR>1978</YR>
<VL>74</VL>
<NO>2 Pt 1</NO>
<PG>169-73</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009573"/><IDENTIFIER TYPE="MEDLINE" VALUE="78085437"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009572"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mal-1991" MODIFIED="2017-11-01 14:55:44 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Mal 1991" YEAR="1991">
<REFERENCE MODIFIED="2017-11-01 14:55:44 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mal F, Huu TRP, Roulot D, Pol S, Labadie H, Ricardet JP, et al</AU>
<TI>In severe alcoholic hepatitis (AH) plasma tumor necrosis factor (pTNF) is inconstantly elevated and is not influenced by corticosteroid (Cs) therapy</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>1991</YR>
<VL>14</VL>
<NO>4 (Pt 2)</NO>
<PG>232A</PG>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="221590"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="6800100000005112"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009575"/><IDENTIFIER TYPE="OTHER" VALUE="CN-00221590"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009574"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mendenhall-1993" MODIFIED="2017-06-21 14:54:46 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Mendenhall 1993" YEAR="1993">
<REFERENCE MODIFIED="2017-06-21 14:54:46 +0200" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Mendenhall CL</AU>
<TI>Alcoholic hepatitis</TI>
<SO>Diseases of the Liver</SO>
<YR>1993</YR>
<VL>2</VL>
<PG>856-74</PG>
<EN>7th</EN>
<ED>Schiff L, Schiff ER</ED>
<PB>JB Lippincott Co</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009577"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009576"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moreno-2014" MODIFIED="2017-10-31 17:12:14 +0100" MODIFIED_BY="[Empty name]" NAME="Moreno 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-06-21 14:56:00 +0200" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moreno C, Deltenre P, Senterre C, Louvet A, Gustot T, Bastens B, et al</AU>
<TI>Intensive enteral nutrition is ineffective for patients with severe alcoholic hepatitis treated with corticosteroids</TI>
<SO>Gastroenterology</SO>
<YR>2016</YR>
<VL>150</VL>
<PG>903&#8211;10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009579"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-10-31 17:12:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Moreno C, Trepo E, Louvet A, Degre D, Bastens B, Hittelet A, et al</AU>
<TI>Impact of intensive enteral nutrition in association with corticosteroids in the treatment of severe alcoholic hepatitis: a multicenter randomized controlled trial</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>2014</YR>
<VL>60</VL>
<NO>Suppl 1</NO>
<PG>269A-70A</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="6800131000024411"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009580"/><IDENTIFIER TYPE="EMBASE" VALUE="71638823"/><IDENTIFIER TYPE="OTHER" VALUE="CN-01023754"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009578"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morris-2005" MODIFIED="2016-02-11 10:47:48 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Morris 2005" YEAR="2005">
<REFERENCE MODIFIED="2016-02-11 10:47:48 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morris JM, Forrest EH</AU>
<TI>Bilirubin response to corticosteroids in severe alcoholic hepatitis</TI>
<SO>European Journal of Gastroenterology &amp; Hepatology</SO>
<YR>2005</YR>
<VL>17</VL>
<PG>759-62</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009582"/><IDENTIFIER TYPE="OTHER" VALUE="PMID: 15947554"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009581"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naganuma-2014" MODIFIED="2017-06-21 14:57:41 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Naganuma 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-06-21 14:57:41 +0200" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naganuma A, Hoshino T, Ogashiwa T, Hayashi E, Uehara S, Miyamae N, et al</AU>
<TI>Pilot study of granulocytapheresis and leukocytapheresis for the treatment of severe alcoholic hepatitis</TI>
<SO>Hepatology International</SO>
<YR>2014</YR>
<VL>8</VL>
<NO>1 Suppl 1</NO>
<PG>S8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="6800131000045556"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009584"/><IDENTIFIER TYPE="OTHER" VALUE="CN-01011068"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009583"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naveau-2004" MODIFIED="2017-06-21 14:57:52 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Naveau 2004" YEAR="2004">
<REFERENCE MODIFIED="2017-06-21 14:57:52 +0200" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet MA, et al</AU>
<TI>A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>2004</YR>
<VL>39</VL>
<PG>1390-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009586"/><IDENTIFIER TYPE="OTHER" VALUE="PMID: 15122768"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009585"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Phillips-2001" MODIFIED="2017-06-21 14:58:02 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Phillips 2001" YEAR="2001">
<REFERENCE MODIFIED="2017-06-21 14:58:02 +0200" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Philips M, Curtis H, Portmann B, Donaldson N, Bomford A, O´Grady J</AU>
<TI>Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis: a randomized trial</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>2001</YR>
<VL>34</VL>
<PG>250A</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009588"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009587"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poynard-1991" MODIFIED="2017-10-31 17:13:36 +0100" MODIFIED_BY="[Empty name]" NAME="Poynard 1991" YEAR="1991">
<REFERENCE MODIFIED="2017-06-21 14:58:13 +0200" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poynard T, Ramond MJ, Rueff B, Mathurin P, Chaput JC, Benhamou JP</AU>
<TI>Corticosteroids reduce mortality from alcoholic hepatitis in patients without encephalopathy. A meta-analysis of the randomized trials (RCTs) including French trials</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>1991</YR>
<VL>14</VL>
<PG>234A</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009590"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009589"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reynolds-1989" MODIFIED="2016-02-11 10:47:48 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Reynolds 1989" YEAR="1989">
<REFERENCE MODIFIED="2016-02-11 10:47:48 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reynolds TB, Benhamou JP, Blake J, Naccarato R, Orrego H</AU>
<TI>Treatment of acute alcoholic hepatitis</TI>
<SO>Gastroenterology International</SO>
<YR>1989</YR>
<VL>2</VL>
<NO>4</NO>
<PG>208-16</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009592"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009591"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schlichting-1976" MODIFIED="2016-02-11 10:47:48 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Schlichting 1976" YEAR="1976">
<REFERENCE MODIFIED="2016-02-11 10:47:48 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schlichting P, Juhl E, Poulsen H, Winkel P</AU>
<TI>Alcoholic hepatitis superimposed on cirrhosis. Clinical significance and effect of long-term prednisone treatment</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>1976</YR>
<VL>11</VL>
<PG>305-12</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009594"/><IDENTIFIER TYPE="MEDLINE" VALUE="1976199128"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009593"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spahr-2002" MODIFIED="2017-06-21 14:58:34 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Spahr 2002" YEAR="2002">
<REFERENCE MODIFIED="2017-06-21 14:58:34 +0200" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spahr L, Rubbia-Brandt L, Giostra E, Rougemont A-L, Pugin J, Fischer M, et al</AU>
<TI>Combination of steroids with anti-TNFa (INFLIXIMAB) or placebo in severe alcoholic hepatitis: early changes in ICAM-1, histology and biochemical parameters. A pilot study</TI>
<SO>Journal of Hepatology</SO>
<YR>2002</YR>
<VL>37</VL>
<PG>448-55</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009596"/><IDENTIFIER TYPE="OTHER" VALUE="PMID: 12217597"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009595"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stewart-2002" MODIFIED="2016-02-11 10:47:48 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Stewart 2002" YEAR="2002">
<REFERENCE MODIFIED="2016-02-11 10:47:48 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stewart S, Prince M, Bassendine M, Hudson M, James O, Jones D, et al</AU>
<TI>A trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis</TI>
<SO>Journal of Hepatology</SO>
<YR>2002</YR>
<VL>36</VL>
<NO>Suppl 1</NO>
<PG>42</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009598"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009597"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tygstrup-1979" MODIFIED="2017-11-01 14:56:03 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Tygstrup 1979" YEAR="1979">
<REFERENCE MODIFIED="2017-11-01 14:56:03 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tygstrup N, Christensen E, Juhl E</AU>
<TI>Randomised clinical trials in hepatology</TI>
<TO>Randomisierte klinische therapiestudien in der hepatologie</TO>
<SO>Internist</SO>
<YR>1979</YR>
<VL>20</VL>
<PG>565-70</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009600"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009599"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Young_x002d_Sun-Lee" MODIFIED="2017-10-31 17:14:35 +0100" MODIFIED_BY="[Empty name]" NAME="Young-Sun Lee" YEAR="2016">
<REFERENCE MODIFIED="2017-06-21 15:03:37 +0200" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee Y-S, Kim HJ, Kim JH, Yoo YJ, Kim TS, Kang SH, et al</AU>
<TI>Systematic review: steroid, pentoxifylline or combined therapy for acute alcoholic hepatitis</TI>
<SO>Hepatology International</SO>
<YR>2016</YR>
<VL>10</VL>
<NO>Suppl 1</NO>
<PG>424</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7009602"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-10-31 17:14:35 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7009601"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2016-09-25 17:24:45 +0200" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2016-10-04 10:20:03 +0200" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2017-11-02 15:44:46 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<ADDITIONAL_REFERENCES MODIFIED="2017-11-02 11:28:02 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<REFERENCE ID="REF-AASLD-2010" MODIFIED="2017-06-21 15:08:01 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="AASLD 2010" TYPE="JOURNAL_ARTICLE">
<AU>O'Shea RS, Dasarathy S, McCullough AJ</AU>
<TI>Alcoholic liver disease</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>2010</YR>
<VL>51</VL>
<PG>307-28</PG>
<IDENTIFIERS MODIFIED="2016-10-21 15:10:55 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-21 15:10:55 +0200" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE=""/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Balshem-2011" MODIFIED="2015-04-14 13:20:40 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Balshem 2011" TYPE="JOURNAL_ARTICLE">
<AU>Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al</AU>
<TI>GRADE guidelines: 3. Rating the quality of evidence</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>401-6</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="21208779"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Becker-1996" MODIFIED="2017-06-21 15:08:13 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Becker 1996" TYPE="JOURNAL_ARTICLE">
<AU>Becker U, Deis A, Sorensen TI, et al</AU>
<TI>Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>1996</YR>
<VL>23</VL>
<PG>1025-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beckett-1961" MODIFIED="2015-05-22 11:08:07 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Beckett 1961" TYPE="JOURNAL_ARTICLE">
<AU>Beckett AG, Livingstone AV, Hill KR</AU>
<TI>Acute alcoholic hepatitis</TI>
<SO>British Medical Journal</SO>
<YR>1961</YR>
<VL>2</VL>
<PG>1113-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Begg-1994" MODIFIED="2015-06-24 14:45:16 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Begg 1994" TYPE="JOURNAL_ARTICLE">
<AU>Begg CB, Mazumdar M</AU>
<TI>Operating characteristics of a rank correlation test for publication bias</TI>
<SO>Biometrics</SO>
<YR>1994</YR>
<VL>50</VL>
<NO>4</NO>
<PG>1088-101</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="7786990"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Brok-2008" MODIFIED="2017-11-01 14:56:58 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Brok 2008" TYPE="JOURNAL_ARTICLE">
<AU>Brok J, Thorlund K, Gluud C, Wetterslev J</AU>
<TI>Trial Sequential Analysis reveals insufficient information size and potentially false positive results in many meta-analyses</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2008</YR>
<VL>61</VL>
<PG>763-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brok-2009" MODIFIED="2017-11-01 14:57:08 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Brok 2009" TYPE="JOURNAL_ARTICLE">
<AU>Brok J, Thorlund K, Wetterslev J, Gluud C</AU>
<TI>Apparently conclusive meta-analyses may be inconclusive--Trial Sequential Analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>1</NO>
<PG>287-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Buzzetti-2017" MODIFIED="2017-07-11 13:21:34 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Buzzetti 2017" TYPE="COCHRANE_REVIEW">
<AU>Buzzetti E, Kalafateli M, Thorburn D, Davidson BR, Thiele M, Gluud LL, et al</AU>
<TI>Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2017</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2017-07-11 13:21:24 +0200" MODIFIED_BY="Dimitrinka Nikolova"><IDENTIFIER MODIFIED="2017-07-11 13:21:24 +0200" MODIFIED_BY="Dimitrinka Nikolova" TYPE="DOI" VALUE="10.1002/14651858.CD011646.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Castellini-2017" MODIFIED="2017-11-01 14:57:22 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Castellini 2017" TYPE="JOURNAL_ARTICLE">
<AU>Castellini G, Nielsen E, Gluud, C</AU>
<TI>Comment on: &#8220;Cell therapy for heart disease: Trial Sequential Analyses of two Cochrane Reviews&#8221;</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>2017</YR>
<VL>102</VL>
<PG>21&#8211;4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Christensen-1995" MODIFIED="2015-04-15 12:50:03 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Christensen 1995" TYPE="JOURNAL_ARTICLE">
<AU>Christensen E, Gluud C</AU>
<TI>Glucocorticoids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables [see comments]</TI>
<SO>Gut</SO>
<YR>1995</YR>
<VL>37</VL>
<NO>1</NO>
<PG>113-8</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="1995402786"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Christensen-1999" MODIFIED="2017-07-11 14:37:07 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Christensen 1999" TYPE="JOURNAL_ARTICLE">
<AU>Christensen E, Gluud C</AU>
<TI>Glucocorticosteroids are not effective in alcoholic hepatitis</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1999</YR>
<VL>94(10)</VL>
<NO>3065</NO>
<PG>66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2011" MODIFIED="2017-11-01 14:57:37 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Deeks 2011" TYPE="OTHER">
<AU>Deeks JJ, Higgins JPT, Altman DG (editors)</AU>
<TI>Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DeMets-1987" MODIFIED="2015-04-14 16:01:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="DeMets 1987" TYPE="JOURNAL_ARTICLE">
<AU>DeMets DL</AU>
<TI>Methods for combining randomized clinical trials: strengths and limitations</TI>
<SO>Statistics in Medicine</SO>
<YR>1987</YR>
<VL>6</VL>
<NO>3</NO>
<PG>341-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" MODIFIED="2015-04-14 16:05:57 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<NO>3</NO>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dominguez-2008" MODIFIED="2015-04-14 17:55:37 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Dominguez 2008" TYPE="JOURNAL_ARTICLE">
<AU>Dominguez M, Rincon D, Abraldes JG, Miquel R, Colmenero J, Bellot P, et al</AU>
<TI>A new scoring system for prognostic stratification of patients with alcoholic hepatitis</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2008</YR>
<VL>103</VL>
<PG>2747&#8211;56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dunn-2005" MODIFIED="2017-06-21 15:10:18 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Dunn 2005" TYPE="JOURNAL_ARTICLE">
<AU>Dunn W, Jamil LH, Brown LS, Wiesner RH, Kim WR, Menon KVN, et al</AU>
<TI>MELD accurately predicts mortality in patients with alcoholic hepatitis</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>2005</YR>
<VL>41</VL>
<PG>353&#8211;8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EASL-2012" MODIFIED="2017-11-01 16:02:09 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="EASL 2012" TYPE="JOURNAL_ARTICLE">
<AU>European Association for the Study of the Liver</AU>
<TI>EASL Clinical Practical Guidelines: management of alcoholic liver disease</TI>
<SO>Journal of Hepatology</SO>
<YR>2012</YR>
<VL>57</VL>
<PG>399&#8211;420</PG>
<IDENTIFIERS MODIFIED="2017-10-16 15:43:23 +0200" MODIFIED_BY="Dimitrinka Nikolova"/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2015-04-14 13:17:14 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey SG, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ellis-2012" MODIFIED="2015-05-22 13:21:59 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Ellis 2012" TYPE="JOURNAL_ARTICLE">
<AU>Ellis EL, Mann DA</AU>
<TI>Clinical evidence for the regression of liver fibrosis</TI>
<SO>Journal of Hepatology</SO>
<YR>2012</YR>
<VL>56</VL>
<NO>5</NO>
<PG>1171-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Feinberg-2017" MODIFIED="2017-06-21 15:15:46 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Feinberg 2017" TYPE="COCHRANE_REVIEW">
<AU>Feinberg J, Nielsen EE, Korang SK, Halberg Engell K, Nielsen MS, Zhang K, et al</AU>
<TI>Nutrition support in hospitalised adults at nutritional risk</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2017</YR>
<NO>5</NO>
<IDENTIFIERS MODIFIED="2017-06-21 15:15:46 +0200" MODIFIED_BY="Sarah  Klingenberg"><IDENTIFIER MODIFIED="2017-06-21 15:15:46 +0200" MODIFIED_BY="Sarah  Klingenberg" TYPE="DOI" VALUE="10.1002/14651858.CD011598.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fisher-1922" MODIFIED="2017-06-13 17:20:49 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Fisher 1922" TYPE="JOURNAL_ARTICLE">
<AU>Fisher RA</AU>
<TI>On the interpretation of X^2 from contingency tables, and the calculation of P</TI>
<SO>Journal of the Royal Statistical Society</SO>
<YR>1922</YR>
<VL>85</VL>
<NO>1</NO>
<PG>87-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Forrest-2005" MODIFIED="2015-04-14 17:51:51 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Forrest 2005" TYPE="JOURNAL_ARTICLE">
<AU>Forrest EH, Evans CD, Stewart S, Phillips M, Oo YH, McAvoy NC, et al</AU>
<TI>Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score</TI>
<SO>Gut</SO>
<YR>2005</YR>
<VL>54</VL>
<PG>1174&#8211;9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Garattini-2016" MODIFIED="2017-03-01 17:01:29 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Garattini 2016" TYPE="JOURNAL_ARTICLE">
<AU>Garattini S, Jakobsen JC, Wetterslev J, Bertelé V, Banzi R, Rath A, et al</AU>
<TI>Evidence-based clinical practice: overview of threats to the validity of evidence and how to minimise them</TI>
<SO>European Journal of Internernal Medicine</SO>
<YR>2016</YR>
<VL>32</VL>
<PG>13-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gerber-1973" MODIFIED="2015-07-03 14:51:09 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Gerber 1973" TYPE="JOURNAL_ARTICLE">
<AU>Gerber MA, Orr W, Denk H, Schaffner F, Popper H</AU>
<TI>Hepatocellular hyalin in cholestasis and cirrhosis: its diagnostic significance</TI>
<SO>Gastroenterology</SO>
<YR>1973</YR>
<VL>64</VL>
<NO>1</NO>
<PG>89-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2017" MODIFIED="2017-06-21 15:16:17 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Gluud 2017" TYPE="OTHER">
<AU>Gluud C, Nikolova D, Klingenberg SL</AU>
<TI>Cochrane Hepato-Biliary Group</TI>
<SO>About Cochrane (Cochrane Review Groups (CRGs)) 2017, Issue 2. Art. No.: LIVER</SO>
<YR>2017</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro-GDT-2015" MODIFIED="2017-11-01 14:57:53 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="GRADEpro GDT 2015" TYPE="COMPUTER_PROGRAM">
<TI>GRADEpro GDT</TI>
<YR>2015</YR>
<PB>McMaster University (developed by Evidence Prime)</PB>
<CY>Hamilton (ON)</CY>
<MD>Available at gradepro.org</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011a" MODIFIED="2015-04-14 13:20:57 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Guyatt 2011a" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al</AU>
<TI>GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>383-94</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="21195583"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011b" MODIFIED="2015-04-14 13:20:57 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Guyatt 2011b" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al</AU>
<TI>GRADE guidelines: 2. Framing the question and deciding on important outcomes</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>395-400</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="21194891"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011c" MODIFIED="2015-04-14 13:20:57 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Guyatt 2011c" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al</AU>
<TI>GRADE guidelines: 4. Rating the quality of evidence - study limitations (risk of bias)</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>407-15</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="21247734"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011d" MODIFIED="2015-04-14 13:20:57 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Guyatt 2011d" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al</AU>
<TI>GRADE guidelines: 5. Rating the quality of evidence - publication bias</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1277-82</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="21802904"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011e" MODIFIED="2015-04-14 13:20:57 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Guyatt 2011e" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al</AU>
<TI>GRADE guidelines 6. Rating the quality of evidence - imprecision</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1283-93</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="21839614"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011f" MODIFIED="2015-04-14 13:20:57 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Guyatt 2011f" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al</AU>
<TI>GRADE guidelines: 7. Rating the quality of evidence - inconsistency</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1294-302</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="21803546"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011g" MODIFIED="2015-04-14 13:20:57 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Guyatt 2011g" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al</AU>
<TI>GRADE guidelines: 8. Rating the quality of evidence - indirectness</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1303-10</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="21802903"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011h" MODIFIED="2015-04-14 13:20:57 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Guyatt 2011h" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al</AU>
<TI>GRADE guidelines: 9. Rating up the quality of evidence</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1311-6</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="21802902"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2013a" MODIFIED="2015-04-14 13:20:57 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Guyatt 2013a" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso-Coello P, et al</AU>
<TI>GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2013</YR>
<VL>66</VL>
<NO>2</NO>
<PG>151-7</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="22542023"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2013b" MODIFIED="2015-04-14 13:20:57 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Guyatt 2013b" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al</AU>
<TI>GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2013</YR>
<VL>66</VL>
<NO>2</NO>
<PG>158-72</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="22609141"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2013c" MODIFIED="2015-04-14 13:20:57 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Guyatt 2013c" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Thorlund K, Oxman AD, Walter SD, Patrick D, Furukawa TA, et al</AU>
<TI>GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2013</YR>
<VL>66</VL>
<NO>2</NO>
<PG>173-83</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="23116689"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2017" MODIFIED="2017-09-14 15:42:32 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Guyatt 2017" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Ebrahim S, Alonso-Coello P, Johnston BC, Mathioudakis AG, Briel M, et al</AU>
<TI>GRADE guidelines 17: assessing the risk of bias associated with missing participant outcome data in a body of evidence</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2017</YR>
<VL>May 18</VL>
<PG>Epub ahead of print</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="28529188"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Harbord-2006" MODIFIED="2015-06-24 15:32:09 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Harbord 2006" TYPE="JOURNAL_ARTICLE">
<AU>Harbord RM, Egger M, Sterne JAC</AU>
<TI>A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints</TI>
<SO>Statistics in Medicine</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>20</NO>
<PG>3443-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" MODIFIED="2015-04-14 13:15:08 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>11</NO>
<PG>1539-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2017-06-21 15:16:58 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JP, Green S, editor(s)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011a" MODIFIED="2017-11-01 14:58:02 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Higgins 2011a" TYPE="OTHER">
<AU>Higgins JPT, Deeks JJ (editors)</AU>
<TI>Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011b" MODIFIED="2017-11-01 14:58:20 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Higgins 2011b" TYPE="OTHER">
<AU>Higgins JPT, Altman DG, Sterne JAC (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Houghton-2009" MODIFIED="2017-09-14 15:45:16 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Houghton 2009" TYPE="JOURNAL_ARTICLE">
<AU>Houghton M</AU>
<TI>Discovery of the hepatitis C virus</TI>
<SO>Liver International</SO>
<YR>2009</YR>
<VL>29</VL>
<NO>Suppl 1</NO>
<PG>82-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICH_x002d_GCP-1997" MODIFIED="2017-06-21 15:17:17 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="ICH-GCP 1997" TYPE="BOOK">
<AU>International Conference on Harmonisation Expert Working Group</AU>
<SO>International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR &amp; ICH Guidelines</SO>
<YR>1997</YR>
<VL>1</VL>
<PB>Barnett International/PAREXEL</PB>
<CY>Philadelphia (PA)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ioannidis-2009" MODIFIED="2017-09-05 15:56:03 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Ioannidis 2009" TYPE="JOURNAL_ARTICLE">
<AU>Ioannidis JP</AU>
<TI>Adverse events in randomized trials: neglected, restricted, distorted, and silenced</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2009</YR>
<VL>169</VL>
<NO>19</NO>
<PG>1737-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jakobsen-2014" MODIFIED="2015-05-22 15:58:45 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Jakobsen 2014" TYPE="JOURNAL_ARTICLE">
<AU>Jakobsen J, Wetterslev J, Winkel P, Lange T, Gluud C</AU>
<TI>Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2014</YR>
<VL>14</VL>
<PG>120</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jensen-1994" MODIFIED="2017-10-31 19:15:52 +0100" MODIFIED_BY="[Empty name]" NAME="Jensen 1994" TYPE="JOURNAL_ARTICLE">
<AU>Jensen K, Gluud C</AU>
<TI>The Mallory body: morphological, clinical and experimental studies (Part 1 of a literature survey)</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>1994</YR>
<VL>20</VL>
<PG>1061-77</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="1995012083"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kjaergard-2001" MODIFIED="2015-04-14 13:12:23 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Kjaergard 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kjaergard LL, Villumsen J, Gluud C</AU>
<TI>Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2001</YR>
<VL>135</VL>
<NO>11</NO>
<PG>982-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefkowitch-2005" MODIFIED="2015-04-14 20:19:30 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Lefkowitch 2005" TYPE="JOURNAL_ARTICLE">
<AU>Lefkowitch JH</AU>
<TI>Morphology of alcoholic liver disease</TI>
<SO>Clinics in Liver Disease</SO>
<YR>2005</YR>
<VL>9</VL>
<NO>1</NO>
<PG>37-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lieber-1999" MODIFIED="2017-06-21 15:17:45 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Lieber 1999" TYPE="JOURNAL_ARTICLE">
<AU>Lieber CS</AU>
<TI>Role of S-adenosyl-L-methionine in the treatment of liver diseases</TI>
<SO>Journal of Hepatology</SO>
<YR>1999</YR>
<VL>30</VL>
<PG>1155-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Louvet-2007" MODIFIED="2017-06-21 15:17:53 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Louvet 2007" TYPE="JOURNAL_ARTICLE">
<AU>Louvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Fartoux L</AU>
<TI>The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>2007</YR>
<VL>45</VL>
<NO>6</NO>
<PG>1348-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lundh-2017" MODIFIED="2017-06-21 15:18:23 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Lundh 2017" TYPE="COCHRANE_REVIEW">
<AU>Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L</AU>
<TI>Industry sponsorship and research outcome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2017</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2017-03-01 16:57:55 +0100" MODIFIED_BY="Dimitrinka Nikolova"><IDENTIFIER MODIFIED="2017-03-01 16:57:55 +0100" MODIFIED_BY="Dimitrinka Nikolova" TYPE="DOI" VALUE="10.1002/14651858.MR000033.pub3"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mathurin-2011" MODIFIED="2015-04-15 17:47:11 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Mathurin 2011" TYPE="JOURNAL_ARTICLE">
<AU>Mathurin P, O'Grady J, Carithers RL, Phillips M, Louvet A, Mendenhall CL, et al</AU>
<TI>Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data</TI>
<SO>Gut</SO>
<YR>2011</YR>
<VL>60</VL>
<NO>2</NO>
<PG>255-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1998" MODIFIED="2015-04-14 13:12:18 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Moher 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al</AU>
<TI>Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9128</NO>
<PG>609-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mustafa-2013" MODIFIED="2015-04-14 13:21:11 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Mustafa 2013" TYPE="JOURNAL_ARTICLE">
<AU>Mustafa RA, Santesso N, Brozek J, Akl EA, Walter SD, Norman G, et al</AU>
<TI>The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2013</YR>
<VL>66</VL>
<NO>7</NO>
<PG>736-42; quiz 742.e1-5</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="23623694"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-NTAWG-2015" MODIFIED="2017-06-21 15:31:58 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="NTAWG 2015" TYPE="OTHER">
<AU>Nordic Trial Alliance Working Group on Transparency and Registration</AU>
<TI>Transparency and registration in clinical research in the Nordic countries (Report)</TI>
<SO>nta.nordforsk.org/projects/nta_transparency_report.pdf</SO>
<YR>2015 (accessed 21 June 2017)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Petrasek-2013" MODIFIED="2015-06-25 14:49:53 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Petrasek 2013" TYPE="JOURNAL_ARTICLE">
<AU>Petrasek J, Iracheta-Vellve A, Csak T, Satishchandran A, Kodys K, Kurt-Jones EA, et al</AU>
<TI>STING-IRF3 pathway links endoplasmic reticulum stress with hepatocyte apoptosis in early alcoholic liver disease</TI>
<SO>Proceedings of the National Academy of Sciences of the United States of America</SO>
<YR>2013</YR>
<VL>110</VL>
<NO>41</NO>
<PG>16544-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Phillips-2006" MODIFIED="2015-04-14 17:45:09 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Phillips 2006" TYPE="JOURNAL_ARTICLE">
<AU>Phillips M, Curtis H, Portmann B, Donaldson N, Bomford A, O&#8217;Grady J</AU>
<TI>Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis &#8211; a randomised clinical trial</TI>
<SO>Journal of Hepatology</SO>
<YR>2006</YR>
<VL>44</VL>
<PG>784&#8211;90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pugh-1973" MODIFIED="2017-06-21 15:19:21 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Pugh 1973" TYPE="JOURNAL_ARTICLE">
<AU>Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R</AU>
<TI>Transection of the oesophagus for bleeding oesophageal varices</TI>
<SO>British Journal of Surgery</SO>
<YR>1973</YR>
<VL>60</VL>
<PG>646-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rambaldi-2006" MODIFIED="2017-06-21 15:24:50 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Rambaldi 2006" TYPE="COCHRANE_REVIEW">
<AU>Rambaldi A, Gluud C</AU>
<TI>Anabolic-androgenic steroids for alcoholic liver disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2017-06-21 15:24:45 +0200" MODIFIED_BY="Sarah  Klingenberg"><IDENTIFIER MODIFIED="2017-06-21 15:24:45 +0200" MODIFIED_BY="Sarah  Klingenberg" TYPE="DOI" VALUE="10.1002/14651858.CD003045.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rambaldi-2008" MODIFIED="2017-06-21 15:25:00 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Rambaldi 2008" TYPE="JOURNAL_ARTICLE">
<AU>Rambaldi A, Saconato HH, Christensen E, Thorlund K, Wetterslev J, Gluud C</AU>
<TI>Systematic review: glucocorticosteroids for alcoholic hepatitis -- a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials</TI>
<SO>Alimentary Pharmacology &amp; Therapeutics</SO>
<YR>2008</YR>
<VL>27</VL>
<NO>12</NO>
<PG>1167-78</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="6800131000005200"/><IDENTIFIER TYPE="EMBASE" VALUE="2008243224"/><IDENTIFIER OTHERTYPE="JC--NLM" TYPE="OTHER" VALUE="Journal ID:a5d, 8707234"/><IDENTIFIER TYPE="PUBMED" VALUE="18363896"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2017-11-01 14:58:36 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager 5 (RevMan 5)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rhen-2005" MODIFIED="2015-04-15 12:35:54 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Rhen 2005" TYPE="JOURNAL_ARTICLE">
<AU>Rhen T, Cidlowski JA</AU>
<TI>Antiinflammatory action of glucocorticoids--new mechanisms for old drugs</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>353</VL>
<NO>16</NO>
<PG>1711-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Royle-2003" MODIFIED="2017-11-01 14:58:46 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Royle 2003" TYPE="JOURNAL_ARTICLE">
<AU>Royle P, Milne R</AU>
<TI>Literature searching for randomized controlled trials used in Cochrane Reviews: rapid versus exhaustive searches</TI>
<SO>International Journal of Technology Assessment in Health Care</SO>
<YR>2003</YR>
<VL>19</VL>
<NO>4</NO>
<PG>591-603</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-R_x00fc_cker-2008" MODIFIED="2015-06-25 14:38:35 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Rücker 2008" TYPE="JOURNAL_ARTICLE">
<AU>Rücker G, Schwarzer G, Carpenter J</AU>
<TI>Arcsine test for publication bias in meta-analyses with binary outcomes</TI>
<SO>Statistics in Medicine</SO>
<YR>2008</YR>
<VL>27</VL>
<PG>746-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Savovi_x0107_-2012a" MODIFIED="2015-04-14 13:13:04 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Savovi&#263; 2012a" TYPE="JOURNAL_ARTICLE">
<AU>Savovi&#263; J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al</AU>
<TI>Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials</TI>
<SO>Health Technology Assessment</SO>
<YR>2012</YR>
<VL>16</VL>
<NO>35</NO>
<PG>1-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Savovi_x0107_-2012b" MODIFIED="2015-04-14 13:13:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Savovi&#263; 2012b" TYPE="JOURNAL_ARTICLE">
<AU>Savovi&#263; J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al</AU>
<TI>Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2012</YR>
<VL>157</VL>
<NO>6</NO>
<PG>429-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2017-11-01 14:59:16 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes, R, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="1995123716"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00e4_cke-2002" MODIFIED="2015-04-16 13:52:01 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Schäcke 2002" TYPE="JOURNAL_ARTICLE">
<AU>Schäcke H, Döcke WD, Asadullah K</AU>
<TI>Mechanisms involved in the side effects of glucocorticoids</TI>
<SO>Pharmacology &amp; Therapeutics</SO>
<YR>2002</YR>
<VL>96</VL>
<NO>1</NO>
<PG>23-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spahr-2001" MODIFIED="2015-04-15 18:33:53 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Spahr 2001" TYPE="JOURNAL_ARTICLE">
<AU>Spahr L, Rubbia-Brandt L, Pugin J, Giostra E, Frossard JL, Borisch B, et al</AU>
<TI>Rapid changes in alcoholic hepatitis histology under steroids: correlation with soluble intercellular adhesion molecule-1 in hepatic venous blood</TI>
<SO>Journal of Hepatology</SO>
<YR>2001</YR>
<VL>35</VL>
<NO>5</NO>
<PG>582-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2011" MODIFIED="2017-11-01 14:58:55 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Sterne 2011" TYPE="OTHER">
<AU>Sterne JAC, Egger M, Moher D (editors)</AU>
<TI>Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Student-1908" MODIFIED="2015-06-24 14:31:10 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Student 1908" TYPE="JOURNAL_ARTICLE">
<AU>Student</AU>
<TI>The probable error of a mean</TI>
<SO>Biometrika</SO>
<YR>1908</YR>
<VL>6</VL>
<NO>1</NO>
<PG>1-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ta_x00ef_eb-2000" MODIFIED="2015-04-15 19:05:01 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Taïeb 2000" TYPE="JOURNAL_ARTICLE">
<AU>Taïeb J, Mathurin P, Elbim C, Cluzel P, Arce-Vicioso M, Bernard B, et al</AU>
<TI>Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: effect of corticosteroids</TI>
<SO>Journal of Hepatology</SO>
<YR>2000</YR>
<VL>32</VL>
<NO>4</NO>
<PG>579-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thorlund-2009" MODIFIED="2017-06-21 12:36:59 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Thorlund 2009" TYPE="JOURNAL_ARTICLE">
<AU>Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al</AU>
<TI>Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>1</NO>
<PG>276-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thorlund-2010" MODIFIED="2015-06-24 15:34:07 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Thorlund 2010" TYPE="JOURNAL_ARTICLE">
<AU>Thorlund K, Anema A, Mills E</AU>
<TI>Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals</TI>
<SO>Clinical Epidemiology</SO>
<YR>2010</YR>
<VL>2</VL>
<PG>57-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thorlund-2011" MODIFIED="2017-06-21 15:32:51 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Thorlund 2011" TYPE="OTHER">
<AU>Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C</AU>
<TI>User manual for Trial Sequential Analysis (TSA)</TI>
<SO>ctu.dk/tsa/files/tsa_manual.pdf</SO>
<YR>2011 (accessed 21 June 2017)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-TSA-2011" MODIFIED="2015-06-24 15:32:46 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="TSA 2011" TYPE="COMPUTER_PROGRAM">
<TI>TSA - Trial Sequential Analysis</TI>
<YR>2011</YR>
<EN>0.9 Beta</EN>
<PB>Copenhagen Trial Unit</PB>
<CY>Copenhagen</CY>
<MD>www.ctu.dk/tsa/downloads.aspx</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2008" MODIFIED="2017-11-01 14:59:02 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Wetterslev 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Thorlund K, Brok J, Gluud C</AU>
<TI>Trial Sequential Analysis may establish when firm evidence is reached in cumulative meta-analysis</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2008</YR>
<VL>61</VL>
<NO>1</NO>
<PG>64-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2009" MODIFIED="2015-04-14 13:16:11 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Wetterslev 2009" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Thorlund K, Brok J, Gluud C</AU>
<TI>Estimating required information size by quantifying diversity in a random-effects meta-analysis</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2009</YR>
<VL>9</VL>
<PG>86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2017" MODIFIED="2017-06-21 12:26:13 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Wetterslev 2017" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Jakobsen JC, Gluud C</AU>
<TI>Trial Sequential Analysis in systematic reviews with meta-analysis</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2017</YR>
<VL>17</VL>
<NO>1</NO>
<PG>39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2010" MODIFIED="2017-06-21 15:33:23 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="WHO 2010" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>Global strategy to reduce the harmful use of alcohol</TI>
<SO>www.who.int/substance_abuse/msbalcstragegy.pdf</SO>
<YR>2010 (accessed 21 June 2017)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2013" MODIFIED="2017-06-21 15:33:52 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="WHO 2013" TYPE="OTHER">
<AU>Sauced RS</AU>
<TI>Update on Background Paper 6.14. Harmful use of alcohol, alcohol use, disorders, and alcoholic liver diseases</TI>
<SO>www.who.int/medicines/areas/priority_medicines/BP6_14Alcohol.pdf</SO>
<YR>(accessed 21 June 2017)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wood-2008" MODIFIED="2015-04-14 13:12:37 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Wood 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al</AU>
<TI>Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2008</YR>
<VL>336</VL>
<PG>601-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wu-1999" MODIFIED="2015-06-25 14:49:53 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Wu 1999" TYPE="JOURNAL_ARTICLE">
<AU>Wu D, Cederbaum AI</AU>
<TI>Ethanol-induced apoptosis to stable HepG2 cell lines expressing human cytochrome P-4502E1</TI>
<SO>Alcoholism: Clinical and Experimental Research</SO>
<YR>1999</YR>
<VL>23</VL>
<PG>67&#8211;76</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2017-11-02 15:44:46 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<REFERENCE ID="REF-Pavlov-2016" MODIFIED="2017-11-01 15:34:51 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Pavlov 2016" TYPE="COCHRANE_PROTOCOL">
<AU>Pavlov CS, Tsochatzis E, Casazza G, Nikolova D, Volcek E, Gluud C</AU>
<TI>Glucocorticosteroids for people with alcoholic hepatitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2016</YR>
<NO>6</NO>
<IDENTIFIERS MODIFIED="2017-11-01 15:34:35 +0100" MODIFIED_BY="Dimitrinka Nikolova"><IDENTIFIER MODIFIED="2017-11-01 15:34:35 +0100" MODIFIED_BY="Dimitrinka Nikolova" TYPE="DOI" VALUE="10.1002/14651858.CD001511.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Saconato-1999" MODIFIED="2017-11-02 15:44:46 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Saconato 1999" TYPE="COCHRANE_PROTOCOL">
<AU>Saconato H, Gluud C, Christensen E, Atallah ÁN</AU>
<TI>Glucocorticosteroids for alcoholic hepatitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1999</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2017-11-02 15:44:46 +0100" MODIFIED_BY="Dimitrinka Nikolova"><IDENTIFIER MODIFIED="2017-11-02 15:44:46 +0100" MODIFIED_BY="Dimitrinka Nikolova" TYPE="DOI" VALUE="10.1002/14651858.CD001511"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2017-07-11 14:39:58 +0200" MODIFIED_BY="Dimitrinka Nikolova"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2017-11-02 15:36:51 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2017-11-02 15:36:51 +0100" MODIFIED_BY="Dimitrinka Nikolova" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2017-11-02 12:44:42 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Blitzer-1977">
<CHAR_METHODS MODIFIED="2017-11-01 14:40:58 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>A prospective, double-blind randomised trial</P>
<P>Country: USA, 1971-1973</P>
<P>Analyses were not performed according to the intention-to-treat principle.</P>
<P>Sample size calculation was not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-02 12:44:42 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Demographic characteristics</B>
</P>
<P>Age (mean): prednisolone/placebo group 47.2/48.4</P>
<P>Sex: male (all participants)</P>
<P>"There were no significant differences between them with respect to mean age, sex, race, duration of hospitalization prior to entry into the study, frequency of histologically proved cirrhosis, or to the histologic severity of the alcoholic hepatitis."</P>
<P>
<B>Inclusion criteria and degree of severity</B>
</P>
<P>".. patients with alcoholic hepatitis who met the following criteria after at least five days in the hospital were included in the study: (1) recent history of heavy alcohol consumption (more than one pint of whiskey per day or its alcoholic equivalent);</P>
<P>(2) hepatomegaly based on physical examination (palpable more than 5 cm below the costal margin) and/or liver scan;</P>
<P>(3) total serum bilirubin greater than 5 mg/100 mL; and</P>
<P>(4) at least two of the following abnormalities:<BR/>(a) serum glutamic oxaloacetic transaminase (SGOT) greater than 100 Reitman-Frankel units per ml,<BR/>(b) serum albumin concentration less than 3g/100 mL, or</P>
<P>(c) prothrombin time more than 2 s greater than control value.</P>
<P>Liver biopsies were performed whenever possible, but were not required for admission to the study."</P>
<P>"14 biopsies proved alcoholic hepatitis."</P>
<P>"Neither positive PPD skin tests nor active tuberculosis excluded patients from randomization. None of the former were encountered, and one of the latter continued to receive INH and PAS throughout the study. If serious life-threatening infection was present, patients' entry into the protocol was postponed until it was eradicated. Patients with either a history of peptic ulcer, active peptic ulcer disease, or gastrointestinal bleeding were included."</P>
<P>The study authors did not clearly describe the degree of severity of alcoholic hepatitis; however, the participants probably had moderate to severe alcoholic hepatitis, since they presented patients with alcoholic hepatitis who met the described criteria.</P>
<P>
<B>Exclusion criteria </B>
<BR/>
<B>"...</B>who had been treated with adrenocorticosteroid in the six months prior to admission or who showed evidence of psychotic behavior precluding their cooperation during the investigation were excluded".</P>
<P>
<B>Randomisation procedure </B>
<BR/>
<B>"... </B>Patients were assigned by random, sealed-envelope technique to receive either placebo or steroid".<BR/>
</P>
<P>
<B>Number of participants</B> <B>randomised</B>
<BR/>n = 33</P>
<P>Prednisolone group: n = 17</P>
<P>Placebo group: n = 16</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-01 14:41:06 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Experimental group: </B>oral prednisolone</P>
<P>Dose: "10 mg q.i.d [four times a day], for 14 days, 5 mg qid [four times a day] for 4 days, 2.5 mg qid [four times a day] for 4 days, and 2.5 nag bid [four times a day] for 4 days"</P>
<P>
<B>Control group:</B> placebo tablets<BR/>Dose: the same dosage schedule as the prednisolone group</P>
<P>
<B>Additional interventions to the trial groups</B>: "Patients were encouraged to eat the standard hospital 2600-calorie diet and were offered supplements when caloric intake seemed inadequate. Low-protein, low-sodium, and other special diets were employed as the clinical situation dictated."</P>
<P>
<B>Duration of treatment: </B>26 days</P>
<P>
<B>Follow-up after randomisation</B>: 9 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-16 18:26:45 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial outcomes were:</P>
<UL>
<LI>Mortality</LI>
<LI>Liver biochemistry</LI>
<LI>Liver histology</LI>
<LI>Adverse events</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-01 14:41:11 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Letter sent to authors in March 2000. No answer received. No further attempts were made as the trial was conducted between 1971-1973.</P>
<P>One participant received placebo treatment during the trial. At the end of the therapy, due to lack of improvement, the ward physician requested the code be broken. The participant received a 7-day course of prednisolone. He died 17 days later; his death was included in the mortality data of the placebo group on an intention-to-treat basis.</P>
<P>On the 26th day treatment period, three participants in the placebo group and one in the glucocorticosteroid group received the alternative medication on a double-blind basis.</P>
<P>"Both prednisolone and placebo tablets were kindly supplied by the Upjohn Co., Kalamazoo, Michigan."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-02 12:45:04 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Bories-1987">
<CHAR_METHODS MODIFIED="2017-11-01 14:41:27 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Randomised controlled trial</P>
<P>Country: France, 1979-1982</P>
<P>Analyses were performed according to intention-to-treat method.</P>
<P>Sample size calculation was not reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-02 12:45:04 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Demographic characteristics</B>
</P>
<P>Age: prednisolone group: average 41 years old (26 to 68); control group: average 49 years old (30 to 70)</P>
<P>Sex: 16 men and 8 women in the treatment group, and 11 men and 10 women in the control group</P>
<P>
<B>Inclusion criteria</B> <B>and degree of severity</B>
<BR/>Not stated clearly, but the average level of bilirubin was &#8805; 147 <U>+</U> 30.78 mmol/L</P>
<P>Alcohol consumption: 155 g + 46 g per day in men; 140 g + 32 g per day in women</P>
<P>
<B>Exclusion criteria </B>
<BR/>48 patients were excluded due to infections (45 patients), diabetes (2 patients), and tuberculosis (1 patient).</P>
<P>
<B>Randomisation procedure </B>
</P>
<P>Random number table</P>
<P>
<B>Number of participants randomised</B>
</P>
<P>n = 45</P>
<P>Prednisolone group: n = 24</P>
<P>Control group: n = 21</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-01 14:41:32 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Experimental group</B>: oral prednisolone</P>
<P>Dose: 40 mg/d<BR/>
</P>
<P>
<B>Control group</B>: no intervention</P>
<P>
<B>Additional interventions to the trial groups:</B> 1500 calories and 50 g of protein/d. Encephalopathy was treated with lactulose and neomycin. In case of infection, participants were treated with antibiotics.</P>
<P>
<B>Duration of treatment</B>: 1 month</P>
<P>
<B>Duration of follow-up</B>: 3 months after randomisation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-16 18:47:47 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial outcomes were:</P>
<UL>
<LI>Mortality</LI>
<LI>Liver histology</LI>
<LI>Adverse events</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-01 14:41:32 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Letter sent to authors in March 2000. No answer received
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-01 15:08:23 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Campra-1973">
<CHAR_METHODS MODIFIED="2017-11-01 14:41:43 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>A prospective randomised control trial</P>
<P>Country: USA, 1971</P>
<P>Analyses were not performed according to intention-to-treat method</P>
<P>Sample size calculation was not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-01 14:41:43 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Demographic characteristics</B>
</P>
<P>Age: (mean <U>+</U> SD): prednisolone/control group 43.1 <U>+</U> 11.1/42.7 <U>+</U> 8.1</P>
<P>Sex: male (%): prednisolone/control group: 8% (40)/9% (35)</P>
<P>
<B>Inclusion criteria</B> <B>and degree of severity</B>
</P>
<P>".....a clinical diagnosis of severe acute alcoholic liver disease, absence of contraindication to corticosteroids therapy, absence of a prior history of liver disease."</P>
<P>Liver biopsy was not required for admission in the trial since some participants had prothrombin time &lt; 50% of normal value.</P>
<P>No clear definition of severity criteria used</P>
<P>
<B>Exclusion criteria </B>
</P>
<P>Participants with other known illness or illnesses</P>
<P>
<B>Randomisation procedure</B>
</P>
<P>"...by using previously prepared sealed envelopes, patients were randomly allocated to one of the two treatment groups"</P>
<P>
<B>Number of participants randomised</B>
</P>
<P>"50 patients entered the trial, but 5 were subsequently withdrawn when additional data favoured another diagnosis. In one case (group 2), jaundice proved to be caused by hepatitis B....the patient died .....2 of these patients were in group 2, one patient in group 1; all survived. The fifth patient was removed from the trial when peptic ulcer was diagnosed after 15 days of prednisolone therapy".</P>
<P>Prednisolone group:<BR/>n = 22 (20)</P>
<P>Control group:</P>
<P>n = 28 (25)</P>
<P>Analyses of 45 participants: 20 prednisolone + 25 control</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-01 14:41:48 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Experimental group</B>: oral prednisone</P>
<P>Dose: 0.5 mg/kg body weight daily, during 3 weeks; and then 0.25 mg/kg body weight, daily, for additional 3 weeks</P>
<P>
<B>Control group</B>: no intervention</P>
<P>
<B>Additional interventions to the trial groups</B>: vitamin supplements, folic acids; "high calorie, high protein diet was given if tolerated .......In patients with encephalopathy, protein intake was reduced to 20 or 40 g..... and neomycin 500 x 4 times daily was given. ...In case of bleeding , vomiting and extreme anorexia, 5% or 10% solutions of dextrose in water was administered."</P>
<P>
<B>Duration of treatment</B>: 6 weeks</P>
<P>
<B>Duration of follow-up:</B> "hospital stay after randomisation ranged between 42 and 92 days, with a mean of 47 days, for group 1; and between 43 and 95 days, with a mean of 48 days, for group 2."</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-16 19:05:01 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial outcomes were:</P>
<UL>
<LI>Mortality</LI>
<LI>Liver biochemistry</LI>
<LI>Liver histology</LI>
<LI>Adverse events</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-01 15:08:23 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Letter sent to authors in March 2000. AG Redeker answered in January 2001 (see the risk of bias table)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-02 12:46:12 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Carithers-1989">
<CHAR_METHODS MODIFIED="2017-11-01 14:42:08 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>A randomised, multi central, double-blind, placebo-controlled, clinical trial</P>
<P>Country: USA, 1979-1984</P>
<P>Analyses were performed according to intention-to-treat method</P>
<P>Sample size calculation was reported</P>
<P>It was ".. calculated that 62 patients should be entered to have a 95% chance of detecting a difference in survival between the two groups"</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-02 12:46:12 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Demographic characteristics</B>
</P>
<P>Age (mean) <U>+</U> SD: 43.1 <U>+</U> 2.0 in the treatment group; 44.4 <U>+</U> 1.7 in the placebo group</P>
<P>Sex: (male (%)): 20 (57)/21 (68)</P>
<P>
<B>Inclusion criteria and degree of severity</B>
</P>
<P>"... a history of long-standing alcoholism and clinical features of alcoholic hepatitis were evaluated by one of the principal investigators within 3 days of admission. All patients admitted to the study had either clinical evidence of spontaneous hepatic encephalopathy or a discriminant function value greater than 32 or both. Hepatic encephalopathy was assessed using standard clinical criteria. Spontaneous hepatic encephalopathy was considered to be present when correctable causes of encephalopathy had been excluded."<BR/>"Each patient had to have a negative hepatitis B surface antigen within the first 3 days of hospitalisation and also have no history of previous viral hepatitis."</P>
<P>
<B>Exclusion criteria </B>
</P>
<P>
<B>"</B>Patients with gastrointestinal haemorrhage requiring transfusions, diabetes requiring insulin administration, active infection requiring treatment, clinical and laboratory evidence of acute pancreatitis, history of recent head trauma, known prior heroin addiction, or preexisting chronic renal disease with a serum creatinine level greater than 175 mmol/L were excluded"</P>
<P>
<B>Randomisation procedure</B>
</P>
<P>".. Random sequences for drug or placebo were submitted to the Upjohn Company (Kalamazoo, Michigan), which provided methylprednisolone (Medrol) in 4-mg tablets and identical placebo tablets as well as intravenous preparations of methylprednisolone sodium succinate (SoluMedrol) and placebo. A random code was prepared for each of the four participating institutions such that within each group of 10 patients, 5 would receive methylprednisolone and 5 placebo. The random code sequence was kept by an independent source."</P>
<P>
<B>Number of participants randomised</B>
</P>
<P>n = 67 ("...67 patients ranging in age from 25 to 66 years were entered into the study over 4 years")</P>
<P>Prednisolone group</P>
<P>n = 36 (2 refused, 1 was excluded from analysis)</P>
<P>Control group</P>
<P>n = 31</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-01 14:42:18 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Experimental group</B>: methylprednisolone</P>
<P>Dose: .......given in a single dose of eight pills (4-mg tablets) each morning for 28 days. 32 mg methylprednisolone (equivalent to 40 mg prednisolone).</P>
<P>In patients unable to take oral medications, intravenous infusions of the study drugs were administered daily (methylprednisolone sodium succinate (SoluMedrol) or identical placebo". After 4 weeks, four tablets were administered daily for 1 week followed by two tablets daily for an additional week; then therapy was discontinued.</P>
<P>
<B>Control group</B>: placebo - identical tablets</P>
<P>
<B>Additional treatment</B>: "All patients were offered a 3000-caIorie diet. Protein (1 to 1.5 g/kg body weight) was provided for patients who had no evidence of hepatic encephalopathy. Protein restriction to 20 g/d or less and lactulose therapy were instituted in patients with signs of hepatic encephalopathy. Ascites was managed with sodium restriction or by the addition of spironolactone in patients who did not respond with diuresis within 5 days.</P>
<P>Fluid intake was restricted in patients with hyponatraemia. B-compIex multivitamins and folic acid (1 mg) were given each day. In patients who developed tremulousness or delirium tremens, Valium, or oxazepam was administered."</P>
<P>
<B>Duration of treatment</B>: 5 weeks; 28 days - 32 mg. "After 4 weeks, four tablets were administered daily for 1 week followed by two tablets daily for an additional week; then therapy was discontinued".</P>
<P>
<B>Duration of follow-up after randomisation: </B>at the moment of discharge</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-16 19:23:50 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial outcomes were:</P>
<UL>
<LI>Mortality</LI>
<LI>Liver biochemistry</LI>
<LI>Adverse events</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-01 14:42:08 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Letter sent to authors in March 2000. No answer received
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-02 14:47:47 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-De-2014">
<CHAR_METHODS MODIFIED="2017-11-02 12:58:34 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>A randomised controlled clinical trial</P>
<P>Country: India (the Medical College and Hospital, Kolkata); January 2010 - August 2012</P>
<P>The study protocol was approved by the institutional ethical committee.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-02 14:47:47 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Demographic characteristics</B>
</P>
<P>Age: mean (year) (PTX +prednisolone)/PTX 42.73 (0.43)/41.33 <U>+</U> 7.81</P>
<P>Sex: male</P>
<P>
<B>Inclusion criteria and degree of severity</B>
</P>
<P>"Patients who had a history of chronic alcohol intake of more than 50 g/day with clinical and biochemical features of severe alcoholic hepatitis (MDF score &#8805; 32 and aspartate aminotransferase (AST): alanine aminotransferase (ALT) &gt; 2:1 with absolute value of AST &lt; 500 IU/L and ALT &lt; 200 IU/L)"</P>
<P>Model for end&#8209;stage liver disease (MELD) score and Glasgow alcoholic hepatitis score (GAHS) and Child&#8209;Pugh score were calculated for all participants who were included in the study.</P>
<P>
<B>Exclusion criteria</B>
</P>
<P>"..Patients with any other potential etiology of liver injury (acute or chronic viral hepatitis, autoimmune liver disease, Wilson&#8217;s disease) even in the background of chronic alcohol intake, positive for HIV antibodies or patients with a history of abstinence from alcohol in the last month, infection, sepsis or spontaneous bacterial peritonitis, acute pancreatitis, gastrointestinal bleeding, hepatorenal syndrome or any other severe associated disease such as uncontrolled diabetes mellitus, systemic hypertension, heart failure, pulmonary disease or malignancy at the time of inclusion or in the previous 3 months".</P>
<P>
<B>Randomisation procedure</B>
</P>
<P>"The recruited patients were then divided into 2 groups by a computer generated randomization table"</P>
<P>
<B>Number of participants randomised</B>
<BR/>n = 62</P>
<P>"... who fulfilled the inclusion and exclusion criteria and who gave informed written consent were randomized and divided into 2 groups:<BR/>Group 1 (PTX only) had 31 patients</P>
<P>Group 2 (prednisolone plus PTX) had 31 patients.</P>
<P>One patient in Group 1 developed severe vertigo within 7 days after starting PTX and one patient in Group 2 withdrew voluntarily from the study, and hence they were excluded. Hence, a total of 60 patients, 30 in each group, were considered for the final analysis."</P>
<P>Prednisolone group<BR/>n = 31 (1 voluntary dropped out)</P>
<P>Control group</P>
<P>n = 31 (1 vertigo and withdrew)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-02 12:59:02 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Experimental group</B>: "received prednisolone tablet (Wysolone, Wreath, Mumbai, India) at a dose of 40 mg once daily for 4 weeks and PTX tablets at a dose of 400 mg thrice daily for the duration for the first 4 weeks".</P>
<P>Dose: 40 mg prednisolone</P>
<P>
<B>Control group</B>: "received PTX (Trental tablets, Sanofi Aventis, Mumbai, India) at a dose of 400 mg thrice daily orally and a placebo tablet in the place of prednisolone for the first 4 weeks."</P>
<P>Dose: 40 mg placebo</P>
<P>
<B>Duration of treatment</B>: 12 weeks</P>
<P>"After the initial 4 weeks, the study was opened and the patients allocated to different groups were revealed. Patients in Group 1 (PTX) who tolerated the drug well, continued to receive the medication at the same dose for the next 8 weeks and then stopped.</P>
<P>After 4 weeks of initial therapy, the dose of prednisolone in Group 2 was tapered by 5 mg/week over a period of 7 weeks and then stopped and received PTX like Group 1 patients". (Thus, we can use only 3 months.)</P>
<P>
<B>Duration of follow-up: </B>12 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-16 19:41:03 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial outcomes were:</P>
<UL>
<LI>Mortality</LI>
<LI>Adverse events</LI>
<LI>Morbidity</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-01 14:50:41 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>"One patient in Group 1 developed severe vertigo within 7 days after starting PTX, and one patient in Group 2 withdrew voluntarily from the study and hence they were excluded. A total of 60 patients, 30 in each group, were considered for the final analysis."</P>
<P>Letter sent to SK Mandal 12.10.2016. No reply received</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-02 12:46:56 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Depew-1980">
<CHAR_METHODS MODIFIED="2017-11-01 14:42:50 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>A randomised, double-blind, controlled clinical trial</P>
<P>Country: USA, 1977-1979</P>
<P>The study was approved by the Human Experimentation Committee of the John Wesley County Hospital.</P>
<P>Analyses were performed according to intention-to-treat method.</P>
<P>Sample size calculation was reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-02 12:46:56 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Demographic characteristics</B>:</P>
<P>Age: (mean) <U>+</U> SD: 49.8 <U>+</U> 2.1 in the treatment group, 48.2 <U>+</U> 2.3 in the placebo group</P>
<P>Sex: (male (%)): 10 (67)/6 (43), hepatic encephalopathy %: 100/100; ascites %: 87/92</P>
<P>
<B>Inclusion criteria and degree of severity</B>
</P>
<P>".... all patients were alcohol abusers from the lower socioeconomic strata with a clinical diagnosis of severe alcoholic hepatitis manifested by hepatomegaly, leukocytosis, and a serum-bilirubin greater than 5 mg/dL, spontaneous hepatic encephalopathy occurring in the absence of gastrointestinal haemorrhage, sedation, diuretic usage, or major electrolyte disturbances."</P>
<P>
<B>Exclusion criteria</B>
</P>
<P>"Severe diabetes, active tuberculosis, and serious bacterial infection prevented participation in the trial"</P>
<P>Liver biopsy was not required.</P>
<P>
<B>Randomisation procedure</B>
</P>
<P>Unclear. It is not described. However, it reads: "All patients fulfilling the criteria who gave informed consent were randomised into two treatment protocols" and "...to avoid introducing bias based on the presence of the hepatorenal syndrome, the randomisation procedure was stratified to distinguish those with a serum creatinine greater than 2.5 mg/dL."</P>
<P>
<B>Number of participants randomised</B>
</P>
<P>n = 28</P>
<P>Prednisolone group: n = 15</P>
<P>Control group: n = 13</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-01 14:42:55 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Prednisolone group</B>: prednisolone</P>
<P>Dose: 40 mg daily by mouth</P>
<P>
<B>Control group</B>: placebo</P>
<P>Dose: 40 mg daily by mouth</P>
<P>Duration of treatment: "....28 days followed by tapered withdrawal over the ensuing 14 days."</P>
<P>
<B>Additional treatment:</B> "none of the patients received prophylactic isoniazid. Supportive measures were attention to fluid and electrolyte balance, multiple vitamin supplementation, and parenteral glucose administration when food intake was poor. Encephalopathy was treated with catharsis, protein restriction, and oral neomycin."</P>
<P>
<B>Duration of treatment</B>: 6 weeks to 28 days followed by tapered withdrawal over the ensuing 14 days</P>
<P>
<B>Duration of follow-up: </B>6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-01 14:42:55 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial outcomes were:</P>
<UL>
<LI>Mortality</LI>
<LI>Liver biochemistry</LI>
<LI>Liver histology</LI>
<LI>Adverse events</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-01 14:43:01 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Letter sent to authors in March 2000. No answer received. No further attempts were made as the trial was conducted between 1977-1979.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-02 13:14:06 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Helman-1971">
<CHAR_METHODS MODIFIED="2017-11-01 14:43:10 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Randomised controlled trial</P>
<P>Country: USA</P>
<P>Analyses were performed according to intention-to-treat method.</P>
<P>Sample size calculation was not reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-01 14:43:18 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Demographic characteristics</B>:</P>
<P>Age: (average) 47.8 years, with a range of 30 to 67 years</P>
<P>Sex : male 12, female 25</P>
<P>I<B>nclusion criteria and degree of severity</B>
</P>
<P>
<B>".</B> .... the diagnosis of alcoholic hepatitis was confirmed in all patients by percutaneous needle biopsy....Seventy per cent of patients had anaemia on admission. The anaemia was attributed to folate deficiency, blood loss, alcoholism, and haemolysis."</P>
<P>
<B>Exclusion criteria</B>
</P>
<P>
<B>"</B>Patients with clinical evidence of alcoholic hepatitis were excluded from the trial if a biopsy could not be obtained within the first week of hospitalisation, if gastrointestinal bleeding requiring transfusion occurred during this period, or if the purified protein derivative test was positive."</P>
<P>The authors reported that participants were classified into three groups, according to clinical severity of their disease. "Group I were severely ill- manifesting precoma or coma, group 2 -were moderately ill,but no evidence of encephalopathy, group 3 - asymptomatic ambulatory patients."</P>
<P>
<B>Randomisation procedure</B>
</P>
<P>
<B>"... </B>patients were selected by a random, double-blind technique....Drug treatment was randomly determined by the hospital pharmacist, without informing physicians, nurses, or patients until completion of the study"</P>
<P>
<B>Number of participants randomised</B>
</P>
<P>n = 37, divided in 3 groups according to the severity of the disease</P>
<P>Prednisolone group: n = 20</P>
<P>Control group: n = 17</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-01 14:43:28 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Experimental group</B>: prednisolone daily</P>
<P>Dose: 40 mg</P>
<P>
<B>Control group</B>: daily lactose placebo</P>
<P>Dose: 40 mg</P>
<P>
<B>Additional intervention</B>: "all patients were treated with bed rest, a high protein (100 g) and high calorie diet (3 000 Kcal) when tolerated and vitamin supplementation including folic acid. Sodium restriction was instituted and all patients with ascites and oedema were treated with diuretics."</P>
<P>
<B>Duration of treatment:</B> 6 weeks: 4 weeks and 2-week period tapered</P>
<P>
<B>Duration of follow-up after randomisation</B>: 4 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-16 22:27:13 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial outcomes were</P>
<UL>
<LI>Mortality</LI>
<LI>Liver biochemistry</LI>
<LI>Liver histology</LI>
<LI>Adverse events</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-02 13:14:06 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>"prednisolone and lactose placebo provided by Upjohn Co, Kalamazoo, Mich"</P>
<P>Letter sent to authors in March 2000. No answer received</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-02 12:47:52 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Maddrey-1978">
<CHAR_METHODS MODIFIED="2017-11-01 14:43:41 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Randomised, double-blind clinical trial with parallel-group design (3 groups)</P>
<P>Country: USA</P>
<P>Analyses were not performed according to the intention-to-treat principle.</P>
<P>Sample size calculation was not reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-02 12:47:24 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Demographic characteristics</B>
</P>
<P>Age: (mean <U>+</U> SD): 40 <U>+</U> 8.5 in the treatment group and 42.3 <U>+</U> 11.1 in the control group</P>
<P>Sex: 12 men (50%) in the treatment group and 23 men (74%) in the control group</P>
<P>
<B>Inclusion criteria and degree of severity</B>
</P>
<P>People with a history of long-standing and recent alcoholism were referred to the Liver Service (The Johns Hopkins Hospital). A percutaneous liver biopsy was performed unless precluded by coagulation abnormalities. Alcoholic hepatitis was defined histologically as an inflammatory hepatic disease with cell swelling and hydropic change, cell necrosis, and polymorphonuclear leukocytic infiltration.</P>
<P>
<B>Exclusion criteria </B>
</P>
<P>People with active gastro-intestinal haemorrhage, pancreatitis, history of peptic ulcer, active infection, presence of hepatitis B infection, or history of previous viral hepatitis were excluded. Maddrey's discriminant-function. All people had wedged hepatic venous pressure determination.</P>
<P>
<B>Randomisation procedure</B>
</P>
<P>"Patients were randomized for treatment within three groups based on apparent severity of disease. Random drug sequences were arranged within each group."</P>
<P>
<B>Number of participants randomised</B>
</P>
<P>n = 57</P>
<P>"Patients were randomised for treatment within three groups based on apparent severity of disease.</P>
<P>
<B>Group A</B> (moderately ill), serum bilirubin &gt; 3 mg per dL; hepatomegaly; and clotting factors adequate to allow liver biopsy</P>
<P>
<B>Group B</B> (more severely ill), hyperbilirubinaemia and hepatomegaly as in A with additional presence of ascites and/or hepatic encephalopathy, but coagulation studies adequate for liver biopsy</P>
<P>
<B>Group C </B>(severely ill), hyperbilirubinaemia and hepatomegaly as in A and B, with or without ascites and/or hepatic encephalopathy, but coagulation abnormalities precluded liver biopsy."</P>
<P>Prednisolone group: n = 25</P>
<P>Control group: n = 32</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-02 12:47:52 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Experimental group</B>:</P>
<P>Dose: 40 mg/d orally (eight tablets 5 mg each every morning)</P>
<P>
<B>Control group</B>: identical placebo tablets</P>
<P>
<B>Additional interventions to the trial groups</B>: all trial participants were offered a 3000 calorie diet. Protein (1 g to 1.5 g per kg) was provided for people with no evidence of hepatic encephalopathy. In people with encephalopathy, protein restriction to 20 g/d or less and lactulose therapy. Ascites was managed with sodium restriction alone or with the addition of spironolactone in those who did not respond with diuresis in 5 days. All participants initially received 100 mg<BR/>of thiamine intramuscularly. B-complex multivitamins and folic acid U mg) were given each day</P>
<P>
<B>Duration of treatment:</B> from 28 to 32 days</P>
<P>
<B>Follow-up</B>: until discharge</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-07-11 16:54:54 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial outcomes were<B> "</B>factors important in determining outcome in alcoholic hepatitis and to evaluate further the effects of corticosteroid therapy on early mortality and on the progression to cirrhosis, as reflected by histological changes and wedged hepatic venous pressure."</P>
<P>
<B>Reported outcomes in the trial</B>
</P>
<UL>
<LI>Early mortality</LI>
<LI>Complications of therapy</LI>
<LI>Liver function and hematological tests</LI>
<LI>Wedged hepatic venous pressure</LI>
<LI>Factors associated with a fatal outcome</LI>
<LI>Discriminant function analysis</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-10-31 09:01:22 +0100" MODIFIED_BY="[Empty name]">
<P>This study was supported by Research Grant AA00201 from the National Institute of Alcohol Abuse and Alcoholism of the National Institutes of Health, and by Grant RR-35 from the Clinical Research Centers Program, United States Public Health Service.<BR/>Prednisolone and placebo tablets were provided by the Division of Steroid Research, The Upjohn Company, Kalamazoo, Mich.</P>
<P>Letter sent to authors in March 2000. No answer received. No further attempts were made.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-02 14:05:53 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Mendenhall-1977">
<CHAR_METHODS MODIFIED="2017-11-02 14:04:44 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>A prospective, randomised clinical trial (three intervention groups)</P>
<P>Country: USA</P>
<P>Intention-to-treat analysis: not mentioned</P>
<P>Sample size calculation was not reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-02 14:05:53 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Demographic characteristics</B>
</P>
<P>Age: not reported</P>
<P>Sex: not reported; most probably men as they came from V.A. (Veteran Affairs) Medical Centers</P>
<P>
<B>Inclusion criteria and degree of severity</B>
</P>
<UL>
<LI>History of daily ethanol ingestion &gt; 100 g/d for &#8805; 1 year;</LI>
<LI>Hepatomegaly (&gt; 12 cm) and significant jaundice (bilirubin &gt; 5 mg %)</LI>
<LI>Liver biopsy was obtained in about 70% of participants to confirm the diagnosis</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<P>Not described</P>
<P>
<B>Randomisation procedure</B>
</P>
<P>Not described, but mentioned that "regimens were chosen randomly and blinded so that neither physician nor patient was aware of the treatment modality"</P>
<P>
<B>Number of participants randomised</B>
</P>
<P>n = 46</P>
<P>29 (n = prednisolone and placebo) + 17 (n = oxandrolone)</P>
<P>Prednisolone group: n = 12 (all severe alcoholic hepatitis)</P>
<P>Control group: n = 17 (all severe alcoholic hepatitis)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-02 13:57:40 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Experimental group: "prednisolone 60 mg/d x 5, then decreased over a 16 day period"</P>
<P>Dose: 60 mg</P>
<P>Placebo group: placebo</P>
<P>Dose: unknown</P>
<P>
<B>Additional treatment</B>: supportive care</P>
<P>
<B>Duration of treatment: </B>21 days</P>
<P>
<B>Duration of follow-up</B>: at the moment of discharge</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-01 14:44:12 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial outcomes were</P>
<UL>
<LI>Mortality</LI>
<LI>Liver biochemistry</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-01 14:44:12 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Letter sent to study authors in 2006. No answer received.</P>
<P>Only published as an abstract</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-02 14:05:05 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Mendenhall-1984">
<CHAR_METHODS MODIFIED="2017-11-02 14:05:05 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>A co-operative, multicentre, randomised clinical trial (three intervention groups)</P>
<P>Country: USA, 1980-1983</P>
<P>Intention-to-treat analysis</P>
<P>Sample size calculation was reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-02 12:44:17 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Demographic characteristics</B>
</P>
<P>Age: (mean 90) prednisolone group 51.5 <U>+</U> 8.2; (mean 88) placebo group 50.4 <U>+</U> 9.2</P>
<P>Sex: male</P>
<P>
<B>Inclusion criteria and degree of severity</B>
</P>
<P>Men hospitalised at 6 Veterans Administration Medical Centers in whom diagnosis of moderate or severe alcoholic hepatitis was based on conventional clinical and laboratory changes of this disease.</P>
<P>"Histological confirmation was not required, so that severely ill patients were not excluded."</P>
<P>Criteria to classify severity<B>:</B> "the degree of jaundice (bilirubin) and coagulopathy (prothrombin time)"</P>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>"..conditions that contradicted corticosteroid therapy: severe infections, active peptic ulcer disease,or insulin - dependent diabetes mellitus) or if they had taken corticosteroids within the preceding three months"</LI>
<LI>"a positive test for hepatitis B surface antigen; clinical or historical evidence of recent parenteral drug abuse, intractable congestive heart failure, neoplasms that commonly metastasize to the liver or nonalcoholic liver diseases"</LI>
</UL>
<P>
<B>Randomisation procedure</B>
</P>
<P>"...One hundred thirty-two patients with moderate disease and 131 with severe disease were randomly assigned to one of three treatments: prednisolone, oxandrolone, or placebo...Treatment assignment were made by the Coordinating Center (Hines, Ill.)The random assignment of treatments was balanced within each hospital, as well as according to disease severity."</P>
<P>
<B>Number of participants randomised</B>
</P>
<P>178 (n = prednisolone and placebo) + 85 (n = oxandrolone)</P>
<P>Prednisolone group: n = 90 (moderate 46, severe 44)</P>
<P>Control group: n = 88 (moderate 45, severe 43)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-01 14:45:48 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Experimental group: </B>prednisolone</P>
<P>Dose: "60 mg per day for four days; 40 mg per day for four days; 30 mg per day for four days; 20 mg per day for four days; 10 mg per day for seven days; 5 mg per day for seven final days"</P>
<P>
<B>Control group:</B> corresponding placebos</P>
<P>
<B>Duration of treatment:</B> 30 days</P>
<P>When possible, participants were evaluated monthly at outpatient clinics. If alcoholic hepatitis recurred and required re-hospitalisation, the person was reassigned to the same therapy for 30 days with his permission.</P>
<P>
<B>Duration of follow-up after randomisation</B>: 1 year (350 days for prednisolone group )</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-01 14:45:48 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial outcomes were</P>
<UL>
<LI>Mortality</LI>
<LI>Liver complications</LI>
<LI>Liver biochemistry</LI>
<LI>Adverse events</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-01 14:45:38 +0100" MODIFIED_BY="Dimitrinka Nikolova"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-02 12:48:41 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Porter-1971">
<CHAR_METHODS MODIFIED="2017-11-01 14:46:08 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>A prospective, double-blind, controlled pilot trial</P>
<P>Country: USA</P>
<P>Analyses were not performed according to the intention-to-treat method.</P>
<P>Sample size calculation was not reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-02 12:48:41 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Demographic characteristics </B>steroid/placebo group</P>
<P>Age (years) 44.6 <U>+</U> 4.4/49.5 <U>+</U> 8.9 (age range 27 to 61 years)</P>
<P>Sex: male 13/7 (64%/67%)</P>
<P>
<B>Inclusion criteria and degree of severity</B>:</P>
<P>"A history of recent heavy alcohol ingestion</P>
<P>a serum bilirubin concentration of 5 mg per 100 mL or more</P>
<P>clinical and laboratory deterioration over the first five hospital days, a striking lack of improvement in the patient's clinical and biochemical status over the same period, or rapid marked deterioration in less than 24 hours</P>
<P>for admission to the study all three absolute criteria were required</P>
<P>In addition, two or more major criteria or one major and four or more minor criteria had to be met. The major criteria were liver biopsy showing alcoholic hepatitis; hepatic encephalopathy (including asterixis); persistent or progressive azotaemia not explained by another process, and total bilirubin levels &gt; 20 mg/100 mL. The minor criteria for inclusion were fever that was not obviously secondary to another process; white blood count &gt; 12,000 not obviously secondary to another process; anorexia or nausea or vomiting; palpable hepatomegaly; palpable splenomegaly; oesophageal varices; spider angiomas, edema or ascites; palmar erythema and a prothrombin time prolonged three or more seconds over control.</P>
<P>The Australia antigen was absent from the serum of all 16 patients in whom it was sought. Before the trial, a percutaneous needle biopsy of the liver was performed if the prothrombin time was not prolonged more than four seconds over control and there was no clinical bleeding tendency.</P>
<P>
<B>Exclusion criteria</B> active gastrointestinal bleeding, pancreatitis, radiological evidence of peptic-ulcer disease, active or questionably active pulmonary tuberculosis and potentially life threatening bacterial infection.</P>
<P>
<B>Randomisation procedure</B>: "the case was randomised into one of the two treatment groups. Both the steroid (6- methyl prednisolone, or Medrol) and the placebo (lactose) were packaged and coded by number in both parenteral and oral forms (prepared and supplied through the courtesy of the Upjohn Co, Kalamazoo,Mich)and randomisation was achieved by a number drawn from a pool. Neither patients nor physicians knew which form of treatment was used until the study had been completed, when the code was broken."</P>
<P>
<B>Number of participants randomised</B>: n = 23 (20) "23 accepted to participate, but 3 died within 36 hours of the start of therapy, and were excluded from the analysis before the code was broken, and did not receive adequate medication. The final series consisted of 20 patients"</P>
<P>Prednisolone group: n = 11</P>
<P>Placebo group: n = 9</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-01 14:46:32 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Prednisolone group</B>: "6-methyl-prednisolone (or Medrol) 40 mg per day (equivalent to 50 mg prednisolone, or 200 mg hydrocortisone) in three divided doses, parenterally for the first 10 days. If clinical improvement occurred over this interval and if nausea and vomiting were absent the drug was administered orally, and the dose gradually tapered (decreased every second day by 4 mg for the 11th to the 18th days, by 2 mg for the 19th to 30th days and every third day by 2 mg for the 31st to 45th days). If there was no clinical improvement within 10 days. The initial parenteral dose of 40 mg daily was continued until improvement or death occurred."</P>
<P>Dose: 50 mg prednisolone</P>
<P>
<B>Placebo group: </B>placebo(lactose). "...packaged and coded by number in both parenteral and oral forms (prepared and supplied through the courtesy of the Upjohn Co, Kalamazoo, Mich)"</P>
<P>
<B>Additional treatment</B>: "early in the study only the patients with a positive intermediate strength PPD test or a suspicious chest film were given isoniazid coverage , however, later in the study, all patients were so treated"</P>
<P>"general supportive care required in hepatic decompensation. Special attention was given to fluid and electrolyte balance , prompt treatment of hepatic encephalopathy and repeated evaluation for infection... most patients had daily estimation of the caloric and protein intake by a hospital dietitian... who were unable to take oral nutrition received parenterally a minimum of 400 calories per day as glucose</P>
<P>
<B>Duration of treatment and of follow-up</B>: 45 days after randomisation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-07-11 16:54:26 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial outcomes were:</P>
<UL>
<LI>Mortality</LI>
<LI>Liver biochemistry</LI>
<LI>Liver histology</LI>
<LI>Adverse events</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-01 14:46:39 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Country: USA</P>
<P>Letter sent to study authors in March 2000. No answer received.</P>
<P>"Twenty-three patients were accepted for studying. However, three died within 36 hours of the start of the therapy and were excluded from analysis before the code was broken because they did not receive adequate medication."</P>
<P>Supported in part by a gastroenterology-research training grant (AM-05099) from the National Institute of Artrithis and Metabolic Diseases (a portion of this work was conducted within the Clinical Research Center of the University of Washington, with support by a grant MO1 FR-37 from the National Institutes of Health</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-02 12:49:16 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Ramond-1992">
<CHAR_METHODS MODIFIED="2017-11-02 12:49:06 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>A randomised, double-blind trial</P>
<P>Intention to-treat analysis</P>
<P>"The study was approved by the hospital ethics committees"</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-02 12:49:16 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Demographic characteristics</B>: 124 alcoholic patients were admitted to 2 centres.</P>
<P>Mean age <U>+</U> SD: 48.1 <U>+</U> 1.3; 48.2 <U>+</U> 1.6<BR/>Sex: (male): prednisolone group/placebo group 10/9</P>
<P>
<B>Randomisation procedure</B>: "... a random code was prepared by computer for each participating center. There was a different code for men and women in each center, so that within each group of six patients (male or female), three patients received prednisolone and three patients placebo. Random sequence of drug or placebo were prepared by the pharmacists at each hospital"</P>
<P>
<B>Inclusion criteria and degree of severity:</B> "all the patients had biopsy proven alcoholic hepatitis (characterised by hyaline necrosis and infiltration of polymorphonuclear leucocytes) and spontaneous hepatic encephalopathy or a discriminant-function value higher than 32 (or both)."</P>
<P>"Eight patients died before inclusion in the trial."</P>
<P>
<B>Exclusion criteria "</B>gastrointestinal bleeding or bacterial infection were excluded from the trial unless they could be effectively treated within 48 hours"<BR/>Presence of hepatitis B surface antigen, presence of HIV antibodies, refusal of liver biopsy, non-alcoholic hepatitis at histology</P>
<P>
<B>Number of participants randomised</B>: n = 65 "65 patients were randomly assigned, but 4 were excluded- one patient assigned to receive prednisolone was found to have anguilluliasis and her treatment was stopped one day after her inclusion in the study. Three patients assigned to placebo were found not to have satisfied the inclusion criteria . These 4 patients were alive at the end of treatment"</P>
<P>Prednisolone group: n = 33 (analysed 32)</P>
<P>Placebo group: n = 32 (analysed 29)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-01 14:47:03 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Prednisolone group</B>:</P>
<P>"prednisolone (Solupred) in 20 mg tablets and identical placebo were provided by the pharmacists at each hospital"</P>
<P>Dose: "prednisolone 40 mg (40 mg of prednisolone equivalent to 32 mg of methylprednisolone) was given in a single dose of two pills each morning for 28 days", if the participant was unable to take oral medication, "received intravenous infusions of prednisolone (Hydrocortancyl) or placebo prepared by the pharmacists and administered by the pharmacist and administered by the attending physician."</P>
<P>
<B>Placebo group</B>:</P>
<P>"identical placebo was given in a single dose of two pills"</P>
<P>
<B>Additional treatment</B>:</P>
<P>"All patients were provided with 3,000 Kcal containing one gram protein/kg. Patients with hepatic encephalopathy received lactulose therapy. Ascites was managed with sodium restriction or by the spironolactone to the treatment regimen" "B complex multivitamins, folic acid, and antiacids were given each day"</P>
<P>
<B>Duration of treatment</B>: 28 days<BR/>
<B>Duration of follow-up</B>: 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-07-11 16:53:05 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial outcomes were:</P>
<UL>
<LI>Mortality</LI>
<LI>Liver biochemistry</LI>
<LI>Liver histology</LI>
<LI>Adverse events</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-01 14:47:08 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Country: France. From March 1987-June 1990</P>
<P>Letter sent to study authors in March 2000. No answer received</P>
<P>The trial was stopped at the first interim analysis conducted after inclusion of 61 participants out of the planned 130 participants. The authors used an alpha error below 0.025. This is too high a value to prevent early stopping at a random high.</P>
<P>"Drug therapy was interrupted by the attending physician if there was severe bacterial infection or gastrointestinal bleeding, or if a corticosteroid-related complication was suspected... in patients with such complications the remaining tablets of the study drug were replaced with placebo tablets provided by the pharmacist (the only person who knew which regimen the patient had received first). The principal investigator and their associates were not aware of randomisation procedure or of the medication that the patients were receiving throughout the trial."</P>
<P>"65 patients were randomly assigned, but 4 were excluded - one patient assigned to receive prednisolone was found to have anguilluliasis and her treatment was stopped one day after her inclusion in the study. Three patients assigned to placebo were found not to have satisfied the inclusion criteria. These 4 patients were alive at the end of treatment."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-02 15:36:51 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Richardet-1993">
<CHAR_METHODS MODIFIED="2017-11-02 12:55:09 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>A randomised clinical trial with a cross-over design</P>
<P>Intention to-treat analysis: not mentioned</P>
<P>Sample size calculation was not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-01 14:47:40 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Demographic characteristics</B>: no information.<BR/>
</P>
<P>
<B>Inclusion criteria and degree of severity</B>: non-infected patients with histologically proven alcoholic hepatitis. All patients had severe hepatic failure (prothrombin time &lt; 50%, or bilirubin &gt; 5.6 mg/dL, or encephalopathy)</P>
<P>
<B>Number of participants randomised</B>: 23</P>
<P>Glucocorticosteroid group: 12 participants</P>
<P>Placebo group: 11 participants<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-02 14:16:27 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Prednisolone group</B>: prednisolone 40 mg daily</P>
<P>
<B>Control group</B>: placebo 40 mg daily</P>
<P>
<B>Duration of treatment</B>:<BR/>Prednisolone group: 1 week of treatment followed by one week of no treatment </P>
<P>Control group: 1 week of no treatment followed by one week of treatment</P>
<P>After that, both groups received glucocorticosteroids for three weeks.</P>
<P>
<B>Duration of follow-up</B>: at discharge from hospital (three months)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-02 15:36:51 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial outcomes were: </P>
<UL>
<LI>Mortality</LI>
<LI>Liver biochemistry</LI>
</UL>
<P/>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-02 14:16:39 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Country: France.</P>
<P>Letter sent to study authors in 2006. No answer received.</P>
<P>Only published as abstract</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-02 12:55:33 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Shumaker-1978">
<CHAR_METHODS MODIFIED="2017-11-01 14:47:55 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>A prospective, double-blind, randomised clinical trial</P>
<P>Sample size calculation was not reported.</P>
<P>Intention-to-treat analysis: not mentioned, but presumably used</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-02 12:55:33 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Demographic characteristics</B>:</P>
<P>mean age <U>+</U> SD: 47/43</P>
<P>Sex: male were 25% in the glucocorticosteroid group and 44% in the placebo group</P>
<P>
<B>Inclusion criteria and degree of severity:</B>
</P>
<P>"history of recent heavy alcoholic ingestion, serum bilirubin greater than 5 mg %, hospitalisation for at least 5 days without improvement in liver tests; or rapid deterioration of the clinical condition during a 24-hour period while under observation. In addition, a patient had to have a minimum of two "major criteria" or one "major" and two "minor" criteria to be placed in the study. The major criteria were a liver biopsy showing alcoholic hepatitis (with or without Mallory bodies), hepatic encephalopathy, azotaemia unexplained by another process (BUN [blood urea nitrogen] &gt; 20 mg % or creatinine &gt; 1.5 mg % ), hyperbilirubinaemia (&gt; 20 mg%) and prothrombin time prolonged more than four seconds over control; and unresponsive to parenteral administration of vitamin K. The minor criteria included fever not obviously secondary to another process, WBC (white blood count) &gt; 12,000, hepatomegaly (span greater than 14 cm), splenomegaly, or liver stigmas (spider telangiectasias, palmar erythema, ascites, edema, etc)"</P>
<P>...."a positive HBAg did not exclude them from the study if a percutaneous liver biopsy confirmed alcoholic hepatitis"</P>
<P>
<B>Exclusion criteria: </B>
</P>
<P>"Patients were not considered for the trial if their SGOT [serum glutamic oxaloacetic transaminase] was greater than 500....Patients were rejected from the study if they manifested active gastrointestinal bleeding, pancreatitis, X-ray evidence of peptic ulcer disease, active or questionably active tuberculosis, active infection, or severe psychiatric disorder"</P>
<P>
<B>Randomisation procedure:</B>
</P>
<P>"The patient was then randomised into a predetermined code provided by the drug manufacturer. Immediately prior to randomisation, patients were stratified into two categories based on the presence or abstinence of criteria permitting liver biopsy" the purpose of this procedure was to provide comparable case material for both steroid and placebo control groups.in the absence of other contradictions, patients with prothrombin times less than four seconds prolonged were placed in the "Biopsy feasible" group (n = 10) whether or not they agreed to a biopsy. All other patients constituted the "Biopsy- Disallowed" group (n = 17)"</P>
<P>
<B>Number of participants randomised</B>: 27</P>
<P>Prednisolone group: n = 12</P>
<P>Control group: n = 15</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-01 14:48:07 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Prednisolone group</B>: "80 mg of 6-methylprednisolone or equivalent number of placebo tablets (or parenteral therapy of the same dosage intravenously if gastrointestinal function precluded oral intake) for four to seven days; the medication was then tapered on a flexible schedule with cessation of therapy planned for four weeks unless death or complications"</P>
<P>Dose: 100 mg prednisolone</P>
<P>
<B>Control group</B>: placebo</P>
<P>
<B>Additional interventions to the trial groups</B>: "Both groups received comparable supportive care required in hepatic decompensation"</P>
<P>All participants with positive tuberculin tests were treated with INH 300 mg daily, and 50 mg of pyridoxine daily.</P>
<P>
<B>Duration of treatment:</B> 5 weeks; participants were placed on treatment for 4-7 days. Then the medication was tapered on flexible schedule with cessation of therapy planned for 4 weeks unless death or complication intervened.<BR/>
<B>Duration of follow-up:</B> until the moment of discharge</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-07-11 16:54:12 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial outcomes were:</P>
<UL>
<LI>Mortality</LI>
<LI>Liver histology</LI>
<LI>Adverse events</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-01 18:17:27 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Country: USA</P>
<P>Letter sent to study authors in March 2000. No answer received</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-02 12:56:17 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Theodossi-1982">
<CHAR_METHODS MODIFIED="2016-10-03 13:16:08 +0200" MODIFIED_BY="[Empty name]">
<P>A randomised controlled trial</P>
<P>Analyses were not by intention-to-treat method.</P>
<P>Sample size calculation was not reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-01 14:48:26 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Demographic characteristics</B>:</P>
<P>Sex: men/women prednisolone group: 19/8, control group 12/16</P>
<P>Age: not mentioned</P>
<P>
<B>Inclusion criteria and degree of severity</B>: "patients had to satisfy the following criteria:</P>
<P>- a history of alcohol intake of about 80 g or more daily for at least five years,</P>
<P>- a serum bilirubin concentration greater than 80 pmol/l (normal up to 20 timol/L),</P>
<P>- a serum aspartate transaminase level at least twice the upper limit of normal (normal up to 40 IU/1),</P>
<P>- a prothrombin time prolonged by at least nine seconds."</P>
<P>"Gastrointestinal bleeding, renal failure, and sepsis did not invalidate entry."</P>
<P>
<B>Exclusion criteria:</B>
</P>
<P>"Patients with hepatoma and those with other diseases such as recent myocardial infarction, an accompanying cerebrovascular accident including evidence of subdural hematoma, and active tuberculosis"</P>
<P>
<B>Randomisation procedure </B>
<BR/>
<B>"</B>Patients .... referred from other hospitals because of the severity of their illness. Patients were allocated by random sealed envelope technique to a control or treatment group..."</P>
<P>
<B>Number of patients</B>: 60 (55). They were referred from other hospitals because of the severity of their illness (after excluded patients from the analyses because of doubts in initial diagnosis)</P>
<P>Prednisolone group: n = 28 (27)</P>
<P>Control group: n = 32 (28)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-02 12:56:17 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Prednisolone group</B>: intravenous methylprednisolone 1 g daily for three days</P>
<P>Dose: 1.25 g prednisolone</P>
<P>
<B>Control group</B>: no intervention</P>
<P>
<B>Additional treatment</B>: "Patients who were too ill to take the standard hospital diet received a minimum of 2000 calories as intravenous 20% glucose. Encephalopathy was treated with protein restriction (maximum of 20 g/day), lactulose (15 to 30 mL twice daily), and daily magnesium sulphate enemas"</P>
<P>
<B>Duration of treatment</B>: 3 days<BR/>
<B>Duration of follow-up:</B> "there was a little difference between the groups in the mean length of stay in hospital (treatment group 24.2 days and control group 28.1 days)"</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-07-11 14:24:20 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial outcomes were:</P>
<UL>
<LI>Mortality</LI>
<LI>Liver biochemistry</LI>
<LI>Adverse events</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-01 14:48:33 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Country: UK</P>
<P>Letter sent to study authors in March 2000. No answer received</P>
<P>"Of the 60 patients who satisfied the entry criteria, one in the treatment group and four in the control group were excluded from the final analysis because subsequent findings in four cases cast doubt on the initial diagnosis, and one patient was later found to have been given corticosteroids at the referring hospital. Thus there were 27 patients in the treatment and 28 in the control group."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-02 12:56:33 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Thursz-2015">
<CHAR_METHODS MODIFIED="2017-11-01 14:48:49 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Multicentre, randomised trial with a 2-by-2 factorial design (09/MRE09/59)</P>
<P>Country: UK (65 hospitals). January 2011-February 2014</P>
<P>Analyses were performed according to intention-to-treat basis</P>
<P>Sample size calculation was reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-02 12:56:33 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Demographic characteristics</B>
</P>
<P>Age: (mean) <U>+</U> SD: glucocorticosteroids group/control group 49.3 ± 10.6; 48.6 ± 9.8/47.9 ± 10.2; 48.8 ± 10.3</P>
<P>Sex (male (%)): glucocorticosteroids group/control group 359 (65,6%)/326 (59,8%)</P>
<P>Hepatic encephalopathy (%): 152/143 (28%/26%)</P>
<P>
<B>Inclusion criteria and degree of severity</B>
</P>
<P>"all patients were alcohol abusers with a clinical diagnosis of severe alcoholic hepatitis manifested by hepatomegaly, leukocytosis, and a serum-bilirubin greater than 5 mg/dL, spontaneous hepatic encephalopathy"</P>
<UL>
<LI>Age of &#8805; 18 years</LI>
<LI>Clinical diagnosis of alcoholic hepatitis</LI>
<LI>Average alcohol consumption of &gt; 80 g/d for men and &gt; 60 g/d for women,</LI>
<LI>Serum bilirubin level &gt; 80 &#956;mol/L (4.7 mg/dL)</LI>
<LI>Discriminant function of &#8805; 32</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>Jaundice for &gt; 3 months</LI>
<LI>Cessation of alcohol consumption for &gt; 2 months before randomisation</LI>
<LI>Presence of other causes of liver disease</LI>
<LI>Serum aspartate aminotransferase level &gt; 500 IU/L or serum alanine transaminase level &gt; 300 IU/L</LI>
<LI>Previous entry into the study within the preceding 6 months</LI>
</UL>
<P>
<B>Randomisation procedure</B>
</P>
<P>"...A web-based computer system (Tenalea, Forms-Vision) was used to enrol eligible patients and randomly assign them to study groups. The randomization schedule was created with the use of Stata software, version 11 (StataCorp). Randomization was performed with a block size of four, with stratification according to geographic area and risk category. The high-risk category consisted of patients who had an occurrence of gastrointestinal bleeding, renal impairment, or sepsis before randomisation. All other patients were assigned to the intermediate-risk category."</P>
<P>
<B>Number of participants randomised</B>
</P>
<P>n = 1103 ("...1103 patients underwent randomisation (data from 1053 were available for the primary end-point analysis..")</P>
<P>Prednisolone group: 274 + 277<BR/>
</P>
<P>Control group: 276 + 276</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-01 14:51:23 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Experimental groups</B>: "the second group receiving 40 mg of prednisolone daily and a pentoxifylline-matched placebo (n = 277), the fourth group receiving 40 mg of prednisolone daily, and 400 mg of pentoxifylline three times daily (n = 274)</P>
<P>Dose: 40 mg</P>
<P>
<B>Control groups</B>: "one group receiving a pentoxifylline matched placebo and a prednisolone matched placebo, placebo (n = 276). The third group receiving 400 mg of pentoxifylline three times daily and prednisolone matched placebo (n = 274)".</P>
<P>
<B>Additional treatment: "</B>Standard supportive care and nutritional support were given to each patient. The clinician responsible for each patient made the decision regarding other treatments, such as terlipressin for patients in whom hepatorenal failure was developing, acid suppression for prophylaxis against gastrointestinal haemorrhage, antibiotics, and vitamin supplementation. Patients with renal failure (defined as a creatinine level &gt; 500 &#956;mol per liter [&gt; 5.7 mg per decilitre] or the requirement for renal-replacement therapy), active gastrointestinal bleeding, or untreated sepsis, and patients requiring inotropic support with epinephrine or norepinephrine, were excluded unless the condition stabilized within the first 7 days after admission to the hospital."</P>
<P>
<B>Duration of treatment</B>: 28 days</P>
<P>
<B>Duration of follow-up: </B>1 year</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-01 14:48:56 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial outcomes were</P>
<UL>
<LI>Mortality</LI>
<LI>Adverse events</LI>
<LI>Quality of life (using the European quality of life -5 dimensions (EQ -5D) score registered to Eudra CT 2009- 013897-42 and ISRCTN 88782125)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-01 14:49:01 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>The "European Quality of Life Five Dimension Five Level Scale (EQ-5D-5L): The EQ-5D-5L is a self-report, multiple choice questionnaire that provides a simple descriptive profile and a single index value for health status. The EQ-5D-5L essentially consists of 2 pages &#8211; the EQ-5D descriptive system (page 2) and the EQ visual analogue scale (EQ VAS) (page 3). The descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The EQ VAS records the respondent&#8217;s self-rated health on a vertical, visual analogue scale. The EQ-5D-5L takes only a few minutes to complete.</P>
<P>A summary index with a maximum score of 1 can be derived from these five dimensions by conversion with a table of scores. The maximum score of 1 indicates the best health state, by contrast with the scores of individual questions, where higher scores indicate more severe or frequent problems. In addition, there is a visual analogue scale (VAS) to indicate the general health status with 100 indicating the best health status."</P>
<P>"The study was approved by the Multicenter Research Ethics Committee (reference number 09/MRE09/59), and clinical trial authorization was received from the Medicines and Healthcare Products Regulatory Agency (Funded by the National Institute for Health Research Health Technology Assessment program; STOPAH EudraCT number, 2009-013897-42, and Current Controlled Trials number, ISRCTN88782125.)"</P>
<P>"The trial was conducted and reported with fidelity to the protocol, the Medicines for Human Use (Clinical Trials) Regulations 2004, as amended in 2006, the European Union Clinical Trials Directive (Directive 2001/20/EC) guidelines, the principles of the International Conference on Harmonisation Good Clinical Practice under the oversight of University Hospital Southampton NHS Foundation Trust, and the provisions of the Declaration of Helsinki.</P>
<P>Letter sent to M. Thursz 12 October 2016. No reply received yet</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>INH = isoniazid; PAS = para-aminosalicylic acid; PPD = purified protein derivative; PTX = pentoxifylline</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2017-11-01 14:52:44 +0100" MODIFIED_BY="Dimitrinka Nikolova" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2017-11-01 14:51:47 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Alvarez-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-01 14:51:47 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>An observational study (patient series). Thirteen participants with severe alcoholic hepatitis were treated with systemic glucocorticosteroids and total enteral nutrition.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-11-01 14:51:52 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Cabr_x00e9_-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-01 14:51:52 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>A randomised trial of glucocorticosteroids versus nutrition in people with alcoholic hepatitis. Participants received oral or intravenous prednisolone or enteral nutrition (2000 kcal/d of a chemically defined polymeric enteral diet enriched in branched-chain amino acids)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-21 16:20:13 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Christensen-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-21 16:20:13 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>A quasi-randomised clinical study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-21 16:20:16 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Copenhagen-1969">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-21 16:20:16 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>A meta-analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-21 16:20:17 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Daures-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-21 16:20:17 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>A meta-analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-10-31 15:48:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dhanda-2016">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-10-31 15:48:22 +0100" MODIFIED_BY="[Empty name]">
<P>A prospective single-
centre cohort of patients with severe alcoholic hepatitis treated with steroids - the incidence and significance of infection</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-11-01 14:51:58 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Galambos-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-01 14:51:58 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Reported in article through private contacts as part of <LINK REF="STD-Shumaker-1978" TYPE="STUDY">Shumaker 1978</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-10-31 15:49:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gill-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-10-31 15:49:27 +0100" MODIFIED_BY="[Empty name]">
<P>The trial randomised 10 patients with severe alcoholic hepatitis to prednisolone, testosterone, and amino acid supplement versus no intervention.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-11 14:31:52 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Goldis-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-11 14:31:52 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>An observational study (patient series); the authors used a control group from the same centre.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-10-31 15:49:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hozo-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-10-31 15:49:26 +0100" MODIFIED_BY="[Empty name]">
<P>The trial randomised patients with alcoholic liver cirrhosis to glucocorticosteroids versus placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-21 16:19:38 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Imperiale-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-21 16:19:38 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>A meta-analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-11-01 14:52:09 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Lesesne-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-01 14:52:09 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>A randomised trial of glucocorticosteroids versus nutrition in patients with alcoholic hepatitis. Participants received glucocorticosteroids plus permission to eat as they wanted or a maximum of 600 kcal/d as intravenous glucose, while the control group received caloric supplements of at least 1600 kcal/d</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-21 16:19:24 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Mal-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-21 16:19:24 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Abstract about influence of corticosteroids on the level of serum TNF concentrations</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-11-01 14:52:26 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Mendenhall-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-01 14:52:26 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>A chapter on alcoholic hepatitis in a book</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-11-01 14:52:24 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Moreno-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-01 14:52:24 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>A multi central study with two groups of comparison of intensive enteral nutrition with complete nutrition, in both groups receiving prednisolone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-12-16 15:14:52 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Morris-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-12-16 15:14:52 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>An observational study (patient series)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-21 15:40:46 +0200" MODIFIED_BY="Sarah  Klingenberg" STUDY_ID="STD-Naganuma-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-21 15:40:46 +0200" MODIFIED_BY="Sarah  Klingenberg">
<P>The trial of granulocytapheresis and leukocytapheresis for the treatment of severe alcoholic hepatitis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-11-01 14:52:18 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Naveau-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-01 14:52:18 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial randomised patients with alcoholic hepatitis to receive infliximab versus placebo. All participants received prednisone too</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-11-01 14:52:18 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Phillips-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-01 14:52:18 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial randomised participants to antioxidants versus glucocorticosteroids</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-12-16 15:14:49 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Poynard-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-12-16 15:14:49 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>A meta-analysis on alcoholic hepatitis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-12-16 15:14:48 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Reynolds-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-12-16 15:14:48 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>A narrative review on alcoholic hepatitis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-12-16 15:14:46 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Schlichting-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-12-16 15:14:46 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>A quasi-randomised clinical study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-11-01 14:52:39 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Spahr-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-01 14:52:39 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial randomised patients with alcoholic hepatitis to receive infliximab versus placebo. All participants received prednisone too</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-11-01 14:52:36 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Stewart-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-01 14:52:36 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial stratified participants by gender and glucocorticosteroid use, and then randomised participants to receive antioxidants versus placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-12-16 15:14:44 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Tygstrup-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-12-16 15:14:44 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>A meta-analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-20 11:13:38 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Young_x002d_Sun-Lee">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-20 11:13:38 +0200" MODIFIED_BY="[Empty name]">
<P>A review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>TNF: tumour necrosis factor</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2016-09-25 17:24:45 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2016-10-04 10:20:03 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2017-11-02 12:57:42 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2017-11-01 17:22:51 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 14:41:19 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Blitzer-1977">
<DESCRIPTION>
<P>"Patients were assigned by random, sealed-envelope technique to receive either placebo or steroid"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-19 22:24:52 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Bories-1987">
<DESCRIPTION>
<P>"By random number table"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 14:42:02 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Campra-1973">
<DESCRIPTION>
<P>"...using previously prepared sealed envelopes, patients were randomly allocated to one of the two treatment groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-16 23:47:09 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carithers-1989">
<DESCRIPTION>
<P>"A random code was prepared for each of the four participating institutions such that within each group of 10 patients, 5 would receive methylprednisolone and 5 placebo. ......".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-16 22:15:59 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-De-2014">
<DESCRIPTION>
<P>"The recruited patients were then divided into 2 groups by a computer generated randomization table"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-16 23:55:01 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Depew-1980">
<DESCRIPTION>
<P>Not described. "All patients fulfilling the criteria who gave informed consent were randomised into two treatment protocols"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-16 22:27:35 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Helman-1971">
<DESCRIPTION>
<P>Not described. It only reads<B>: "</B>patients were selected by a random, double-blind technique...."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-17 00:02:43 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maddrey-1978">
<DESCRIPTION>
<P>"Patients were randomised for treatment within three groups based on apparent severity of disease. Random drug sequences were arranged within each group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-16 22:43:21 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Mendenhall-1977">
<DESCRIPTION>
<P>".....regimens were chosen randomly"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 14:45:58 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Mendenhall-1984">
<DESCRIPTION>
<P>"Treatment assignment was made by the Coordinating Center (Hines, Ill.). The random assignment of treatments was balanced within each hospital, as well as according to disease severity".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 14:46:44 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Porter-1971">
<DESCRIPTION>
<P>"... randomisation was achieved by a number drawn from a pool"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 14:47:15 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Ramond-1992">
<DESCRIPTION>
<P>"a random code was prepared by computer for each participating centre... There was a different code prepared for men and women in each center, so that within each group of six patients (male and female), three patients received prednisolone and three received placebo"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 17:22:51 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Richardet-1993">
<DESCRIPTION>
<P>No information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 14:48:21 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Shumaker-1978">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-08 16:48:42 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Theodossi-1982">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-16 21:55:07 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Thursz-2015">
<DESCRIPTION>
<P>
<B>"</B>A web-based computer system (Tenalea, Forms-Vision) was used to enrol eligible patients and randomly assign them to study groups."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2017-11-01 17:22:53 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 14:41:19 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Blitzer-1977">
<DESCRIPTION>
<P>"Patients were assigned by random, sealed-envelope technique to receive either placebo or steroid"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-16 22:07:12 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Bories-1987">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-16 23:44:59 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Campra-1973">
<DESCRIPTION>
<P>Information obtained through personal communication with the authors in 2001 reads: "they were never in the possession of the investigators, but were kept by the department secretary who opened them upon request"</P>
<P>However, the publication reads: "using previously prepared sealed envelopes, patients were randomly allocated to one of the two treatment groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-29 22:45:06 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carithers-1989">
<DESCRIPTION>
<P>"the random code sequence was kept by an independent source"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-08 16:51:40 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-De-2014">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-16 22:16:46 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Depew-1980">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-17 00:00:34 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Helman-1971">
<DESCRIPTION>
<P>"Drug treatment was randomly determined by the hospital pharmacist, without informing physicians, nurses, or patients until completion of the study "</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 14:43:59 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Maddrey-1978">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 14:45:15 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Mendenhall-1977">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-17 00:04:54 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mendenhall-1984">
<DESCRIPTION>
<P>"Treatment assignment were made by the Coordinating Center (Hines,Ill.)".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 14:46:44 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Porter-1971">
<DESCRIPTION>
<P>"the case was randomised into one of the two treatment groups. Both the steroid (6- methyl prednisolone, or Medrol) and the placebo (lactose) were packaged and coded by number in both parenteral and oral forms (prepared and supplied through the courtesy of the Upjohn Co, Kalamazoo, Mich)..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 14:47:15 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Ramond-1992">
<DESCRIPTION>
<P>"a random code was prepared by computer for each participating centre. Random sequences of drug or placebo were prepared by the pharmacist at each hospital"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 17:22:53 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Richardet-1993">
<DESCRIPTION>
<P>No information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 14:48:21 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Shumaker-1978">
<DESCRIPTION>
<P>"The patient was then randomised into a predetermined code provided by the drug manufacturer"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-07-11 14:30:09 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Theodossi-1982">
<DESCRIPTION>
<P>"Patients were allocated by random sealed envelope technique to a control or treatment group,..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 14:49:19 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Thursz-2015">
<DESCRIPTION>
<P>"The randomization schedule was created with the use of Stata software, version 11 (StataCorp). Randomization was performed with a block size of four, with stratification according to geographic area and risk category. "Treatment allocation was blinded to site staff and the patient by providing each patient with a unique four-digit patient pack number."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2017-11-01 17:22:57 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-10-02 22:37:08 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blitzer-1977">
<DESCRIPTION>
<P>"Only the pharmacist was aware of the type of therapy which any individual patient was receiving."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-11-16 22:07:14 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Bories-1987">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-10-01 18:21:28 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Campra-1973">
<DESCRIPTION>
<P>"the trial was not double blind"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-10-16 23:48:05 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carithers-1989">
<DESCRIPTION>
<P>"neither the principal investigators nor their associates were aware of which regimen patients received throughout the trial."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-10-10 15:18:25 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-De-2014">
<DESCRIPTION>
<P>"The investigator, who allocated the patients to the groups, administered the drugs and collected the clinical and laboratory data, as well as statisticians were all blinded regarding the nature of the pharmacotherapy."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-01 14:43:06 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Depew-1980">
<DESCRIPTION>
<P>"Neither the principal investigators nor the physicians attending the patients were aware of the identity of the coded drugs. Provision was made for breaking the code if serious complications developed which could be related to steroid therapy"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-10-17 00:02:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Helman-1971">
<DESCRIPTION>
<P>".....The treatment code was broken during the study in only one case because of a medical emergency"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-11-16 22:37:05 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Maddrey-1978">
<DESCRIPTION>
<P>"Prednisolone (5 mg) or identical placebo tablets were given in a single dose of 8 pills each morning for 28 to 32 days. (Prednisolone (5 mg) and identical placebo tablets were provided by the Division of Steroid Research, The Upjohn Company, Kalamazoo, Mich.). The investigators were not aware of which regimen the patient was receiving until the completion of the study."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-10-03 13:04:43 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mendenhall-1977">
<DESCRIPTION>
<P>"blinded so that neither physician nor patient was aware of the treatment modality"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-11-16 22:57:32 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Mendenhall-1984">
<DESCRIPTION>
<P>"Medication was packed into unit dose kits at the Veterans Administration Center Pharmacy(Albuquerque, N.M.). The patient, physician and the local hospital pharmacy had no knowledge of the specific medication in use"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-01 14:46:44 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Porter-1971">
<DESCRIPTION>
<P>"Neither patients nor physicians knew which form of treatment was used until the study had been completed, when the code was broken"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-01 14:47:15 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Ramond-1992">
<DESCRIPTION>
<P>"a random code was prepared by computer for each participating centre. Random sequences of drug or placebo were prepared by the pharmacist at each hospital"</P>
<P>"prednisolone (Solupred) in 20 mg tablets and identical placebo were provided by the pharmacists at each hospital"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-01 17:22:57 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Richardet-1993">
<DESCRIPTION>
<P>No information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-10-17 00:13:27 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shumaker-1978">
<DESCRIPTION>
<P>Double-blind: "80 mg of 6-methylprednisolone or equivalent number of placebo tablets (or parenteral therapy of the same dosage intravenously if gastrointestinal function precluded oral intake"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-02-08 16:48:48 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Theodossi-1982">
<DESCRIPTION>
<P>Not blinded</P>
<P>"Patients were allocated by random sealed envelope technique to a control or treatment group, the latter receiving intravenous methylprednisolone 1 g daily for three days."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-11-16 21:55:16 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Thursz-2015">
<DESCRIPTION>
<P>Double-blinded</P>
<P>"The treatment arm was also concealed to investigators and researchers. Only the study statisticians were unblinded and this was for analysis purposes only."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2017-11-01 18:11:59 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-01 14:41:19 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Blitzer-1977">
<DESCRIPTION>
<P>No information was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-11-16 22:07:16 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Bories-1987">
<DESCRIPTION>
<P>No information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-01 18:11:59 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Campra-1973">
<DESCRIPTION>
<P>".. all statistical analyses and interpretation were done under supervision of Dr. John Weiner of the Department of Biostatics, University of Southern California School of Medicine"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-15 18:52:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carithers-1989">
<DESCRIPTION>
<P>"Data obtained at initial evaluation and follow-up were recorded on standardized data collection forms that were submitted to the statistical coordinating center at the end of each study.... A study overview committee, chaired by Dr. Hyman Zimmerman, reviewed the ongoing results of the study on a yearly basis from reports generated by the statistical coordinating center, which had access to the randomisation codes"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-15 19:09:19 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-De-2014">
<DESCRIPTION>
<P>"as well as statisticians were all blinded regarding the nature of the pharmacotherapy."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-11-16 22:16:49 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Depew-1980">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-11-16 22:28:10 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Helman-1971">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-11-16 22:37:19 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Maddrey-1978">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-11-16 22:43:29 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Mendenhall-1977">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-11-16 22:57:51 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Mendenhall-1984">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-17 00:09:03 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Porter-1971">
<DESCRIPTION>
<P>"At the conclusion of the study, all needle biopsy and post-mortem liver specimens were coded and read in blind review by the same observer"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-01 14:47:15 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Ramond-1992">
<DESCRIPTION>
<P>No information was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-01 17:23:00 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Richardet-1993">
<DESCRIPTION>
<P>No information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-02 21:48:37 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shumaker-1978">
<DESCRIPTION>
<P>"Clinical evaluation was carried out by junior staff physicians blinded to treatment status of the patients."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-02-08 16:48:50 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Theodossi-1982">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-11-07 14:28:32 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Thursz-2015">
<DESCRIPTION>
<P>"An independent data monitoring and ethics committee, whose members were aware of the group assignments, was convened to review the conduct of the trial and to analyze primary end-point data, using prespecified stopping guidelines, after the recruitment of 200, 400, and 800 patients, to avoid continued recruitment in the event that a definitive result had been achieved. Data collected by site investigative teams were submitted to the clinical trials unit and analysed by study statisticians. The first author wrote the first draft of the manuscript, with substantial contributions from the coauthors. All the authors vouch for the accuracy and completeness of the data and analyses."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2017-11-02 12:57:42 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-02 12:57:42 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Blitzer-1977">
<DESCRIPTION>
<P>"5 participants, who had each received less than 5 days of therapy, were subsequently excluded from analysis. Of these, three had left the hospital against medical advice or withdrew from the study, and in two participants experimental therapy had been stopped following gastrointestinal haemorrhage. One bled after 4 days of therapy from a gastric varix and the other from an unknown site after three days of treatment. On breaking the code at the end of the investigation, it was learned that all five participants had been in the steroid group....Furthemore, the addition of two deaths among the five excluded participants ......"</P>
<P>3/17 people in the prednisolone group and 0/16 people in the placebo group dropped out (9%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-01 14:41:37 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Bories-1987">
<DESCRIPTION>
<P>No dropouts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-01 14:42:02 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Campra-1973">
<DESCRIPTION>
<P>"50 patients entered the trial, but five were subsequently withdrawn when additional data favoured another diagnosis. In one case (group 2), jaundice proved to be caused by hepatitis B...the patient died .....2 of these patients were in group 2, one patient in group 1; all survived. The fifth patient was removed from the trial when peptic ulcer was diagnosed after 15 days of prednisolone therapy".</P>
<P>0/22 prednisolone group/control group 0/28</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-16 19:26:06 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Carithers-1989">
<DESCRIPTION>
<P>3%</P>
<P>"One patient who received methylprednisolone was belatedly discovered to have had neither encephalopathy nor elevation of discriminant function sufficient to meet the entry criteria and was excluded from analysis. Of the remaining 66 patients, 64 remained in the hospital for the duration of the study. Two methylprednisolone recipients refused to continue in the study. The first patient signed out of the hospital after 10 days on the trial and was alive at the end of the study. The second patient was discharged at his insistence after 15 days on the trial and was given the study drug to take at home, but he never returned for follow-up. His status at the end of the study was unknown. He was the only patient lost to follow-up."</P>
<P>2/36 prednisolone group / placebo group 0/31</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-01 14:50:35 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-De-2014">
<DESCRIPTION>
<P>1.6%</P>
<P>"One patient in Group 1 developed severe vertigo within 7 days after starting PTX, and one patient in Group 2 withdrew voluntarily from the study and hence they were excluded."</P>
<P>1/31 prednisolone/1/31 placebo group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-01 14:43:06 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Depew-1980">
<DESCRIPTION>
<P>There were no withdrawals and dropouts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-01 14:43:36 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Helman-1971">
<DESCRIPTION>
<P>None of the participants withdrew or dropped out</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-01 14:43:59 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Maddrey-1978">
<DESCRIPTION>
<P>3.5% dropped out or were withdrawn, i.e. "Two additional patients were removed from the study after randomisation. One patient who was randomised to the placebo group bled from oesophageal varices before receiving the study drug. He subsequently stopped bleeding and survived. Another patient had an episode of upper gastrointestinal haemorrhage presumably from oesophageal varices after receiving prednisolone for 9 days and the drug was stopped."</P>
<P>1/25 prednisolone group and 1/32 placebo group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-01 14:45:15 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Mendenhall-1977">
<DESCRIPTION>
<P>"one additional mortality withdrew from the study on the 8 day" (not mentioned from what group out of 50 participants</P>
<P>17 participants were treated with oxandrolone</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-07-11 16:54:36 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Mendenhall-1984">
<DESCRIPTION>
<P>4.5%</P>
<P>"Ten patients withdrew from the study before completing treatment (5 given placebo, 3 prednisolone). However, these patients were included in the outcome assessment"</P>
<P>3/ 90 prednisolone group/ 5/88 control group</P>
<P>"324 days...37 patients were lost to follow-up: 13 given placebo, 11 prednisolone"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-17 00:09:16 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Porter-1971">
<DESCRIPTION>
<P>13%</P>
<P>"Twenty three patients were accepted for study, three died within 36 hours of the start of therapy and were excluded from analysis before the code was broken because they didn't receive adequate medication. The final series thus consisted of 20 patients "</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-01 14:47:15 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Ramond-1992">
<DESCRIPTION>
<P>1.5%</P>
<P>1 woman left the hospital and then "she was re hospitalised 56 days after enrolment and left again the following day. She was the only patient lost to follow up"</P>
<P>1/33 prednisolone group 0/32 placebo group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-01 17:23:04 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Richardet-1993">
<DESCRIPTION>
<P>No information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-01 14:48:21 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Shumaker-1978">
<DESCRIPTION>
<P>3.7 % "a steroid treated patient voluntarily withdrew from the study after eight days but was retained for statistical purposes"</P>
<P>1/12 prednisolone group; 0/15 control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-01 14:48:39 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Theodossi-1982">
<DESCRIPTION>
<P>8%</P>
<P>"Of the 60 patients who satisfied the entry criteria, one in the treatment group and four in the control group were excluded from the final analysis because subsequent findings in four cases cast doubt on the initial diagnosis, and one patient was later found to have been given corticosteroids at the referring hospital. Thus there were 27 patients in the treatment and 28 in the control group."</P>
<P>1/28 prednisolone and 4/32 control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-07-11 16:53:55 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Thursz-2015">
<DESCRIPTION>
<P>"At the time the trial was stopped, 33 patients who underwent randomization during the last 90 days of the trial could not be included in the 90-day or 12-month analyses. In addition, there were 159 patients who underwent randomization within 90 days to 12 months before the end of trial who could not be included in 12-month analyses. The four groups were well matched with regard to their baseline characteristics, including laboratory values (See Table 1 in the published article). At 28 days, 16% of the patients had died, 1% had been lost to follow-up, and 2% had withdrawn from the study. At 90 days, 29% of the patients (285 of 968 patients) had died, 5% had been lost to follow-up, 3% had withdrawn, and 4% had not completed follow-up owing to cessation of the study. At 1 year, 56% of the patients (421 of 747 patients) had died or undergone liver transplantation (the latter were 3 patients), 8% had been lost to follow-up, 4% had withdrawn, and 20% had not completed follow-up owing to cessation of the study due to limitations on funding."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2017-11-01 17:23:07 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 14:41:19 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Blitzer-1977">
<DESCRIPTION>
<P>All-cause mortality, serious adverse events, and liver-related mortality were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 14:41:37 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Bories-1987">
<DESCRIPTION>
<P>All-cause mortality, serious adverse events, and liver-related mortality were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 14:42:02 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Campra-1973">
<DESCRIPTION>
<P>All-cause mortality, serious adverse events, and liver-related mortality were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 14:42:29 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Carithers-1989">
<DESCRIPTION>
<P>All-cause mortality, serious adverse events, and liver-related mortality were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-29 16:58:44 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-De-2014">
<DESCRIPTION>
<P>All-cause mortality, serious adverse events, and liver-related mortality are reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 14:43:06 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Depew-1980">
<DESCRIPTION>
<P>All-cause mortality, serious adverse events, and liver-related mortality were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 14:43:36 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Helman-1971">
<DESCRIPTION>
<P>All-cause mortality was reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 14:43:59 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Maddrey-1978">
<DESCRIPTION>
<P>All-cause mortality, serious adverse events, and liver-related mortality were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 14:45:15 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Mendenhall-1977">
<DESCRIPTION>
<P>All-cause mortality was reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-03 12:07:15 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mendenhall-1984">
<DESCRIPTION>
<P>All-cause mortality, serious adverse events, and liver-related mortality are reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-03 16:49:00 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Porter-1971">
<DESCRIPTION>
<P>All-cause mortality, serious adverse events, and liver-related mortality are reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 14:47:15 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Ramond-1992">
<DESCRIPTION>
<P>All-cause mortality, serious adverse events, and liver-related mortality were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 17:23:07 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Richardet-1993">
<DESCRIPTION>
<P>No information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 14:48:21 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Shumaker-1978">
<DESCRIPTION>
<P>All-cause mortality, serious adverse events, and liver-related mortality were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 14:48:39 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Theodossi-1982">
<DESCRIPTION>
<P>All-cause mortality, serious adverse events, and liver-related mortality were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 14:49:14 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Thursz-2015">
<DESCRIPTION>
<P>All-cause mortality, serious adverse events, liver-related mortality, and quality of life were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2017-11-01 17:23:17 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="9">
<NAME>For-profit bias</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-22 09:30:03 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blitzer-1977">
<DESCRIPTION>
<P>Prednisolone and placebo tablets were supplied by the Upjohn Co., Kalamazoo, Michigan.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-03-01 16:01:13 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Bories-1987">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-03-01 16:02:18 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Campra-1973">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-22 15:31:43 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Carithers-1989">
<DESCRIPTION>
<P>"random sequences for drug or placebo were submitted to the Upjohn Company (Kalamazoo, Michigan), which provided methylprednisolone (Medrol) in 4-mg tablets and identical placebo tablets as well as intravenous preparations of methylprednisolone sodium succinate (Solu-Medrol) and placebo."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-03-01 16:02:48 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-De-2014">
<DESCRIPTION>
<P>"Prednisolone tablet (Wysolone, Wreath, Mumbai, India) and ptx (trental tablets, Sanofi Aventis, Mumbai, India"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-03-01 16:03:25 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Depew-1980">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 14:43:37 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Helman-1971">
<DESCRIPTION>
<P>"tablets 40 mg of prednisolone daily or lactose placebo (provided by Upjohn Co, Kalamazoo, Mich)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 14:43:59 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Maddrey-1978">
<DESCRIPTION>
<P>Prednisolone and placebo tablets were provided by the Division of Steroid Research, The Upjohn Company, Kalamazoo, Mich. However, no further details were provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-03-01 16:10:59 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Mendenhall-1977">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-03 11:02:05 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mendenhall-1984">
<DESCRIPTION>
<P>"Matching placebos were prepared for each of these medications by Upjohn Company and G.D. Searle and Company."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-17 00:10:07 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Porter-1971">
<DESCRIPTION>
<P>"The drugs were provided by Upjohn Co., Kalamazoo, Mich."</P>
<P>Supported in part by a gastroenterology-research training grant (AM-05099) from the National Institute of Artrithis and Metabolic Diseases (a portion of this work was conducted within the Clinical Research Center of the University of Washington, with support by a grant MO1 FR-37 from the National Institutes of Health</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 14:47:20 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Ramond-1992">
<DESCRIPTION>
<P>Prednisolone tablets and placebo were provided by Laboratoire Houdé (Paris)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 17:23:17 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Richardet-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 14:48:21 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Shumaker-1978">
<DESCRIPTION>
<P>"The patient was then randomised into a predetermined code provided by the drug manufacturer. (Upjohn Co., Kalamazoo, MI, prepared and supplied the medication and placebo."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 14:48:39 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Theodossi-1982">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-16 22:23:26 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Thursz-2015">
<DESCRIPTION>
<P>"Owing to limitations on funding, the trial was stopped after all enrolled patients had completed at least 28 days of follow-up."</P>
<P>"This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme. The NIHR Clinical Research Network provided research nurse support and the Imperial College Biomedical Research Centre also provided funding."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2017-11-01 17:23:20 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-16 18:35:27 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Blitzer-1977">
<DESCRIPTION>
<P>None suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-16 22:07:31 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Bories-1987">
<DESCRIPTION>
<P>None suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-16 19:17:02 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Campra-1973">
<DESCRIPTION>
<P>Not suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-16 19:27:01 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Carithers-1989">
<DESCRIPTION>
<P>Not suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-08 16:51:30 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-De-2014">
<DESCRIPTION>
<P>Not suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-16 20:04:48 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Depew-1980">
<DESCRIPTION>
<P>None suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-16 22:28:31 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Helman-1971">
<DESCRIPTION>
<P>None suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-16 22:37:54 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Maddrey-1978">
<DESCRIPTION>
<P>None suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-16 22:44:50 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Mendenhall-1977">
<DESCRIPTION>
<P>None suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-16 22:58:26 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Mendenhall-1984">
<DESCRIPTION>
<P>None suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-18 19:15:07 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Porter-1971">
<DESCRIPTION>
<P>None suspected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 14:47:20 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Ramond-1992">
<DESCRIPTION>
<P>Not suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 17:23:20 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Richardet-1993">
<DESCRIPTION>
<P>No information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 14:48:21 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Shumaker-1978">
<DESCRIPTION>
<P>None suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-08 16:49:00 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Theodossi-1982">
<DESCRIPTION>
<P>None suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-16 20:17:29 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Thursz-2015">
<DESCRIPTION>
<P>None suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2017-11-02 14:34:03 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<SOF_TABLE ID="SOF-01" MODIFIED="2017-11-02 14:34:03 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1">
<TITLE MODIFIED="2017-11-01 14:52:55 +0100" MODIFIED_BY="Dimitrinka Nikolova">Glucocorticosteroids for people with alcoholic hepatitis</TITLE>
<TABLE COLS="7" ROWS="13">
<TR>
<TD COLSPAN="7">
<P>
<B>Glucocorticosteroids for people with alcoholic hepatitis </B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>participants with alcoholic hepatitis at high risk of mortality and morbidity</P>
<P>
<B>Settings: </B>hospitals and clinics</P>
<P>
<B>Intervention: </B>glucocorticosteroids</P>
<P>
<B>Comparison: </B>placebo or no intervention</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>
<B>Placebo or no intervention</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Glucocorticosteroids</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>All-cause mortality: 3 months following randomisation</B>
</P>
</TD>
<TD>
<P>298 per 1000</P>
</TD>
<TD>
<P>278 per 1000</P>
</TD>
<TD>
<P>
<B>RR </B>0.90</P>
<P> (0.70 to 1.15)</P>
</TD>
<TD>
<P>1861</P>
<P>(15 RCTs)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<SUP>1</SUP>
<BR/>very low</P>
</TD>
<TD>
<P>The Trial Sequential Analysis-adjusted CI was 0.36 to 2.32</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Health-related quality of life: up to 3 months</B>
</P>
<P>
<B>(measured with </B>
<I>European Quality of Life - 5 Dimensions-3 Levels (EQ- 5D-3L) scale)</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean value is 0.592</P>
</TD>
<TD VALIGN="TOP">
<P>The mean value is 0.553</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>MD</B> -0.04; (-0.11 to 0.03)</P>
</TD>
<TD VALIGN="TOP">
<P>377</P>
<P>(1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<SUP>2</SUP>
</P>
<P>low</P>
</TD>
<TD VALIGN="TOP">
<P>We did not perform Trial Sequential Analysis</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Serious adverse events during treatment</B>
</P>
</TD>
<TD>
<P>361 per 1000</P>
</TD>
<TD>
<P>389 per 1000</P>
</TD>
<TD>
<P>
<B>RR </B>1.05</P>
<P>(0.85 to</P>
<P>1.29)</P>
</TD>
<TD>
<P>1861</P>
<P>(15 RCTs)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<SUP>3</SUP>
<BR/>low</P>
</TD>
<TD>
<P>The Trial Sequential Analysis-adjusted CI was 0.60 to 1.82</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Liver-related mortality: up to 3 months following randomisation</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>298 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>277 per 1000<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR </B>0.89</P>
<P> (0.69 to 1.14)</P>
</TD>
<TD VALIGN="TOP">
<P>1861</P>
<P>(15 RCTs)</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<SUP>4</SUP>
<BR/>low</P>
</TD>
<TD VALIGN="TOP">
<P>The Trial Sequential Analysis-adjusted CI was 0.32 to 2.45</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Any complication: up to 3 months following randomisation</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>443 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>474 per 1000<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR</B> 1.04</P>
<P>(0.86 to 1.27)</P>
</TD>
<TD VALIGN="TOP">
<P>1861</P>
<P>(15 RCTs)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<SUP>5</SUP>
<BR/>low</P>
</TD>
<TD VALIGN="TOP">
<P>The Trial Sequential Analysis-adjusted CI was 0.67 to 1.63</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Number of participants with non-serious adverse events: up to 3 months' follow-up after end of treatment</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>51 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>120 per 1000<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR</B> 1.99</P>
<P>(0.72 to 5.48)</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>160</P>
<P>(4 RCTs)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<SUP>6</SUP>
<BR/>very low</P>
</TD>
<TD VALIGN="TOP">
<P>The Trial Sequential Analysis-adjusted CI was 0.01 to 249.60</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RCT</B>: randomised controlled trial; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> this research provides a very good indication of the likely effect; the likelihood that the effect will be substantially different is low.<BR/>
<B>Moderate quality:</B> this research provides a good indication of the likely effect; the likelihood that the effect will be substantially different is moderate.<BR/>
<B>Low quality:</B> this research provides some indication of the likely effect; however, the likelihood that it will be substantially different is high.<BR/>
<B>Very low quality:</B> this research does not provide a reliable indication of the likely effect; the likelihood that the effect will be substantially different is very high.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Downgraded 3 levels: 1 level due to within-study risk of bias (high overall risk of bias in all the trials); 1 level due to inconsistency of the data (there is wide variation in the effect estimates across studies; there is little overlap of confidence intervals associated with the effect estimates; presence of moderate heterogeneity: I² = 45%; heterogeneity could be explained with selection bias); 1 level due to imprecision of effect estimates (the trial sequential analysis showed that additional evidence is needed and that we have not yet reached the required information size).<BR/>
<SUP>2</SUP>Downgraded 2 levels: 1 level due to within-study risk of bias (high overall risk of bias in the trial); 1 level due to imprecision of effect estimates.<BR/>
<SUP>3</SUP>Downgraded 2 levels: 1 level due to within-study risk of bias (high overall risk of bias in all the trials); 1 level due to inconsistency of the data (there is wide variation in the effect estimates across studies; there is little overlap of confidence intervals associated with the effect estimates; presence of moderate heterogeneity: I² = 36%; heterogeneity could be explained with selection bias).<BR/>
<SUP>4</SUP>Downgraded 2 levels: 1 level due to within-study risk of bias (high overall risk of bias in all the trials); 1 level due to inconsistency of the data (there is wide variation in the effect estimates across studies; there is little overlap of confidence intervals associated with the effect estimates; presence of moderate heterogeneity: I² = 46%; heterogeneity could be explained with selection bias).<BR/>
<SUP>5</SUP>Downgraded 2 levels: 1 level due to within-study risk of bias (high overall risk of bias in all the trials); 1 level due to inconsistency of the data (there is wide variation in the effect estimates across studies; there is little overlap of confidence intervals associated with the effect estimates; presence of moderate heterogeneity: I² = 41%; heterogeneity could be explained with selection bias).<BR/>
<SUP>6</SUP>Downgraded 4 levels: 1 level due to within-study risk of bias (high overall risk of bias in all the trials); 1 level due to inconsistency of the data (there is little overlap of confidence intervals associated with the effect estimates);1 level due to imprecision of effect estimates (the Trial Sequential Analysis showed that additional evidence is needed and that we have not yet reached the required information size); 1 level due to publication bias (only 4 trials with a small number of participants reported on non-serious adverse events).</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2017-11-02 11:25:22 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2017-11-02 11:25:22 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1">
<TITLE MODIFIED="2017-06-13 16:26:52 +0200" MODIFIED_BY="Dimitrinka Nikolova">Number of participants with most often occurring serious adverse events during treatment</TITLE>
<TABLE COLS="9" ROWS="16">
<TR>
<TH ROWSPAN="2">
<P>Trial</P>
</TH>
<TH COLSPAN="2">
<P>Gastrointestinal haemorrhage</P>
</TH>
<TH COLSPAN="2">
<P>Hepatorenal syndrome (with or without hepatic failure)</P>
</TH>
<TH COLSPAN="2">
<P>Septicaemia</P>
</TH>
<TH COLSPAN="2">
<P>Hepatocellular carcinoma</P>
</TH>
</TR>
<TR>
<TH>
<P>Prednisolone</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
<TH>
<P>Prednisolone</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
<TH>
<P>Prednisolone</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
<TH>
<P>Prednisolone</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Helman-1971" TYPE="STUDY">Helman 1971</LINK>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Porter-1971" TYPE="STUDY">Porter 1971</LINK>
</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Campra-1973" TYPE="STUDY">Campra 1973</LINK>
</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Blitzer-1977" TYPE="STUDY">Blitzer 1977</LINK>
</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>2 fungal</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Mendenhall-1977" TYPE="STUDY">Mendenhall 1977</LINK>
</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Maddrey-1978" TYPE="STUDY">Maddrey 1978</LINK>
</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Shumaker-1978" TYPE="STUDY">Shumaker 1978</LINK>
</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Depew-1980" TYPE="STUDY">Depew 1980</LINK>
</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Theodossi-1982" TYPE="STUDY">Theodossi 1982</LINK>
</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Bories-1987" TYPE="STUDY">Bories 1987</LINK>
</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Carithers-1989" TYPE="STUDY">Carithers 1989</LINK>
</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Mendenhall-1984" TYPE="STUDY">Mendenhall 1984</LINK>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>2</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ramond-1992" TYPE="STUDY">Ramond 1992</LINK>
</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-De-2014" TYPE="STUDY">De 2014</LINK>
</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2017-06-13 16:29:24 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="2">
<TITLE MODIFIED="2017-06-13 16:29:24 +0200" MODIFIED_BY="Dimitrinka Nikolova">Most often occurring serious adverse events in Thursz trial. Number of events.</TITLE>
<TABLE COLS="3" ROWS="5">
<TR>
<TH>
<P>Type of adverse event</P>
</TH>
<TH>
<P>Prednisolone group</P>
</TH>
<TH>
<P>Placebo group</P>
</TH>
</TR>
<TR>
<TD>
<P>Gastrointestinal haemorrhage plus</P>
<P>variceal bleeding</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>28</P>
</TD>
</TR>
<TR>
<TD>
<P>Infections</P>
</TD>
<TD>
<P>74</P>
</TD>
<TD>
<P>43</P>
</TD>
</TR>
<TR>
<TD>
<P>- lung</P>
</TD>
<TD>
<P>38</P>
</TD>
<TD>
<P>17</P>
</TD>
</TR>
<TR>
<TD>
<P>- sepsis</P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P>14</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2017-11-02 12:27:21 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<COMPARISON ID="CMP-001" MODIFIED="2017-11-01 15:02:39 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1">
<NAME>Glucocorticosteroids versus no intervention/placebo</NAME>
<DICH_OUTCOME CHI2="51.67390925257876" CI_END="1.0911181856145662" CI_START="0.8856666129556344" CI_STUDY="95" CI_TOTAL="95" DF="31" EFFECT_MEASURE="RR" EFFECT_SIZE="0.983039647108676" ESTIMABLE="YES" EVENTS_1="696" EVENTS_2="748" I2="40.00840956608492" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.03787179420003532" LOG_CI_START="-0.05272972664706534" LOG_EFFECT_SIZE="-0.007428966223514984" METHOD="MH" MODIFIED="2016-12-16 15:26:31 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1" P_CHI2="0.011318762240132507" P_Q="0.414736882452155" P_Z="0.7478932026704432" Q="1.7602238692370993" RANDOM="YES" SCALE="66.86" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0436237549424011" TOTALS="SUB" TOTAL_1="2506" TOTAL_2="2522" WEIGHT="300.0" Z="0.3214185833596827">
<NAME>All-cause mortality</NAME>
<GROUP_LABEL_1>Glucocorticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no intervention</GROUP_LABEL_2>
<GRAPH_LABEL_1>Glucocorticosteroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo/no intervention</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="25.23499261394367" CI_END="1.1496265305492956" CI_START="0.702963611675485" DF="14" EFFECT_SIZE="0.8989691974661258" ESTIMABLE="YES" EVENTS_1="258" EVENTS_2="279" I2="44.52148168149549" ID="CMP-001.01.01" LOG_CI_END="0.06055677768898189" LOG_CI_START="-0.1530671552896447" LOG_EFFECT_SIZE="-0.04625518880033139" MODIFIED="2016-12-16 15:26:17 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1" P_CHI2="0.032317149285978064" P_Z="0.39601079905035674" STUDIES="15" TAU2="0.08003493816991894" TOTAL_1="927" TOTAL_2="934" WEIGHT="100.0" Z="0.8487672975838388">
<NAME>Up to 3 months after randomisation</NAME>
<DICH_DATA CI_END="3.6470591644592263" CI_START="0.6217836230896183" EFFECT_SIZE="1.5058823529411764" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.5619428087181544" LOG_CI_START="-0.20636072085100313" LOG_EFFECT_SIZE="0.17779104393357562" MODIFIED="2016-09-29 12:38:16 +0200" MODIFIED_BY="[Empty name]" ORDER="15" O_E="0.0" SE="0.4513052964327311" STUDY_ID="STD-Blitzer-1977" TOTAL_1="17" TOTAL_2="16" VAR="0.2036764705882353" WEIGHT="5.550066883203648"/>
<DICH_DATA CI_END="2.271566119051022" CI_START="0.21571020798844465" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.3563253824542302" LOG_CI_START="-0.6661293024257166" LOG_EFFECT_SIZE="-0.1549019599857432" MODIFIED="2016-10-10 13:47:14 +0200" MODIFIED_BY="[Empty name]" ORDER="16" O_E="0.0" SE="0.6005949431307973" STUDY_ID="STD-Bories-1987" TOTAL_1="24" TOTAL_2="21" VAR="0.3607142857142857" WEIGHT="3.572592324177013"/>
<DICH_DATA CI_END="1.959321304462537" CI_START="0.4050989526101174" EFFECT_SIZE="0.8909090909090909" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.2921056607588947" LOG_CI_START="-0.3924388796903551" LOG_EFFECT_SIZE="-0.0501666094657302" MODIFIED="2016-10-01 19:06:40 +0200" MODIFIED_BY="[Empty name]" ORDER="17" O_E="0.0" SE="0.4021048516100144" STUDY_ID="STD-Campra-1973" TOTAL_1="22" TOTAL_2="28" VAR="0.16168831168831171" WEIGHT="6.514132567136962"/>
<DICH_DATA CI_END="0.652966466690005" CI_START="0.037540679447284" EFFECT_SIZE="0.15656565656565657" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.18510912148976028" LOG_CI_START="-1.4254978713647564" LOG_EFFECT_SIZE="-0.8053034964272584" MODIFIED="2016-09-29 23:19:03 +0200" MODIFIED_BY="[Empty name]" ORDER="18" O_E="0.0" SE="0.7286104916999097" STUDY_ID="STD-Carithers-1989" TOTAL_1="36" TOTAL_2="31" VAR="0.5308732486151841" WEIGHT="2.5775023615612187"/>
<DICH_DATA CI_END="4.76392574408339" CI_START="0.6801113564845032" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.6779649834601594" LOG_CI_START="-0.16741997325354727" LOG_EFFECT_SIZE="0.25527250510330607" MODIFIED="2016-09-27 16:46:23 +0200" MODIFIED_BY="[Empty name]" ORDER="23" O_E="0.0" SE="0.49658330829665737" STUDY_ID="STD-De-2014" TOTAL_1="31" TOTAL_2="31" VAR="0.24659498207885308" WEIGHT="4.820799309923615"/>
<DICH_DATA CI_END="1.976541991306356" CI_START="0.4963431529485624" EFFECT_SIZE="0.9904761904761905" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.29590604529114234" LOG_CI_START="-0.3042179648334578" LOG_EFFECT_SIZE="-0.0041559597711577035" MODIFIED="2016-10-01 21:45:22 +0200" MODIFIED_BY="[Empty name]" ORDER="19" O_E="0.0" SE="0.35251581420895045" STUDY_ID="STD-Depew-1980" TOTAL_1="15" TOTAL_2="13" VAR="0.12426739926739927" WEIGHT="7.707289666320103"/>
<DICH_DATA CI_END="1.0635091819729094" CI_START="0.01887096490056978" EFFECT_SIZE="0.14166666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.02674124380428928" LOG_CI_START="-1.7242058931429909" LOG_EFFECT_SIZE="-0.8487323246693509" MODIFIED="2016-10-02 23:21:28 +0200" MODIFIED_BY="[Empty name]" ORDER="21" O_E="0.0" SE="1.0285150155709453" STUDY_ID="STD-Helman-1971" TOTAL_1="20" TOTAL_2="17" VAR="1.057843137254902" WEIGHT="1.3838189944452615"/>
<DICH_DATA CI_END="2.3096079660641027" CI_START="0.1773461150196915" EFFECT_SIZE="0.64" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.36353826879945483" LOG_CI_START="-0.7511783208316805" LOG_EFFECT_SIZE="-0.1938200260161128" MODIFIED="2016-10-09 14:17:11 +0200" MODIFIED_BY="[Empty name]" ORDER="529" O_E="0.0" SE="0.6547900426854397" STUDY_ID="STD-Maddrey-1978" TOTAL_1="25" TOTAL_2="32" VAR="0.42875" WEIGHT="3.094858310467143"/>
<DICH_DATA CI_END="13.05963254309707" CI_START="0.6147016580509396" EFFECT_SIZE="2.8333333333333335" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.115930957432902" LOG_CI_START="-0.21133561544364132" LOG_EFFECT_SIZE="0.4522976709946303" MODIFIED="2016-10-02 23:21:27 +0200" MODIFIED_BY="[Empty name]" ORDER="23" O_E="0.0" SE="0.7796429549831781" STUDY_ID="STD-Mendenhall-1977" TOTAL_1="12" TOTAL_2="17" VAR="0.6078431372549019" WEIGHT="2.2890935914234958"/>
<DICH_DATA CI_END="1.3741962892744457" CI_START="0.6565280702147891" EFFECT_SIZE="0.9498412698412698" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="35" LOG_CI_END="0.1380487714863567" LOG_CI_START="-0.18274670068071025" LOG_EFFECT_SIZE="-0.02234896459717677" MODIFIED="2016-10-04 16:15:49 +0200" MODIFIED_BY="[Empty name]" ORDER="821" O_E="0.0" SE="0.18843684831413268" STUDY_ID="STD-Mendenhall-1984" TOTAL_1="90" TOTAL_2="88" VAR="0.035508445802563446" WEIGHT="13.627931258363468"/>
<DICH_DATA CI_END="1.3334993458285727" CI_START="0.36881897991307366" EFFECT_SIZE="0.7012987012987013" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.12499280697519317" LOG_CI_START="-0.4331867376742198" LOG_EFFECT_SIZE="-0.15409696534951337" MODIFIED="2016-10-02 23:21:29 +0200" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.0" SE="0.3278774275603728" STUDY_ID="STD-Porter-1971" TOTAL_1="11" TOTAL_2="9" VAR="0.10750360750360752" WEIGHT="8.396232830326161"/>
<DICH_DATA CI_END="0.6471159716752733" CI_START="0.09081759048972873" EFFECT_SIZE="0.24242424242424243" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="16" LOG_CI_END="-0.1890178810851679" LOG_CI_START="-1.0418300246867198" LOG_EFFECT_SIZE="-0.6154239528859439" MODIFIED="2016-09-29 18:58:25 +0200" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="0.5009460746397457" STUDY_ID="STD-Ramond-1992" TOTAL_1="33" TOTAL_2="32" VAR="0.2509469696969697" WEIGHT="4.757411981469848"/>
<DICH_DATA CI_END="2.343887675927311" CI_START="0.4897671485982377" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.36993679553129327" LOG_CI_START="-0.3100103487764068" LOG_EFFECT_SIZE="0.029963223377443202" MODIFIED="2016-10-02 23:21:26 +0200" MODIFIED_BY="[Empty name]" ORDER="28" O_E="0.0" SE="0.39940431835899015" STUDY_ID="STD-Shumaker-1978" TOTAL_1="12" TOTAL_2="15" VAR="0.15952380952380957" WEIGHT="6.5729901717002"/>
<DICH_DATA CI_END="1.9176931273639117" CI_START="0.7688872504566056" EFFECT_SIZE="1.2142857142857142" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.2827791118256619" LOG_CI_START="-0.11413734042559018" LOG_EFFECT_SIZE="0.08432088570003587" MODIFIED="2016-10-03 14:30:16 +0200" MODIFIED_BY="[Empty name]" ORDER="29" O_E="0.0" SE="0.23315068882051151" STUDY_ID="STD-Theodossi-1982" TOTAL_1="28" TOTAL_2="32" VAR="0.05435924369747899" WEIGHT="11.716409685720661"/>
<DICH_DATA CI_END="1.257721969620654" CI_START="0.8438943704799494" EFFECT_SIZE="1.0302351623740202" ESTIMABLE="YES" EVENTS_1="145" EVENTS_2="141" LOG_CI_END="0.09958464714687978" LOG_CI_START="-0.07371191023286199" LOG_EFFECT_SIZE="0.012936368457008879" MODIFIED="2016-10-17 18:38:39 +0200" MODIFIED_BY="[Empty name]" ORDER="22" O_E="0.0" SE="0.10179525563665424" STUDY_ID="STD-Thursz-2015" TOTAL_1="551" TOTAL_2="552" VAR="0.010362274070131789" WEIGHT="17.41887006376118"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="22.608667279547568" CI_END="1.1527902826251162" CI_START="0.6624585074571022" DF="13" EFFECT_SIZE="0.8738854215736097" ESTIMABLE="YES" EVENTS_1="162" EVENTS_2="202" I2="42.49992784068186" ID="CMP-001.01.02" LOG_CI_END="0.06175030696270115" LOG_CI_START="-0.17884131821642585" LOG_EFFECT_SIZE="-0.058545505626862324" MODIFIED="2016-12-16 15:26:17 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="2" P_CHI2="0.04661924871574974" P_Z="0.3401472921489078" STUDIES="14" TAU2="0.09760272194031606" TOTAL_1="907" TOTAL_2="917" WEIGHT="99.99999999999999" Z="0.9538742871860566">
<NAME>At the end of treatment</NAME>
<DICH_DATA CI_END="8.904535677629193" CI_START="0.3979154807653138" EFFECT_SIZE="1.8823529411764706" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9496112783303223" LOG_CI_START="-0.40020916444705823" LOG_EFFECT_SIZE="0.27470105694163205" MODIFIED="2016-10-13 16:54:44 +0200" MODIFIED_BY="[Empty name]" ORDER="15" O_E="0.0" SE="0.7928912098063865" STUDY_ID="STD-Blitzer-1977" TOTAL_1="17" TOTAL_2="16" VAR="0.6286764705882353" WEIGHT="2.749999491664022"/>
<DICH_DATA CI_END="4.487245911235435" CI_START="0.042655618565665326" EFFECT_SIZE="0.4375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6519798705061411" LOG_CI_START="-1.3700237557894768" LOG_EFFECT_SIZE="-0.3590219426416679" MODIFIED="2016-10-13 16:54:53 +0200" MODIFIED_BY="[Empty name]" ORDER="16" O_E="0.0" SE="1.1877349391654206" STUDY_ID="STD-Bories-1987" TOTAL_1="24" TOTAL_2="21" VAR="1.4107142857142856" WEIGHT="1.3241695214757125"/>
<DICH_DATA CI_END="1.959321304462537" CI_START="0.4050989526101174" EFFECT_SIZE="0.8909090909090909" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.2921056607588947" LOG_CI_START="-0.3924388796903551" LOG_EFFECT_SIZE="-0.0501666094657302" MODIFIED="2016-10-13 12:02:59 +0200" MODIFIED_BY="[Empty name]" ORDER="17" O_E="0.0" SE="0.4021048516100144" STUDY_ID="STD-Campra-1973" TOTAL_1="22" TOTAL_2="28" VAR="0.16168831168831171" WEIGHT="7.702801683147591"/>
<DICH_DATA CI_END="0.652966466690005" CI_START="0.037540679447284" EFFECT_SIZE="0.15656565656565657" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.18510912148976028" LOG_CI_START="-1.4254978713647564" LOG_EFFECT_SIZE="-0.8053034964272584" MODIFIED="2016-10-13 12:04:15 +0200" MODIFIED_BY="[Empty name]" ORDER="18" O_E="0.0" SE="0.7286104916999097" STUDY_ID="STD-Carithers-1989" TOTAL_1="36" TOTAL_2="31" VAR="0.5308732486151841" WEIGHT="3.1779534999473706"/>
<DICH_DATA CI_END="4.76392574408339" CI_START="0.6801113564845032" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.6779649834601594" LOG_CI_START="-0.16741997325354727" LOG_EFFECT_SIZE="0.25527250510330607" MODIFIED="2016-10-13 12:04:28 +0200" MODIFIED_BY="[Empty name]" ORDER="23" O_E="0.0" SE="0.49658330829665737" STUDY_ID="STD-De-2014" TOTAL_1="31" TOTAL_2="31" VAR="0.24659498207885308" WEIGHT="5.802674994451562"/>
<DICH_DATA CI_END="1.976541991306356" CI_START="0.4963431529485624" EFFECT_SIZE="0.9904761904761905" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.29590604529114234" LOG_CI_START="-0.3042179648334578" LOG_EFFECT_SIZE="-0.0041559597711577035" MODIFIED="2016-10-13 12:03:55 +0200" MODIFIED_BY="[Empty name]" ORDER="19" O_E="0.0" SE="0.35251581420895045" STUDY_ID="STD-Depew-1980" TOTAL_1="15" TOTAL_2="13" VAR="0.12426739926739927" WEIGHT="9.001966553170204"/>
<DICH_DATA CI_END="2.3096079660641027" CI_START="0.1773461150196915" EFFECT_SIZE="0.64" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.36353826879945483" LOG_CI_START="-0.7511783208316805" LOG_EFFECT_SIZE="-0.1938200260161128" MODIFIED="2016-10-13 12:03:44 +0200" MODIFIED_BY="[Empty name]" ORDER="529" O_E="0.0" SE="0.6547900426854397" STUDY_ID="STD-Maddrey-1978" TOTAL_1="25" TOTAL_2="32" VAR="0.42875" WEIGHT="3.7945418100946866"/>
<DICH_DATA CI_END="13.05963254309707" CI_START="0.6147016580509396" EFFECT_SIZE="2.8333333333333335" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.115930957432902" LOG_CI_START="-0.21133561544364132" LOG_EFFECT_SIZE="0.4522976709946303" MODIFIED="2016-12-05 14:20:46 +0100" MODIFIED_BY="Dimitrinka Nikolova" ORDER="23" O_E="0.0" SE="0.7796429549831781" STUDY_ID="STD-Mendenhall-1977" TOTAL_1="12" TOTAL_2="17" VAR="0.6078431372549019" WEIGHT="2.8312128907215954"/>
<DICH_DATA CI_END="2.0162825737974504" CI_START="0.6001142973333823" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="16" LOG_CI_END="0.3045513966431257" LOG_CI_START="-0.22176602632667544" LOG_EFFECT_SIZE="0.04139268515822508" MODIFIED="2016-10-13 16:56:05 +0200" MODIFIED_BY="[Empty name]" ORDER="821" O_E="0.0" SE="0.30916145956572283" STUDY_ID="STD-Mendenhall-1984" TOTAL_1="90" TOTAL_2="88" VAR="0.09558080808080807" WEIGHT="10.338704391835453"/>
<DICH_DATA CI_END="1.3334993458285727" CI_START="0.36881897991307366" EFFECT_SIZE="0.7012987012987013" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.12499280697519317" LOG_CI_START="-0.4331867376742198" LOG_EFFECT_SIZE="-0.15409696534951337" MODIFIED="2016-10-13 12:02:46 +0200" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.0" SE="0.3278774275603728" STUDY_ID="STD-Porter-1971" TOTAL_1="11" TOTAL_2="9" VAR="0.10750360750360752" WEIGHT="9.737717093736634"/>
<DICH_DATA CI_END="0.6471159716752733" CI_START="0.09081759048972873" EFFECT_SIZE="0.24242424242424243" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="16" LOG_CI_END="-0.1890178810851679" LOG_CI_START="-1.0418300246867198" LOG_EFFECT_SIZE="-0.6154239528859439" MODIFIED="2016-10-13 12:04:22 +0200" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="0.5009460746397457" STUDY_ID="STD-Ramond-1992" TOTAL_1="33" TOTAL_2="32" VAR="0.2509469696969697" WEIGHT="5.730222858260641"/>
<DICH_DATA CI_END="2.343887675927311" CI_START="0.4897671485982377" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.36993679553129327" LOG_CI_START="-0.3100103487764068" LOG_EFFECT_SIZE="0.029963223377443202" MODIFIED="2016-10-13 12:03:37 +0200" MODIFIED_BY="[Empty name]" ORDER="28" O_E="0.0" SE="0.39940431835899015" STUDY_ID="STD-Shumaker-1978" TOTAL_1="12" TOTAL_2="15" VAR="0.15952380952380957" WEIGHT="7.767644197924134"/>
<DICH_DATA CI_END="1.9176931273639117" CI_START="0.7688872504566056" EFFECT_SIZE="1.2142857142857142" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.2827791118256619" LOG_CI_START="-0.11413734042559018" LOG_EFFECT_SIZE="0.08432088570003587" MODIFIED="2016-10-13 12:04:03 +0200" MODIFIED_BY="[Empty name]" ORDER="29" O_E="0.0" SE="0.23315068882051151" STUDY_ID="STD-Theodossi-1982" TOTAL_1="28" TOTAL_2="32" VAR="0.05435924369747899" WEIGHT="13.143205945494326"/>
<DICH_DATA CI_END="1.0198882784889167" CI_START="0.5810598490281527" EFFECT_SIZE="0.7698156461935237" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="95" LOG_CI_END="0.008552600494085369" LOG_CI_START="-0.23577913307604143" LOG_EFFECT_SIZE="-0.11361326629097802" MODIFIED="2016-10-13 17:03:24 +0200" MODIFIED_BY="[Empty name]" ORDER="365" O_E="0.0" SE="0.14352166976067954" STUDY_ID="STD-Thursz-2015" TOTAL_1="551" TOTAL_2="552" VAR="0.020598469690893555" WEIGHT="16.897185068076062"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3961424920432164" CI_END="1.1710004771333413" CI_START="0.9089711840685933" DF="2" EFFECT_SIZE="1.0317003878281625" ESTIMABLE="YES" EVENTS_1="276" EVENTS_2="267" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="0.06855707202909674" LOG_CI_START="-0.041449884433000385" LOG_EFFECT_SIZE="0.013553593798048167" MODIFIED="2016-12-16 15:26:31 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="3" P_CHI2="0.497544076930442" P_Z="0.629123160449907" STUDIES="3" TAU2="0.0" TOTAL_1="672" TOTAL_2="671" WEIGHT="100.0" Z="0.482961379163556">
<NAME>At 1 year after randomisation</NAME>
<DICH_DATA CI_END="4.023081095767875" CI_START="0.6904602993710199" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.6045587870056439" LOG_CI_START="-0.1608612877729312" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2016-10-03 12:20:49 +0200" MODIFIED_BY="[Empty name]" ORDER="121" O_E="0.0" SE="0.44961154081541166" STUDY_ID="STD-De-2014" TOTAL_1="31" TOTAL_2="31" VAR="0.2021505376344086" WEIGHT="2.065573256114072"/>
<DICH_DATA CI_END="1.3750297975832495" CI_START="0.8413052248901403" EFFECT_SIZE="1.0755555555555556" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="50" LOG_CI_END="0.13831210964683427" LOG_CI_START="-0.0750464139086967" LOG_EFFECT_SIZE="0.03163284786906881" MODIFIED="2016-10-03 12:20:37 +0200" MODIFIED_BY="[Empty name]" ORDER="24" O_E="0.0" SE="0.12532785287824372" STUDY_ID="STD-Mendenhall-1984" TOTAL_1="90" TOTAL_2="88" VAR="0.0157070707070707" WEIGHT="26.58399850831181"/>
<DICH_DATA CI_END="1.1638689997414937" CI_START="0.8623247617086154" EFFECT_SIZE="1.0018148820326678" ESTIMABLE="YES" EVENTS_1="211" EVENTS_2="211" LOG_CI_END="0.06590410068235815" LOG_CI_START="-0.06432914292753052" LOG_EFFECT_SIZE="7.874788774138089E-4" MODIFIED="2016-10-17 18:39:16 +0200" MODIFIED_BY="[Empty name]" ORDER="76" O_E="0.0" SE="0.07649965196140152" STUDY_ID="STD-Thursz-2015" TOTAL_1="551" TOTAL_2="552" VAR="0.005852196750215564" WEIGHT="71.35042823557411"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2017-02-22 15:37:46 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="279" TOTAL_2="268" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Health-related quality of life</NAME>
<GROUP_LABEL_1>Glucocorticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no intervention</GROUP_LABEL_2>
<GRAPH_LABEL_1>Glucocorticosteroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo/no intervention</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.01" MODIFIED="2016-12-05 12:36:46 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="191" TOTAL_2="186" WEIGHT="0.0" Z="0.0">
<NAME>Up to three months</NAME>
<CONT_DATA CI_END="0.03277206582335386" CI_START="-0.11077206582335371" EFFECT_SIZE="-0.038999999999999924" ESTIMABLE="YES" MEAN_1="0.553" MEAN_2="0.592" MODIFIED="2016-12-05 12:36:46 +0100" MODIFIED_BY="Dimitrinka Nikolova" ORDER="154" SD_1="0.358" SD_2="0.353" SE="0.03661907381435714" STUDY_ID="STD-Thursz-2015" TOTAL_1="191" TOTAL_2="186" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.02" MODIFIED="2016-12-05 12:37:46 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="88" TOTAL_2="82" WEIGHT="0.0" Z="0.0">
<NAME>Up to one year</NAME>
<CONT_DATA CI_END="0.1003283016881947" CI_START="-0.10832830168819471" EFFECT_SIZE="-0.0040000000000000036" ESTIMABLE="YES" MEAN_1="0.583" MEAN_2="0.587" MODIFIED="2016-12-05 12:37:46 +0100" MODIFIED_BY="Dimitrinka Nikolova" ORDER="154" SD_1="0.356" SD_2="0.338" SE="0.053229703459412026" STUDY_ID="STD-Thursz-2015" TOTAL_1="88" TOTAL_2="82" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="21.823032883357243" CI_END="1.2864670939864817" CI_START="0.8498072406007641" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="1.045585506433757" ESTIMABLE="YES" EVENTS_1="361" EVENTS_2="338" I2="35.84759700986966" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.10939868204822206" LOG_CI_START="-0.07067957291753144" LOG_EFFECT_SIZE="0.019359554565345327" METHOD="MH" MODIFIED="2016-12-15 05:36:46 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0823244898212182" P_Q="1.0" P_Z="0.6734505218193383" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.046771215233738554" TOTALS="YES" TOTAL_1="927" TOTAL_2="934" WEIGHT="100.00000000000001" Z="0.42141711904117246">
<NAME>Number of participants with serious adverse events during treatment</NAME>
<GROUP_LABEL_1>Glucocorticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no intervention</GROUP_LABEL_2>
<GRAPH_LABEL_1>Glucocorticosteroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo/no intervention</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.6470591644592263" CI_START="0.6217836230896183" EFFECT_SIZE="1.5058823529411764" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.5619428087181544" LOG_CI_START="-0.20636072085100313" LOG_EFFECT_SIZE="0.17779104393357562" MODIFIED="2016-09-29 14:10:02 +0200" MODIFIED_BY="[Empty name]" ORDER="75" O_E="0.0" SE="0.4513052964327311" STUDY_ID="STD-Blitzer-1977" TOTAL_1="17" TOTAL_2="16" VAR="0.2036764705882353" WEIGHT="4.467666307654609"/>
<DICH_DATA CI_END="8.608580580398396" CI_START="0.35574970477400936" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9349315490240584" LOG_CI_START="-0.4488554516514696" LOG_EFFECT_SIZE="0.24303804868629444" MODIFIED="2016-10-10 13:46:54 +0200" MODIFIED_BY="[Empty name]" ORDER="47" O_E="0.0" SE="0.8128433340529316" STUDY_ID="STD-Bories-1987" TOTAL_1="24" TOTAL_2="21" VAR="0.6607142857142858" WEIGHT="1.5815400969738052"/>
<DICH_DATA CI_END="1.959321304462537" CI_START="0.4050989526101174" EFFECT_SIZE="0.8909090909090909" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.2921056607588947" LOG_CI_START="-0.3924388796903551" LOG_EFFECT_SIZE="-0.0501666094657302" MODIFIED="2016-10-01 19:25:42 +0200" MODIFIED_BY="[Empty name]" ORDER="46" O_E="0.0" SE="0.4021048516100144" STUDY_ID="STD-Campra-1973" TOTAL_1="22" TOTAL_2="28" VAR="0.16168831168831171" WEIGHT="5.36754882013763"/>
<DICH_DATA CI_END="0.9058949243709684" CI_START="0.14210785243700305" EFFECT_SIZE="0.3587962962962963" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="-0.04292217363921447" LOG_CI_START="-0.8473819236500268" LOG_EFFECT_SIZE="-0.4451520486446206" MODIFIED="2016-09-30 12:52:19 +0200" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="0.47254363929633686" STUDY_ID="STD-Carithers-1989" TOTAL_1="36" TOTAL_2="31" VAR="0.2232974910394265" WEIGHT="4.143081600298979"/>
<DICH_DATA CI_END="3.7083298042967927" CI_START="0.6067421504400592" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.5691783516366348" LOG_CI_START="-0.21699583352527232" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2016-10-01 19:24:58 +0200" MODIFIED_BY="[Empty name]" ORDER="31" O_E="0.0" SE="0.4618026079890841" STUDY_ID="STD-De-2014" TOTAL_1="31" TOTAL_2="31" VAR="0.21326164874551973" WEIGHT="4.302981825659354"/>
<DICH_DATA CI_END="2.0186549725080996" CI_START="0.7034730866761564" EFFECT_SIZE="1.1916666666666667" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.3050620958922779" LOG_CI_START="-0.15275251305740395" LOG_EFFECT_SIZE="0.07615479141743697" MODIFIED="2016-10-01 21:50:06 +0200" MODIFIED_BY="[Empty name]" ORDER="101" O_E="0.0" SE="0.26892256751590654" STUDY_ID="STD-Depew-1980" TOTAL_1="15" TOTAL_2="13" VAR="0.0723193473193473" WEIGHT="9.395510977438962"/>
<DICH_DATA CI_END="2.8535694500320847" CI_START="0.5696812460554348" EFFECT_SIZE="1.275" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.4553884468512155" LOG_CI_START="-0.24436807731126758" LOG_EFFECT_SIZE="0.10551018476997394" MODIFIED="2016-10-04 10:26:11 +0200" MODIFIED_BY="[Empty name]" ORDER="68" O_E="0.0" SE="0.4110404461437014" STUDY_ID="STD-Helman-1971" TOTAL_1="20" TOTAL_2="17" VAR="0.16895424836601308" WEIGHT="5.186762235231036"/>
<DICH_DATA CI_END="2.7001521358041995" CI_START="0.2696802776858724" EFFECT_SIZE="0.8533333333333334" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.43138823448449654" LOG_CI_START="-0.5691508133001222" LOG_EFFECT_SIZE="-0.06888128940781285" MODIFIED="2016-10-01 19:25:09 +0200" MODIFIED_BY="[Empty name]" ORDER="105" O_E="0.0" SE="0.5877215894168485" STUDY_ID="STD-Maddrey-1978" TOTAL_1="25" TOTAL_2="32" VAR="0.34541666666666665" WEIGHT="2.8530118838833594"/>
<DICH_DATA CI_END="13.05963254309707" CI_START="0.6147016580509396" EFFECT_SIZE="2.8333333333333335" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.115930957432902" LOG_CI_START="-0.21133561544364132" LOG_EFFECT_SIZE="0.4522976709946303" MODIFIED="2016-10-04 10:26:10 +0200" MODIFIED_BY="[Empty name]" ORDER="110" O_E="0.0" SE="0.7796429549831781" STUDY_ID="STD-Mendenhall-1977" TOTAL_1="12" TOTAL_2="17" VAR="0.6078431372549019" WEIGHT="1.709276131088672"/>
<DICH_DATA CI_END="2.0162825737974504" CI_START="0.6001142973333823" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="16" LOG_CI_END="0.3045513966431257" LOG_CI_START="-0.22176602632667544" LOG_EFFECT_SIZE="0.04139268515822508" MODIFIED="2016-10-04 10:26:09 +0200" MODIFIED_BY="[Empty name]" ORDER="57" O_E="0.0" SE="0.30916145956572283" STUDY_ID="STD-Mendenhall-1984" TOTAL_1="90" TOTAL_2="88" VAR="0.09558080808080807" WEIGHT="7.860209231480308"/>
<DICH_DATA CI_END="1.3334993458285727" CI_START="0.36881897991307366" EFFECT_SIZE="0.7012987012987013" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.12499280697519317" LOG_CI_START="-0.4331867376742198" LOG_EFFECT_SIZE="-0.15409696534951337" MODIFIED="2016-10-04 10:26:08 +0200" MODIFIED_BY="[Empty name]" ORDER="59" O_E="0.0" SE="0.3278774275603728" STUDY_ID="STD-Porter-1971" TOTAL_1="11" TOTAL_2="9" VAR="0.10750360750360752" WEIGHT="7.2527497871889475"/>
<DICH_DATA CI_END="0.6471159716752733" CI_START="0.09081759048972873" EFFECT_SIZE="0.24242424242424243" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="16" LOG_CI_END="-0.1890178810851679" LOG_CI_START="-1.0418300246867198" LOG_EFFECT_SIZE="-0.6154239528859439" MODIFIED="2016-10-01 19:25:05 +0200" MODIFIED_BY="[Empty name]" ORDER="60" O_E="0.0" SE="0.5009460746397457" STUDY_ID="STD-Ramond-1992" TOTAL_1="33" TOTAL_2="32" VAR="0.2509469696969697" WEIGHT="3.7583081733395596"/>
<DICH_DATA CI_END="1.974876697012832" CI_START="0.6251366999782602" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.29553998528976677" LOG_CI_START="-0.20402500416841643" LOG_EFFECT_SIZE="0.04575749056067514" MODIFIED="2016-10-04 10:26:06 +0200" MODIFIED_BY="[Empty name]" ORDER="54" O_E="0.0" SE="0.29344694769431684" STUDY_ID="STD-Shumaker-1978" TOTAL_1="12" TOTAL_2="15" VAR="0.08611111111111112" WEIGHT="8.420357458772523"/>
<DICH_DATA CI_END="2.170404590612756" CI_START="0.9402930381539794" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="16" LOG_CI_END="0.3365406993287701" LOG_CI_START="-0.026736779357283788" LOG_EFFECT_SIZE="0.1549019599857432" MODIFIED="2016-10-04 10:26:07 +0200" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="0.21339098923270938" STUDY_ID="STD-Theodossi-1982" TOTAL_1="28" TOTAL_2="32" VAR="0.04553571428571429" WEIGHT="12.121697619040594"/>
<DICH_DATA CI_END="1.2953504555277" CI_START="0.9795979341128587" EFFECT_SIZE="1.126464659981433" ESTIMABLE="YES" EVENTS_1="244" EVENTS_2="217" LOG_CI_END="0.11238728217100727" LOG_CI_START="-0.008952139435779785" LOG_EFFECT_SIZE="0.051717571367613756" MODIFIED="2016-10-21 15:43:57 +0200" MODIFIED_BY="[Empty name]" ORDER="52" O_E="0.0" SE="0.0712753768916507" STUDY_ID="STD-Thursz-2015" TOTAL_1="551" TOTAL_2="552" VAR="0.005080179351046854" WEIGHT="21.57929785181168"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="25.807545909089317" CI_END="1.1433138700974934" CI_START="0.6935246236693902" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8904584894846913" ESTIMABLE="YES" EVENTS_1="257" EVENTS_2="279" I2="45.75230031822106" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.058165472161703195" LOG_CI_START="-0.1589381146427603" LOG_EFFECT_SIZE="-0.05038632124052857" METHOD="MH" MODIFIED="2017-11-01 15:02:39 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="4" P_CHI2="0.027383434086144964" P_Q="1.0" P_Z="0.362952528209606" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="YEAR" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.08450720058362501" TOTALS="YES" TOTAL_1="927" TOTAL_2="934" WEIGHT="100.00000000000003" Z="0.909753508898465">
<NAME>Liver-related mortality</NAME>
<GROUP_LABEL_1>Glucocorticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no intervention</GROUP_LABEL_2>
<GRAPH_LABEL_1>Glucocorticosteroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo/no intervention</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="25.807545909089317" CI_END="1.1433138700974934" CI_START="0.6935246236693902" DF="14" EFFECT_SIZE="0.8904584894846913" ESTIMABLE="YES" EVENTS_1="257" EVENTS_2="279" I2="45.75230031822106" ID="CMP-001.04.01" LOG_CI_END="0.058165472161703195" LOG_CI_START="-0.1589381146427603" LOG_EFFECT_SIZE="-0.05038632124052857" MODIFIED="2017-11-01 15:02:39 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1" P_CHI2="0.027383434086144964" P_Z="0.362952528209606" STUDIES="15" TAU2="0.08450720058362501" TOTAL_1="927" TOTAL_2="934" WEIGHT="100.00000000000003" Z="0.909753508898465">
<NAME>Up to 3 months' follow-up after randomisation</NAME>
<DICH_DATA CI_END="1.3334993458285727" CI_START="0.36881897991307366" EFFECT_SIZE="0.7012987012987013" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.12499280697519317" LOG_CI_START="-0.4331867376742198" LOG_EFFECT_SIZE="-0.15409696534951337" MODIFIED="2016-10-03 16:59:51 +0200" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="0.3278774275603728" STUDY_ID="STD-Porter-1971" TOTAL_1="11" TOTAL_2="9" VAR="0.10750360750360752" WEIGHT="8.470002251747792"/>
<DICH_DATA CI_END="1.0635091819729094" CI_START="0.01887096490056978" EFFECT_SIZE="0.14166666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.02674124380428928" LOG_CI_START="-1.7242058931429909" LOG_EFFECT_SIZE="-0.8487323246693509" MODIFIED="2016-10-02 01:05:54 +0200" MODIFIED_BY="[Empty name]" ORDER="9" O_E="0.0" SE="1.0285150155709453" STUDY_ID="STD-Helman-1971" TOTAL_1="20" TOTAL_2="17" VAR="1.057843137254902" WEIGHT="1.4236718132687745"/>
<DICH_DATA CI_END="1.959321304462537" CI_START="0.4050989526101174" EFFECT_SIZE="0.8909090909090909" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.2921056607588947" LOG_CI_START="-0.3924388796903551" LOG_EFFECT_SIZE="-0.0501666094657302" MODIFIED="2016-10-01 19:07:11 +0200" MODIFIED_BY="[Empty name]" ORDER="7" O_E="0.0" SE="0.4021048516100144" STUDY_ID="STD-Campra-1973" TOTAL_1="22" TOTAL_2="28" VAR="0.16168831168831171" WEIGHT="6.605855492046492"/>
<DICH_DATA CI_END="3.6470591644592263" CI_START="0.6217836230896183" EFFECT_SIZE="1.5058823529411764" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.5619428087181544" LOG_CI_START="-0.20636072085100313" LOG_EFFECT_SIZE="0.17779104393357562" MODIFIED="2016-09-29 13:54:51 +0200" MODIFIED_BY="[Empty name]" ORDER="5" O_E="0.0" SE="0.4513052964327311" STUDY_ID="STD-Blitzer-1977" TOTAL_1="17" TOTAL_2="16" VAR="0.2036764705882353" WEIGHT="5.6433869769425575"/>
<DICH_DATA CI_END="13.05963254309707" CI_START="0.6147016580509396" EFFECT_SIZE="2.8333333333333335" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.115930957432902" LOG_CI_START="-0.21133561544364132" LOG_EFFECT_SIZE="0.4522976709946303" MODIFIED="2016-10-04 14:56:03 +0200" MODIFIED_BY="[Empty name]" ORDER="55" O_E="0.0" SE="0.7796429549831781" STUDY_ID="STD-Mendenhall-1977" TOTAL_1="12" TOTAL_2="17" VAR="0.6078431372549019" WEIGHT="2.3490014924179516"/>
<DICH_DATA CI_END="2.3096079660641027" CI_START="0.1773461150196915" EFFECT_SIZE="0.64" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.36353826879945483" LOG_CI_START="-0.7511783208316805" LOG_EFFECT_SIZE="-0.1938200260161128" MODIFIED="2016-09-29 10:05:36 +0200" MODIFIED_BY="[Empty name]" ORDER="10" O_E="0.0" SE="0.6547900426854397" STUDY_ID="STD-Maddrey-1978" TOTAL_1="25" TOTAL_2="32" VAR="0.42875" WEIGHT="3.168649119796994"/>
<DICH_DATA CI_END="2.343887675927311" CI_START="0.4897671485982377" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.36993679553129327" LOG_CI_START="-0.3100103487764068" LOG_EFFECT_SIZE="0.029963223377443202" MODIFIED="2016-10-03 12:37:35 +0200" MODIFIED_BY="[Empty name]" ORDER="231" O_E="0.0" SE="0.39940431835899015" STUDY_ID="STD-Shumaker-1978" TOTAL_1="12" TOTAL_2="15" VAR="0.15952380952380957" WEIGHT="6.664447998403074"/>
<DICH_DATA CI_END="1.976541991306356" CI_START="0.4963431529485624" EFFECT_SIZE="0.9904761904761905" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.29590604529114234" LOG_CI_START="-0.3042179648334578" LOG_EFFECT_SIZE="-0.0041559597711577035" MODIFIED="2016-09-30 18:46:38 +0200" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="0.35251581420895045" STUDY_ID="STD-Depew-1980" TOTAL_1="15" TOTAL_2="13" VAR="0.12426739926739927" WEIGHT="7.789893876071504"/>
<DICH_DATA CI_END="1.9176931273639117" CI_START="0.7688872504566056" EFFECT_SIZE="1.2142857142857142" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.2827791118256619" LOG_CI_START="-0.11413734042559018" LOG_EFFECT_SIZE="0.08432088570003587" MODIFIED="2016-10-04 10:26:24 +0200" MODIFIED_BY="[Empty name]" ORDER="12" O_E="0.0" SE="0.23315068882051151" STUDY_ID="STD-Theodossi-1982" TOTAL_1="28" TOTAL_2="32" VAR="0.05435924369747899" WEIGHT="11.711482822780628"/>
<DICH_DATA CI_END="1.3741962892744457" CI_START="0.6565280702147891" EFFECT_SIZE="0.9498412698412698" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="35" LOG_CI_END="0.1380487714863567" LOG_CI_START="-0.18274670068071025" LOG_EFFECT_SIZE="-0.02234896459717677" MODIFIED="2016-10-04 16:16:05 +0200" MODIFIED_BY="[Empty name]" ORDER="56" O_E="0.0" SE="0.18843684831413268" STUDY_ID="STD-Mendenhall-1984" TOTAL_1="90" TOTAL_2="88" VAR="0.035508445802563446" WEIGHT="13.550999605714184"/>
<DICH_DATA CI_END="1.9380885175016556" CI_START="0.14221486661264665" EFFECT_SIZE="0.525" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.2873736085169239" LOG_CI_START="-0.84705500170501" LOG_EFFECT_SIZE="-0.2798406965940431" MODIFIED="2016-10-11 16:27:35 +0200" MODIFIED_BY="[Empty name]" ORDER="6" O_E="0.0" SE="0.6663689811565504" STUDY_ID="STD-Bories-1987" TOTAL_1="24" TOTAL_2="21" VAR="0.444047619047619" WEIGHT="3.0769409651650004"/>
<DICH_DATA CI_END="0.652966466690005" CI_START="0.037540679447284" EFFECT_SIZE="0.15656565656565657" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.18510912148976028" LOG_CI_START="-1.4254978713647564" LOG_EFFECT_SIZE="-0.8053034964272584" MODIFIED="2016-10-01 19:06:57 +0200" MODIFIED_BY="[Empty name]" ORDER="8" O_E="0.0" SE="0.7286104916999097" STUDY_ID="STD-Carithers-1989" TOTAL_1="36" TOTAL_2="31" VAR="0.5308732486151841" WEIGHT="2.642807354338549"/>
<DICH_DATA CI_END="0.6471159716752733" CI_START="0.09081759048972873" EFFECT_SIZE="0.24242424242424243" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="16" LOG_CI_END="-0.1890178810851679" LOG_CI_START="-1.0418300246867198" LOG_EFFECT_SIZE="-0.6154239528859439" MODIFIED="2016-10-01 19:06:56 +0200" MODIFIED_BY="[Empty name]" ORDER="61" O_E="0.0" SE="0.5009460746397457" STUDY_ID="STD-Ramond-1992" TOTAL_1="33" TOTAL_2="32" VAR="0.2509469696969697" WEIGHT="4.848149526650413"/>
<DICH_DATA CI_END="1.257721969620654" CI_START="0.8438943704799494" EFFECT_SIZE="1.0302351623740202" ESTIMABLE="YES" EVENTS_1="145" EVENTS_2="141" LOG_CI_END="0.09958464714687978" LOG_CI_START="-0.07371191023286199" LOG_EFFECT_SIZE="0.012936368457008879" MODIFIED="2016-10-17 18:40:57 +0200" MODIFIED_BY="[Empty name]" ORDER="22" O_E="0.0" SE="0.10179525563665424" STUDY_ID="STD-Thursz-2015" TOTAL_1="551" TOTAL_2="552" VAR="0.010362274070131789" WEIGHT="17.14283738572774"/>
<DICH_DATA CI_END="4.76392574408339" CI_START="0.6801113564845032" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.6779649834601594" LOG_CI_START="-0.16741997325354727" LOG_EFFECT_SIZE="0.25527250510330607" MODIFIED="2016-10-03 12:37:44 +0200" MODIFIED_BY="[Empty name]" ORDER="59" O_E="0.0" SE="0.49658330829665737" STUDY_ID="STD-De-2014" TOTAL_1="31" TOTAL_2="31" VAR="0.24659498207885308" WEIGHT="4.911873318928367"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="24.293223629399957" CI_END="1.2651615863770376" CI_START="0.8567026860531387" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0410894915137978" ESTIMABLE="YES" EVENTS_1="440" EVENTS_2="414" I2="42.37076061384859" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.10214599712469451" LOG_CI_START="-0.0671698714366957" LOG_EFFECT_SIZE="0.017488062843999393" METHOD="MH" MODIFIED="2017-10-31 19:28:48 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.04222064301311523" P_Q="1.0" P_Z="0.68556859619917" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.04720707576709533" TOTALS="YES" TOTAL_1="927" TOTAL_2="934" WEIGHT="100.0" Z="0.4048760889908468">
<NAME>Any complication</NAME>
<GROUP_LABEL_1>Glucocorticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no intervention</GROUP_LABEL_2>
<GRAPH_LABEL_1>Glucocorticosteroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo/no intervention</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="24.293223629399957" CI_END="1.2651615863770376" CI_START="0.8567026860531387" DF="14" EFFECT_SIZE="1.0410894915137978" ESTIMABLE="YES" EVENTS_1="440" EVENTS_2="414" I2="42.37076061384859" ID="CMP-001.05.01" LOG_CI_END="0.10214599712469451" LOG_CI_START="-0.0671698714366957" LOG_EFFECT_SIZE="0.017488062843999393" MODIFIED="2017-10-31 19:28:48 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.04222064301311523" P_Z="0.68556859619917" STUDIES="15" TAU2="0.04720707576709533" TOTAL_1="927" TOTAL_2="934" WEIGHT="100.0" Z="0.4048760889908468">
<NAME>Number of participants with complications up to 3 months' follow-up after randomisation</NAME>
<DICH_DATA CI_END="4.3102765727306" CI_START="0.8220476193041659" EFFECT_SIZE="1.8823529411764706" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.6345051379465902" LOG_CI_START="-0.08510302406332619" LOG_EFFECT_SIZE="0.27470105694163205" MODIFIED="2016-09-29 13:55:25 +0200" MODIFIED_BY="[Empty name]" ORDER="44" O_E="0.0" SE="0.42270139648247596" STUDY_ID="STD-Blitzer-1977" TOTAL_1="17" TOTAL_2="16" VAR="0.17867647058823533" WEIGHT="4.3791107829978815"/>
<DICH_DATA CI_END="2.271566119051022" CI_START="0.21571020798844465" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.3563253824542302" LOG_CI_START="-0.6661293024257166" LOG_EFFECT_SIZE="-0.1549019599857432" MODIFIED="2016-10-10 13:42:52 +0200" MODIFIED_BY="[Empty name]" ORDER="45" O_E="0.0" SE="0.6005949431307973" STUDY_ID="STD-Bories-1987" TOTAL_1="24" TOTAL_2="21" VAR="0.3607142857142857" WEIGHT="2.424901382840622"/>
<DICH_DATA CI_END="2.1411357518179877" CI_START="0.4841795827265041" EFFECT_SIZE="1.018181818181818" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.33064420321057786" LOG_CI_START="-0.3149935281866648" LOG_EFFECT_SIZE="0.007825337511956526" MODIFIED="2016-10-01 19:27:26 +0200" MODIFIED_BY="[Empty name]" ORDER="370" O_E="0.0" SE="0.37925079938105455" STUDY_ID="STD-Campra-1973" TOTAL_1="22" TOTAL_2="28" VAR="0.14383116883116887" WEIGHT="5.177858892215858"/>
<DICH_DATA CI_END="0.9058949243709684" CI_START="0.14210785243700305" EFFECT_SIZE="0.3587962962962963" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="-0.04292217363921447" LOG_CI_START="-0.8473819236500268" LOG_EFFECT_SIZE="-0.4451520486446206" MODIFIED="2016-09-30 12:52:37 +0200" MODIFIED_BY="[Empty name]" ORDER="488" O_E="0.0" SE="0.47254363929633686" STUDY_ID="STD-Carithers-1989" TOTAL_1="36" TOTAL_2="31" VAR="0.2232974910394265" WEIGHT="3.6567555410402095"/>
<DICH_DATA CI_END="2.7409750432619995" CI_START="0.5700526182611604" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.4379050812808546" LOG_CI_START="-0.2440850552647417" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2016-09-29 16:44:23 +0200" MODIFIED_BY="[Empty name]" ORDER="51" O_E="0.0" SE="0.40060438211250504" STUDY_ID="STD-De-2014" TOTAL_1="31" TOTAL_2="31" VAR="0.16048387096774194" WEIGHT="4.762697118470551"/>
<DICH_DATA CI_END="2.2609458587288294" CI_START="0.8772447027514872" EFFECT_SIZE="1.4083333333333334" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.3542901627271209" LOG_CI_START="-0.05687924559502341" LOG_EFFECT_SIZE="0.14870545856604875" MODIFIED="2016-10-01 21:48:35 +0200" MODIFIED_BY="[Empty name]" ORDER="34" O_E="0.0" SE="0.241522945769824" STUDY_ID="STD-Depew-1980" TOTAL_1="15" TOTAL_2="13" VAR="0.05833333333333335" WEIGHT="9.372420307800498"/>
<DICH_DATA CI_END="1.924234078627763" CI_START="0.4752093690971838" EFFECT_SIZE="0.95625" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.2842579018352783" LOG_CI_START="-0.3231150055119303" LOG_EFFECT_SIZE="-0.019428551838325956" MODIFIED="2016-10-04 10:26:50 +0200" MODIFIED_BY="[Empty name]" ORDER="73" O_E="0.0" SE="0.35677385232013065" STUDY_ID="STD-Helman-1971" TOTAL_1="20" TOTAL_2="17" VAR="0.1272875816993464" WEIGHT="5.668764235585059"/>
<DICH_DATA CI_END="3.1725163089757364" CI_START="0.5164354854109374" EFFECT_SIZE="1.28" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.5014038633530189" LOG_CI_START="-0.2869839240572822" LOG_EFFECT_SIZE="0.10720996964786837" MODIFIED="2016-10-01 19:26:08 +0200" MODIFIED_BY="[Empty name]" ORDER="108" O_E="0.0" SE="0.46310288890729856" STUDY_ID="STD-Maddrey-1978" TOTAL_1="25" TOTAL_2="32" VAR="0.2144642857142857" WEIGHT="3.7801961511818463"/>
<DICH_DATA CI_END="13.05963254309707" CI_START="0.6147016580509396" EFFECT_SIZE="2.8333333333333335" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.115930957432902" LOG_CI_START="-0.21133561544364132" LOG_EFFECT_SIZE="0.4522976709946303" MODIFIED="2016-10-03 13:00:58 +0200" MODIFIED_BY="[Empty name]" ORDER="822" O_E="0.0" SE="0.7796429549831781" STUDY_ID="STD-Mendenhall-1977" TOTAL_1="12" TOTAL_2="17" VAR="0.6078431372549019" WEIGHT="1.5100660283476817"/>
<DICH_DATA CI_END="1.3741962892744457" CI_START="0.6565280702147891" EFFECT_SIZE="0.9498412698412698" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="35" LOG_CI_END="0.1380487714863567" LOG_CI_START="-0.18274670068071025" LOG_EFFECT_SIZE="-0.02234896459717677" MODIFIED="2016-10-04 16:16:45 +0200" MODIFIED_BY="[Empty name]" ORDER="35" O_E="0.0" SE="0.18843684831413268" STUDY_ID="STD-Mendenhall-1984" TOTAL_1="90" TOTAL_2="88" VAR="0.035508445802563446" WEIGHT="11.958687496317152"/>
<DICH_DATA CI_END="1.3334993458285727" CI_START="0.36881897991307366" EFFECT_SIZE="0.7012987012987013" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.12499280697519317" LOG_CI_START="-0.4331867376742198" LOG_EFFECT_SIZE="-0.15409696534951337" MODIFIED="2016-10-04 10:26:49 +0200" MODIFIED_BY="[Empty name]" ORDER="111" O_E="0.0" SE="0.3278774275603728" STUDY_ID="STD-Porter-1971" TOTAL_1="11" TOTAL_2="9" VAR="0.10750360750360752" WEIGHT="6.393670124354926"/>
<DICH_DATA CI_END="0.6471159716752733" CI_START="0.09081759048972873" EFFECT_SIZE="0.24242424242424243" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="16" LOG_CI_END="-0.1890178810851679" LOG_CI_START="-1.0418300246867198" LOG_EFFECT_SIZE="-0.6154239528859439" MODIFIED="2016-09-30 12:46:47 +0200" MODIFIED_BY="[Empty name]" ORDER="243" O_E="0.0" SE="0.5009460746397457" STUDY_ID="STD-Ramond-1992" TOTAL_1="33" TOTAL_2="32" VAR="0.2509469696969697" WEIGHT="3.3176443137198675"/>
<DICH_DATA CI_END="1.974876697012832" CI_START="0.6251366999782602" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.29553998528976677" LOG_CI_START="-0.20402500416841643" LOG_EFFECT_SIZE="0.04575749056067514" MODIFIED="2017-07-19 21:37:58 +0200" MODIFIED_BY="[Empty name]" ORDER="36" O_E="0.0" SE="0.29344694769431684" STUDY_ID="STD-Shumaker-1978" TOTAL_1="12" TOTAL_2="15" VAR="0.08611111111111112" WEIGHT="7.419610907625761"/>
<DICH_DATA CI_END="2.170404590612756" CI_START="0.9402930381539794" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="16" LOG_CI_END="0.3365406993287701" LOG_CI_START="-0.026736779357283788" LOG_EFFECT_SIZE="0.1549019599857432" MODIFIED="2016-10-03 14:57:04 +0200" MODIFIED_BY="[Empty name]" ORDER="1051" O_E="0.0" SE="0.21339098923270938" STUDY_ID="STD-Theodossi-1982" TOTAL_1="28" TOTAL_2="32" VAR="0.04553571428571429" WEIGHT="10.665724774757987"/>
<DICH_DATA CI_END="1.2600796123455713" CI_START="0.9996459890038741" EFFECT_SIZE="1.12233396558547" ESTIMABLE="YES" EVENTS_1="298" EVENTS_2="266" LOG_CI_END="0.10039798488749328" LOG_CI_START="-1.5377224228909852E-4" LOG_EFFECT_SIZE="0.05012210632260211" MODIFIED="2017-01-03 16:35:25 +0100" MODIFIED_BY="[Empty name]" ORDER="1053" O_E="0.0" SE="0.0590645998772594" STUDY_ID="STD-Thursz-2015" TOTAL_1="551" TOTAL_2="552" VAR="0.0034886269586607514" WEIGHT="19.5118919427441"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.9367260680387806" CI_END="5.475430608132915" CI_START="0.7217199587194847" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9878952569169963" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" I2="0.0" I2_Q="100.0" ID="CMP-001.06" LOG_CI_END="0.7384182793810484" LOG_CI_START="-0.1416312843906243" LOG_EFFECT_SIZE="0.2983934974952121" METHOD="MH" MODIFIED="2017-10-31 19:29:02 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.5856430115919506" P_Q="0.0" P_Z="0.18381230345736527" Q="4.6124427806628623E-32" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="83" TOTAL_2="77" WEIGHT="100.0" Z="1.3291081147863495">
<NAME>Number of participants with non-serious adverse events up to 3 months' follow-up after randomisation</NAME>
<GROUP_LABEL_1>Glucocorticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no intervention</GROUP_LABEL_2>
<GRAPH_LABEL_1>Glucocorticosteroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo/no intervention</GRAPH_LABEL_2>
<DICH_DATA CI_END="91.41467225220828" CI_START="0.24393658224279977" EFFECT_SIZE="4.722222222222222" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9610159065300856" LOG_CI_START="-0.6127230653081122" LOG_EFFECT_SIZE="0.6741464206109866" MODIFIED="2016-09-27 09:59:55 +0200" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="1.5118270122711395" STUDY_ID="STD-Blitzer-1977" TOTAL_1="17" TOTAL_2="16" VAR="2.28562091503268" WEIGHT="9.871541501976285"/>
<DICH_DATA CI_END="5.2337006044292" CI_START="0.0477673483631121" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.718808875055234" LOG_CI_START="-1.3208688663831967" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2016-09-27 11:18:22 +0200" MODIFIED_BY="[Empty name]" ORDER="33" O_E="0.0" SE="1.1981168018885897" STUDY_ID="STD-De-2014" TOTAL_1="31" TOTAL_2="31" VAR="1.435483870967742" WEIGHT="38.38932806324111"/>
<DICH_DATA CI_END="83.62425592825048" CI_START="0.22888843419333532" EFFECT_SIZE="4.375" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9223322665284344" LOG_CI_START="-0.6403761518117705" LOG_EFFECT_SIZE="0.640978057358332" MODIFIED="2016-10-01 21:49:24 +0200" MODIFIED_BY="[Empty name]" ORDER="50" O_E="0.0" SE="1.5053476105442982" STUDY_ID="STD-Depew-1980" TOTAL_1="15" TOTAL_2="13" VAR="2.2660714285714283" WEIGHT="10.237154150197629"/>
<DICH_DATA CI_END="9.590268931796777" CI_START="0.47085488760678357" EFFECT_SIZE="2.125" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.9818307858940977" LOG_CI_START="-0.3271129171214371" LOG_EFFECT_SIZE="0.32735893438633035" MODIFIED="2016-09-26 17:39:54 +0200" MODIFIED_BY="[Empty name]" ORDER="74" O_E="0.0" SE="0.7688800105271532" STUDY_ID="STD-Helman-1971" TOTAL_1="20" TOTAL_2="17" VAR="0.5911764705882352" WEIGHT="41.501976284584984"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2017-11-02 12:19:38 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="2">
<NAME>Subgroup analysis: all-cause mortality up to 3 months after randomisation</NAME>
<DICH_OUTCOME CHI2="21.13116991222542" CI_END="1.1609972875069492" CI_START="0.7495767677193609" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9328754440440613" ESTIMABLE="YES" EVENTS_1="256" EVENTS_2="269" I2="29.0148152596049" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.06483120507695429" LOG_CI_START="-0.12518388237593533" LOG_EFFECT_SIZE="-0.030176338649490507" METHOD="MH" MODIFIED="2016-12-27 14:59:31 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1" P_CHI2="0.13269053741470282" P_Q="0.7468972860227903" P_Z="0.5335969505290177" Q="0.10415676200782455" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.043124156566074975" TOTALS="SUB" TOTAL_1="927" TOTAL_2="934" WEIGHT="200.0" Z="0.622524639817869">
<NAME>Severity of alcoholic hepatitis</NAME>
<GROUP_LABEL_1>Glucocorticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no intervention</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours corticosteroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/no interv</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5081856617994706" CI_END="1.8002515090439655" CI_START="0.5750320365050959" DF="1" EFFECT_SIZE="1.017448913443286" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="17" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.25533318363637314" LOG_CI_START="-0.24030795898027682" LOG_EFFECT_SIZE="0.007512612328048114" MODIFIED="2016-10-18 16:06:02 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4759253839160339" P_Z="0.9526209541257407" STUDIES="4" TAU2="0.0" TOTAL_1="92" TOTAL_2="90" WEIGHT="100.0" Z="0.05941576808999691">
<NAME>Mild alcoholic hepatitis</NAME>
<DICH_DATA CI_END="2.271566119051022" CI_START="0.21571020798844465" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.3563253824542302" LOG_CI_START="-0.6661293024257166" LOG_EFFECT_SIZE="-0.1549019599857432" MODIFIED="2016-10-18 16:06:02 +0200" MODIFIED_BY="[Empty name]" ORDER="16" O_E="0.0" SE="0.6005949431307973" STUDY_ID="STD-Bories-1987" TOTAL_1="24" TOTAL_2="21" VAR="0.3607142857142857" WEIGHT="23.498847378242893"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-10-16 13:28:55 +0200" MODIFIED_BY="[Empty name]" ORDER="492" O_E="0.0" SE="0.0" STUDY_ID="STD-Helman-1971" TOTAL_1="11" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-10-07 12:37:29 +0200" MODIFIED_BY="[Empty name]" ORDER="493" O_E="0.0" SE="0.0" STUDY_ID="STD-Maddrey-1978" TOTAL_1="11" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.191485086527816" CI_START="0.5943803233589544" EFFECT_SIZE="1.141304347826087" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.34073851954361095" LOG_CI_START="-0.22593557609484535" LOG_EFFECT_SIZE="0.057401471724382785" MODIFIED="2016-10-06 13:38:45 +0200" MODIFIED_BY="[Empty name]" ORDER="2313" O_E="0.0" SE="0.33286716886004236" STUDY_ID="STD-Mendenhall-1984" TOTAL_1="46" TOTAL_2="45" VAR="0.11080055210489995" WEIGHT="76.5011526217571"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="20.60613747682672" CI_END="1.1646546683344712" CI_START="0.7252082150038888" DF="13" EFFECT_SIZE="0.9190305398183392" ESTIMABLE="YES" EVENTS_1="238" EVENTS_2="252" I2="36.912000055228404" ID="CMP-002.01.02" LOG_CI_END="0.0661971718262433" LOG_CI_START="-0.13953728495345893" LOG_EFFECT_SIZE="-0.036670056563607833" MODIFIED="2016-12-05 13:56:40 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="2" P_CHI2="0.08109307111024999" P_Z="0.48474769542499097" STUDIES="14" TAU2="0.05968818385958243" TOTAL_1="835" TOTAL_2="844" WEIGHT="99.99999999999999" Z="0.6986869511379669">
<NAME>Severe alcoholic hepatitis</NAME>
<DICH_DATA CI_END="3.6470591644592263" CI_START="0.6217836230896183" EFFECT_SIZE="1.5058823529411764" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.5619428087181544" LOG_CI_START="-0.20636072085100313" LOG_EFFECT_SIZE="0.17779104393357562" MODIFIED="2016-10-06 13:37:46 +0200" MODIFIED_BY="[Empty name]" ORDER="1864" O_E="0.0" SE="0.4513052964327311" STUDY_ID="STD-Blitzer-1977" TOTAL_1="17" TOTAL_2="16" VAR="0.2036764705882353" WEIGHT="5.5453860243784145"/>
<DICH_DATA CI_END="1.5918138429496782" CI_START="0.254400776497552" EFFECT_SIZE="0.6363636363636364" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.20189227715358282" LOG_CI_START="-0.5944815674415193" LOG_EFFECT_SIZE="-0.19629464514396822" MODIFIED="2016-10-10 13:46:55 +0200" MODIFIED_BY="[Empty name]" ORDER="668" O_E="0.0" SE="0.4677939384292713" STUDY_ID="STD-Campra-1973" TOTAL_1="22" TOTAL_2="28" VAR="0.21883116883116888" WEIGHT="5.24365240684647"/>
<DICH_DATA CI_END="0.652966466690005" CI_START="0.037540679447284" EFFECT_SIZE="0.15656565656565657" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.18510912148976028" LOG_CI_START="-1.4254978713647564" LOG_EFFECT_SIZE="-0.8053034964272584" MODIFIED="2016-10-06 14:56:11 +0200" MODIFIED_BY="[Empty name]" ORDER="2305" O_E="0.0" SE="0.7286104916999097" STUDY_ID="STD-Carithers-1989" TOTAL_1="36" TOTAL_2="31" VAR="0.5308732486151841" WEIGHT="2.4730004260015424"/>
<DICH_DATA CI_END="4.76392574408339" CI_START="0.6801113564845032" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.6779649834601594" LOG_CI_START="-0.16741997325354727" LOG_EFFECT_SIZE="0.25527250510330607" MODIFIED="2016-10-06 12:34:36 +0200" MODIFIED_BY="[Empty name]" ORDER="2331" O_E="0.0" SE="0.49658330829665737" STUDY_ID="STD-De-2014" TOTAL_1="31" TOTAL_2="31" VAR="0.24659498207885308" WEIGHT="4.76832825472275"/>
<DICH_DATA CI_END="1.976541991306356" CI_START="0.4963431529485624" EFFECT_SIZE="0.9904761904761905" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.29590604529114234" LOG_CI_START="-0.3042179648334578" LOG_EFFECT_SIZE="-0.0041559597711577035" MODIFIED="2016-10-06 16:27:24 +0200" MODIFIED_BY="[Empty name]" ORDER="2141" O_E="0.0" SE="0.35251581420895045" STUDY_ID="STD-Depew-1980" TOTAL_1="15" TOTAL_2="13" VAR="0.12426739926739927" WEIGHT="7.9391918922191484"/>
<DICH_DATA CI_END="0.7165067631146048" CI_START="0.03641929971851388" EFFECT_SIZE="0.16153846153846155" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="-0.14477970593727" LOG_CI_START="-1.4386684092085649" LOG_EFFECT_SIZE="-0.7917240575729175" MODIFIED="2016-10-06 12:41:44 +0200" MODIFIED_BY="[Empty name]" ORDER="2325" O_E="0.0" SE="0.760036629153936" STUDY_ID="STD-Helman-1971" TOTAL_1="9" TOTAL_2="6" VAR="0.5776556776556776" WEIGHT="2.2914768028329253"/>
<DICH_DATA CI_END="2.2568397452628033" CI_START="0.2040283031349442" EFFECT_SIZE="0.6785714285714286" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.35350072158595003" LOG_CI_START="-0.6903095823647305" LOG_EFFECT_SIZE="-0.16840443038939024" MODIFIED="2016-10-15 16:44:47 +0200" MODIFIED_BY="[Empty name]" ORDER="186" O_E="0.0" SE="0.6131393394849658" STUDY_ID="STD-Maddrey-1978" TOTAL_1="14" TOTAL_2="19" VAR="0.3759398496240602" WEIGHT="3.3525360211810558"/>
<DICH_DATA CI_END="13.05963254309707" CI_START="0.6147016580509396" EFFECT_SIZE="2.8333333333333335" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.115930957432902" LOG_CI_START="-0.21133561544364132" LOG_EFFECT_SIZE="0.4522976709946303" MODIFIED="2016-10-07 15:19:04 +0200" MODIFIED_BY="[Empty name]" ORDER="23" O_E="0.0" SE="0.7796429549831781" STUDY_ID="STD-Mendenhall-1977" TOTAL_1="12" TOTAL_2="17" VAR="0.6078431372549019" WEIGHT="2.1878504092539863"/>
<DICH_DATA CI_END="1.3026375410867188" CI_START="0.5543860420874246" EFFECT_SIZE="0.849802371541502" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="23" LOG_CI_END="0.11482359007625742" LOG_CI_START="-0.2561877125966826" LOG_EFFECT_SIZE="-0.0706820612602126" MODIFIED="2016-10-06 13:38:43 +0200" MODIFIED_BY="[Empty name]" ORDER="2319" O_E="0.0" SE="0.21793387572565245" STUDY_ID="STD-Mendenhall-1984" TOTAL_1="44" TOTAL_2="43" VAR="0.047495174188804126" WEIGHT="13.625796958431492"/>
<DICH_DATA CI_END="1.3334993458285727" CI_START="0.36881897991307366" EFFECT_SIZE="0.7012987012987013" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.12499280697519317" LOG_CI_START="-0.4331867376742198" LOG_EFFECT_SIZE="-0.15409696534951337" MODIFIED="2016-10-06 17:09:34 +0200" MODIFIED_BY="[Empty name]" ORDER="676" O_E="0.0" SE="0.3278774275603728" STUDY_ID="STD-Porter-1971" TOTAL_1="11" TOTAL_2="9" VAR="0.10750360750360752" WEIGHT="8.735229535986196"/>
<DICH_DATA CI_END="2.078680760911017" CI_START="0.20104892823730253" EFFECT_SIZE="0.6464646464646465" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3177877964885126" LOG_CI_START="-0.6966982377158379" LOG_EFFECT_SIZE="-0.1894552206136627" MODIFIED="2016-10-07 11:48:06 +0200" MODIFIED_BY="[Empty name]" ORDER="2520" O_E="0.0" SE="0.5959141182784952" STUDY_ID="STD-Ramond-1992" TOTAL_1="33" TOTAL_2="32" VAR="0.35511363636363635" WEIGHT="3.520858884621714"/>
<DICH_DATA CI_END="2.343887675927311" CI_START="0.4897671485982377" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.36993679553129327" LOG_CI_START="-0.3100103487764068" LOG_EFFECT_SIZE="0.029963223377443202" MODIFIED="2016-10-06 14:25:59 +0200" MODIFIED_BY="[Empty name]" ORDER="2148" O_E="0.0" SE="0.39940431835899015" STUDY_ID="STD-Shumaker-1978" TOTAL_1="12" TOTAL_2="15" VAR="0.15952380952380957" WEIGHT="6.662311908892238"/>
<DICH_DATA CI_END="1.9176931273639117" CI_START="0.7688872504566056" EFFECT_SIZE="1.2142857142857142" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.2827791118256619" LOG_CI_START="-0.11413734042559018" LOG_EFFECT_SIZE="0.08432088570003587" MODIFIED="2016-10-16 00:58:00 +0200" MODIFIED_BY="[Empty name]" ORDER="1244" O_E="0.0" SE="0.23315068882051151" STUDY_ID="STD-Theodossi-1982" TOTAL_1="28" TOTAL_2="32" VAR="0.05435924369747899" WEIGHT="12.805713424438851"/>
<DICH_DATA CI_END="1.257721969620654" CI_START="0.8438943704799494" EFFECT_SIZE="1.0302351623740202" ESTIMABLE="YES" EVENTS_1="145" EVENTS_2="141" LOG_CI_END="0.09958464714687978" LOG_CI_START="-0.07371191023286199" LOG_EFFECT_SIZE="0.012936368457008879" MODIFIED="2016-10-17 18:42:44 +0200" MODIFIED_BY="[Empty name]" ORDER="1245" O_E="0.0" SE="0.10179525563665424" STUDY_ID="STD-Thursz-2015" TOTAL_1="551" TOTAL_2="552" VAR="0.010362274070131789" WEIGHT="20.848667050193214"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="25.23499261394367" CI_END="1.1597626765054305" CI_START="0.7605724379697394" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9391930186793583" ESTIMABLE="YES" EVENTS_1="258" EVENTS_2="279" I2="44.52148168149549" I2_Q="32.51528955291096" ID="CMP-002.02" LOG_CI_END="0.06436912816753428" LOG_CI_START="-0.11885941683468867" LOG_EFFECT_SIZE="-0.027245144333577186" METHOD="MH" MODIFIED="2017-11-02 12:19:38 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="2" P_CHI2="0.032317149285978064" P_Q="0.22349077016964825" P_Z="0.5599786846812309" Q="1.4818171306877632" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.08003493816991894" TOTALS="SUB" TOTAL_1="927" TOTAL_2="934" WEIGHT="200.00000000000003" Z="0.5828731723734312">
<NAME>Glucocorticosteroid (prednisolone) dose</NAME>
<GROUP_LABEL_1>Glucocorticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no intervention</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticostero</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/no interv</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="21.4021694020211" CI_END="1.138449646482804" CI_START="0.4986807950642108" DF="9" EFFECT_SIZE="0.75347393773681" ESTIMABLE="YES" EVENTS_1="191" EVENTS_2="212" I2="57.9481881909126" ID="CMP-002.02.01" LOG_CI_END="0.05631382657323371" LOG_CI_START="-0.3021773567831226" LOG_EFFECT_SIZE="-0.1229317651049445" MODIFIED="2017-03-01 16:19:27 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1" P_CHI2="0.0109796141510633" P_Z="0.17888388792199156" STUDIES="10" TAU2="0.2083788598192892" TOTAL_1="774" TOTAL_2="773" WEIGHT="100.0" Z="1.344199485777155">
<NAME>Less than or equal to 40 mg</NAME>
<DICH_DATA CI_END="3.6470591644592263" CI_START="0.6217836230896183" EFFECT_SIZE="1.5058823529411764" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.5619428087181544" LOG_CI_START="-0.20636072085100313" LOG_EFFECT_SIZE="0.17779104393357562" MODIFIED="2016-10-16 23:34:41 +0200" MODIFIED_BY="[Empty name]" ORDER="1988" O_E="0.0" SE="0.4513052964327311" STUDY_ID="STD-Blitzer-1977" TOTAL_1="17" TOTAL_2="16" VAR="0.2036764705882353" WEIGHT="10.761594553342706"/>
<DICH_DATA CI_END="2.271566119051022" CI_START="0.21571020798844465" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.3563253824542302" LOG_CI_START="-0.6661293024257166" LOG_EFFECT_SIZE="-0.1549019599857432" MODIFIED="2016-10-18 19:03:24 +0200" MODIFIED_BY="[Empty name]" ORDER="1989" O_E="0.0" SE="0.6005949431307973" STUDY_ID="STD-Bories-1987" TOTAL_1="24" TOTAL_2="21" VAR="0.3607142857142857" WEIGHT="7.791997556448918"/>
<DICH_DATA CI_END="1.959321304462537" CI_START="0.4050989526101174" EFFECT_SIZE="0.8909090909090909" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.2921056607588947" LOG_CI_START="-0.3924388796903551" LOG_EFFECT_SIZE="-0.0501666094657302" MODIFIED="2016-10-16 23:34:43 +0200" MODIFIED_BY="[Empty name]" ORDER="1990" O_E="0.0" SE="0.4021048516100144" STUDY_ID="STD-Campra-1973" TOTAL_1="22" TOTAL_2="28" VAR="0.16168831168831171" WEIGHT="11.98261488941168"/>
<DICH_DATA CI_END="0.652966466690005" CI_START="0.037540679447284" EFFECT_SIZE="0.15656565656565657" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.18510912148976028" LOG_CI_START="-1.4254978713647564" LOG_EFFECT_SIZE="-0.8053034964272584" MODIFIED="2016-10-18 19:02:22 +0200" MODIFIED_BY="[Empty name]" ORDER="1991" O_E="0.0" SE="0.7286104916999097" STUDY_ID="STD-Carithers-1989" TOTAL_1="36" TOTAL_2="31" VAR="0.5308732486151841" WEIGHT="5.998457561088585"/>
<DICH_DATA CI_END="4.76392574408339" CI_START="0.6801113564845032" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.6779649834601594" LOG_CI_START="-0.16741997325354727" LOG_EFFECT_SIZE="0.25527250510330607" MODIFIED="2016-10-18 19:07:20 +0200" MODIFIED_BY="[Empty name]" ORDER="1992" O_E="0.0" SE="0.49658330829665737" STUDY_ID="STD-De-2014" TOTAL_1="31" TOTAL_2="31" VAR="0.24659498207885308" WEIGHT="9.746433730979625"/>
<DICH_DATA CI_END="1.976541991306356" CI_START="0.4963431529485624" EFFECT_SIZE="0.9904761904761905" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.29590604529114234" LOG_CI_START="-0.3042179648334578" LOG_EFFECT_SIZE="-0.0041559597711577035" MODIFIED="2016-10-18 19:10:14 +0200" MODIFIED_BY="[Empty name]" ORDER="1993" O_E="0.0" SE="0.35251581420895045" STUDY_ID="STD-Depew-1980" TOTAL_1="15" TOTAL_2="13" VAR="0.12426739926739927" WEIGHT="13.330594522735446"/>
<DICH_DATA CI_END="1.0635091819729094" CI_START="0.01887096490056978" EFFECT_SIZE="0.14166666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.02674124380428928" LOG_CI_START="-1.7242058931429909" LOG_EFFECT_SIZE="-0.8487323246693509" MODIFIED="2016-12-05 13:55:39 +0100" MODIFIED_BY="Dimitrinka Nikolova" ORDER="1996" O_E="0.0" SE="1.0285150155709453" STUDY_ID="STD-Helman-1971" TOTAL_1="20" TOTAL_2="17" VAR="1.057843137254902" WEIGHT="3.5020497271693056"/>
<DICH_DATA CI_END="2.3096079660641027" CI_START="0.1773461150196915" EFFECT_SIZE="0.64" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.36353826879945483" LOG_CI_START="-0.7511783208316805" LOG_EFFECT_SIZE="-0.1938200260161128" MODIFIED="2016-10-18 19:09:29 +0200" MODIFIED_BY="[Empty name]" ORDER="1997" O_E="0.0" SE="0.6547900426854397" STUDY_ID="STD-Maddrey-1978" TOTAL_1="25" TOTAL_2="32" VAR="0.42875" WEIGHT="6.959930210424276"/>
<DICH_DATA CI_END="0.6471159716752733" CI_START="0.09081759048972873" EFFECT_SIZE="0.24242424242424243" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="16" LOG_CI_END="-0.1890178810851679" LOG_CI_START="-1.0418300246867198" LOG_EFFECT_SIZE="-0.6154239528859439" MODIFIED="2016-12-05 13:55:40 +0100" MODIFIED_BY="Dimitrinka Nikolova" ORDER="2001" O_E="0.0" SE="0.5009460746397457" STUDY_ID="STD-Ramond-1992" TOTAL_1="33" TOTAL_2="32" VAR="0.2509469696969697" WEIGHT="9.654088915616882"/>
<DICH_DATA CI_END="1.257721969620654" CI_START="0.8438943704799494" EFFECT_SIZE="1.0302351623740202" ESTIMABLE="YES" EVENTS_1="145" EVENTS_2="141" LOG_CI_END="0.09958464714687978" LOG_CI_START="-0.07371191023286199" LOG_EFFECT_SIZE="0.012936368457008879" MODIFIED="2016-12-27 15:17:36 +0100" MODIFIED_BY="Dimitrinka Nikolova" ORDER="1994" O_E="0.0" SE="0.10179525563665424" STUDY_ID="STD-Thursz-2015" TOTAL_1="551" TOTAL_2="552" VAR="0.010362274070131789" WEIGHT="20.27223833278257"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.774127494557457" CI_END="1.2977132681979833" CI_START="0.794332084108018" DF="4" EFFECT_SIZE="1.0152907391000527" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="67" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="0.11317874501018883" LOG_CI_START="-0.09999789537625421" LOG_EFFECT_SIZE="0.006590424816967301" MODIFIED="2016-12-05 13:54:00 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="2" P_CHI2="0.43743659078334574" P_Z="0.9035438382729273" STUDIES="5" TAU2="0.0" TOTAL_1="153" TOTAL_2="161" WEIGHT="100.00000000000003" Z="0.12118584156931224">
<NAME>More than 40 mg</NAME>
<DICH_DATA CI_END="13.05963254309707" CI_START="0.6147016580509396" EFFECT_SIZE="2.8333333333333335" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.115930957432902" LOG_CI_START="-0.21133561544364132" LOG_EFFECT_SIZE="0.4522976709946303" MODIFIED="2016-12-05 13:54:00 +0100" MODIFIED_BY="Dimitrinka Nikolova" ORDER="1998" O_E="0.0" SE="0.7796429549831781" STUDY_ID="STD-Mendenhall-1977" TOTAL_1="12" TOTAL_2="17" VAR="0.6078431372549019" WEIGHT="2.5796626361551613"/>
<DICH_DATA CI_END="1.3741962892744457" CI_START="0.6565280702147891" EFFECT_SIZE="0.9498412698412698" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="35" LOG_CI_END="0.1380487714863567" LOG_CI_START="-0.18274670068071025" LOG_EFFECT_SIZE="-0.02234896459717677" MODIFIED="2016-10-16 23:31:06 +0200" MODIFIED_BY="[Empty name]" ORDER="1999" O_E="0.0" SE="0.18843684831413268" STUDY_ID="STD-Mendenhall-1984" TOTAL_1="90" TOTAL_2="88" VAR="0.035508445802563446" WEIGHT="44.15935967849665"/>
<DICH_DATA CI_END="1.3334993458285727" CI_START="0.36881897991307366" EFFECT_SIZE="0.7012987012987013" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.12499280697519317" LOG_CI_START="-0.4331867376742198" LOG_EFFECT_SIZE="-0.15409696534951337" MODIFIED="2016-10-16 23:31:06 +0200" MODIFIED_BY="[Empty name]" ORDER="2000" O_E="0.0" SE="0.3278774275603728" STUDY_ID="STD-Porter-1971" TOTAL_1="11" TOTAL_2="9" VAR="0.10750360750360752" WEIGHT="14.585838245169448"/>
<DICH_DATA CI_END="2.343887675927311" CI_START="0.4897671485982377" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.36993679553129327" LOG_CI_START="-0.3100103487764068" LOG_EFFECT_SIZE="0.029963223377443202" MODIFIED="2016-10-16 23:31:06 +0200" MODIFIED_BY="[Empty name]" ORDER="2002" O_E="0.0" SE="0.39940431835899015" STUDY_ID="STD-Shumaker-1978" TOTAL_1="12" TOTAL_2="15" VAR="0.15952380952380957" WEIGHT="9.82944323170623"/>
<DICH_DATA CI_END="1.9176931273639117" CI_START="0.7688872504566056" EFFECT_SIZE="1.2142857142857142" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.2827791118256619" LOG_CI_START="-0.11413734042559018" LOG_EFFECT_SIZE="0.08432088570003587" MODIFIED="2016-12-05 13:52:23 +0100" MODIFIED_BY="Dimitrinka Nikolova" ORDER="1662" O_E="0.0" SE="0.23315068882051151" STUDY_ID="STD-Theodossi-1982" TOTAL_1="28" TOTAL_2="32" VAR="0.05435924369747899" WEIGHT="28.84569620847253"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="25.234992613943675" CI_END="1.153814487939868" CI_START="0.7352722172748001" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9210688013776902" ESTIMABLE="YES" EVENTS_1="258" EVENTS_2="279" I2="44.5214816814955" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.062135987900712064" LOG_CI_START="-0.1335518438095764" LOG_EFFECT_SIZE="-0.03570792795443213" METHOD="MH" MODIFIED="2017-02-08 16:35:28 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="3" P_CHI2="0.03231714928597773" P_Q="0.8341812616538129" P_Z="0.47443316643722233" Q="0.043824146321374595" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.08003493816991897" TOTALS="SUB" TOTAL_1="927" TOTAL_2="934" WEIGHT="200.0" Z="0.7152846668243644">
<NAME>Alcoholic hepatitis without cirrhosis and with cirrhosis</NAME>
<GROUP_LABEL_1>Glucocorticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no intervention</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucocorticosteroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/no interv</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="8.779853406684083" CI_END="3.481648987591438" CI_START="0.17801945853751294" DF="2" EFFECT_SIZE="0.7872745820796629" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="20" I2="77.22057638824124" ID="CMP-002.03.01" LOG_CI_END="0.5417849843469826" LOG_CI_START="-0.7495325242439472" LOG_EFFECT_SIZE="-0.10387376994848224" MODIFIED="2017-02-08 16:35:28 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1" P_CHI2="0.012401683583750156" P_Z="0.7525190195625702" STUDIES="3" TAU2="1.316917904912443" TOTAL_1="60" TOTAL_2="63" WEIGHT="100.0" Z="0.3153195812539983">
<NAME>Alcoholic hepatitis</NAME>
<DICH_DATA CI_END="0.652966466690005" CI_START="0.037540679447284" EFFECT_SIZE="0.15656565656565657" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.18510912148976028" LOG_CI_START="-1.4254978713647564" LOG_EFFECT_SIZE="-0.8053034964272584" MODIFIED="2016-10-17 13:39:28 +0200" MODIFIED_BY="[Empty name]" ORDER="18" O_E="0.0" SE="0.7286104916999097" STUDY_ID="STD-Carithers-1989" TOTAL_1="36" TOTAL_2="31" VAR="0.5308732486151841" WEIGHT="31.137834037310032"/>
<DICH_DATA CI_END="13.05963254309707" CI_START="0.6147016580509396" EFFECT_SIZE="2.8333333333333335" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.115930957432902" LOG_CI_START="-0.21133561544364132" LOG_EFFECT_SIZE="0.4522976709946303" MODIFIED="2016-10-17 13:39:28 +0200" MODIFIED_BY="[Empty name]" ORDER="23" O_E="0.0" SE="0.7796429549831781" STUDY_ID="STD-Mendenhall-1977" TOTAL_1="12" TOTAL_2="17" VAR="0.6078431372549019" WEIGHT="29.892653172866186"/>
<DICH_DATA CI_END="2.343887675927311" CI_START="0.4897671485982377" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.36993679553129327" LOG_CI_START="-0.3100103487764068" LOG_EFFECT_SIZE="0.029963223377443202" MODIFIED="2016-10-17 13:39:28 +0200" MODIFIED_BY="[Empty name]" ORDER="28" O_E="0.0" SE="0.39940431835899015" STUDY_ID="STD-Shumaker-1978" TOTAL_1="12" TOTAL_2="15" VAR="0.15952380952380957" WEIGHT="38.96951278982379"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="16.79469358013511" CI_END="1.1611314849317829" CI_START="0.7360497220039499" DF="11" EFFECT_SIZE="0.9244730967930177" ESTIMABLE="YES" EVENTS_1="246" EVENTS_2="259" I2="34.50312178954618" ID="CMP-002.03.02" LOG_CI_END="0.06488140143285626" LOG_CI_START="-0.1330928469905391" LOG_EFFECT_SIZE="-0.03410572277884145" MODIFIED="2017-02-08 16:35:28 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="2" P_CHI2="0.11409693325562209" P_Z="0.49948529533438946" STUDIES="12" TAU2="0.045299467914873194" TOTAL_1="867" TOTAL_2="871" WEIGHT="99.99999999999999" Z="0.6752998316253453">
<NAME>Alcoholic hepatitis with cirrhosis</NAME>
<DICH_DATA CI_END="3.6470591644592263" CI_START="0.6217836230896183" EFFECT_SIZE="1.5058823529411764" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.5619428087181544" LOG_CI_START="-0.20636072085100313" LOG_EFFECT_SIZE="0.17779104393357562" MODIFIED="2016-10-17 13:39:37 +0200" MODIFIED_BY="[Empty name]" ORDER="15" O_E="0.0" SE="0.4513052964327311" STUDY_ID="STD-Blitzer-1977" TOTAL_1="17" TOTAL_2="16" VAR="0.2036764705882353" WEIGHT="5.4316932022799325"/>
<DICH_DATA CI_END="2.271566119051022" CI_START="0.21571020798844465" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.3563253824542302" LOG_CI_START="-0.6661293024257166" LOG_EFFECT_SIZE="-0.1549019599857432" MODIFIED="2016-10-17 13:39:37 +0200" MODIFIED_BY="[Empty name]" ORDER="16" O_E="0.0" SE="0.6005949431307973" STUDY_ID="STD-Bories-1987" TOTAL_1="24" TOTAL_2="21" VAR="0.3607142857142857" WEIGHT="3.3308253737970848"/>
<DICH_DATA CI_END="1.959321304462537" CI_START="0.4050989526101174" EFFECT_SIZE="0.8909090909090909" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.2921056607588947" LOG_CI_START="-0.3924388796903551" LOG_EFFECT_SIZE="-0.0501666094657302" MODIFIED="2016-10-17 13:39:37 +0200" MODIFIED_BY="[Empty name]" ORDER="17" O_E="0.0" SE="0.4021048516100144" STUDY_ID="STD-Campra-1973" TOTAL_1="22" TOTAL_2="28" VAR="0.16168831168831171" WEIGHT="6.533530217538465"/>
<DICH_DATA CI_END="4.76392574408339" CI_START="0.6801113564845032" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.6779649834601594" LOG_CI_START="-0.16741997325354727" LOG_EFFECT_SIZE="0.25527250510330607" MODIFIED="2016-10-17 13:39:37 +0200" MODIFIED_BY="[Empty name]" ORDER="23" O_E="0.0" SE="0.49658330829665737" STUDY_ID="STD-De-2014" TOTAL_1="31" TOTAL_2="31" VAR="0.24659498207885308" WEIGHT="4.633047708607228"/>
<DICH_DATA CI_END="1.976541991306356" CI_START="0.4963431529485624" EFFECT_SIZE="0.9904761904761905" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.29590604529114234" LOG_CI_START="-0.3042179648334578" LOG_EFFECT_SIZE="-0.0041559597711577035" MODIFIED="2016-10-17 13:39:37 +0200" MODIFIED_BY="[Empty name]" ORDER="19" O_E="0.0" SE="0.35251581420895045" STUDY_ID="STD-Depew-1980" TOTAL_1="15" TOTAL_2="13" VAR="0.12426739926739927" WEIGHT="7.975384196046436"/>
<DICH_DATA CI_END="1.0635091819729094" CI_START="0.01887096490056978" EFFECT_SIZE="0.14166666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.02674124380428928" LOG_CI_START="-1.7242058931429909" LOG_EFFECT_SIZE="-0.8487323246693509" MODIFIED="2016-10-17 13:39:37 +0200" MODIFIED_BY="[Empty name]" ORDER="21" O_E="0.0" SE="1.0285150155709453" STUDY_ID="STD-Helman-1971" TOTAL_1="20" TOTAL_2="17" VAR="1.057843137254902" WEIGHT="1.225916673293994"/>
<DICH_DATA CI_END="2.3096079660641027" CI_START="0.1773461150196915" EFFECT_SIZE="0.64" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.36353826879945483" LOG_CI_START="-0.7511783208316805" LOG_EFFECT_SIZE="-0.1938200260161128" MODIFIED="2016-10-17 13:39:37 +0200" MODIFIED_BY="[Empty name]" ORDER="529" O_E="0.0" SE="0.6547900426854397" STUDY_ID="STD-Maddrey-1978" TOTAL_1="25" TOTAL_2="32" VAR="0.42875" WEIGHT="2.852784370051121"/>
<DICH_DATA CI_END="1.3741962892744457" CI_START="0.6565280702147891" EFFECT_SIZE="0.9498412698412698" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="35" LOG_CI_END="0.1380487714863567" LOG_CI_START="-0.18274670068071025" LOG_EFFECT_SIZE="-0.02234896459717677" MODIFIED="2016-10-17 13:39:37 +0200" MODIFIED_BY="[Empty name]" ORDER="821" O_E="0.0" SE="0.18843684831413268" STUDY_ID="STD-Mendenhall-1984" TOTAL_1="90" TOTAL_2="88" VAR="0.035508445802563446" WEIGHT="16.735500899422302"/>
<DICH_DATA CI_END="1.3334993458285727" CI_START="0.36881897991307366" EFFECT_SIZE="0.7012987012987013" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.12499280697519317" LOG_CI_START="-0.4331867376742198" LOG_EFFECT_SIZE="-0.15409696534951337" MODIFIED="2016-10-17 13:39:37 +0200" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.0" SE="0.3278774275603728" STUDY_ID="STD-Porter-1971" TOTAL_1="11" TOTAL_2="9" VAR="0.10750360750360752" WEIGHT="8.850351401599081"/>
<DICH_DATA CI_END="0.6471159716752733" CI_START="0.09081759048972873" EFFECT_SIZE="0.24242424242424243" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="16" LOG_CI_END="-0.1890178810851679" LOG_CI_START="-1.0418300246867198" LOG_EFFECT_SIZE="-0.6154239528859439" MODIFIED="2016-10-17 13:39:37 +0200" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="0.5009460746397457" STUDY_ID="STD-Ramond-1992" TOTAL_1="33" TOTAL_2="32" VAR="0.2509469696969697" WEIGHT="4.564986244562145"/>
<DICH_DATA CI_END="1.9176931273639117" CI_START="0.7688872504566056" EFFECT_SIZE="1.2142857142857142" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.2827791118256619" LOG_CI_START="-0.11413734042559018" LOG_EFFECT_SIZE="0.08432088570003587" MODIFIED="2016-10-17 13:39:37 +0200" MODIFIED_BY="[Empty name]" ORDER="29" O_E="0.0" SE="0.23315068882051151" STUDY_ID="STD-Theodossi-1982" TOTAL_1="28" TOTAL_2="32" VAR="0.05435924369747899" WEIGHT="13.569921693940326"/>
<DICH_DATA CI_END="1.257721969620654" CI_START="0.8438943704799494" EFFECT_SIZE="1.0302351623740202" ESTIMABLE="YES" EVENTS_1="145" EVENTS_2="141" LOG_CI_END="0.09958464714687978" LOG_CI_START="-0.07371191023286199" LOG_EFFECT_SIZE="0.012936368457008879" MODIFIED="2016-10-17 18:44:12 +0200" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="0.10179525563665424" STUDY_ID="STD-Thursz-2015" TOTAL_1="551" TOTAL_2="552" VAR="0.010362274070131789" WEIGHT="24.29605801886187"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.187587999996294" CI_END="1.170694673000452" CI_START="0.8487887967758818" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9968312409269625" ESTIMABLE="YES" EVENTS_1="204" EVENTS_2="216" I2="36.56427012116259" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.06844364219327506" LOG_CI_START="-0.07120036135285611" LOG_EFFECT_SIZE="-0.0013783595797905329" METHOD="MH" MODIFIED="2017-11-02 11:29:39 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="4" P_CHI2="0.11580715227675586" P_Q="0.6448562234940924" P_Z="0.9691361544891912" Q="0.21244698001782628" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.05792497688808164" TOTALS="SUB" TOTAL_1="751" TOTAL_2="760" WEIGHT="200.0" Z="0.03869174566085461">
<NAME>Hepatorenal syndrome</NAME>
<GROUP_LABEL_1>Glucocorticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no intervention</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucocorticosteroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/no interv</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.167289909144322" CI_END="1.1740188414505102" CI_START="0.8506072533780367" DF="7" EFFECT_SIZE="0.9993142359339645" ESTIMABLE="YES" EVENTS_1="193" EVENTS_2="200" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="0.06967506681988034" LOG_CI_START="-0.07027091824952252" LOG_EFFECT_SIZE="-2.9792571482105976E-4" MODIFIED="2017-11-01 15:02:02 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1" P_CHI2="0.5203574848761544" P_Z="0.9933417414690222" STUDIES="8" TAU2="0.0" TOTAL_1="684" TOTAL_2="698" WEIGHT="100.00000000000001" Z="0.008344986400690058">
<NAME>With hepatorenal syndrome</NAME>
<DICH_DATA CI_END="1.959321304462537" CI_START="0.4050989526101174" EFFECT_SIZE="0.8909090909090909" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.2921056607588947" LOG_CI_START="-0.3924388796903551" LOG_EFFECT_SIZE="-0.0501666094657302" MODIFIED="2016-10-17 13:41:22 +0200" MODIFIED_BY="[Empty name]" ORDER="17" O_E="0.0" SE="0.4021048516100144" STUDY_ID="STD-Campra-1973" TOTAL_1="22" TOTAL_2="28" VAR="0.16168831168831171" WEIGHT="4.1794339350181495"/>
<DICH_DATA CI_END="1.976541991306356" CI_START="0.4963431529485624" EFFECT_SIZE="0.9904761904761905" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.29590604529114234" LOG_CI_START="-0.3042179648334578" LOG_EFFECT_SIZE="-0.0041559597711577035" MODIFIED="2016-10-17 13:41:22 +0200" MODIFIED_BY="[Empty name]" ORDER="19" O_E="0.0" SE="0.35251581420895045" STUDY_ID="STD-Depew-1980" TOTAL_1="15" TOTAL_2="13" VAR="0.12426739926739927" WEIGHT="5.437995972795774"/>
<DICH_DATA CI_END="1.0635091819729094" CI_START="0.01887096490056978" EFFECT_SIZE="0.14166666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.02674124380428928" LOG_CI_START="-1.7242058931429909" LOG_EFFECT_SIZE="-0.8487323246693509" MODIFIED="2016-10-17 13:41:22 +0200" MODIFIED_BY="[Empty name]" ORDER="21" O_E="0.0" SE="1.0285150155709453" STUDY_ID="STD-Helman-1971" TOTAL_1="20" TOTAL_2="17" VAR="1.057843137254902" WEIGHT="0.6388145774802967"/>
<DICH_DATA CI_END="2.3096079660641027" CI_START="0.1773461150196915" EFFECT_SIZE="0.64" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.36353826879945483" LOG_CI_START="-0.7511783208316805" LOG_EFFECT_SIZE="-0.1938200260161128" MODIFIED="2016-10-17 13:41:22 +0200" MODIFIED_BY="[Empty name]" ORDER="529" O_E="0.0" SE="0.6547900426854397" STUDY_ID="STD-Maddrey-1978" TOTAL_1="25" TOTAL_2="32" VAR="0.42875" WEIGHT="1.576129718404482"/>
<DICH_DATA CI_END="1.3334993458285727" CI_START="0.36881897991307366" EFFECT_SIZE="0.7012987012987013" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.12499280697519317" LOG_CI_START="-0.4331867376742198" LOG_EFFECT_SIZE="-0.15409696534951337" MODIFIED="2016-10-17 13:41:22 +0200" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.0" SE="0.3278774275603728" STUDY_ID="STD-Porter-1971" TOTAL_1="11" TOTAL_2="9" VAR="0.10750360750360752" WEIGHT="6.285980837836022"/>
<DICH_DATA CI_END="2.343887675927311" CI_START="0.4897671485982377" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.36993679553129327" LOG_CI_START="-0.3100103487764068" LOG_EFFECT_SIZE="0.029963223377443202" MODIFIED="2016-10-17 13:41:22 +0200" MODIFIED_BY="[Empty name]" ORDER="28" O_E="0.0" SE="0.39940431835899015" STUDY_ID="STD-Shumaker-1978" TOTAL_1="12" TOTAL_2="15" VAR="0.15952380952380957" WEIGHT="4.236142672263986"/>
<DICH_DATA CI_END="1.9176931273639117" CI_START="0.7688872504566056" EFFECT_SIZE="1.2142857142857142" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.2827791118256619" LOG_CI_START="-0.11413734042559018" LOG_EFFECT_SIZE="0.08432088570003587" MODIFIED="2016-10-17 13:41:22 +0200" MODIFIED_BY="[Empty name]" ORDER="29" O_E="0.0" SE="0.23315068882051151" STUDY_ID="STD-Theodossi-1982" TOTAL_1="28" TOTAL_2="32" VAR="0.05435924369747899" WEIGHT="12.431475693935411"/>
<DICH_DATA CI_END="1.257721969620654" CI_START="0.8438943704799494" EFFECT_SIZE="1.0302351623740202" ESTIMABLE="YES" EVENTS_1="145" EVENTS_2="141" LOG_CI_END="0.09958464714687978" LOG_CI_START="-0.07371191023286199" LOG_EFFECT_SIZE="0.012936368457008879" MODIFIED="2016-10-17 18:45:14 +0200" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="0.10179525563665424" STUDY_ID="STD-Thursz-2015" TOTAL_1="551" TOTAL_2="552" VAR="0.010362274070131789" WEIGHT="65.21402659226588"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.046624182536" CI_END="6.493722863439373" CI_START="0.048491858264197205" DF="1" EFFECT_SIZE="0.5611529993690482" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" I2="87.57242817217248" ID="CMP-002.04.02" LOG_CI_END="0.812493750035703" LOG_CI_START="-1.3143311728978118" LOG_EFFECT_SIZE="-0.2509187114310543" MODIFIED="2017-11-01 15:02:10 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="2" P_CHI2="0.00455887799279564" P_Z="0.6437474972663371" STUDIES="2" TAU2="2.7392632177810396" TOTAL_1="67" TOTAL_2="62" WEIGHT="100.0" Z="0.4624655580711745">
<NAME>Without hepatorenal syndrome</NAME>
<DICH_DATA CI_END="0.652966466690005" CI_START="0.037540679447284" EFFECT_SIZE="0.15656565656565657" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.18510912148976028" LOG_CI_START="-1.4254978713647564" LOG_EFFECT_SIZE="-0.8053034964272584" MODIFIED="2016-10-17 13:41:25 +0200" MODIFIED_BY="[Empty name]" ORDER="18" O_E="0.0" SE="0.7286104916999097" STUDY_ID="STD-Carithers-1989" TOTAL_1="36" TOTAL_2="31" VAR="0.5308732486151841" WEIGHT="47.72795309377671"/>
<DICH_DATA CI_END="4.76392574408339" CI_START="0.6801113564845032" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.6779649834601594" LOG_CI_START="-0.16741997325354727" LOG_EFFECT_SIZE="0.25527250510330607" MODIFIED="2016-10-17 13:41:25 +0200" MODIFIED_BY="[Empty name]" ORDER="23" O_E="0.0" SE="0.49658330829665737" STUDY_ID="STD-De-2014" TOTAL_1="31" TOTAL_2="31" VAR="0.24659498207885308" WEIGHT="52.27204690622328"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="23.292080109623672" CI_END="1.12268616059835" CI_START="0.6036378693988523" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8232228628914322" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="136" I2="48.480342058234996" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.050258369111624325" LOG_CI_START="-0.2192235224500318" LOG_EFFECT_SIZE="-0.08448257666920372" METHOD="MH" MODIFIED="2017-11-02 11:29:25 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="5" P_CHI2="0.025346194590653126" P_Q="1.0" P_Z="0.21911027278929096" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.1368828234930115" TOTALS="SUB" TOTAL_1="364" TOTAL_2="365" WEIGHT="100.00000000000001" Z="1.2288974716128458">
<NAME>Ascites</NAME>
<GROUP_LABEL_1>Glucocorticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no intervention</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticostero</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/no interv</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="23.292080109623672" CI_END="1.12268616059835" CI_START="0.6036378693988523" DF="12" EFFECT_SIZE="0.8232228628914322" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="136" I2="48.480342058234996" ID="CMP-002.05.01" LOG_CI_END="0.050258369111624325" LOG_CI_START="-0.2192235224500318" LOG_EFFECT_SIZE="-0.08448257666920372" MODIFIED="2016-12-05 14:01:14 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1" P_CHI2="0.025346194590653126" P_Z="0.21911027278929096" STUDIES="13" TAU2="0.1368828234930115" TOTAL_1="364" TOTAL_2="365" WEIGHT="100.00000000000001" Z="1.2288974716128458">
<NAME>With ascites</NAME>
<DICH_DATA CI_END="3.6470591644592263" CI_START="0.6217836230896183" EFFECT_SIZE="1.5058823529411764" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.5619428087181544" LOG_CI_START="-0.20636072085100313" LOG_EFFECT_SIZE="0.17779104393357562" MODIFIED="2016-10-17 13:42:44 +0200" MODIFIED_BY="[Empty name]" ORDER="15" O_E="0.0" SE="0.4513052964327311" STUDY_ID="STD-Blitzer-1977" TOTAL_1="17" TOTAL_2="16" VAR="0.2036764705882353" WEIGHT="7.357692633785204"/>
<DICH_DATA CI_END="2.271566119051022" CI_START="0.21571020798844465" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.3563253824542302" LOG_CI_START="-0.6661293024257166" LOG_EFFECT_SIZE="-0.1549019599857432" MODIFIED="2016-10-17 13:42:44 +0200" MODIFIED_BY="[Empty name]" ORDER="16" O_E="0.0" SE="0.6005949431307973" STUDY_ID="STD-Bories-1987" TOTAL_1="24" TOTAL_2="21" VAR="0.3607142857142857" WEIGHT="5.035661508203818"/>
<DICH_DATA CI_END="1.959321304462537" CI_START="0.4050989526101174" EFFECT_SIZE="0.8909090909090909" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.2921056607588947" LOG_CI_START="-0.3924388796903551" LOG_EFFECT_SIZE="-0.0501666094657302" MODIFIED="2016-10-17 13:42:44 +0200" MODIFIED_BY="[Empty name]" ORDER="17" O_E="0.0" SE="0.4021048516100144" STUDY_ID="STD-Campra-1973" TOTAL_1="22" TOTAL_2="28" VAR="0.16168831168831171" WEIGHT="8.392407417103264"/>
<DICH_DATA CI_END="0.652966466690005" CI_START="0.037540679447284" EFFECT_SIZE="0.15656565656565657" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.18510912148976028" LOG_CI_START="-1.4254978713647564" LOG_EFFECT_SIZE="-0.8053034964272584" MODIFIED="2016-10-17 13:42:44 +0200" MODIFIED_BY="[Empty name]" ORDER="18" O_E="0.0" SE="0.7286104916999097" STUDY_ID="STD-Carithers-1989" TOTAL_1="36" TOTAL_2="31" VAR="0.5308732486151841" WEIGHT="3.7524639821211214"/>
<DICH_DATA CI_END="4.76392574408339" CI_START="0.6801113564845032" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.6779649834601594" LOG_CI_START="-0.16741997325354727" LOG_EFFECT_SIZE="0.25527250510330607" MODIFIED="2016-10-17 13:42:44 +0200" MODIFIED_BY="[Empty name]" ORDER="23" O_E="0.0" SE="0.49658330829665737" STUDY_ID="STD-De-2014" TOTAL_1="31" TOTAL_2="31" VAR="0.24659498207885308" WEIGHT="6.534225900484608"/>
<DICH_DATA CI_END="1.976541991306356" CI_START="0.4963431529485624" EFFECT_SIZE="0.9904761904761905" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.29590604529114234" LOG_CI_START="-0.3042179648334578" LOG_EFFECT_SIZE="-0.0041559597711577035" MODIFIED="2016-10-17 13:42:44 +0200" MODIFIED_BY="[Empty name]" ORDER="19" O_E="0.0" SE="0.35251581420895045" STUDY_ID="STD-Depew-1980" TOTAL_1="15" TOTAL_2="13" VAR="0.12426739926739927" WEIGHT="9.594977874966363"/>
<DICH_DATA CI_END="1.0635091819729094" CI_START="0.01887096490056978" EFFECT_SIZE="0.14166666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.02674124380428928" LOG_CI_START="-1.7242058931429909" LOG_EFFECT_SIZE="-0.8487323246693509" MODIFIED="2016-10-17 13:42:44 +0200" MODIFIED_BY="[Empty name]" ORDER="21" O_E="0.0" SE="1.0285150155709453" STUDY_ID="STD-Helman-1971" TOTAL_1="20" TOTAL_2="17" VAR="1.057843137254902" WEIGHT="2.097326660467024"/>
<DICH_DATA CI_END="2.3096079660641027" CI_START="0.1773461150196915" EFFECT_SIZE="0.64" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.36353826879945483" LOG_CI_START="-0.7511783208316805" LOG_EFFECT_SIZE="-0.1938200260161128" MODIFIED="2016-10-17 13:42:44 +0200" MODIFIED_BY="[Empty name]" ORDER="529" O_E="0.0" SE="0.6547900426854397" STUDY_ID="STD-Maddrey-1978" TOTAL_1="25" TOTAL_2="32" VAR="0.42875" WEIGHT="4.429959693560177"/>
<DICH_DATA CI_END="1.3741962892744457" CI_START="0.6565280702147891" EFFECT_SIZE="0.9498412698412698" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="35" LOG_CI_END="0.1380487714863567" LOG_CI_START="-0.18274670068071025" LOG_EFFECT_SIZE="-0.02234896459717677" MODIFIED="2016-10-17 13:42:44 +0200" MODIFIED_BY="[Empty name]" ORDER="821" O_E="0.0" SE="0.18843684831413268" STUDY_ID="STD-Mendenhall-1984" TOTAL_1="90" TOTAL_2="88" VAR="0.035508445802563446" WEIGHT="14.535136377077517"/>
<DICH_DATA CI_END="1.3334993458285727" CI_START="0.36881897991307366" EFFECT_SIZE="0.7012987012987013" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.12499280697519317" LOG_CI_START="-0.4331867376742198" LOG_EFFECT_SIZE="-0.15409696534951337" MODIFIED="2016-10-17 13:42:44 +0200" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.0" SE="0.3278774275603728" STUDY_ID="STD-Porter-1971" TOTAL_1="11" TOTAL_2="9" VAR="0.10750360750360752" WEIGHT="10.25314948628774"/>
<DICH_DATA CI_END="0.6471159716752733" CI_START="0.09081759048972873" EFFECT_SIZE="0.24242424242424243" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="16" LOG_CI_END="-0.1890178810851679" LOG_CI_START="-1.0418300246867198" LOG_EFFECT_SIZE="-0.6154239528859439" MODIFIED="2016-10-17 13:45:18 +0200" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="0.5009460746397457" STUDY_ID="STD-Ramond-1992" TOTAL_1="33" TOTAL_2="32" VAR="0.2509469696969697" WEIGHT="6.460902832705346"/>
<DICH_DATA CI_END="2.343887675927311" CI_START="0.4897671485982377" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.36993679553129327" LOG_CI_START="-0.3100103487764068" LOG_EFFECT_SIZE="0.029963223377443202" MODIFIED="2016-10-17 13:42:44 +0200" MODIFIED_BY="[Empty name]" ORDER="28" O_E="0.0" SE="0.39940431835899015" STUDY_ID="STD-Shumaker-1978" TOTAL_1="12" TOTAL_2="15" VAR="0.15952380952380957" WEIGHT="8.453692766337245"/>
<DICH_DATA CI_END="1.9176931273639117" CI_START="0.7688872504566056" EFFECT_SIZE="1.2142857142857142" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.2827791118256619" LOG_CI_START="-0.11413734042559018" LOG_EFFECT_SIZE="0.08432088570003587" MODIFIED="2016-10-17 13:42:44 +0200" MODIFIED_BY="[Empty name]" ORDER="29" O_E="0.0" SE="0.23315068882051151" STUDY_ID="STD-Theodossi-1982" TOTAL_1="28" TOTAL_2="32" VAR="0.05435924369747899" WEIGHT="13.102402866900594"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2017-11-02 12:03:18 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="3">
<NAME>Sensitivity analysis: all-cause mortality</NAME>
<DICH_OUTCOME CHI2="26.27532863753995" CI_END="1.0453513656160118" CI_START="0.6420201734659923" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8192293116617007" ESTIMABLE="YES" EVENTS_1="258" EVENTS_2="351" I2="46.71807841825432" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.019262290925376756" LOG_CI_START="-0.19245132537769985" LOG_EFFECT_SIZE="-0.08659451722616154" METHOD="MH" MODIFIED="2017-11-02 12:02:10 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1" P_CHI2="0.02387656264406446" P_Q="1.0" P_Z="0.10886444550561919" Q="0.0" RANDOM="YES" SCALE="66.86" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.08022421034081198" TOTALS="SUB" TOTAL_1="927" TOTAL_2="934" WEIGHT="100.0" Z="1.6033180858707348">
<NAME>Best-worst scenario all-cause mortality to 3 months follow-up</NAME>
<GROUP_LABEL_1>Glucocorticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no intervention</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticosteroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/no interv</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="26.27532863753995" CI_END="1.0453513656160118" CI_START="0.6420201734659923" DF="14" EFFECT_SIZE="0.8192293116617007" ESTIMABLE="YES" EVENTS_1="258" EVENTS_2="351" I2="46.71807841825432" ID="CMP-003.01.01" LOG_CI_END="0.019262290925376756" LOG_CI_START="-0.19245132537769985" LOG_EFFECT_SIZE="-0.08659451722616154" MODIFIED="2016-11-07 15:33:12 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1" P_CHI2="0.02387656264406446" P_Z="0.10886444550561919" STUDIES="15" TAU2="0.08022421034081198" TOTAL_1="927" TOTAL_2="934" WEIGHT="100.0" Z="1.6033180858707348">
<NAME>Up to 3 months</NAME>
<DICH_DATA CI_END="3.6470591644592263" CI_START="0.6217836230896183" EFFECT_SIZE="1.5058823529411764" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.5619428087181544" LOG_CI_START="-0.20636072085100313" LOG_EFFECT_SIZE="0.17779104393357562" MODIFIED="2016-10-09 14:09:09 +0200" MODIFIED_BY="[Empty name]" ORDER="15" O_E="0.0" SE="0.4513052964327311" STUDY_ID="STD-Blitzer-1977" TOTAL_1="17" TOTAL_2="16" VAR="0.2036764705882353" WEIGHT="5.447614293988301"/>
<DICH_DATA CI_END="2.271566119051022" CI_START="0.21571020798844465" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.3563253824542302" LOG_CI_START="-0.6661293024257166" LOG_EFFECT_SIZE="-0.1549019599857432" MODIFIED="2016-10-10 13:48:29 +0200" MODIFIED_BY="[Empty name]" ORDER="16" O_E="0.0" SE="0.6005949431307973" STUDY_ID="STD-Bories-1987" TOTAL_1="24" TOTAL_2="21" VAR="0.3607142857142857" WEIGHT="3.507476487852029"/>
<DICH_DATA CI_END="1.959321304462537" CI_START="0.4050989526101174" EFFECT_SIZE="0.8909090909090909" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.2921056607588947" LOG_CI_START="-0.3924388796903551" LOG_EFFECT_SIZE="-0.0501666094657302" MODIFIED="2016-10-09 14:11:00 +0200" MODIFIED_BY="[Empty name]" ORDER="17" O_E="0.0" SE="0.4021048516100144" STUDY_ID="STD-Campra-1973" TOTAL_1="22" TOTAL_2="28" VAR="0.16168831168831171" WEIGHT="6.393143250831381"/>
<DICH_DATA CI_END="0.652966466690005" CI_START="0.037540679447284" EFFECT_SIZE="0.15656565656565657" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.18510912148976028" LOG_CI_START="-1.4254978713647564" LOG_EFFECT_SIZE="-0.8053034964272584" MODIFIED="2016-10-16 18:06:13 +0200" MODIFIED_BY="[Empty name]" ORDER="18" O_E="0.0" SE="0.7286104916999097" STUDY_ID="STD-Carithers-1989" TOTAL_1="36" TOTAL_2="31" VAR="0.5308732486151841" WEIGHT="2.5308261142899897"/>
<DICH_DATA CI_END="3.7083298042967927" CI_START="0.6067421504400592" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.5691783516366348" LOG_CI_START="-0.21699583352527232" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2016-10-09 14:10:57 +0200" MODIFIED_BY="[Empty name]" ORDER="23" O_E="0.0" SE="0.4618026079890841" STUDY_ID="STD-De-2014" TOTAL_1="31" TOTAL_2="31" VAR="0.21326164874551973" WEIGHT="5.269696510478714"/>
<DICH_DATA CI_END="1.976541991306356" CI_START="0.4963431529485624" EFFECT_SIZE="0.9904761904761905" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.29590604529114234" LOG_CI_START="-0.3042179648334578" LOG_EFFECT_SIZE="-0.0041559597711577035" MODIFIED="2016-10-09 14:25:29 +0200" MODIFIED_BY="[Empty name]" ORDER="19" O_E="0.0" SE="0.35251581420895045" STUDY_ID="STD-Depew-1980" TOTAL_1="15" TOTAL_2="13" VAR="0.12426739926739927" WEIGHT="7.563055572134281"/>
<DICH_DATA CI_END="1.0635091819729094" CI_START="0.01887096490056978" EFFECT_SIZE="0.14166666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.02674124380428928" LOG_CI_START="-1.7242058931429909" LOG_EFFECT_SIZE="-0.8487323246693509" MODIFIED="2016-10-16 18:06:15 +0200" MODIFIED_BY="[Empty name]" ORDER="21" O_E="0.0" SE="1.0285150155709453" STUDY_ID="STD-Helman-1971" TOTAL_1="20" TOTAL_2="17" VAR="1.057843137254902" WEIGHT="1.3589542049241679"/>
<DICH_DATA CI_END="2.3096079660641027" CI_START="0.1773461150196915" EFFECT_SIZE="0.64" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.36353826879945483" LOG_CI_START="-0.7511783208316805" LOG_EFFECT_SIZE="-0.1938200260161128" MODIFIED="2016-10-10 16:14:39 +0200" MODIFIED_BY="[Empty name]" ORDER="531" O_E="0.0" SE="0.6547900426854397" STUDY_ID="STD-Maddrey-1978" TOTAL_1="25" TOTAL_2="32" VAR="0.42875" WEIGHT="3.0386243076372974"/>
<DICH_DATA CI_END="13.05963254309707" CI_START="0.6147016580509396" EFFECT_SIZE="2.8333333333333335" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.115930957432902" LOG_CI_START="-0.21133561544364132" LOG_EFFECT_SIZE="0.4522976709946303" MODIFIED="2016-10-09 14:25:35 +0200" MODIFIED_BY="[Empty name]" ORDER="23" O_E="0.0" SE="0.7796429549831781" STUDY_ID="STD-Mendenhall-1977" TOTAL_1="12" TOTAL_2="17" VAR="0.6078431372549019" WEIGHT="2.2477180655443796"/>
<DICH_DATA CI_END="1.3741962892744457" CI_START="0.6565280702147891" EFFECT_SIZE="0.9498412698412698" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="35" LOG_CI_END="0.1380487714863567" LOG_CI_START="-0.18274670068071025" LOG_EFFECT_SIZE="-0.02234896459717677" MODIFIED="2016-10-09 14:25:27 +0200" MODIFIED_BY="[Empty name]" ORDER="821" O_E="0.0" SE="0.18843684831413268" STUDY_ID="STD-Mendenhall-1984" TOTAL_1="90" TOTAL_2="88" VAR="0.035508445802563446" WEIGHT="13.363396806395832"/>
<DICH_DATA CI_END="1.3334993458285727" CI_START="0.36881897991307366" EFFECT_SIZE="0.7012987012987013" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.12499280697519317" LOG_CI_START="-0.4331867376742198" LOG_EFFECT_SIZE="-0.15409696534951337" MODIFIED="2016-11-07 15:33:12 +0100" MODIFIED_BY="Dimitrinka Nikolova" ORDER="25" O_E="0.0" SE="0.3278774275603728" STUDY_ID="STD-Porter-1971" TOTAL_1="11" TOTAL_2="9" VAR="0.10750360750360752" WEIGHT="8.238424253052514"/>
<DICH_DATA CI_END="0.6471159716752733" CI_START="0.09081759048972873" EFFECT_SIZE="0.24242424242424243" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="16" LOG_CI_END="-0.1890178810851679" LOG_CI_START="-1.0418300246867198" LOG_EFFECT_SIZE="-0.6154239528859439" MODIFIED="2016-10-18 19:27:42 +0200" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="0.5009460746397457" STUDY_ID="STD-Ramond-1992" TOTAL_1="33" TOTAL_2="32" VAR="0.2509469696969697" WEIGHT="4.670036225149931"/>
<DICH_DATA CI_END="2.343887675927311" CI_START="0.4897671485982377" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.36993679553129327" LOG_CI_START="-0.3100103487764068" LOG_EFFECT_SIZE="0.029963223377443202" MODIFIED="2016-10-10 10:05:47 +0200" MODIFIED_BY="[Empty name]" ORDER="28" O_E="0.0" SE="0.39940431835899015" STUDY_ID="STD-Shumaker-1978" TOTAL_1="12" TOTAL_2="15" VAR="0.15952380952380957" WEIGHT="6.450862069164942"/>
<DICH_DATA CI_END="1.5460727049509322" CI_START="0.6763081512146606" EFFECT_SIZE="1.0225563909774436" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="19" LOG_CI_END="0.18922991300828323" LOG_CI_START="-0.16985537820201985" LOG_EFFECT_SIZE="0.009687267403131698" MODIFIED="2016-10-10 10:05:49 +0200" MODIFIED_BY="[Empty name]" ORDER="29" O_E="0.0" SE="0.21092847755779068" STUDY_ID="STD-Theodossi-1982" TOTAL_1="28" TOTAL_2="32" VAR="0.04449082264484741" WEIGHT="12.400922089961096"/>
<DICH_DATA CI_END="0.8287110319305621" CI_START="0.5829284741789222" EFFECT_SIZE="0.6950390329891715" ESTIMABLE="YES" EVENTS_1="145" EVENTS_2="209" LOG_CI_END="-0.08159687972191138" LOG_CI_START="-0.23438473027541912" LOG_EFFECT_SIZE="-0.15799080499866527" MODIFIED="2016-10-17 18:48:37 +0200" MODIFIED_BY="[Empty name]" ORDER="22" O_E="0.0" SE="0.08974833972718836" STUDY_ID="STD-Thursz-2015" TOTAL_1="551" TOTAL_2="552" VAR="0.008054764483786817" WEIGHT="17.519249748595147"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="37.13423255978316" CI_END="1.371347308087237" CI_START="1.0589689780196923" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2050785274641638" ESTIMABLE="YES" EVENTS_1="334" EVENTS_2="279" I2="62.29893810930086" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.13714745835191264" LOG_CI_START="0.02488323784856039" LOG_EFFECT_SIZE="0.08101534810023651" METHOD="MH" MODIFIED="2017-11-02 12:03:18 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="2" P_CHI2="7.039980164331716E-4" P_Q="1.0" P_Z="0.004672119440448781" Q="0.0" RANDOM="NO" SCALE="66.86" SORT_BY="YEAR" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="927" TOTAL_2="934" WEIGHT="100.0" Z="2.828811597488401">
<NAME>Worst-best scenario all-cause mortality to 3 months follow-up</NAME>
<GROUP_LABEL_1>Glucocorticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no intervention</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticosteroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no interv/placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="37.13423255978316" CI_END="1.371347308087237" CI_START="1.0589689780196923" DF="14" EFFECT_SIZE="1.2050785274641638" ESTIMABLE="YES" EVENTS_1="334" EVENTS_2="279" I2="62.29893810930086" ID="CMP-003.02.01" LOG_CI_END="0.13714745835191264" LOG_CI_START="0.02488323784856039" LOG_EFFECT_SIZE="0.08101534810023651" MODIFIED="2016-11-07 15:33:37 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1" P_CHI2="7.039980164331716E-4" P_Z="0.004672119440448781" STUDIES="15" TAU2="0.0" TOTAL_1="927" TOTAL_2="934" WEIGHT="100.0" Z="2.828811597488401">
<NAME>Up to 3 months</NAME>
<DICH_DATA CI_END="1.0635091819729094" CI_START="0.01887096490056978" EFFECT_SIZE="0.14166666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.02674124380428928" LOG_CI_START="-1.7242058931429909" LOG_EFFECT_SIZE="-0.8487323246693509" MODIFIED="2016-10-16 18:06:31 +0200" MODIFIED_BY="[Empty name]" ORDER="21" O_E="0.0" SE="1.0285150155709453" STUDY_ID="STD-Helman-1971" TOTAL_1="20" TOTAL_2="17" VAR="1.057843137254902" WEIGHT="2.3301028036859606"/>
<DICH_DATA CI_END="1.3334993458285727" CI_START="0.36881897991307366" EFFECT_SIZE="0.7012987012987013" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.12499280697519317" LOG_CI_START="-0.4331867376742198" LOG_EFFECT_SIZE="-0.15409696534951337" MODIFIED="2016-11-07 15:33:37 +0100" MODIFIED_BY="Dimitrinka Nikolova" ORDER="25" O_E="0.0" SE="0.3278774275603728" STUDY_ID="STD-Porter-1971" TOTAL_1="11" TOTAL_2="9" VAR="0.10750360750360752" WEIGHT="2.7660262032088756"/>
<DICH_DATA CI_END="2.1411357518179877" CI_START="0.4841795827265041" EFFECT_SIZE="1.018181818181818" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.33064420321057786" LOG_CI_START="-0.3149935281866648" LOG_EFFECT_SIZE="0.007825337511956526" MODIFIED="2016-10-09 14:04:51 +0200" MODIFIED_BY="[Empty name]" ORDER="17" O_E="0.0" SE="0.37925079938105455" STUDY_ID="STD-Campra-1973" TOTAL_1="22" TOTAL_2="28" VAR="0.14383116883116887" WEIGHT="3.1611728036672866"/>
<DICH_DATA CI_END="13.05963254309707" CI_START="0.6147016580509396" EFFECT_SIZE="2.8333333333333335" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.115930957432902" LOG_CI_START="-0.21133561544364132" LOG_EFFECT_SIZE="0.4522976709946303" MODIFIED="2016-10-10 10:06:44 +0200" MODIFIED_BY="[Empty name]" ORDER="23" O_E="0.0" SE="0.7796429549831781" STUDY_ID="STD-Mendenhall-1977" TOTAL_1="12" TOTAL_2="17" VAR="0.6078431372549019" WEIGHT="0.5945779568026244"/>
<DICH_DATA CI_END="4.641144293624498" CI_START="0.9237669352422174" EFFECT_SIZE="2.070588235294118" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.6666250708863297" LOG_CI_START="-0.03443758668661556" LOG_EFFECT_SIZE="0.31609374209985713" MODIFIED="2016-10-15 23:22:59 +0200" MODIFIED_BY="[Empty name]" ORDER="15" O_E="0.0" SE="0.4118076753744716" STUDY_ID="STD-Blitzer-1977" TOTAL_1="17" TOTAL_2="16" VAR="0.16958556149732618" WEIGHT="1.8505488175738247"/>
<DICH_DATA CI_END="2.3096079660641027" CI_START="0.1773461150196915" EFFECT_SIZE="0.64" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.36353826879945483" LOG_CI_START="-0.7511783208316805" LOG_EFFECT_SIZE="-0.1938200260161128" MODIFIED="2016-10-09 14:18:38 +0200" MODIFIED_BY="[Empty name]" ORDER="530" O_E="0.0" SE="0.6547900426854397" STUDY_ID="STD-Maddrey-1978" TOTAL_1="25" TOTAL_2="32" VAR="0.42875" WEIGHT="1.8906535907100996"/>
<DICH_DATA CI_END="2.343887675927311" CI_START="0.4897671485982377" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.36993679553129327" LOG_CI_START="-0.3100103487764068" LOG_EFFECT_SIZE="0.029963223377443202" MODIFIED="2016-10-10 10:06:44 +0200" MODIFIED_BY="[Empty name]" ORDER="28" O_E="0.0" SE="0.39940431835899015" STUDY_ID="STD-Shumaker-1978" TOTAL_1="12" TOTAL_2="15" VAR="0.15952380952380957" WEIGHT="2.235172689461718"/>
<DICH_DATA CI_END="1.976541991306356" CI_START="0.4963431529485624" EFFECT_SIZE="0.9904761904761905" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.29590604529114234" LOG_CI_START="-0.3042179648334578" LOG_EFFECT_SIZE="-0.0041559597711577035" MODIFIED="2016-10-10 10:06:45 +0200" MODIFIED_BY="[Empty name]" ORDER="19" O_E="0.0" SE="0.35251581420895045" STUDY_ID="STD-Depew-1980" TOTAL_1="15" TOTAL_2="13" VAR="0.12426739926739927" WEIGHT="2.694181366761892"/>
<DICH_DATA CI_END="2.0023720383666395" CI_START="0.8255514923381667" EFFECT_SIZE="1.2857142857142858" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="16" LOG_CI_END="0.301544772043704" LOG_CI_START="-0.0832558331935679" LOG_EFFECT_SIZE="0.10914446942506807" MODIFIED="2016-10-10 10:06:46 +0200" MODIFIED_BY="[Empty name]" ORDER="29" O_E="0.0" SE="0.22603378031008958" STUDY_ID="STD-Theodossi-1982" TOTAL_1="28" TOTAL_2="32" VAR="0.05109126984126984" WEIGHT="5.364414454708123"/>
<DICH_DATA CI_END="1.3741962892744457" CI_START="0.6565280702147891" EFFECT_SIZE="0.9498412698412698" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="35" LOG_CI_END="0.1380487714863567" LOG_CI_START="-0.18274670068071025" LOG_EFFECT_SIZE="-0.02234896459717677" MODIFIED="2016-10-10 10:06:46 +0200" MODIFIED_BY="[Empty name]" ORDER="821" O_E="0.0" SE="0.18843684831413268" STUDY_ID="STD-Mendenhall-1984" TOTAL_1="90" TOTAL_2="88" VAR="0.035508445802563446" WEIGHT="12.714114315056118"/>
<DICH_DATA CI_END="2.271566119051022" CI_START="0.21571020798844465" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.3563253824542302" LOG_CI_START="-0.6661293024257166" LOG_EFFECT_SIZE="-0.1549019599857432" MODIFIED="2016-10-10 13:48:12 +0200" MODIFIED_BY="[Empty name]" ORDER="16" O_E="0.0" SE="0.6005949431307973" STUDY_ID="STD-Bories-1987" TOTAL_1="24" TOTAL_2="21" VAR="0.3607142857142857" WEIGHT="1.915862305252901"/>
<DICH_DATA CI_END="0.884793319145779" CI_START="0.11081821838121897" EFFECT_SIZE="0.31313131313131315" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="-0.053158165276579336" LOG_CI_START="-0.9553888362499751" LOG_EFFECT_SIZE="-0.5042735007632773" MODIFIED="2016-10-16 18:06:32 +0200" MODIFIED_BY="[Empty name]" ORDER="18" O_E="0.0" SE="0.5299747622436225" STUDY_ID="STD-Carithers-1989" TOTAL_1="36" TOTAL_2="31" VAR="0.28087324861518415" WEIGHT="4.246351527314266"/>
<DICH_DATA CI_END="0.729550069718708" CI_START="0.12586848849187707" EFFECT_SIZE="0.30303030303030304" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="16" LOG_CI_END="-0.13694489670221144" LOG_CI_START="-0.9000829830535634" LOG_EFFECT_SIZE="-0.5185139398778875" MODIFIED="2016-10-18 19:28:52 +0200" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="0.4482710895172359" STUDY_ID="STD-Ramond-1992" TOTAL_1="33" TOTAL_2="32" VAR="0.2009469696969697" WEIGHT="5.836011329847298"/>
<DICH_DATA CI_END="1.7984669821659176" CI_START="1.2615544075135927" EFFECT_SIZE="1.506274858091671" ESTIMABLE="YES" EVENTS_1="212" EVENTS_2="141" LOG_CI_END="0.25490246906875075" LOG_CI_START="0.10090598523282003" LOG_EFFECT_SIZE="0.1779042271507854" MODIFIED="2016-11-07 14:18:28 +0100" MODIFIED_BY="Dimitrinka Nikolova" ORDER="64" O_E="0.0" SE="0.09045829690011485" STUDY_ID="STD-Thursz-2015" TOTAL_1="551" TOTAL_2="552" VAR="0.008182703478069328" WEIGHT="50.60468892477441"/>
<DICH_DATA CI_END="5.177139269271194" CI_START="0.772627467014828" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.7140898480149713" LOG_CI_START="-0.1120298566870089" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2016-10-09 14:18:43 +0200" MODIFIED_BY="[Empty name]" ORDER="23" O_E="0.0" SE="0.48526680390043375" STUDY_ID="STD-De-2014" TOTAL_1="31" TOTAL_2="31" VAR="0.235483870967742" WEIGHT="1.7961209111745946"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2017-11-02 12:27:21 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="4">
<NAME>Sensitivity analysis: serious adverse events</NAME>
<DICH_OUTCOME CHI2="19.541068946641357" CI_END="1.2103803775561235" CI_START="0.8307999199300644" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="1.002788073701791" ESTIMABLE="YES" EVENTS_1="361" EVENTS_2="367" I2="28.356017584154394" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.08292187437718047" LOG_CI_START="-0.08050355399290006" LOG_EFFECT_SIZE="0.0012091601921401835" METHOD="MH" MODIFIED="2017-11-02 12:27:21 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1" P_CHI2="0.14528708991409767" P_Q="1.0" P_Z="0.9768622313400629" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.031031810604298483" TOTALS="YES" TOTAL_1="927" TOTAL_2="934" WEIGHT="100.0" Z="0.029002958129228377">
<NAME>Best-worse scenario of serious adverse events during treatment</NAME>
<GROUP_LABEL_1>Glucocorticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no intervention</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticosteroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no interv/placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.6470591644592263" CI_START="0.6217836230896183" EFFECT_SIZE="1.5058823529411764" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.5619428087181544" LOG_CI_START="-0.20636072085100313" LOG_EFFECT_SIZE="0.17779104393357562" MODIFIED="2016-10-10 15:45:51 +0200" MODIFIED_BY="[Empty name]" ORDER="75" O_E="0.0" SE="0.4513052964327311" STUDY_ID="STD-Blitzer-1977" TOTAL_1="17" TOTAL_2="16" VAR="0.2036764705882353" WEIGHT="3.926323279564368"/>
<DICH_DATA CI_END="8.608580580398396" CI_START="0.35574970477400936" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9349315490240584" LOG_CI_START="-0.4488554516514696" LOG_EFFECT_SIZE="0.24303804868629444" MODIFIED="2016-10-10 16:07:49 +0200" MODIFIED_BY="[Empty name]" ORDER="47" O_E="0.0" SE="0.8128433340529316" STUDY_ID="STD-Bories-1987" TOTAL_1="24" TOTAL_2="21" VAR="0.6607142857142858" WEIGHT="1.3321948519220395"/>
<DICH_DATA CI_END="1.959321304462537" CI_START="0.4050989526101174" EFFECT_SIZE="0.8909090909090909" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.2921056607588947" LOG_CI_START="-0.3924388796903551" LOG_EFFECT_SIZE="-0.0501666094657302" MODIFIED="2016-10-10 16:08:05 +0200" MODIFIED_BY="[Empty name]" ORDER="46" O_E="0.0" SE="0.4021048516100144" STUDY_ID="STD-Campra-1973" TOTAL_1="22" TOTAL_2="28" VAR="0.16168831168831171" WEIGHT="4.781755933890467"/>
<DICH_DATA CI_END="0.9058949243709684" CI_START="0.14210785243700305" EFFECT_SIZE="0.3587962962962963" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="-0.04292217363921447" LOG_CI_START="-0.8473819236500268" LOG_EFFECT_SIZE="-0.4451520486446206" MODIFIED="2016-10-10 16:08:32 +0200" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="0.47254363929633686" STUDY_ID="STD-Carithers-1989" TOTAL_1="36" TOTAL_2="31" VAR="0.2232974910394265" WEIGHT="3.6234149285862367"/>
<DICH_DATA CI_END="3.017444504100101" CI_START="0.5478348391308003" EFFECT_SIZE="1.2857142857142858" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.4796392914339345" LOG_CI_START="-0.26135035258379835" LOG_EFFECT_SIZE="0.10914446942506807" MODIFIED="2016-10-10 16:09:05 +0200" MODIFIED_BY="[Empty name]" ORDER="31" O_E="0.0" SE="0.43526098485391024" STUDY_ID="STD-De-2014" TOTAL_1="31" TOTAL_2="31" VAR="0.1894521249359959" WEIGHT="4.179626901590614"/>
<DICH_DATA CI_END="2.0186549725080996" CI_START="0.7034730866761564" EFFECT_SIZE="1.1916666666666667" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.3050620958922779" LOG_CI_START="-0.15275251305740395" LOG_EFFECT_SIZE="0.07615479141743697" MODIFIED="2016-10-10 16:09:23 +0200" MODIFIED_BY="[Empty name]" ORDER="101" O_E="0.0" SE="0.26892256751590654" STUDY_ID="STD-Depew-1980" TOTAL_1="15" TOTAL_2="13" VAR="0.0723193473193473" WEIGHT="8.916596648424635"/>
<DICH_DATA CI_END="2.8535694500320847" CI_START="0.5696812460554348" EFFECT_SIZE="1.275" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.4553884468512155" LOG_CI_START="-0.24436807731126758" LOG_EFFECT_SIZE="0.10551018476997394" MODIFIED="2016-10-10 16:10:45 +0200" MODIFIED_BY="[Empty name]" ORDER="68" O_E="0.0" SE="0.4110404461437014" STUDY_ID="STD-Helman-1971" TOTAL_1="20" TOTAL_2="17" VAR="0.16895424836601308" WEIGHT="4.608024144770963"/>
<DICH_DATA CI_END="2.7001521358041995" CI_START="0.2696802776858724" EFFECT_SIZE="0.8533333333333334" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.43138823448449654" LOG_CI_START="-0.5691508133001222" LOG_EFFECT_SIZE="-0.06888128940781285" MODIFIED="2016-10-10 16:11:21 +0200" MODIFIED_BY="[Empty name]" ORDER="105" O_E="0.0" SE="0.5877215894168485" STUDY_ID="STD-Maddrey-1978" TOTAL_1="25" TOTAL_2="32" VAR="0.34541666666666665" WEIGHT="2.4479859635332413"/>
<DICH_DATA CI_END="13.05963254309707" CI_START="0.6147016580509396" EFFECT_SIZE="2.8333333333333335" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.115930957432902" LOG_CI_START="-0.21133561544364132" LOG_EFFECT_SIZE="0.4522976709946303" MODIFIED="2016-10-10 16:11:34 +0200" MODIFIED_BY="[Empty name]" ORDER="110" O_E="0.0" SE="0.7796429549831781" STUDY_ID="STD-Mendenhall-1977" TOTAL_1="12" TOTAL_2="17" VAR="0.6078431372549019" WEIGHT="1.4424428308556567"/>
<DICH_DATA CI_END="2.0162825737974504" CI_START="0.6001142973333823" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="16" LOG_CI_END="0.3045513966431257" LOG_CI_START="-0.22176602632667544" LOG_EFFECT_SIZE="0.04139268515822508" MODIFIED="2016-10-10 16:11:40 +0200" MODIFIED_BY="[Empty name]" ORDER="57" O_E="0.0" SE="0.30916145956572283" STUDY_ID="STD-Mendenhall-1984" TOTAL_1="90" TOTAL_2="88" VAR="0.09558080808080807" WEIGHT="7.278426099413628"/>
<DICH_DATA CI_END="1.3334993458285727" CI_START="0.36881897991307366" EFFECT_SIZE="0.7012987012987013" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.12499280697519317" LOG_CI_START="-0.4331867376742198" LOG_EFFECT_SIZE="-0.15409696534951337" MODIFIED="2016-11-07 15:34:06 +0100" MODIFIED_BY="Dimitrinka Nikolova" ORDER="59" O_E="0.0" SE="0.3278774275603728" STUDY_ID="STD-Porter-1971" TOTAL_1="11" TOTAL_2="9" VAR="0.10750360750360752" WEIGHT="6.652021561987795"/>
<DICH_DATA CI_END="0.6471159716752733" CI_START="0.09081759048972873" EFFECT_SIZE="0.24242424242424243" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="16" LOG_CI_END="-0.1890178810851679" LOG_CI_START="-1.0418300246867198" LOG_EFFECT_SIZE="-0.6154239528859439" MODIFIED="2016-10-10 16:13:19 +0200" MODIFIED_BY="[Empty name]" ORDER="60" O_E="0.0" SE="0.5009460746397457" STUDY_ID="STD-Ramond-1992" TOTAL_1="33" TOTAL_2="32" VAR="0.2509469696969697" WEIGHT="3.268120343552818"/>
<DICH_DATA CI_END="1.974876697012832" CI_START="0.6251366999782602" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.29553998528976677" LOG_CI_START="-0.20402500416841643" LOG_EFFECT_SIZE="0.04575749056067514" MODIFIED="2016-10-10 16:13:51 +0200" MODIFIED_BY="[Empty name]" ORDER="54" O_E="0.0" SE="0.29344694769431684" STUDY_ID="STD-Shumaker-1978" TOTAL_1="12" TOTAL_2="15" VAR="0.08611111111111112" WEIGHT="7.866805564160355"/>
<DICH_DATA CI_END="1.741904928578932" CI_START="0.8308301254206577" EFFECT_SIZE="1.2030075187969924" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="19" LOG_CI_END="0.24102444796194755" LOG_CI_START="-0.08048776458426966" LOG_EFFECT_SIZE="0.08026834168883897" MODIFIED="2016-11-07 15:38:41 +0100" MODIFIED_BY="Dimitrinka Nikolova" ORDER="63" O_E="0.0" SE="0.1888578651607677" STUDY_ID="STD-Theodossi-1982" TOTAL_1="28" TOTAL_2="32" VAR="0.03566729323308271" WEIGHT="13.81638635804747"/>
<DICH_DATA CI_END="1.1537695110679744" CI_START="0.8843105782618528" EFFECT_SIZE="1.0100943438676486" ESTIMABLE="YES" EVENTS_1="244" EVENTS_2="242" LOG_CI_END="0.062119058326501546" LOG_CI_START="-0.05339517985507752" LOG_EFFECT_SIZE="0.00436193923571201" MODIFIED="2016-11-27 16:23:49 +0100" MODIFIED_BY="[Empty name]" ORDER="52" O_E="0.0" SE="0.06785363531256049" STUDY_ID="STD-Thursz-2015" TOTAL_1="551" TOTAL_2="552" VAR="0.004604115825129956" WEIGHT="25.85987458969972"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="22.56191124763736" CI_END="1.313422108043678" CI_START="1.0532611061678971" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1761702352905619" ESTIMABLE="YES" EVENTS_1="395" EVENTS_2="338" I2="37.9485193149758" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.11840432223067332" LOG_CI_START="0.022536047264352002" LOG_EFFECT_SIZE="0.07047018474751265" METHOD="MH" MODIFIED="2017-03-01 16:23:17 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="2" P_CHI2="0.06778224982096992" P_Q="1.0" P_Z="0.003958709032153522" Q="0.0" RANDOM="NO" SCALE="309.82" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="927" TOTAL_2="934" WEIGHT="99.99999999999999" Z="2.881433386332028">
<NAME>Worst-best scenario of serious adverse events during treatment</NAME>
<GROUP_LABEL_1>Glucocorticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no intervention</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticosteroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no interv/placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.641144293624498" CI_START="0.9237669352422174" EFFECT_SIZE="2.070588235294118" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.6666250708863297" LOG_CI_START="-0.03443758668661556" LOG_EFFECT_SIZE="0.31609374209985713" MODIFIED="2016-10-16 11:46:33 +0200" MODIFIED_BY="[Empty name]" ORDER="75" O_E="0.0" SE="0.4118076753744716" STUDY_ID="STD-Blitzer-1977" TOTAL_1="17" TOTAL_2="16" VAR="0.16958556149732618" WEIGHT="1.5294603248752587"/>
<DICH_DATA CI_END="8.608580580398396" CI_START="0.35574970477400936" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9349315490240584" LOG_CI_START="-0.4488554516514696" LOG_EFFECT_SIZE="0.24303804868629444" MODIFIED="2016-10-10 15:58:17 +0200" MODIFIED_BY="[Empty name]" ORDER="47" O_E="0.0" SE="0.8128433340529316" STUDY_ID="STD-Bories-1987" TOTAL_1="24" TOTAL_2="21" VAR="0.6607142857142858" WEIGHT="0.633376511007166"/>
<DICH_DATA CI_END="2.1411357518179877" CI_START="0.4841795827265041" EFFECT_SIZE="1.018181818181818" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.33064420321057786" LOG_CI_START="-0.3149935281866648" LOG_EFFECT_SIZE="0.007825337511956526" MODIFIED="2016-10-10 15:58:34 +0200" MODIFIED_BY="[Empty name]" ORDER="46" O_E="0.0" SE="0.37925079938105455" STUDY_ID="STD-Campra-1973" TOTAL_1="22" TOTAL_2="28" VAR="0.14383116883116887" WEIGHT="2.61267810790456"/>
<DICH_DATA CI_END="1.1167175841011903" CI_START="0.22594806133148335" EFFECT_SIZE="0.5023148148148148" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.04794335469632333" LOG_CI_START="-0.6459913806290886" LOG_EFFECT_SIZE="-0.29902401296638265" MODIFIED="2016-10-10 15:59:59 +0200" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="0.40762069856248634" STUDY_ID="STD-Carithers-1989" TOTAL_1="36" TOTAL_2="31" VAR="0.16615463389656934" WEIGHT="3.828619208326899"/>
<DICH_DATA CI_END="4.023081095767875" CI_START="0.6904602993710199" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.6045587870056439" LOG_CI_START="-0.1608612877729312" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2016-10-10 16:00:18 +0200" MODIFIED_BY="[Empty name]" ORDER="31" O_E="0.0" SE="0.44961154081541166" STUDY_ID="STD-De-2014" TOTAL_1="31" TOTAL_2="31" VAR="0.2021505376344086" WEIGHT="1.7813714372076543"/>
<DICH_DATA CI_END="2.0186549725080996" CI_START="0.7034730866761564" EFFECT_SIZE="1.1916666666666667" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.3050620958922779" LOG_CI_START="-0.15275251305740395" LOG_EFFECT_SIZE="0.07615479141743697" MODIFIED="2016-10-10 16:00:19 +0200" MODIFIED_BY="[Empty name]" ORDER="101" O_E="0.0" SE="0.26892256751590654" STUDY_ID="STD-Depew-1980" TOTAL_1="15" TOTAL_2="13" VAR="0.0723193473193473" WEIGHT="2.5448163388680776"/>
<DICH_DATA CI_END="2.8535694500320847" CI_START="0.5696812460554348" EFFECT_SIZE="1.275" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.4553884468512155" LOG_CI_START="-0.24436807731126758" LOG_EFFECT_SIZE="0.10551018476997394" MODIFIED="2016-10-10 16:03:16 +0200" MODIFIED_BY="[Empty name]" ORDER="68" O_E="0.0" SE="0.4110404461437014" STUDY_ID="STD-Helman-1971" TOTAL_1="20" TOTAL_2="17" VAR="0.16895424836601308" WEIGHT="1.9258069591434102"/>
<DICH_DATA CI_END="2.7001521358041995" CI_START="0.2696802776858724" EFFECT_SIZE="0.8533333333333334" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.43138823448449654" LOG_CI_START="-0.5691508133001222" LOG_EFFECT_SIZE="-0.06888128940781285" MODIFIED="2016-10-10 16:03:39 +0200" MODIFIED_BY="[Empty name]" ORDER="105" O_E="0.0" SE="0.5877215894168485" STUDY_ID="STD-Maddrey-1978" TOTAL_1="25" TOTAL_2="32" VAR="0.34541666666666665" WEIGHT="1.5626065238663636"/>
<DICH_DATA CI_END="13.05963254309707" CI_START="0.6147016580509396" EFFECT_SIZE="2.8333333333333335" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.115930957432902" LOG_CI_START="-0.21133561544364132" LOG_EFFECT_SIZE="0.4522976709946303" MODIFIED="2016-10-10 16:04:02 +0200" MODIFIED_BY="[Empty name]" ORDER="110" O_E="0.0" SE="0.7796429549831781" STUDY_ID="STD-Mendenhall-1977" TOTAL_1="12" TOTAL_2="17" VAR="0.6078431372549019" WEIGHT="0.4914128102641805"/>
<DICH_DATA CI_END="2.0162825737974504" CI_START="0.6001142973333823" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="16" LOG_CI_END="0.3045513966431257" LOG_CI_START="-0.22176602632667544" LOG_EFFECT_SIZE="0.04139268515822508" MODIFIED="2016-10-10 16:04:19 +0200" MODIFIED_BY="[Empty name]" ORDER="57" O_E="0.0" SE="0.30916145956572283" STUDY_ID="STD-Mendenhall-1984" TOTAL_1="90" TOTAL_2="88" VAR="0.09558080808080807" WEIGHT="4.803698257638619"/>
<DICH_DATA CI_END="1.3334993458285727" CI_START="0.36881897991307366" EFFECT_SIZE="0.7012987012987013" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.12499280697519317" LOG_CI_START="-0.4331867376742198" LOG_EFFECT_SIZE="-0.15409696534951337" MODIFIED="2016-11-07 15:34:15 +0100" MODIFIED_BY="Dimitrinka Nikolova" ORDER="59" O_E="0.0" SE="0.3278774275603728" STUDY_ID="STD-Porter-1971" TOTAL_1="11" TOTAL_2="9" VAR="0.10750360750360752" WEIGHT="2.2860933444164897"/>
<DICH_DATA CI_END="0.729550069718708" CI_START="0.12586848849187707" EFFECT_SIZE="0.30303030303030304" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="16" LOG_CI_END="-0.13694489670221144" LOG_CI_START="-0.9000829830535634" LOG_EFFECT_SIZE="-0.5185139398778875" MODIFIED="2016-10-18 19:35:01 +0200" MODIFIED_BY="[Empty name]" ORDER="60" O_E="0.0" SE="0.4482710895172359" STUDY_ID="STD-Ramond-1992" TOTAL_1="33" TOTAL_2="32" VAR="0.2009469696969697" WEIGHT="4.823405737669956"/>
<DICH_DATA CI_END="1.974876697012832" CI_START="0.6251366999782602" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.29553998528976677" LOG_CI_START="-0.20402500416841643" LOG_EFFECT_SIZE="0.04575749056067514" MODIFIED="2016-10-10 16:05:46 +0200" MODIFIED_BY="[Empty name]" ORDER="54" O_E="0.0" SE="0.29344694769431684" STUDY_ID="STD-Shumaker-1978" TOTAL_1="12" TOTAL_2="15" VAR="0.08611111111111112" WEIGHT="2.3751619162768725"/>
<DICH_DATA CI_END="2.2538111361451265" CI_START="0.9983090259498651" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="16" LOG_CI_END="0.3529175204205801" LOG_CI_START="-7.350023092176193E-4" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2016-10-10 16:05:47 +0200" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="0.20773724245970415" STUDY_ID="STD-Theodossi-1982" TOTAL_1="28" TOTAL_2="32" VAR="0.043154761904761904" WEIGHT="4.433635577050162"/>
<DICH_DATA CI_END="1.420466709698816" CI_START="1.0857478801000942" EFFECT_SIZE="1.2418811210451044" ESTIMABLE="YES" EVENTS_1="269" EVENTS_2="217" LOG_CI_END="0.15243105997833412" LOG_CI_START="0.03572899008425052" LOG_EFFECT_SIZE="0.09408002503129231" MODIFIED="2016-11-27 16:24:23 +0100" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="0.0685513735403475" STUDY_ID="STD-Thursz-2015" TOTAL_1="551" TOTAL_2="552" VAR="0.004699290814268255" WEIGHT="64.36785694548432"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2017-11-02 12:57:43 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2017-11-01 15:01:28 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAAKpCAYAAACW16oJAABEHklEQVR42u2dDYRV3dv/b5IkSSQZ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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2017-11-02 12:57:43 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias domain presented as percentages across all included studies</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEZCAMAAABxStv9AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2017-11-02 12:57:43 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias domain for each included study</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAWgAAAM1CAIAAADSCPyCAAArQklEQVR42u3dvY4dxbrG8ZGQEMEE
DnwFXMNEaEQEEfeEwwmQIPRdIC4BYQiNIzIEjBF2QDBAxpf6LO8552jtWb26qz+qut7q36PRFnvZ
ftx+V9W/q6qr67m4ICKaoY6IKFnAQUTAQUTAQUTAQUTAQUTAQUQEHEQEHEQEHEQEHLSDhmKrMQEH
pTeRlA8JOIj+t33M/lUCDiIi4KC5Qw8NhoCDJlPDJIWAg4CDgIOAg4CDamsoqEHAQUTAQUTAQTU2
FLvOCTgovZUc/4cGQ8BBk8GBHQQcBBwEHJSfHRoMAQcRAQcRAQfVMEORN0zAQUTAQUTAQVU3FPMU
Ag5KbyWjnxBwEAEHAQetyg4NhoCDEtqHx7EEHEQEHEQEHEQEHEQEHEREwEGTGoqjAwk4KL2VnPsP
Ag4i4CDgIOAg4KDtG4ptowQcRAQcRAQcVFlD6f1vAg6icWpgBwEHAQcBB+VuKJ6qEHAQEXAQEXBQ
xVMVbUZ70AhovJUoAgEHVQQOAxngIOyY3PhSPiTgoLCtZNWhwbCDNgkcRAQcRHkmQZoicFD7s5XV
qWGSAhzU7KBg3b4NHMBBewHHit0bOICDgGN+E0QN4KDG2aHBEHAQEXBQ0CZo1zlwkO49YwbUWeMA
DmqsleR2tj4KHDTt7g0cwAEcNF7ulA/3yQ5NEThoWt+r/FuwhEnAQbUMNwg4qNnBeaZTfLo8J30Q
cDROjUD3c42EgAM4ZrUS4wICDuCok0paCHDQUNHNUzqptMBBOxkoAQcBB82ZTazbZo6tNEXgoAn9
UBEscwAHJd1gvQ9KwEEzwdHFWR81KCDgAI6ZyxAWIwg4tmdH0Mex2ow2DBwEHAQclK+hZFjj8FQF
OGj8vh3rAWTua9P2gINahh1wEHDQoqlEvp2jBBy0wXpBuHGBnaPAQTM74Z5PKibgoGbBgR0EHHV1
woj7zVdf4zBPAQ6a1v12Xn9by4CDCDiAg6hvuLRu3wYO4KD2xwU53ug1awMOAg4CDiLgIOCobb0g
1ubRdS9YBCRw0Jy7NxFwEHCsUw31AQ5qhx05piq2wwEHLeowux0XaHvAQSYUBBxEZ0ix+pmjeAQc
tMF6wSbTq1Uu3lgGOEhXqasa1lyBQ1ep5WpXv/Ic3bvXSlMHDuDQCbeEHQFHI2scubu3YT8BR/uj
mED32EwnfXQBM3qBg2hy314Xc97oBY6mOkmZcKNwiS3AARzUWicEDgKO6tYjdt5V8i27Hhtq5MAR
vNbZpio5wOEdVgKOSkcce77H2kcLHER1jWWMkoCj2UFHlOIXy1VZ3TnHDhECjqYG54FWT4rV2foo
cADHNvfYMoFMga6ZgGP76X39XSXobgtbzoGDahkXRIEdAQc1e48FDuCgjWf1Jm7H6LFpDThMKKrr
3tqMZqwRhAdH7nusFkLAYcRRBTjK7xzV9oDDrL4Fdpw6Z92Tqp0DBxVFUslJUP3OBBxtToICdZXc
G/BRAzhaGw4EunvHGiU5QwQ4qJZ7rE5IwGEss3Qsk9tTmwQOOtvPu7DndK1Yh5QPCThUPOrO0TLD
pYhDPOAg4EidCu35TmuUBBzA0f6UcC3YWZcBDgPdvQCagINK32Pjwi53DMVuJynA4R473znEprV8
D4NMNoFjyx6e6Ri+EOAosPfEme/A0SY1wt1jC4w4dv4NAgeVbnbOtijcbXZLDeBwv6qmCYIdcJD7
1eZTFedxAAdtf4+1oFtmlAQcNK2T5NjXGCtvLQo4xFkDx5aTlOEPdwKOiAu6VqmAo6kJRdARR9yR
I3AAByRNGCtpMLacAwfVAru1kCQCEjiorhusYT8BR2sdO/dCYyxwZHq/xlgGOGjybCLEC2PiEYBj
L/2w2nts+WrUP70i4GhkvcA9tg3YAQdtcCfMfeZVlEiH3CsR3oIBjtbYkfuCM205j3UDBw7gqGKB
o/6Y5ZLPPqKMv/ZMDeBofCAT4l2VQCM7a0nAARyL+kz9QwPdGzgan62EcC45d9NCgIOKjgsaqIY6
Awe106ADbdOyEgEcwDGzz3SZD+mKeAIYAUcTRY9zMlXW5zXhtmkZzgBHm2OZ3CeD1r9zNHff7q2G
tHoCjvCrBuWXXYGDMjY4eWsDvIuyTgwcwEEtT69KAho4aIP7FXCsPr3a7XAAOFqsdYapStydC8XA
gR3A0dqIQ0GyPgZyFABwUDujpMLDGYcSAkeDvXF159XbtxMo/POBo6JZ/c53juYYF+QO98YO4Nge
HF3M43Yqv+bc4d7WOIADOOb0lvqr0TmLHDgaZsfOD/Lx0BQ4iJZOK3YevAAcNGG9IFJDMfIn4GiP
HXYubPL1GXHQBrduIQaBMuKc4gMczd4Jcx/kE+iay5wtZqpCwNHaKKnACazAQUVHvF2GjeGxnmvG
3dWiDQNHOxOK0BgNdHSzNQ7gaAEcZd7O8HYsAUdrI47cb2dkWi8g4KCNB+dd2DdKcowLgkZwAwcZ
JW02ccu628IGMOCgWsYFgTatAQdwVDFVccp5F+oZE3AARxXNTkEyUUPwFXAAhzvhorGMRg4c2DF+
azUJstEOOFqsuJev+nq4QwmBg5q9gdshYkoIHI0PZyrv3p6qAAdN7t5dkFc2gWOg1KYqVHrMn6kT
BrrmLsPj2AI7Ry1FA0c74MjNjnCPJ4wLgAM4Zt4J1Rk7gKO1NY5wB1vk6IQRX0ULdMAycND2jMv9
vMYhA8BBW/bzbvfPayJONoGDJt/DdULXDByUegPPcfJooIySLubJoFaggWNLaqw7vQ+a5EbAQVuC
o8u/HEiqARx1DXTrj02NW+cuw/MabRg4aBrpQrQZG+2Ag+a3aRMKB/kABzU4fs699yRWYh5wUFPg
CHfSR5dnqThrYh5wUFPsyLcxPO55HPZxAEcjg/POCWAEHM0PChzkk/vubakYOIBj+zWOWPN5rRo4
gENvUQrgUPQiuYSBhgZ2ygMHgV1F06uShxUDB9FI9w60oJvbfJ/Pg4Bj434YJRAgX7fMvfekGEaB
g0LevWPBLu4aB3AAB3BsPKLJHQRTZh3aVIU26Ich7t4RVyIIOGhCJ4w1ctb8gIMqAke33ovkhXNY
jeyAg8o1Oy+MDQ9kHN0MHE016EyDjp1/rcABHMBR12XHCmrMcdm6DHBgR1137/rXOOw3B44qFjjq
T1EPCg4CDpq2wBHo7g0cwEHNgqPYECzTDGvFWG9TFeDYuKt0Dv7Nj1FjGeAwLih99457j7UuAxzA
sZehQeUPenMfXwAc1BQ43L1NeYCjojWOEMuBQY8IsnMUOKjlrhJxQqHLAAdwtNlPgh4RBBy0QbMr
MwkKATsCjn0NE3YCuwKrJ8YFwIEd/u0V/UV4BBxNdR732AJ1LvPCfuVfn+a1/bA/xN27gQlFoAe9
9e/xAQ531MkNOkT8WklAAwdhx8YNes9v9AIHTRuc53tOARwRm0f9pQCOjccF4dJPch/DV/+4gICj
itmE+oerMyQBhwatzvV+g9Y4KHv3DoqkuM8+8jnXH+IJHO6xe7l7Zyq1pyoEHE2Bo8yAcd3nYsBB
4y2vi/MORe57bCBwlKG/LecU9a5S4B7bWdANffNTCOCgGsaMwEEbgCPi1jLfYBcwhgI4th/5Wy+I
NS4wZgSONu+EK4Ij7jsp+bo3cACHsUzqEDpTxy52FEC37+1wwNHaJDnuI5WanTvBV8DRMDXiNugQ
E5ZwJ60FOpQQOICDKmVHzQu6wAEcbc7qs26TjxgWARwtsCMcNfJ1wtWdZcoDBy3tMzsEhwlggdsV
cJh4twkOKnGLUgjgaGyNo/NGCXCQ8fnms/pNvr5qDyUEjuZuApYD84Nj9bFM4acq1jga6eFqEggc
BZzrr4aGazaxF0CbBAEHcBTtKpQbHAXO47DlHDtSbbPulaz/PbdAgA7XB4GjnTWOMq9IrT5EX905
4s7RcM+MgaOdqUr5bVo5DgqKkkVU4HayYuTC6s7AYY0DOBaVOkrbMOLAjlpm9fniEQIFL+yzBwHH
9gsc6h9r4pZvxNHF2dqv4bbTSSCpDDjyFTbQy4TAQTMHSiGcY00PgYM2GI5GPNsi99LDuqOw3CO7
8g/UgWPXQ+hir0gFAoebSta2ARwtD0ejDA18g1EBpz9rdlPvWpU751g9iTuyAw7D0aJdpSVAhxgi
RfnKgKPBruKwvK6JXXbS6mkDcHR1v+5d8kXyrFQK+qAXOGLfT3aellq44Jk64Q7ZARwbf4WZ3pLy
tcZNeC2zTuxxbPgGXf8r5KFDDwuUZYdtAziAo5ZRUlZnbQM4Wpt7198Jg0ZARnw4nRWjK0Y6AIex
TJvOZdDfZc5MWvcZVueUcyrcCSNGQOaus3gE4NhyqhKie5sSAgdw1DUuoKATt3zgKHAYsjUO4Ghq
lBTlbIusI7sw7z3qz22wI/Te7SgjDncX4Kji1h3x2UeIHhL6WWzlY0bgMKtvmR0FoB9icOclN9pm
xBHxIB+jUeBovH3sdnBejKSq4e3YRr4/x+2Enrjl2DkaaHoFHBuDo6v+7dgu5kE+QfdxRBkzAkcL
4CiwaNfAlLB+9AtkotSWp/jQnxUcpirUzgw5+ihJFh9w6N47KstukWSNo5GmnPVuQKqam0fAsU1T
Pn6mkLWtrAu7TLu/Vnfucm7BfLBEFeid+vWXTvTq8uDI2rJzzI1XjzvP5Jx1Yl+gGmVGXhZHA484
MvEiU9+LBY6sB/AVqwZwULnGARyFv0HgICMO4GgKHNY4WgBHgYemBd5erXwfR9Y6P7Ba3bbMW8ir
GerVrXJKHSjjXVAhiAg4iAg4iAg4iAg4iAg4aGE1iVoRcBQCB2fOe3AGDo2DM2fgAA7OnIEDODhz
Bg7g4MwZOEiz4wwclPsrvPv77ub25vrF9aOvH118eXH57PLq+dWTH5/8+tevO3T+99+73367ef36
+uXLRz/9dHF7e/nq1dXd3ZN//13q/Pfd3e3NzYvr668fPfry4uLZ5eXzq6sfnzz569c9ViPHNQNH
OXA8/eXp428eH76505/DN/rZz5/tyvmPP56+fPn40ENOfw495/ff5zv/8vTpN48f913yxYEjP3+2
r2pkumbgKASOA+B7v7zjn8Pv2Ynz4Uba20mOfw6/Z4bzYVgxdskXh9+zk2rku2bgKAGOA/VHv7/7
n3N3gJacD3fX0X5y/3PuTnvO+TDWSLvki3Pjjpaqke+aqwDHuS2uhYP2Tv/206sa3Y3b++Fhhnlu
rNg7enz95+uGnQ8z+eMx+VdfXbz//sU777z5+eiji2+/fThK/+efVOe/7+7OzVB65yx/vm65Gvmu
uSJw9P7fTHF4w3lI6ThI//Dm9ibx+xsYOjbj/NtvN8ed4d1333wdX3xx8fnnb/7jvfeShui9zrc3
N1MuuX/C0kw18l1zGHA8COwZHgs88Ok1nwSOdECc+/z6xXXPV3Wvvq/w6vlVw86vX1/3jsO///6N
99tvP/z81atU5xfX15PA8fyq5Wrku+Zg4Egcm6ScIpsOjknUOPdL98/A0r/Cy2eXDTvfP2t88PPd
dxcffPDG+9NPH/7S7W2q8/2T1/SfZ5ctVyPfNYdf4xgFxwxU5QBH/5d3rJNvsWHn3hvshx++sfz4
4/5FwUTn0+7weOSSW65GvmuOPeJIWcicujhqxLHVPfatt94Y//BDTz/Z4YhjlWrsYsQxFRw5uveS
hVJrHMtn9ed+9rnGsbwa1jimgWPJVCUTODxVGXiOcP9zr/SNT60+VVmxGrt4qpK+xjH1qcqkqcrC
gUxnH0eC84OdC8NdZW/7OFasRvv7OFqSnaMpznaOlqlG4ztH9wCOzrsqD+6H3lUpUg3vqoQHx/0d
oH+t+z9jxU9efrIr5/+8D/ro/Pug850P445zT1gOn7/8ZF/VyHTNwFEOHN35kxF6Z5jNO587gaJ3
Jj/J+dx5HL3rGs1XI8c1A0dRcHDm3IYzcGgcnDkDB3Bw5gwcwMGZM3AAB2fOwEGaHWfgoOWFJpJW
T+5XnDkDB3Bw5gwcwMGZM3AAB2fOwAEcnDkDB2l2nDkDxwZfYb5E8ojJ77Hy2XM7S6sHjn7lSySP
mPweLp+9k1YPHOXBke+Up4inaUU888oJYMBRGhz5zpWMeH5nxFM2nTlaCzgSd7bmWApKP+U8JcJ+
9NryJZJHTH6PmM8urb4ucJRZGe79B5/7q0dT42Z8mC+RPGLye8R8dmn1McAxHD0//DvPfXjqswQc
k9Lq8yWSR0x+j5jPLq0+ADhGo+fTs6aXpNVPjbAf+KV8ieQRk98j5rNLqw+wxpHejacmP6Ywa3Q4
MwMc+RLJIya/R8xnl1YfeMRxrp8PLGFOXRwtOeJYJZE8YvJ7xHx2afWtgWPe85eUnj8piXrePHZ5
InnE5PeI+ezS6psFR7E1jhngyJdIHjH5PWI+u7T6AGsc3Vj0/JKnKsNTlRSfGeDIl0geMfk9Yj67
tPqKwNGk7Bzd9prtHC1zzcBRCBydd1VKXbN3VcpcM3AUAkeXM5E8YvJ7uHz2Tlo9cGwCji5nInnE
5PdY+ey5naXVAwdnzo07A4fGwZkzcAAHZ87AARycOQMHcHDmDByk2XEGDlpeaCJp9eR+xZkzcAAH
Z87AARycOQMHcHDmDBzAwZkzcJBmx5kzcGzwFUZMUZdWX8ZZWj1w9Ctiirq0+jLO0uqBo18RT6Zy
AlgZZyeAAUc7Z2E6c7SMszNHu5G/oxo8pZxyPi/tqZnTt6XVl3GWVp/US2tgR2Jafe9vmBdhHzHv
Q1p9GWdp9RPu7cP3+e4kYnr4N3QnGfSrpNWP1i4dHBETxqTVl3GWVj9ncaX3lj6aUJ/4YbcsyW3S
9Q9/GDHTVFp9GWdp9XMeFKXPBeaFyE4FR2Ju29Q1jogp6tLqyzhLq58DjtPVx1XAMXqaQEpavRGH
tPqtRhzS6oeWDOZFPa8SED11AmWNQ1q9tPpanqpMWqEYXeNImXdMXeMYXdn1VEVavbT67E9AUyYI
iSOOgSz7gXnH6FQlfYHDPg5p9dLqI+0crfxS7RxNcbZzNHo1gKPc5XlX5b/uh95VCV4N76qU41rE
FHVp9WWcpdUDx5AipqhLqy/jLK0eODhzbtwZODQOzpyBAzg4cwYO4ODMGTiAgzNn4CDNjjNw0PJC
E0mrJ/crzpyBAzg4cwYO4ODMGTiAgzNn4AAOzpyBgzQ7zpyBY4OvMGKKOucyztLqgaNfEVPUOZdx
llYPHP2KeDIV5zLOTgADjnbOwuRcxtmZo//tONFzOPQgd/c+d8p54ofDhY54+jbnMs7S6nv+pnm2
ucGRmFY/Kflp+MOIeR+cyzhLqz97Jx+4Vx+nnxwHppx+MnzPz5FWvyI4IiaMcS7jLK1+/K/p7YcD
M5R5oW1rpdWvCI6ImaacyzhLq58wuUjsnCv250RwnA5kzkXGDY9oHn4YMEWdcxlnafXjnTYxmz5l
cDHgk7I6uzCMciBf0j2Ws7T6Ndc4ZgwfRv/I1CnJpCnVvFmJWT1nafVrPlVJX49YcapSyRqH5wic
O2n1s/dxJE4HeucCiUsPC6cq9nFwlla/GTj2LHslOds5SmsuD3s7g/O5X/KuCnC0lqLOuYyztHrg
GFLEFHXOZZyl1QMHZ86NOwOHxsGZM3AAB2fOwAEcnDkDB3Bw5gwcpNlxBg5aXmgiafXkfsWZM3AA
B2fOwAEcnDkDB3Bw5gwcwMGZM3CQZseZM3Bs8BXKOufcxjcIHOXAIeucczPfIHAUAofzozi39A0C
RwlwOLGSszNHq+ifKbtih//s6IfdSoktss45d9LqK7yxp1//1FiWc+Epk8Ah65xzJ62+zhnBcPDK
sMkATVYBh6xzzp20+srBkR5AnfJHzv1Fk8Ah65xzJ62+DXAkpkauAg5Z55w7afX1gyPxNIEZ4BjO
vu5knXOWVt/AiGPG2uooOIapJOucs7T6kE9VZgTKT5qqzPhc1jnnTlp9JeAYuPMPjwh6/2Ab+zhC
ZJ1zjv4NBgZHoDnUvew75GznKE0GR+dNB87eVaEZhe5knXNu6BsEjnLg6GSdc27lGwSOouDgzLkN
Z+DQODhzBg7g4MwZOICDM2fgAA7OnIGDNDvOwEHLC00krZ7crzhzBg7g4MwZOICDM2fgAA7OnIED
ODhzBg7S7DhzBo4NvsJ8ieQR0+ojXrNqAEdpcORLJI+YVh/xmlUDOEqDI98pTxHPj3JqWfRqAEcJ
cOQ7VzLiiZXOSY1ejQ3AsSRoPl/3To+wH77ywonkEbPOI16zalQBjjILwsP/4HPXkJJEPXDlhRPJ
I2adR7xm1agOHN1Y0Pz/Z7UO3/knRToWBke+RPKIWecRr1k1qgbHub56+ht6yZICjtFRTw5w5Esk
j5h1HvGaVSMkOCZ9ePq/6eAYjXebB458ieQRs84jXrNq1A6O03XTgWFI7++cAY5jZBQbcaySSB4x
6zziNatGmBFH+jyid84yFRybrHEsTySPmHUe8ZpVo+qnKkvWOBI79iZrHPkSySNmnUe8ZtWoAhyT
guYTn6osAUdXdh/HionkEbPOI16zamwPjuVTm5pl52ir16wawLHN1XpXJfo1q0YkcMTSVonkEdPq
I16zagDHNuOjfInkEdPqI16zagBHpIkVZ85VOQOHxsGZM3AAB2fOwAEcnDkDB3Bw5gwcpNlxBg5a
XmgiafXkfsWZM3AAB2fOwAEcnDkDB3Bw5gwcwMGZM3CQZseZM3Bs8BXKZ1eNNqoBHOXAIZ9dNZqp
BnAUAoczr1SjpWoARwlwOGVTNZw5urQvDf91BSiWeLr6uY23k85P7+Szq0Zb1dgpOGaEKpwCZdLF
y2dXjU5a/brgGMhnPU1USUk5OZfD8uBX08ExHHCdUmj57KrRSatfERzDaWnnkDEj3X74kgbAkR7X
NvBL8tlVo5NWP29qMClQerg/D3fmlDC3xLT6tcAhn101Omn16444BmiSGBCbAqPExdGSIw757KrR
SatfPlVJHzsszIVO7/kL//joPFY+u2pIq8+yxpEIjoUjjql59wufqshnV43Q1YjxVCVlqrJ8xDFp
v8bCfRzy2VUjdDUKgWNXsldSNewcpdXA0Xk7QzW8q0IzCt3JZ1eNhqoBHOXA0clnV41WqgEcRcHB
mXMbzsChcXDmDBzAwZkzcAAHZ87AARycOQMHaXacgYOWF5pIWj25X3HmDBzAwZkzcAAHZ87AARyc
OQMHcHDmDByk2XHmDBwbfIWyzqNfs2oAR2lwyDqPfs2qARylweH8qOjXrBrAURocTqyMfs2qUQ4c
U+OmR3/nWte5JK1+eCuurPMmr1k1SoMjPee9GDiWpNVPyrX/f8k6j37NqlEROM5FmZxGMZ4LTzmN
khzt3quk1U8Fh6zz6NesGhtMVU7/t5uVzDYaXt/LhZTunZ5WPw8css6jX7Nq1AKO9InAvJC3gb+u
W5ZWP2ONQ9Z59GtWjYrAkRg0n/LhOavV0+pDjDgqzzqXVh+9GvVOVbrFkfRTwbFwvaO2GXLNWefS
6qNXo9zj2OH/WPJhNz1rvluQVl/5U5UQWefS6qNXY0twpD9A6cYi6buJWfPdsrT6mvdxhMg6l1Yf
vRrZwbGtNvlH2XfY6jWrxi7AsdW/yJsODV+zauxixFEhsGSdR79m1QCObUY6ss6jX7NqAEekKRJn
zlU5A4fGwZkzcAAHZ87AARycOQMHcHDmDByk2XEGDlpeaCJp9eR+xZkzcAAHZ87AARycOQMHcHDm
DBzAwZkzcJBmx5kzcGzwFeZLJJdWX+aaVQM4SoMjXyK5tPoy16wawFEaHPlOeXICWJlrVg3gKA2O
fOdKOnO0zDWrxhxwLMmdX2s5Z0Zg9dRAppScp+HduIUTyaXVl7lm1ZgPjtm587WBY0la/bwP8yWS
S6svc82qkQUcvbfrc110IAty+I8Pe44Gvj0wSQdHOiC64onk0urLXLNqLJqqTApznJre1s2Ndxvg
xdTQ6W4sOzalmqcf5kskl1Zf5ppVoxw4ynw4PEPJkVY/Axz5Esml1Ze5ZtXIAo6FufNL/ng3mHq/
elr9iiOOVRLJpdU3OeJoJ60+ccQxPPhPXIZYcWyyelr96Bpt4URyafWtrnE0klafkjs/qT+vPn9Z
MuKYlHc/Axz5Esml1Tf2VKW1tPqU3PmU7jfpqcqkqcrCEcektPqp4MiXSC6tvrF9HNLqdyo7R1u9
ZtUAjg3A0XlXJf41qwZwbACOLmciubT6MtesGsCxATi6nInk0urLXLNqAMcG4ODMuQ1n4NA4OHMG
DuDgzBk4gIMzZ+AADs6cgYM0O87AQcsLTSStntyvOHMGDuDgzBk4gIMzZ+AADs6cgQM4OHMGDtLs
OHMGjg2+QvnsqtFGNYCjHDjks6tGM9UAjkLgcOaVarRUDeAoAQ6nbKqGtPoV1mPqT6s/9+FU504+
u2q0VY1p4NhbWv1woOwkcMhnV41OWn23j7T6FcEhn101Omn1O0mrHw6ImgQO+eyq0Umr309a/UC8
2yRwyGdXjU5a/U7S6leMs5bPrhqdtPqdpNWnY272PFY+u2pIq5/Wn+tPqx+eGS15qiKfXTVCV2Md
cHRNp9Xn2Mchn101QldjAjho4WYTeyVVQ1o9TQZH5+0M1fCuCs0odCefXTUaqgZwlANHJ59dNVqp
BnAUBQdnzm04A4fGwZkzcAAHZ87AARycOQMHcHDmDByk2XEGDlpeaCJp9eR+xZkzcAAHZ87AARyc
OQMHcHDmDBzAwZkzcJBmx5kzcGzwFUZMUY/o/Pfd3e3NzYvr668fPfry4uLZ5eXzq6sfnzz561d1
llYfDRwRU9QjOv/y9Ok3jx/3Hltz4MjPn6mztPo44Ih4MlVE58OwYvSsvMPvUWcngAUAR8SzMCM6
H8Yaicd6nxt3qHMYcCRucV1xTSjllPOBq0qJZXkwwwx3+nZE57/v7s7NUHrnLH++VufIp5ynd8tV
wJGYVj/wG6aCI2LeR0Tn25ubKcb9ExZ1bgEcw0H2D0KYzv3OU/NJ4EhPnO4aShiL6Pzi+noSOJ5f
qXPmJLdNwDEpyH74d05C1WjhpoIjYqZpROf7J6/pP88u1TlzduwmaxwrptunoyoHOCKmqEd0Pu0O
j0eM1TlzWv0mTyJWjLxPXBw14jDiUOd9gWN5905cKLXGYY3DGkeD4FgyVckEDmvynqp4qlIOHF1C
kP3oU5VJU5XEB8P2cdjHYR+HnaMlIGjfYRlnO0fLOANHudGTNx3KOHtXpYwzcBQCRxczRT2i82Hc
ce4Jy+Hzl5+os7T6UODoYqaoR3Q+dx5H77qGOgNH7eDgzLkNZ+DQODhzBg7g4MwZOICDM2fgAA7O
nIGDNDvOwEHLC00krZ7crzhzBg7g4MwZOICDM2fgAA7OnIEDODhzBg7S7DhzBo4NvkJZ58f699+7
3367ef36+uXLRz/9dHF7e/nq1dXd3ZN//1WN2qsBHOXAIev8WH/88fTly8eHHnL6c+g5v/+uGlVX
AzgKgcP5Uf91D7x70ttJjn8Ov0c1qq0GcJQAhxMrH9xdR/vJ/c+5O61qbHvNucCRvnF1k26cfsp5
4ofDf6Mzsh/M5I/H5F99dfH++xfvvPPm56OPLr799uEo/Z9/VKOuauQFR7GF36ngSEyrT/9w9G+U
ynGs3367Oe4M77775uv44ouLzz9/8x/vvZc0RFeNDa95M3AMZ9APdO/RP/Xgz567jNngSKHS6Ydy
wI71+vV17zj8++/feL/99sPPX71SjbqqsQ04UjLoZ+TR9/7HkrT6FcEhefRY988aH/x8993FBx+8
8f7004e/dHurGnVVY/s1jtFeujD5cSo4zpEofeYl63zUufcG++GHbyw//rh/UVA1qqpGoRHHwEpk
JeA4N7sZnfIYcax1j33rrTfGP/zQ0092OOKovBrlpirzuFASHJMmINLqc8zqz/3sc42j5mpsDI7c
I45MaxzDtfJUZepzhPufe6VvfFKN/T5VmdpLR5PrU6YYC/dxjC7c2McxdefCcFfZ2z6OENXICI7d
ys7RFGc7R6NXAzgKgaPzrsqD+6F3VYJXAzgKgaOTdX5yp+19pvB/74OqRtXVAI5y4OhknZ/M8HtP
oOidyatGVdcMHEXBwZlzG87AoXFw5gwcwMGZM3AAB2fOwAEcnDkDB2l2nIGDlheaSFo9uV9x5gwc
wMGZM3AAB2fOwAEcnDkDB3Bw5gwcpNlx5gwcG3yF+RLJOXMu6Qwc5cCRL5GcM+fCzsBRCBz5Tnni
zLm8M3CUAEe+cyU5cy7vvBo4BnaqTk0hWXFqUElafb5Ecs6cyzuvDI4ZUNgEHOXT6vMlknPmXN65
EDh6E0+Of2lSMP0Dn4HglXPjha546HS+RHLOnMs7lwbHcNjavGD69AHCwNXmBke+RHLOnMs7l17j
GI13G7ju5RmRKeBITKufusaRL5GcM+fyzrlGHAPdMvFPzYuzH/5TKYuj3ZQoyYUjjlUSyTlzLu+c
caqyZMSxPM5+xlOVtWYlhRPJOXMu77wZOGbEzc/Lu199jWOVpyorJpJz5lzeuZanKgO/7RwCUp6q
DCxGbLuPY8VEcs6cyzuvCQ4aLrR9h5ztHKXJ4Oi86cDZuyo0o9BdzkRyzpwLOwNHOXB0ORPJOXMu
6QwcRcHBmXMbzsChcXDmDBzAwZkzcAAHZ87AARycOQMHaXacgYOWF5pIWj25X3HmDBzAwZkzcAAH
Z87AARycOQMHcHDmDByk2XHmDBwbfIX5Esnv/r67ub25fnH96OtHF19eXD67vHp+9eTHJ7/+xTmG
c6y2ARzlwJEvkfzpL08ff/P40CZOfw5t5bOfOdfuHK5tAEchcOQ7i+lw6+htFsc/h9/DuVrniG0D
OEqAI9/pj4f7yWjLuP85d2/hvK1zxLaxFBxT4+krWQpKOeV8IJiunrT6w9z13Ci0d1z6+k/OdTlH
bBtLwZGe2FYVOBLT6kf/aTWk1d/c3iS2jIFBKecNnSO2jbzgSIlQOf2d6cn1p1bDAfejHw4MRmYg
5lj5csOvX1z3NIJ79TWOq+ec63KO2DZWBkfvLX1SFNuMqLdE80TkDf/SbHDkyw2/f7qW3jgun3Gu
yzli2yixxrEwEXZ4RJP+N6aPlYbBMW+NI19ueH+zONZJ++BclXPEtrHyU5UZjEiPgzwdm4wuZE5K
lj4XTJ9vxLFKbri7d5MjjsrbRonF0RUz6BOnKon/5pRfSl/vmDePXZ4bbr2g1TWOmtvGNuAYjZhP
/1PzourTxxFrgSNfbrgnFI09VQnRNoqucXRjGfQL/9Sk7STpafUD/+TZ+zhWzA23J6KxfRwh2sbK
axzU2TnK2c5RWhEcnXdVOHtXhWYUusuZSH64t/Svov9nFPrJS861O4drG8BRDhxdzkTyc2cu9M5d
OVfoHKttAEdRcHDm3IYzcGgcnDkDB3Bw5gwcwMGZM3AAB2fOwEGaHWfgoOWFJpJWT+5XnDkDB3Bw
5gwcwMGZM3AAB2fOwAEcnDkDB2l2nDkDxwZfYcS0+r/v7m5vbl5cX3/96NGXFxfPLi+fX139+OTJ
X7/Wm8+e75ql1QNHaXBETKv/5enTbx4/7j0C5tAnf/6sxnz2fNcsrR44SoMj4ilPh1v06Llzh99T
VTXyXbMTwICjNDginit5uG8nHpF97h5evhr5rtmZo0vBcW5f6or0Wcsq/Szyc6ecJ344/DdGTCT/
++7u3Gi/d/z/5+vt89nzXbO0+jVHHClhArWtEnfJafWTEqSGP4yYSH57czPFuH/wX7ga+a5ZWn12
cCy5b/cOXpaMBc4lKs0Gx2hNm0kkf3F9PakTPr/aPp893zVLq88LjhkZazOi3uZ9mDhWygGOiInk
908x03+eXW6fz57vmqXVF5qq5Oj5M5Jip4LjXJb1ktWTLmYi+WnTejxivH0+e75rlla/ATiGc+Rn
p1LPm6oML46mjzgmgSNiInnhEccq1WhmxLHTtPpJo4Mci5FTpyqjfzZ9GbiZRPLyaxzLq9HSGsce
0+rbXuMYrlUzieTFnqqsWI0GnqrsIq0+pfvV9lRl4T6O0VPVmkkkL7aPY8VqNLCPQ1r9TmXn6LbV
sHO0zDUDRyFwdN5VKVUN76qUuWbgKASOLmZa/eEefu5pxeHzl5/UmM+e75ql1QPHBuDoYqbVnzvb
oneNoJJq5LtmafXAsQE4OHNuwxk4NA7OnIEDODhzBg7g4MwZOICDM2fgIM2OM3DQ8kITSasn9yvO
nIEDODhzBg7g4MwZOICDM2fgAA7OnIGDNDvOnIFjg68wX9Y552NFTKuP5Qwc5cCRL+uc87EiptWH
cwaOQuDIdxYT52NFPAEsojNwlABHvtMfOT8Ya4Q7czSi8zbgKJB3n/K3j37YDZ6Hnn7Keb7zpjk/
WNcId8p5ROftRxz58u5T/sbEvLhJ88nCCRecjxUxVyWic6XgGMhGedDVT4Mme0c0o397yl+RiLbC
mVqcjxUxyS2ic43gSM+7X5jV2M1KexzlUeEUT87HipgdG9G56qnKwkzZSb80CRzD5oVzwzkfK2Ja
fUTnRsAxsN45dbGjW5wv7X5lxGHEEQYc6b9h6jhiFXCYIVvjsMaxGThS1jVSwDH8oCTHVMWavKcq
nqqUBkfXl2I/PFUZeKpy7pdm7ONIH4bYBVDG2T6OMs7bg6M92Xe4rbOdo2WcgaMQODpvOpRy9q5K
GWfgKASOLmfWOecH445wafXhnIGjHDi6nFnnnB+sd4RLq4/lDBxFwcGZcxvOwKFxcOYMHMDBmTNw
AAdnzsABHJw5AwdpdpyBg5YXmkhaPRERcBARcBARcBARcBARcBARAQcRAQcRFQYHEdEk/Q8+3Vy7
c+UX9gAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="3 &#1084;&#1077;&#1089;&#1103;&#1094;&#1072; &#1082;&#1088;&#1080;&#1089;&#1090;&#1080;&#1072;&#1085;.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2017-07-19 22:24:17 +0200" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>
<B>All-cause mortality up to three months after randomisation.</B> Fifteen trials provided data. The diversity-adjusted required information size (DARIS) was calculated based on all-cause mortality of 30% in the control group; risk ratio reduction in the glucocorticosteroid group of 20%; type I error of 1%; and type II error of 20% (80% power). Trial diversity was 62%. The required information size was 6734 participants. The cumulative Z-curve (blue line) did not cross the trial sequential monitoring boundaries for benefit or harm (red inward sloping lines) and did not enter the trial sequential monitoring area for futility (inner-wedge with red outward sloping lines). The green dotted lines show the conventional boundaries of the naive alpha of 5% equal to Z-scores of +1.96 and -1.96.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAaUAAAF+CAIAAACtSZIVAABWWklEQVR42u2dCVhN6RvAr+z7kG1M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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2017-11-02 11:25:23 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="5" REF_ID="CMP-001.01" SETTINGS="SHOW_CI_LINES:YES;SHOW_STUDY_NAMES:NO;SHOW_EFFECT_ESTIMATE:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison 1. Glucocorticosteroids versus no intervention/placebo, outcome 1.1 all-cause mortality</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAG8CAMAAAA1hSvnAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="&#1082;&#1086;&#1085;&#1094; &#1090;&#1077;&#1088;&#1072;&#1087;&#1080;&#1080;  &#1082;&#1088;&#1080;&#1089;&#1090;&#1080;&#1072;&#1085;.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2017-11-01 15:05:10 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="6" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>
<B>All-cause mortality at the end of treatment (median 28 days (range 3 days to 12 weeks) (post hoc analysis).</B> Fourteen trials provided data. The diversity-adjusted required information size (DARIS) was calculated based on all-cause mortality of 22% in the control group; risk ratio reduction in the glucocorticosteroid group of 20%; type I error of 1%; and type II error of 20% (80% power). Trial diversity was 59%. The required information size was 9242 participants. The cumulative Z-curve (blue line) did not cross the trial sequential monitoring boundaries for benefit or harm (red inward sloping lines) and did not enter the trial sequential monitoring area for futility (inner-wedge with red outward sloping lines). The green dotted lines show the conventional boundaries of the naive alpha of 5% equal to Z-scores of +1.96 and -1.96.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAdwAAAGHCAIAAACViHSWAABaZElEQVR42uydB1gTSRuAI78N69nP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==
</FILE>
</FIGURE>
<FIGURE FILENAME="1 &#1075;&#1086;&#1076;  &#1082;&#1088;&#1080;&#1089;&#1090;&#1080;&#1072;&#1085;.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2017-11-01 15:05:04 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="7" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>
<B>All-cause mortality up to 1 year (post hoc analysis). </B>Three trials provided data. The diversity-adjusted required information size (DARIS) was calculated based on mortality in the control group of 40%; risk ratio reduction of 20% in the glucocorticosteroid group; type I error of 1%; and type II error of 20% (80% power). Trial diversity was 0%. The required information size was 1695 participants. The cumulative Z-curve (blue line) did not cross the trial sequential monitoring boundaries for benefit or harm (red inward sloping lines). The cumulative Z-curve crossed the inner-wedge futility line (red outward sloping lines). The green dotted lines show the conventional boundaries of the naive alpha of 5% equal to Z-scores of +1.96 and -1.96.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAeEAAAGHCAIAAAAIhX0eAABgc0lEQVR42uydB1gTSRuAY1fsZ293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</FILE>
</FIGURE>
<FIGURE FILENAME="sae.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2017-11-01 15:04:49 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="8" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>
<B>Serious adverse events during treatment</B>. There are 15 trials providing data. The diversity-adjusted required information size (DARIS) was calculated based on an incidence rate of serious adverse events in the control group of 36%; risk ratio reduction of 20% in the glucocorticosteroid group; type I error of 1%; and type II error of 20% (80% power). Trial diversity was 70%. The required information size was 6566 participants. The cumulative Z-curve (blue line) did not cross the trial sequential monitoring boundaries for benefit or harm (red inward sloping lines), but it entered the trial sequential monitoring area for futility (inner-wedge futility line red outward sloping lines) indicating that sufficient information was provided. The green dotted lines show the conventional boundaries of the naive alpha of 5% equal to Z-scores of +1.96 and -1.96.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAeQAAAGKCAIAAABSMqWEAABVp0lEQVR42u2dB1zUSBuHF0HF3s52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</FILE>
</FIGURE>
<FIGURE FILENAME="liver related mortality.png" FILE_TYPE="PNG" ID="FIG-09" MODIFIED="2017-08-03 16:39:55 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="9" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>
<B>Liver-related mortality up to three months after randomisation.</B> Fifteen trials provided data. The diversity-adjusted required information size (DARIS) was calculated based on liver- related mortality of 30% in the control group; risk ratio reduction in the glucocorticosteroid group of 20%; type I error of 1%; and type II error of 20% (80% power). Trial diversity was 68%. The required information size was 8059 participants. The cumulative Z-curve (blue line) did not cross the trial sequential monitoring boundaries for benefit or harm (red inward sloping lines) and did not enter the trial sequential monitoring area for futility (inner-wedge with red outward sloping lines). The green dotted lines show the conventional boundaries of the naive alpha of 5% equal to Z-scores of +1.96 and -1.96.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAeMAAAGKCAIAAACw7r79AABWaklEQVR42u2dBVgUWxvH177Gp9e4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</FILE>
</FIGURE>
<FIGURE FILENAME="any comp rhbcnbfy.png" FILE_TYPE="PNG" ID="FIG-10" MODIFIED="2017-08-03 16:40:14 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="10" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>
<B>Any complications up to three months after randomisation.</B> Fifteen trials provided data. The diversity-adjusted required information size (DARIS) was calculated based on any complications of 44% in the control group; risk ratio reduction in the glucocorticosteroid group of 20%; type I error of 1%; and type II error of 20% (80% power). Trial diversity was 75%. The required information size was 5887 participants. The cumulative Z-curve (blue line) did not cross the trial sequential monitoring boundaries for benefit or harm (red inward sloping lines). The cumulative Z-curve crossed the inner-wedge futility line (red outward sloping lines). The green dotted lines show the conventional boundaries of the naive alpha of 5% equal to Z-scores of +1.96 and -1.96.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAeQAAAGKCAIAAABSMqWEAABdO0lEQVR42uydCVxMXxuARwvhT9n3
fSnyWRPZK1v2LUuhCNlCyJao7Gt22bKvURRtRFEhuxRliyRbm/b1fO+ZM02jmlRqmmbe5+c37tw5
3bn3zpznvvfMOe/hEARBEETs4eApQBAEQVkjCIIgKGsEQRCUNYIgCIKyRhAEQVDWCIIgKGsEQRAE
ZY0gCIKgrBEEQVDWCIIgiBTJOioqqkqVKlWrVr1y5cqAAQOSk5MLu4UHDx5wOJw7d+4IK6ChoYHf
AARBUNZFJzAwsFq1ag8fPoTlLVu2gHMzMjKKsJ1ly5adOXMmx8oKFSrgB48gCMq6GDA0NNy7dy//
6YIFC1JSUjZv3hwSEuLs7HzixImYmBgbG5t3796dOnUqPj7+1q1br169gpIbN258/fq1i4vL4cOH
4ampqemlS5dSU1N37tzJQuyDBw/Ky8tD0O3k5GRnZwdPYWuRkZFhYWEHDhyA7d+/fx8W0tPT8cuB
IAjK+i9Mnz7dzc0tx8pu3bqZmZmBrCHQhqctWrSwtrZeu3btrFmz9u3b16VLF1jZu3dvExMT+FtW
ZtGiRa6urhMnTjx9+rSOjs6LFy8cHBzKlSvn7e3t7u4OZWbOnDl06NCEhIS3b99CxH306NGtW7du
27YNLgz45UAQBGX998gaguUcK0HT8+bNgwWwLT9qhoVGjRrBY9OmTSGC9vT0nDFjhmAZ+CsItBUV
FUHNEE3Dyvr167MNQogNj8uXLw8PD3ficuzYMSgG62Fr+OVAEARl/RdWrVo1depUthwUFKSmpgYL
EBRDEM0X8YIFCyBqhoXmzZvDo7KyMjzCGgMDA34ZiMT9/PzAvykpKRCG29vbw8o6deqwLcvIyMDj
kSNH9uzZY25uDssQp58/fx4WINbGLweCICjrv5Cenj527NjJkyfv379fR0fn6tWrsNLf379Pnz52
dnYg38uXL7dr127YsGEZGRnwNCwsTFVV1cLC4v3797169WIBMpTp0KHDpEmTNDU1t2/fDluDawBs
p3LlyjExMRCDQxnYMmwB/O7h4QEv+fj4jB8/HrTOv1QgCIKgrP/iazDshg0bBNtDQKkPHjw4dOjQ
tm3bbGxsrKysMjMzwa3gcXd3dygMZaA8RNMQL7MysPLbt2/Hjx9/+PDhtWvXoMDp06fB6Y6Ojjt2
7ID1sAbK83ub3Lx5c+PGjfHx8fjlQBAEZY0gCIKgrBEEQVDWpcW3b98OHjy4n8u5c+fCw8P5L2Vm
Zjo4OFy6dOnNmzf+/v74uSIIgrIuNezt7TkcjrW19fLlyxs3bvz9+3f+S6dOndLS0jpz5sy8efPG
jBmDnyuCICjrUoMNTYQFPT29Fy9eCL40ffr0Xbt2wQIYPDQ0FD9XBEFQ1qXMzp07bWxscqwMCQn5
3//+d+LEibS0NHgaGxvbvn376tWr37lz58mTJxwuffr0gZcaNmxYtWrVlStXQjDes2fPzp07f/jw
Ab8HCIKgrIuTp0+f5tMD2tLScubMmV++fNHX1799+/a3b9+8vb3B2uBreHXixIksqVPFihXhcfbs
2cuWLZszZ87ChQvxe4AgCMq62IB4efHixc+fP4fl8PDw169fr1u3rn///myoC+P06dMQNXfr1i0p
KYmtUVVVTUxMhAVYf+7cOVioW7cuPEJYbW5uvn37drZBBEEQlHXxAKoFF7Nle3v7jRs3hoWF+fj4
fPr0CZwL4ibcfKoQKRsZGTk4OLx69erYsWMdOnRg+faGDx9+9uxZkpUbZPz48devX4foe8eOHfg9
QBAEZV08pKamKigolC9fnjVA16xZ093dnf8qxMgnT56EYLl9+/ZxcXGwRkVFRV1dPTQ0NCoqqlq1
avAnrP2kRo0alSpV2rNnDyx37NgRigl2AUQQBEFZIwiCIChrBEEQlDWCIAiCspYQWLcTBEEQlLX4
cuzYsU6dOvn5+eGpQBAEZV0g0tLSpkyZIsrZXg4dOlSxYkUOh1O7dm0p6rh9+TKZNIno6pIxY8iI
EUSgfw7JzCQrVvxReNAgYmBARo8m48cT9tFs2UL09cmyZXR53TqyYAHx9SV2drzyoaFk5EhaAB4X
LyapqX/ZmdWrs5e/fSOnTtGF2bNJTAxv5cWL5OXLPP5w4UIybRrvEB48oGtgN8aNIxMn0rfevJmw
2ZOHD+cVg4UfP/7Ywt279DyYmvKe2trSMtOnk5QUkpFBli4lnz/zXnJ25r1FQYBD3ruXd+DwaG5O
goN5L7m5kXv3cpZ3caHvmzXCQLA+kMOHyahRhDsojBYwNibDhpF9++jTX7/I/Pl0V7O+yiQsLJ8v
Ot0O4OVFvL2L8p1hH/dfcXQkOjr02wJnjx0+LMA+s48Vvg9fvvBKOjmRguduO3KEbtbMjC7DNw0+
8cmT6bHD19XSkm4fvkXwkcEpmjCBvvvYsSQoCGVdUqSnpxsaGoI3x44dm/rXGl5MDBgwgJPFzp07
pUXW8fGkRg1aWx4/Jg4OpF49qjlGQADhcMibN9mFwXp9+1LdbNpEuEP/yc+ftEx0NK1CUDGg8JIl
pF+/7D8BXYJJobaA+PgqzBOoyZUqZT/93//I1Klk7VpaGzt3pmsiI+mWudkIcvLpE92N9+/JhQuk
Zk2eGrp0IQcOUAuArw8e5Lm+aVMSEkJdzJ1DLvskWFmRJ0+IiQlZtYrArRUcHZh0+XIq9z17yODB
pFUrWvL3b7o/AgnI/gK8L+wYa1vbvp3070+4043Sd4QL3sePOcuDYuDjyHEhYWI9cYIey9ChxNOT
zJpFFi2i+6mlRfezWzcqKeYv+AhA9/kAh8CdippERdEPrgi8ekUf4YNmC3kChwzXFbiqwT/2icB3
DD7ip0/p+8LZHjKEtG5N18fG0p2H601BePuWfkY3b9IFHx+ioUGvsuBoMDJchMDOjx7Ri+7GjeT+
fXL7Nv1Ww0vcaapQ1sXP79+/Bw8efPjw4cqVK58/f75v374/wQgiuEJkZIwcORJMvQw0IVWoqhJ+
Sz1oiJP1jYLKf/489RQf8IKREW9ZQYG3wJ0qk6xfT/WRG6g2EBISmmeAtymolhClslCXz5UrVKBV
qvCegh+hYoOswQh6eqRlS7oSnsJG+PDjMoasLG+BOy0nBW4X4HoDwA6wWwSI1nv1yqo3QioOHBe4
gAWPoFR1dSpZCEXZtJ9w4YFX+URE0IBO8JqR2+Nt2vDuDODOA1SrpESXV64k3DmPsm8jsuY5Impq
dDvwL0+TwqUUbjVA+vDWbJtw6uAtQP1gMaBduz/KC54luM7B9Yx/iiD6ho3AI1wFAbhCsPEKcD/E
HehAC4NJ4VU4RriufPhAtwB/Aithb2E/L12iC/ASq6FQEt4ux68+t27R+y1CZ2UlHTpkix7ub7jj
kOk9AXfI2x/ABRU2C/9gH9iRMuBC1bAhvegCcBc4cybvwgDqh4/p2DHeev4dIXyC8DX+M2ccyrp4
SExMHD16tLW1NSzLyckRbtanIUOG/Crghfff+PH48fny5Ql3bnUpAqq6oBf4FoMKAFhY0PCEL2u4
ktnb0xAbImXB8lBdDQ1phczRTAFVCC4GcLsK4e22beTrV6psiHlBzXzAAmvWEO5HTh8hJoKnYD0m
d4iMIBiE+pljnCp35uU/dpsZv2dP3hp9fXqvffYsrdKgFQDevVYt2vKze7fQ8BNiajc3ahN2XQG/
AAYG1J6gaYj0czQIJCdnB9HjxlG5Q0AnCMSPTNYQ7Bsb08gXQsIc7UtwvPyPoHt3GiR27UoXBG9r
+LKG8wCyZpkpIagEQ8H5gTsYMClc4bgzkeZ9luBMwo0FVC72kcF9TPXqdBneDnQMlh84kJ6oQYPI
vHm0QIsWdOfhswafwnGBnbdsoXcb8CfwccMdQJMmdH/gKewPwF6C2FYQuNbyfwSCiwFcrljby5Qp
1OxwqiHKzkFKCj12+PrBP9iyQC4K3s0H1FB2q7R1K20Igg8d9gdOAoQL8HGfPJl9Mp89I3PnErGZ
O1uiZD1u3LjVWQ2XnCxrbNu2bdCgQfwpFksQqBtwtYevEcoawplOnahh27alymOAZSDIBSlrauYh
d+D6dVo3QJp8oHpD5Ye4m9UuECiEWvBR8ltLQXYODrzqxJpBWNwEweaIEbwyIE3QJVRIqKhz5mT7
MYesIVzt1i27bQE+x2nTaEMBRPf8QFhRke4hqCdPTp0ir1/TqxFf1vxAFfYZ7rLBL+BciG1z13+I
3yG2hbgvR2sPX9Z8IKiEnYR7C9hO7plCO3fmtbGCZ1moKAhc8EDKcEFisoaLB/+y5+LC8xrIcefO
P0L+HJ8UWzhwgGoa/hw+EfAjeJ/QHGn0MOH24u1b2l4Bl1XWJAXvC9cqtmPsz+HyAOeKNfcz4YIo
4SqYA/j+CNZc8PXkydmR/qRJdA07pfyQHJ7CxmEN/IOYgJs5OSdwMQPgNMKn3LcvbyVEFdraf1yf
XF15cT3KuhiJiYlRV1ffDJfx7K8WR6Dp72Dbtm2/F7ytsGjAd7F2bamTNVQnvjKgwrDTDt9yCNMg
yAX/QmDFbpDBsOzGU0eHylSwGYQPVF1QPB/QNEQ6fMAyOX77Cgyk76ikRFs2YaFCBbpBiPj++48+
PX+eljEyIjdu8KJO2DjU4dywqHzdOl4Qzb3y06svKB5Ez1q6Qda9e/8hmhxNsXA1As6c4UW+cDbg
SsaAOs+uIsOG0asIbDwHoGC4jQBb5bCDisofRoZgnKXHASfCduBM5gDMyMpDuM3/qZZx7Rq9OWBN
JawubNjAuwrC5RbCdvbrZbVqpEcPegOR5ynif2Qg9P37eZeThw95ITmcc/iA2MmBOx5wHwPC+VGj
eLdN7M/hKfwVY+pU2gYC28lxhfj8mV6qBQERs68QawCB6yIAt1BwKuCE8K+Lnp70s4B/8HVibVk5
gD8JCaE/3gJHj1JBw+cOheFvzcwI/zcnWIBrEsq6eImLi/Pl/7SVS9bcqM7nN9zpoKyLHQgG4dYV
5Atqrl+fahqCPqiK3GnjKebmvOAaAk9W9yAQg3tkqBsQ5LKPCaJaiJpjY2mrLliDDwTCgn08IMiF
a4Czc97CFfzEwbPMFBcu0FrNaNWKvguEY8y8/O8DKID/tyB0CPHAd/Dn3ByN9BHcCqEiHCD7UQto
2pTeg/M16u9Prwdw5YC4+84deusAoSv7SZBwfxzjN9bD9Qb2ge3bjx9/NF+cOEHVkCMDMNyr8TsX
wbnlx5VwJmE7cCvAGpEgjOVrCEKWT5/oW/OFC58IXCrgcgJng3XgsbamVoWNsOsZfEb8iyJIGa5J
7JIAuuTfiMjL0zMAATI7V/Pm8T4FiK9hgdm/Tx96HuDmCTYOJoWrAvtcHjygbwpy51/Ox4/PbnaH
zcIlP0d7BQAy3bqVd/8EnxccJrwpU/zVq9ntjXAS4FTk0HqeQNAAtztwiXJ0pKED/CF8TCBr+DjA
y+z2C75y7MaIXVlZMz3KumQPjCPyQ5NCWYOR4S4SBATfe7gBZy0YIDu4zYSvPjgCfASVCl4C0cBN
MSjJy4uWAUd06kT/CuoY2BnEBwpetIgGrfz7WfAj/EnHjn/87AaFQVh55t7S1c1eBltxszD+cVcL
RoPImhl2+XLeD48sUu7Xj3dVgD+EN4UdGziQGoRdWiCehZVwmGAxZnC49wf1c5M40gJgWPgTOCL2
cyjoEnYbwl72XnCB4fdCgQsS7AM8Aps20UZw/vqxY+lZAlOw+JfQrvv0HSHO5V/2+JeHuDi6HdZC
YmND7yQYCQm0YRf2BG5K+IEq6wcCHwocFFxZIX6Ev4U9tLKiZeBaJRjOg47h2sl+woWj5l/qwG7t
2tF+O3DhgdOlpUU/VthVeEd20wC8e0d9zSJuKDxkCG32hY8M4m6WNR4+O7iSwUUXgl/Bq3K9enn8
Igoa5WaipxuBgBo+X/5PxKam2UfH+tj8NRSDjwA+Jvhasv6LLHCGQwBTw1cOtgZXAjgn8IVh1yfW
51KsnFYWFREeHj5s2LARI0Z4C+/pWQqyhrtI+M5JW2RdRoG74wJ2+C3RL0yefWAKC1zV+EotXiAS
F2yGKiF8fOgPiYhEyrpLly4PuPTu3Ts5z9+LSkPWXx892icrm93PARFn4LZaBL855w/cMRTLOAC4
eecPaSnusKhkz8CvX7Tn+IQJ2YOGCsO+ffs+5u5sjrIWK+rVqxfJ7d3Zs2fP+Nw/iHMpl+OXqxLm
y5cvHbt0gSvEaNZlDUGQkmT69OlQ3dq0afMWbixQ1mLLmTNnxo8fb2FhsZf9nsudm/HAgQNHs7h8
+bKII+s/RjCyUbwIgpQMBw8e5Fe3voJDXlHW4kb37t3ZAiibJQC5ffv20qVLzbPYvHmziGXt4OBQ
vXp1eNOWHE7opk1YnRCk5Pj8+XNn7o1sVQ7nXI4eiihrsaJW1m/oPXr0ENYhT8TNIIDj1auaw4e/
kZGh3X5zD4FFEKT4+BIeriknd659e954d5S1eOLp6cnugDYJj2FLoTcIAyJ9eOsaNQhOmo4gJcqg
QQRkLZLkPyjrkjwwTukdmp8f9XXr1nQQF4IgJUT//nTEZu4sgyhrlHUhsLOjvmajKhAEQVmjrMVU
1oQ7hJqfUQxBEJQ1ylpMZU24OZ1VVEp/8AWCoKxR1ijrAlG0OTUQBBFGZiadC6J16+wMjihrlPW/
EhZGs9Dx0yIjCFIsrF1L0xwKGcOMskZZF56oKNrBCPZHbCZzQxBJIDlZfKZxQVlLhKwJNw99y5bU
1y4uWMUQBEFZi6usCTfrrpwcncqEP6ccgiD/ws6ddMqCpCSUNcq6uLlzh8q6WTOa4R5BkH8hI4NO
BwE3rPgDI8q6RDh/njaGtGiBdQ1B/hXsuoeyLlkOHKC+7tAB6xqCoKxR1mIsa8Kdo2/gwOx5+RAE
QVmjrMUUNt2nkDnJEARBWUuCrNu3b1+zZs06XNLZNMxlTtaEO1hGUzN73nsEQVDWEibrSpUqsYUu
XbokCOkVL/rJBwrN79+0MQQuKnv2YL1DEJS1BMqa8fDhw/nz52dw0yS9fPnSzs7udBbOzs5lILIm
3JwhEFzDrp47h1UPQQpBZibp3ZvmBvn+HWUt7mzYsMEua/q1mzdvmpiYLM3CysqqbMgaiI8nNWsS
WVk4BqyACFIILCzI7NmYG0TcSUtLAzv7+voKK1AGmkH4PH9Og2slJZxZBkEKQVISiYuTnsMtq7J+
9uzZnDlzIoXPlVlmImuGnx+pVImOb2S9RBAEQSRD1k+ePDl27Fh+B8Ypa4fm4kLj68aN8UuJIAVi
1y5ibo65Qcr+gXHK4KHZ2RFDQxwsgyB/B3ODoKxLmZQUrIYIUiCw6x7KupT59YtOVmBigpURQVDW
KGsxJjqaTgMG+79tG9ZHBEFZo6zFmG/fSL9+1NdHj2KVRBCUNcpajElPJ4qK1NdublgrEQRljbIW
Y379InXr0sGNOBMYgqCsUdZiTVAQqVOHxtehoVg3ESQbzA2CshY7IKyWkSENGpDUVKyhCJKNuTmZ
NUt6RpyjrMsC7u5k4kSsmwjyB4mJNM+w1ICyLlPg4EYEkVZQ1mWH2FjaSKenh99aBKHs3k2zpGJu
EJS12JGQQCZNoj82LluG9RSRdjA3SFlh7969SkpKysrKqUJ+dpPMZpD4eNpdCQ7NxgZrKyLtYNc9
8efSpUubN28mtPdOphRF1nzq1qW+PnkSayuCskZZizVGRkYfPny4du3aB+FTq5SlmWIKC9xM1K9P
fX3hAlZYBGWNshZfunTpMmXKFAsLi/3797Pg2tnZefLkyTOyWLRokSRH1oQ7E1ijRtTXjx9jnUVQ
1ijrv1C/fn1zc3MfH5/GjRt/+vRJNHv8+fPnli1bsmUnJ6c0bm+2kJAQBwcH5yxglyRc1sDt27yZ
G6VmwlAEQVkXEW1tbVCnkZGRnZ1d7dq1RbPH79+/b9asWSqXrVu3pgjJ1i/JzSB8vLyIgQHWWQRl
jbL+C02aNBk+fPi+fftOnDixZ88eke00BNStWrXq06fPjRs3hB6YxEfWgsBtDcbXiFSBuUEKRUxM
zJYtWzIyMsCe8vLy4nVg0iPrnz9p8utx47D+ItLFqlVk5kzMDZIfHh4eDRs2bN68ubq6upqaGgS5
PXr0qFixIsq6dEhPJ0ZGtP16yRKsv4gUkZBAh/VKDUUxmp2d3YYNG2Bh9erVgYGBsHD48OEDBw6g
rEsTNrjRygqrMIKgrPMTorjJUepkDfTtS329fz9+rRGpYO9esnYt5gYpENra2sOGDVu4cKGmpuYy
MUtYIY2yhrvCdu2or52csCIjEk5GBunRg7RogblBCsqDBw8ePXoUEBCgpaWFsi593r4ljRtTX796
hdUZkXCw695fOXz48MaNG5kQK1eu/N9//1WqVElWVhZlLRYEB/Nm2o2IwOqMoKwxsqZMnjyZvzx0
6FCUtbjw9CkOlkFQ1ijrbL59+2ZkZDRv3jx4FLsDk2ZZ8wkNpVMfIQjKWspl3aBBg127drm5uVlZ
WXXt2hVlLV58+UJ69aI/wiAIylrKZY1d98SdJUto47WY/faLIChrUctaRUXFxsbGw8PD0tJSXV0d
ZS2OLF5MfT1zJp4JRKLA3CCFYsyYMUuXLp0zZw62WYs1bHAjd9ApgkgOK1bQRAuYG6Qg7Nu3j79s
IGbdD1DW2SQlEU1N6uvTp/FkIJJDfDyJiZGew/3XNuty5crJysrCgoyMjMh2Oj09nZNFcnIyyvrv
/PhB1NWpr2/dwpOBIFIn64kTJ/KXdXR0RLbTCQkJqqqq+ZeRiskHCkVkJOnQgfpamhKVIZLM/v00
c5mQcA1lneMuJH7BggWBgYG7du2KE2HLEUTTEDibmpr6+fmxNa6urjNmzJifxfLlyzGyzoPnz8nK
lUT4lPAIUmbA3CCFQk1NbdasWVu3bg0JCenUqZMo99vJycne3h52gDWDBAUFnT9//nIWnp6eKOv8
+PqVcOeuRJAyDHbdKzi1atXatm2blZUVBNeKiooi2+nU1FS20LRp09+/f+dZBptBhBIeTlRV6XgZ
BEFZS4msMzMzIbZt167dX1uQi/sz6m9ubm5nZ9eyZUthE+ZiZJ0fGzbQxutRo/BMIChrqZD1qlWr
+MsXLlwQ2U6DoC0sLAwNDe/duyf0wFDW+WNhQX1tYoJnAkFZS7Ksra2tVVRUQIidO3duy6VBgwbi
dWAo678yfjz19ebNeCYQlHXZlvWZM2dAebGxsaqqqurq6j8ETkpSUtLv37/r169PuH1CkpOT08Ts
ByuUdYHo0QPO1HEdHWtUNoKyLruyvnbt2v79+729vSdMmGBjY3Po0KEcBR49evT69eu4uDg3N7eM
jAyUddkjMvJomzZseNH69esz0tKWLVs2atSoTOzeh4g5mBtEEF9f3yFDhsjJyUHg3KNHD3d39xwF
ypcvf/jw4bVr10Lora+vj7Iuc7z79KmBsjKTdQUOZ5SGRjnueNSpU6f+/PkTzw8i1ixbRqZNI0L6
g0mXrC9fvmxqaurv78+Wv+e6gikqKrq4uJiZmQUHB2/atAllXeaA+6EDBw4wWU/ncJpnDeIHZd++
fRvPDyLWxMWRqCjpOdz8jBYeHm5vb89GnVy4cOHIkSM5CrB6/uDBg379+uEPjGUX+BxXrFwJCz6u
roqVK8OpO79/P54WBCkzst63bx/U25YtWzZr1gwWdu3alTsue/z4sbe39/3798XuwFDWRcL77t2L
Fy/ieUDKRJRBrK0xNwglICDgW9a4eycnpy1btuQooK2tPXjw4Llz5/bu3XummKW3R1kjiCSDuUH+
CLK8vdu3b9+uXbtOnTpVqVJl586d+QgRp/VCEESkYNc9Pnv37l2xYgUsxMTE2NraBgYG5hbix48f
YeHZs2eysrIoawRBUNalIOvExMT79+97enq6ubkNGjTo6NGjOQo8efKkEZeGDRtGidnPsihrBEFZ
S4ust23bVr16dWNjYwMDg3379uUeKOHh4eHq6goLp0+ffv/+PcoaQRCUdSnI+suXL0lJSfkUqFKl
yps3b2DBz89PQ0MDZY0gCMq6FGQdHx+vo6PDRkn07t07Ojo6R4GKFSsyWT98+BBicJQ1giAo61KQ
9Y4dO/gd8hYtWrR27drcZfr166eiogIqf/funSj3G64cI0eOBCMLi/1R1ggiybDcIMrKmBuEYmNj
Y2Zmxpatra2trKzY8v37929xJ8levXr1pk2btm/fvnPnThHL8dSpUydOnGjfvj2E/3kWEOVs6wiC
lAJgJ0NDzA1Cef/+fZ8+fVi6atDi8+fP2fqQkJCAgAAWvV6/fv3cuXOOjo6ilHVmZiabTB12jMna
1ta2efPm/8tCTU0NI2sEkXBA05GR0nO4+Rnt9OnTEDgnJibGxsbCY+4Cgk0fCQkJIttpCwuLw4cP
w4KysjKbgxHe/du3bz+yINgMgiCI9MjawcGhRo0aoEX2K6Igr1+/9vf3ByE+efLk5s2bfn5+bdq0
EdlO9+/fv3Hjxq1atYIdWLx4cd4HhrJGEMnG1pasX4+5QbKBsNrS0hKcyG8GIdwm40mTJsnIyMyb
N8/AwEBfX9/GxkbEu/7+/Xswsrm5OcoaQaQOzA0iiKen57Nnz/bv3z9gwICDBw9+/vxZrIT44sWL
ixcvnj17FmWNINIIdt0TuMmwhdj5+PHjwqbscnR0BGOy5Xbt2onXgaGsEQRlLSWydnBwWL169Zs3
b3x9fTdt2nTp0qXcQmzRokW9evXq1q2LWfcQBEFZl46snzx5MmzYMLCeiYnJyJEjPT09cxTYsWMH
f9nCwgJljSAIyroUZL1169ajR48qKioS7qwxx48fz1EgICBARUWlc+fOysrKouy6h7JGEARlnc33
7981NDRsbW1BfGDk8PDw3EL09/f//fu3h4dHtWrVUNYIgqCsRSrrZ8+ePXz4sFBCxDZrBEFER2Ym
6dMHc4NQ023ZsuXt27erVq1atGiRsD/u2bOnvr6+paXliBEjYAFljSCI6FiyhEydKu25QeTl5eHx
169fTZs25edyyk16evqVK1dOnjzp6OgodgeGskYQySY2FiQlPYebt9EUFBTYwujRo1+/fg0Lx48f
F+z7wZg2bZqRkRHhJko9d+4cyhpBEESkslZSUqpTp07t2rWVlZUbNmxYr149cN/27dvzEaK4pSRF
WSOIhHP4MNm4kaSkSLWsly9fnmNNQEAAy2EtiKmp6cyZM1evXj1+/PhVq1ahrBEEERGYG6Sw3Lt3
z83NzcvLS+wODGWNIJINdt0rOOfPnwcnVq1aFR75SUJQ1giCoKzFS9Z8ISYlJYlSjpcuXRo0aJCs
rOykSZNQ1giCskZZFyJ6FaUct2zZwhZq1KghbA5GlDWCoKxR1jwMDQ2bNGnSs2fP2rVrb9q0SZT7
/eTJE01NTTs7O2EFIO7GLzOCoKxR1jwiIiK+fv0KjyLe78zMzIsXLy5btow9tba25gggIyODkTWC
oKxR1jw6duxoYmICC0OHDs3d26/k+PjxI1to2LDhbyGDTTGyRhBJBnODFO6PS6nN2sbGZv369cbG
xl27dk1PT//rviEIIoGYmpLJk6U9N0gBOXv2rLq6uoaGhoqKio+Pj8h2Oikp6eLFi4cOHXr79m1B
LiQIgkggMTHk50/pOdx/NVp0dPRP7vn63//+J14HhrJGEARlzRdi3bp169WrJy8v36VLF5Q1giAi
4/vevWnbtpHUVJT139m4cSNbgOCapd9DWSMIIgLu37/fisPZ1LAh/sBYIIYNG9a9e/devXo1aNBg
zZo1KGsEQUTAw+Dg2nXrQh0vx+GsW7sWZV0gISYmJn7nInYHhrJGEMkjNJTMmHGsWjX+oIqBgwej
rIUSHR3t6+vr4+Pz4cMHf3//R48evXjxAudgRBCk2EhKorlP370jDg5k/nzSvTsJCqLrr16Fuk0a
Nz7UsSPU8fE1a2Z+/YqyFsq+ffsUFRX19PR0uYwfPx6WUdYIgvyroO/fJ+fPEwsLMmIEadiQehn+
ycuTRo3I8+e0TGIi4c5dBVxv2/a7mpr0zOxVFKOFhoaGh4fnWHn58mWUNYIghSMwkBw9St6/p8sP
H5Jq1XiCrl6d6OgQS0vi5EQePyYgnMzMnH87aBAONy8onz9/Hjt2rJgeGMoaQcSQjAzi7EwHH0JQ
XL48T81WVvQl0O6uXRD30QaQ+HgiZHByNpgb5K9cu3aNNe3Hx8fDY+3ateHxKFweUdYIgvBJS6Mm
jY3lidjIiKdm9k9JibRuTRYtIqdPk6ioQm8cc4MUhLCwsGXLlkVFRcXGxtra2oqnHFHWCFIKhIaS
Bw9o7LxlC5k4kTRtStgMIRERxMCADB5MliwhR46QO3dIrqbUQgOi19PjXQxQ1nmyf//+rVu35liJ
s5sjiPTi6UkWLCCamnQG24oVebFzvXq0WfnwYV6ZpCTaBlKMREdLT1hNitwbZNy4cYJrPn78iJE1
gkgRbm40Rp45k/d0yBCeoNu3JwsXEldX2kkjIYG2hCClKOuMjIzhw4fr6ek9e/bs8ePH586dk5OT
CwsLE9lOJycn+/r6+vn5RQlv6kJZI0jxEBdHGzd8fMj69bQdQ1Y2u90ZgmjGjx+l8EPf8eO0sSUl
BWX9F1+bmpqOGjVq7NixIO6HDx+KcqdHjx6tpqamqamppaWVkdeNVWJiIsoaQYoIBMVPnpBLl3hP
wdFMzTIypGVLMnQomTeP2NkRX9/SzSXtr6wcgz8wijmnTp1iCx06dIiDy/6fxMfH6+jogKw/fPiA
9Q5BCsSXL+SaE1m3jgwfTtq1I5X/o3ZOSKQveXkRs2Xk7Fni/4iEfirmdueicvnKlUocztwmTbDr
XhkgPDz8CVz/ufDnYJSVlS1fvjxbbtSgUYD/C6yGCCI8On1Ohg3nDkWRyW7c0OhNLDYS51tiu9eu
jjf4uUEMDAxQ1mJNcHDwo0eP8nxp9OjR7FOs2bpu9+dTe5EFPcg89q87matFTPklx5E13cgc/qv8
Mn3IAn6ZicRanczOUUaDzIV//DJTyIY8y6gRY36ZaWRz1zzKzOtMZvHLzCLbuxLj3GW6CJSZR2zU
8y4zk19mAdn71/daQg7kWQbeK4PwhootJ4eF7U8K4SURXk2OCisTT5JYmbXkeO4yPbhlYgjvxmg9
OZ17f1iZnySGldlCzqkJ2U4E4f16sYNcyvO91MisMMILwfaQK0L2x/gj4U39vJ9cFfZeIYT388xh
4qyW1z7DewWSUFbGjrgI258X5B0rc5p4CHkv4yckhJW5QDzV8t6O8UPCG35tT7xhswKvmvQgy3qQ
JWop03x+epGPX4jbzcDlE506ccI5nJk3tNqTpeZOo9Nr14ztpHLLtO+nq4dJDG3WuE7eq5HlPYhZ
DzKfu535bAHe6yZ5zN7LnfgL2x83wmsU9SRPuvyxP9llnIkvK+NNXqjlVQZOmgO5x8r4kleC79WL
LFR3naAgw4vJ5s6ejbIW5zu2L6yV/MqVK6m5Uo/HxsaOGTMGPsWI8AiCIFIL1IzLN8m6PWTMNNKs
dVbgLENaqJB+2uT+S16xpOSyeHA3brhU53CWNGsmPTN7lUlZKysrd+7cedCgQWwUZe4C6enp+AMj
InW8e0fHapuaEnd3+jQqiifo//4j/fqRxYshuiF+fuTDB8noQRGgphbfuTPKWqz5+PHjWy75/ISI
skakArjF3LGD5jyqXJmUK8ezs54e79V796C20DF+Etm/beBAzA0iEQeGskYkDHDu58+EP6ChadPs
nwSrVaN5NiZPpsMF376VirOBuUFQ1ggiLkRE0PzOly+T/fuJsTGBW374Vrdrx3vVxISOITxzhmYQ
TUqSxvOzYAFNPIK5QVDWCFJqHDtGBgwgbdsSBQVe7KyoSO/6LSyIhweeHh5RUTSZqtSAskaQ0sbX
l6xdS/M7q6vz7DNoEBV08+Z0rKCjI01QB/Fjro5PiFSBskYQ0RIXR3/3276d5tkQzO9cqRLNpi/C
HDtlnuPHybZt0nMNQ1kjSEkCEXFAALl2jSbTiOB2/D95kmfnunVJ375k1iyyZw+5eVN6uqAVDxkZ
REOD3nxITUsIyhpBipvv36l8N24kurq0caNWLZ6dXV3pq6Dsw4fJ7dt0uu5cmW2QQoDTeqGsEaSI
BAfTzs6CSUQhfAZlHzxIZ4bF5M4oa5Q1yhoRESBcCIe/fqWjUXbvJoaGdB5u+LKtX09f/fmTdOxI
xwqeOEEw6SPKGmWNskZKR9Pbt5MJE2ifDX7gXKcObXeeM4c8fYpnCGWNskZZIyInLIw4OZHVq+lI
7gMH6JrYWGpneXkq63nz6O+E9+6R169JYiKeLZQ1yhpljYgQMO/hw3TsCcTLcnLZ4TMEzpnctLHf
vtFZVNDOKGuUdQFJTEz88OHDz3y7OqGsEaFkZND5qMC89+/TsdqEO/F2ly7Z8wo2aULGjKFN0iEh
eLbEFMwNUiYIDQ2dOnXqHIh3UNZIAYGI+OVLXp4NQ0PSqRNt0IAvibo6ieFObnDtGrG0JA4ONFkS
UiaYP5/+hIC5QcQcFxcXY2NjlDWSH9HRvIUDB4iKCqlZkxc7V6lCM28sX87LgpSejqeqTBIZyRtn
hLIWZ65evTo73+l85CFuQqSQ589p84W2Ns18BFL+8oWu3LGD1KhBRo6keTY+fqQJgJKT8VQhKOtS
kPW6desglJbJQkFBgfMnTZo0wQ9bMvn6lezdS2+HWbMG+1e5Mh2IDPdeOERQgjlxgl6GMTeImOPp
6bl48eJ8CuTwtbq6On63JaFZ480b2qy8fTsxMiKfPtGVdnbUzkpKpGdPMm0a2byZXL9Ob5ARyQZz
g5QJhgwZ0qpVq//++09DQyNVyHVVXl5eUNa9e/fGr3eZ5OdPcuMGHR84Zgzp1o3Ur58dPvtyZ8hm
iTieP6cdPBCpArvuiT8BAQGvX78OCQl5KnzYWA5Zw9PmzZtDuB2H98XiD4TMLI2Gnx9p0OCPPKLD
h9Ow+sED2vqBPwyirFHWEoCMjEzr1i2qVWvF4fzRHoKyFq87WQiHIyKIvz85coQ2MTdsyJOytTUv
rN66lezcSVs/EARlLamyhse9e6HijxKUdXx8PH7JS5OoKF6/5thYsmIFnVGQHzXXqkV69aLtzhA7
s/ZoBEFZS7ysWT/rzZthYRDKupSBuxlXV2JlxRuNoq9PV0ZG8qYZnDOHHDpE3N1pElEcyY2grKVN
1uXK0UNbsgRk3VlQ1jEsrENKms+faT+N4cNJo0Z0wip++FyuHFm5klcGgmupGX6GoKxR1nkjI0MP
bcwYwkYyHjtGF1geCKSYgXD41y+ad//sWRo+M1geUdB0gwZkyBCybx+d9RVBiguWG0RFBXODlHlk
ZTns0stk7eJCF65exe94cZCSQjPr371Lh2tDmNy7N01+xALnmjV5ZR48IM7OOCYFKUHmzaOz8EjN
vbLEylpenpOaSpo25cn66VO6sGsXfsHz4MmTJx4eHrmXczZrgJ0Ze/Zkd9uAfxoaZNEievNy6xbN
MoogogHu575+lZ7DlVhZV6jA+fGDmqR+ffr00SO6nG82ESklNDS0VatW8vLyrwIDo2JiWrduLScn
5//8OX0tJIQ2X+jo0JPIBnMzF8N9ytix5OhROm833IQmJOBpRBCUdRFRUODAnTpLHA/4+9NlPT38
xP/gfVhY/ebN+b++VshaKMfh3OEHzqDpBg3I0KG8CVMQREw4dYrY2GBuEEmQ9cePVDUmJvRpYCAv
yk5Jwe94NjF+fjOaNGGCHqKkZFivHlvWadTo06RJNL+zszN2eUbEEcwNIjFUrMj5/JkK+tAh+jQ8
nP5uDE+xI282J0+SunVTORzD+vX79u+f9PgxCQiYNnlynz59fuOIQUT8wa57kkGVKuWfP6d29ven
T3//pk2v8BS7J2SzdSs9I5cuJUVH/84aK5SUnPwbMyIhKGvhvHv3Lv85BVHWhaBTp06CA2ESEuLg
nklPj6qphH4Me/v27ScuoaGhX1jCe/EEvmSmpjQRMIKgrIvEzp07NTQ0IkQ+SY1kynro0KGCsk5K
om0f5uZU1r9+lcx5FEBRUVEcTwrEzufP08lT4Cxs3Ig1HUFZF5kjR46AZL6KtuOgpMk6JCRk6tSp
9evXF7RnMncOp4MHqaZK6Ncywbdr2bKFOJyKHz9+mJubJyYl0Sfu7rwBQt260ezP+DMrgrL+N/bu
3duzZ89UEfZFkTRZ37lzh5MLWF+jhlKNGi04nBa1ajXU1R1borKWkWnZvDlp0YIOydHSoukxtmzh
JcoXJV26dIGd6aGtTaZM4XXCO3SIDtJFEMlg4EDSoUP2tMgi59SpU6qqqiLztaTJ+t69e7llHRAQ
IPhURUXl+/fvQcXE69evf/78+ecb1uRwYM0HDucLh/ODw4njcNI4nEzBHPo9e5KFC8nly3T61i9f
SFgY/EsPC0sMC/sRFvYxLOxNWFjQ589BoaFBHz4EvX8fFBICb1TQXYKjq1atGn9v/sfh/NLSCnr5
MigioiAbCoV3RRBx5s2boMDAeDW15GbNgn186Le6FHbhTUREBNy8du7c+ZNIurdKuKzhujd9+vQh
Q4YIrqxcuTKs0Sw+tLQ0J0/Wb9lSn8PRHzdOf8oUXX19LX39Wfr61vr6x/X1/fT1I/X10yZNoj1S
VFVJ48Z/TH6S9e83h/OKw7HjcOZy07r243A04Z+SkmaDBppqaprDhmmOG6c5dqzmqFGaw4drDh6s
2b+/sP3RGjUqO4v3ag5ngoJC3549NUeM0NTWzv9YWHM/PGoiiLjST1NTu39/fzW1kA4dxmhr9yml
3dDR0Wnbti3UF0dHR5R1obl165agl5cuXZq7maJHjx7F/r5JSaROHercv7YGf/hAB2kfOUJOn6bN
EkeP0kYSfX2ahV9wfkH2T1GRJnzu1o3mq1m0iCbrhwOCv3V1/Xvju4WFBRzsNhMTUqMGb/jm7dsF
ORZZWVm8w0bKAL9/l3ona21t7auiyg8nabJOSkoKDAyMiooC4/z48YPfHVJQ1srKjYv9fUNDqQ/B
uUWbFzA1lebi//aNTl/19i3NNrptG80pVq8eKV8+zzCcKCiQunVpszjE6WpqRFmZpldycCDcH1MZ
mckpofT/hAhibpqVdEmNBL74a/s7egBB/qqaZs2aOUCVExUSPPlAudwrhw2jvhI+y27RgVAXtnz5
cskeFFx6bGzIunWkSRMaiUPErKREU0bLyeUt9Natif5ksvcQcfUnH17Ffeuv94VTOZbDSZhtmsm9
BXB3vyp4GTMzM8sta7gPgEsI/Pv4kV5REERcOHuWRiilkRvk48ePLVq0uH79uijfVMKn9crBypVU
YatXF//btW9Pp0C5c6cUjhQMDj61sKDNI3p6xMiIjBtHW8YFk5gK/mvKea1e//PMKUknTsIJcReU
9S5uDlnB6xzcKMCh9evHG/8JtQNBxILSyw3y+PFjHR2dixcvitpp0iPrW7dctbT0OZyZVarMNDKa
9OLFi2J9O9rjE2JPMSE0lMDxubjQxGRwo2ZrS6cIX7GCNG9BmrQSdLeXoKy7d++upaUFC8bGxk5O
ToIb9PWlIx9z4OZGRo+mlwoAvroPH9KFwEBy/DhdmDuX2NvTfoNsgh4oBk+B7dvJyJEFbD9HEOGU
Uj/rCxcuHGIph1DWJSRra2trQTHdu3eveGUNVhJ/vn+nkfiHD+T9R/LuYaJZS2OOEFYKjHKMjCXD
R5HoP1OGvH9PDAzolAONG/PUDBcGwk12PWEC75w4O9OE2GvX0qc7dpBz54ijI9X0/fvwcdCmeQQp
c7JOS0srHadJj6w3b96cp5VmzJjxj++1YAEVE1NV2eJpwGP+eVAqX17wtFjBIdWuTfQmkpPH5+v9
cLsYQ0hSYgoJDCKvuDMQ3HD7YzKHRYuoiwl3sOTUqTxZE+4od3B3cjIZNYo+7dePmjo6mv58ihlK
kLIo61JzGsp61apV//hetWrRn/jc3MrYKfr161dAQEBKSoqWtnaLJk20atUSPC1rWrb8WqN6EIdz
naO9jmNCqlcnWj2e3Y7qqE7aNYsjb4NdHJJmLhSQtSlhjXgQOEPEzZc1MHYsbQkZOpQua2mRLl2I
piYdffbsGfoGQVmjrHPJmvU7zk379u2nTp2aUNR0fPB3lSvTqVTKHL25ENpd9ff/2rfvP3iw4Glp
2qKF+YK5t20OLBn1/c68ubZwPkd2A8PTvzy+nTSs4aNiNKPDA7Jvz5IltKVkwRqylTvFJYTbs2b9
IetLl2jPwitX6LKREa8rurMzCQpC3yAilXVGRoa5ufk5dg/IdcL48eNXrlz51z8MCQkZNGjQy5cv
i7an6enp69evHzFixLN/iFCkSNYskPzw4cOFCxdyKzsqKqpob7R3b/bkYWWLe/futWvXTvB0wSlq
1apVYGDg1q1bZ3PbOIzmcn+HLBfL4UTIcRIGDOb9JTGYktKo+QLOchnOx3WcqaRWuVd1tJpUj63R
jkzSJxMn/iHrdIHlmBgaaMONiL4+dgRESiGy/vnzZ4UKFUJDQ9kyfPN/FGwLw4cPP1vU7lBHjhyZ
MGGCjY0Nv8ahrPOTNR+4PCooKJT/s4k2pvAT2gv+efPmNcrcKYqPj2/Tpg1bhgvYwoULfXx8WCf/
IVzguM6csWUFVP/XkJC8Jm4IDyRHd5MxY0jjuqQCh8hmnfb168isccTJic4//TuakGR0C1KcZGaS
vn3p/E/fvxeh5hoYGERygwXWURVitXfv3sHCmzdvEhMTv337FhYWBnfbYPPMzMyP3G5eEICfOHEi
IiKCn7D+CxdYgJWfPn1i5dlLycnJIVwglufebs6GyBqbQQota8a4ceOKUdYQkJa5UxQdHc2XNWBl
ZaWhoQFf1rS0tGbNmuU4ja1atYyP/9ssO5G/aMc9xsyZdLA86yEI9aGHBu0KDrefN2+S8C+oGqQY
MDamUULhay4EahCxQXRCspIrnD59mpv4PklGRsbU1HTfvn3wFAIXCFns7e07deoEBTZu3LhgwYLx
48erqKh4enq+evVKT08PNAL367t374by58+ft7OzY28xcuRICKKVlZWNjIxiY2OrVKlSvXp1WEBZ
F0XWPXv2FLRtZOHvyQX/vHXr1mVa1suXL4enZ86cgXu9uLg4/noBWbeKK9SUaAkJVNyOjrSD99y5
pFOn7N7dw4bxyri6kuvXSWnMkIRIAj9+0HyVhQeMTOhsJObu7u5ycnJsJXznIUy5efMm6x7GypiZ
mdna2v7+/btFixbbt2/fv38/rAQpz5s3b86cOb169QKPz+G2gebIqMPfLKtB27ZtO/vPI8qkV9Zw
2xIcHLBnTxCHE2Rj8xxuq/5F1vxQtGzxv//9L8fpUlBQgFu5//77j9CMJan89YIxeFGA8Cc0lDx6
RCepYQMKPnwgjRpRdyspwdZpd79jx3AmdUQEsKaP+Ph4CE3433DQMTx6eXnNhJvCrDIQZbOMevD9
B1lf4f5K7uvrCyH2gAED7ty5A3ei8dz5S3Pkt6hWrZpgzVq/fv3Ro0dR1kWUNePlS6qL8+eL+BaV
KtXmcGorKSn17NmjLH5l4RA2bNgAy97e3uyqs3fvXni6Z88e9tTHxweeWlpawrK8vHwx78HjxzTR
SY8eBK4NgiPi69enQTc/Qk/G9m4kLy5cIBDqFnKISkpKCnyZU7h9kr5+/cqPiLW1tXft2rVw4UJd
XV0IpaEMBCsQWbOuvYqKihCJT506NSwszNjYGGoEuBse7e3tra2tISSH8qx5mlGlShWoO7du3apc
uTI8nTRpEj8DKMq6iLKGUA8KmpgU8V3U1QmmqCseIND29CSbN9P8Jioq5MwZujIggOaH7d4dLhd0
0JGXFx31iJOvI4SbGwS+GHBHW8jcICYmJv379zfJqvPnsyI1ELSenh7Id+DAgf369Rs6dOiSJUs8
PT3btm0L1u7evTvEMRYWFmpqarNmzWKuhxh8KncAGKyHbYK7+e8Cf9itWzd1dfWXL1+C3+HPu3bt
+uvfZoDllM16/WHLli3Ozs7FFVn37EmKMIIUvAF/q62NkV9xw72vpISF0ZGRqqrZQXeDBnREzZw5
ZNMmbOyWdnBQjPiTnp6+b9++WWzoxb/JOiSEJoxu0qQown32jNrjyBGsNCVJZiaJiqIpsiDu3rKF
DB6cLe5bt2gBf38ybRrZvZtwu14hKGuUtXjh5OQ0WyAzRVRU1Nu3bz9kwZqcCrId8ECfPrTiF2HW
zREjiIwM4TbqIqIF7oOeP+dN9HDq1B/t3Q0b0pRa9vbk82dSqO4rCMr6b0RERAg2TKOsc+Lv779n
zx5bW1t4fPToEVt59epVQVnb2dl16NChRxaampoFlDXU9+nTaR0vQg9I9ksYJrgofcLC6OgbMzPa
KRBqr5IST9y1akH1ogW+fKHt3aBvBGVdeC5cuMAW1q5dG51vWMfGSEuvrD09PVeuXGlpaQmPd7LS
++eQdW5YN8mCwMaLF2G6CTaPFyJe/PxJr5/nz5M1a+gPx2zExJIl9NNSUaGp/8Dp8OrTp6UywwhS
FmVd8InuFixYwDc7NoPw8PLyWrx48b+f37p1a9atq8rhqDZt2kpXd1zBd8DOjlb/0khBjhSely/p
LEFqatmtJeXK0RmOu3en/U+SkvAMSbOs/fz8KlSocOrUqRYtWmhpaaWnp0dFRbVp06Y/bJ87yhxk
0q9fPwsLCwUFhbS0tKdPnzZq1OgEN8MvBIUrVqzQ1dX19fUNCwuDAlDYycnJ0dGxd+/enTp1+l74
0fASJWs5OTlZWdmKFSvCeUkW8stgAWUtOLClbdu2Bd+HunVplWdToiBlibQ0mnJ72zbaKRA+woED
eX0Bp08nVavSKdGgEr57R1f+daZ6pBT5h9wguTE1NWW591avXm1mZmZgYPDp06dZXIjA6MT27dtH
RkZqa2uDr/v06ZOYmPjgwQNY+Pz5MxOOpaUl6wsIT1+8eKGhocFPJCK9kXVx3bkIyrpjx44F336l
SnT8HSIJdZ5wp5eHugpX6xo1sqNviLvh7u3UKTpbMCKGgElHjSpK34BcmJiY3Lhxg3AbXWH5zp07
qqqqKioqLH8IXyagCNZ5QUdHZ8CAAbDm7t27rKs1K7Nq1arj3AjOyspqwYIF8Co2g5SyrOHaCZvX
1cXqIlnExNAGE3t72olbX59OIM+szSZTgJB861Y6ZO7hQ+npLibWQExdTD8aQ2S9bNkyWLC1tYXI
ukOHDr6+vrdu3TI2NhaUiZqaWkJCArwKy2wYOkTWhoaGJGu4OYTnLLKGBTc3twYNGnz9+hVlXfyy
VlWt99fytWrV6tixnaJiOw5HuXv3EVhfJLm1JDKStod4eBA2t3JUVHZ7d7VqBGrskiXk9GnyBZMI
lnnA1OPHj69Tp079+vWDgoJA03Xr1t22bRsE1ykpKbBy3759x44dA0tUrFjx7NmzcnJyUJ4vkOfP
n7Nw+/Tp0+3atcvMzISnixYtGjZsWErxNaZJu6wZ8+fTOpjvIJs85N6qVTP8lksXycnU3WvWkEGD
SMWKf/TvPnaMV+bXL5rPhPUBR0oUuAeytSXFMX0tRNau/HQ0Yus0lDXhznwCxQcPFlrg3bt3cHfj
4eEhKGtlZWWsL1LNmzd0djILCzqz5NWrdM3bt7z+3UOG0PyCTk70uxUSkj2AHiku+LlBWFf6fyA6
OrpDhw6jR49GWZcBWRPaw4QOOhd2kYYbotwzgaGskZxERZG1a2m6144d/8hn0q8f/a0SB8QXL8XU
dS80NNTKysrc3DytOIJ0lHWJy7prV1qt1q3L+1U2c0QOFBUVsb4geQd90dE0j6CPD81nMnw4jQXg
6+XuTl+FlU2b0nwmdnak+H59QllLPChrHrdu0dq0YEHer9ra/iFrJ7i9RZCiceXKH43d8A9u0ebP
p5PmREbyuhIixSfrjIyMqVOnxsfHs8rLHwUNjB07Nq4kE8hMnz5dmIhat25dt27de/fuHS/wYA2U
teCf0Pg6zxawRYu2C8r61KlTWFOQf+LtW5o739SUGgdkraBAv3+ysrymkvv3ycWLNKFgWBjq+x9l
vWnTJiZE0DTrnydKcswgI0ilSpXg0dDQ8AXrboSyLjidO9P6cvv2HytjY+k4KQ7nubz85s2bd+3Z
sws+++DgYKwpSLEBAYKfHx0Oa2tLEhPpmkGDeH0EVVTonLCrVpGTJ+nEOjiospCyhqpqYWHBpsO+
cuXK3Llz+S9du3YNIuv09PQxY8ZcvHhxw4YNbIJzDw8PPT29T9wZ5s6cOTN69OhPXGDBy8uLTRwD
JCYmzp49e8eOHfb29vB0+/btc+bM+fr1a0pKyvz58+GqkMpNPsNE5O3tra+v/4Y7uurSpUvDhw+H
Kweb+svPz48NvUFZF4LLl2kFEZzW0tGRNG7Mi7jfv8fKgYiKL1/AJWTpUt6YePZPRoYOsJw2DU9P
wWXt7OzMn08rh6x///6toKAAsra0tOzfvz94uVWrVqB1eHrv3j1wa1BQkKmp6e3bt9n0jCNGjJgx
Y8bTp0/Zn48bN279+vVmZmYTJkxwdHSEknv37gV3g7KfPHnCH78uJyeXlpa2evVqHx+f8ePHg807
deoEe+Xk5MSfp7FWrVolLuvMzMzPnz9/+fLls/glnyyCrO/c+cHhRHXsGBUREZmUFMMytcE/WECQ
Usbfn46r7NWLTJjAW8M6emtr0znPfH1p8m6p6t9dsNwgEPYuyPolKoesAWVl5YyMjFu3brEUnvLy
8iEhIdy5VSvVq0eHyOnq6laoUIHJZMWKFecFZmuFUHro0KH379+H5S5duvCn7Hr58iXIF/6ETbwL
f/79+3d4Wrly5apVq378+BHCeVYSLhVsoYApQv9J1nDxady4cc+ePWHnrK2txeqjzKepKB+/C1Af
PqAmTWgtQBBxxMqKznCmrEzz1LCwonJlumbZMvLkiVScARMTAuLLNzeIi4sLP7J2d3dftGgRW37x
4kVCQkK7du0INx/IvHnzuJe/iiDr+fPnw/Lr169v3rwJcmPRMZM1G2LOl7Kfn5+mpiYE1KNGjXr2
7FlqaiqErZ07d3Z1dYWofNKkSWybP378YPlD3rx5A0E3SyoSERGhpKTENtWgQYMSl7Vg9MoR4cSx
7969Gz16NNyGCP6wK8i3b9+K9AOjIO2HDSvsVJwIInIgoHv8mFy6RPt3jxlDWrak1p4zh76UkkJT
CS5eTPsIQtARFSVhh+5y4sR3OPZ8ef/+/cqVK6O4x96yZcvq1atPmTIFYtuOHTsuWbIE6vmIESM6
deoEOo6NjYWnYGoQ9+DBg6dNmwbBcu/evc+ePQsh8MWLF6tUqdK9e3f+TDFgWFtbWyjg4OAA8XWv
Xr0mTJgAobednV3fvn0PHjwIL1lZWcE2IZw3NTUdNGgQFEhMTOzTp4+Ojs7u3bvhJTc3N7B8AX/2
LB5Zs24xIvuQ4G7i8OHDly9fhluVpFzJiOGSpa6uzgbsF1nWysrt0QNIGSM5hXz/RYLekJ9cL0fF
EnkFXtAtK0fzd/foQRYvIVccyPcy3zf5yJEjUE8nTp78174yW7nAwu3bt8GqXl5eEORB5BsWFgZP
79696+vrC48QaEPYCxF3ZGQkFGBd+j58+PDlyxeIiCHivnfvHoTSfFlD6A02f5x1tXjKJZ3bDOXv
7w8bCQ4OhlcfPHgAOo6JiYFtst854X0hZofrB7w7FICLRwE7LPyTYeGmAM4XqBMeYddF/4HB1Q9O
seAaOB1wnWTClZOXc7zjHEsSf5Bo9u879192UEJivpMoWP+TxCaQNEFZq6i0zioTy8rk+PeNZMcp
kULLRBaqTBT5XSxloklcsZSJIfH/UCb7/MQK304mycwqkyBsO/wyv4WXySAZBS8TRxKFlUkvQJk0
wmsXjidJ3wpQRth2UglvvFyC8O0IlEkWViYlq0wiSftGfv8gCT/oYzT3Mf1H3JdvDnYp82eTNm3B
2qkcTiKHk8HhRNnt+UZSY5J+ES/vjNiYxOQ4/j5D+MPdTmzu90omvOl1kkmKsP1JIilZZVL/pUwi
4aWqT/mzTDxJ2X08e9zDYB2dv4pi6dKlqWI5MdD169dZatYSlzUE1PBO7u7u8JYldzxwvTp06NDx
48fh8ZnAjIdwDWRXKgCCaHj11KlTNjY2NWvWZJ/i/3p1mvx29RSyUZ+sZ/8mkXXTyRb+FhaRfROJ
NayfTDZMJVuG9Bg4ggvcpPA70ywlB1gZwX96ZB38429nBTk0kVjlLjOeWPLLrCZHJ+Qqo0/W6ZK1
/DKW5LiQMtnbWUdO5VVmveB2NpKzeZYZJ1BmK7kgbDsZWXLcSeyFlLHkS2QPuSKsDL+y7SeOE4hl
nu8VR3jX2kPESdj+RJPfrMxRcmO8kPeCyy0rc4K45bkd+Cz4148z5KaQ/bH8Qn6yMueJ53gh+xxK
eK1j9sRrvJD3ek/CeQENuSdsf4IJ72d5J+Ir5L0sg0go75afPMizDKx8SXgdldzJo1xl4Mu/eTzZ
/pTwfv5699jpzkHjX0a6a9+tHk227z47Lp3DieNwfBpwwsf2JVu3E8+73gFnxv800Scb9MmmrI1s
Yu91nwSy7fiSAGH740NesjIPSJBu3mWsvAivIj8iwXluB07aLcJreX9G3gqWmUI2Tb6/ol6tuqya
W65eLSU3Tv8k627dukEMb2VlNXr06An8H6mLGw8PD1NT0xUrVsDjrVu32Eq4o3knkGnB09OTlTE3
N9+5cyfsDHyKCXGYPQdB8uVbDG0V2bCRTJxM2qjy2kwqKZLOfYmOLmFNjJmEiN/EZ37377fgcDa0
bk2yumGgrAvUZk1E+wOjn58fS+kNUo4Xks9MlPuDIGWetDQ61zAEQJ6etC8gdyQYryPgpk20vbtf
P7JiBR0rX5LjswtFRM+eqR070t1GWQsjNTU1IiIiJiZm+/btr169io6OvnHjRvXq1UW20/Be4OJy
5crBo7Dc3ihrBCkeQND8SXP4/7p1o/PEu7iU5o4NGICJnP4CS0HXrVs3bW3tgQMH9uzZU11dPTY2
VrwODGWNIMVLcDDNWDJnDo27mzWjo+H5tezcOdp30N2dPHsmulSCmHXvr0A0zQa5x8fHm5qahoeH
Hzx4MCwsDGWNINIC1Pc7d3hJXwlNR8SLuCtUoAIdO5ZYW1Ozg7tLLp8JyrrgtG3bdsmSJVu2bPn+
/bu4ZeJHWSOI6Pj5kwQF0TyCxsa0zaR8+ewGkyFDeGU+fy5mcaOsC06zZs0sLS1XrFhx9+7dxo0b
o6wRBOGRnk7c3OiI8CNH6NPgYNpywvTdqxfNHA9x969f9IfNouWALVhuEJR1NsOHD+/Vq9egQYPE
7sBQ1ggiPkBM7exMFi4kvXvTnDuystlznmlrE29vnn+jokjBR69Mn05n4ck3NwjKmseFCxfOcjOK
2tjYvHz5EmWNIMjf+fSJtncfP05zTg0ZQqpWpYm8Cf01jLZsDBtG5yAGsTx9SqeTz4e4OKmaF+2f
jMay/8FCSEhIx44dUdYIghSOhATqbpY0IjiY17+b/atYkaaT19Li9TPJFXEfPHIkNDwcZV0g6tev
f/fu3ejoaCcnp2bNmqGsEQQpBiAEhMjayIg39wf75+XFi8p37QKtz5k/n+bGbNUqVGrmjP9Xo+nq
6vbt23fs2LGRkZEoawRBihkIqH18aJZXluLVyQnq9kGBnGt9+/VDWf+d169fL168eM2aNcuXL+/S
pQvKGkGQkiUujri4hB440EFFBep4FQ7n1KFDKOu/06BBg2HDhhkZGd27d+/YsWMoawRBRMOnDx/6
yMmdUlXFRE4Fonbt2vb29rq6uh4eHo0aNUJZIwgiOgYOJB06YCKnAvHy5ctVq1YdOnRIXV39xIkT
KGsEQUQHjmD8K8+ePZsyZYqhoeGcOXMWcVmxYoW4yRFljSAoa2mX9d69e0eOHHn37t2bN296enre
vn374cOHopTjjx8/xo4dq6SkdObMGZQ1gqCsUdZ/Jz4+PiEhITExUZQ7PXDgwOjo6JiYmP/++0/Y
5APlypXDLzOCSCwsN0ibNpgbpEAYGBjUrl27c+fOVapUYfMHiwyQ9enTp42Njdl0wgEBASdPnjyX
hYuLC0bWCCLhTJtGhg7F3CAF+2ORTOt15cqViRMnGhoawuPVq1fZyvfv3+vq6trZ2bGnHh4ec+fO
Nc3CwsICZY0gEk5EBPn4UXoO95+MZmtrm5GRAQt3797dvHkzLKxfv/758+fFu4shISHOzs6urq7w
+PbtW8GXunXrlpCQkOdfYTMIgiAo6+xoWkZGRk5ODsyooKAgLy8Pax4+fFjSO21mZhYWFhYcHFyt
WjVhzeUYWSOIhOPsTE6d4s3qi7LOk8+fP1+6dCkyMnLGjBk5Xtq9e/erV69K/u4nYuDAgS1atLh4
8WI+FxL8MiOIxAL39N26kaZNaWMIyloYT58+NTY2nj9//tKlS2fNmrVp06av4pdVFmWNIBIOdt3j
c/369UqVKsXFxU2aNElfXz/lz/nTPn36dOfOnRs3bhw7dmzw4MGjRo1CWSMIgrIuBVmDiCFqDg8P
b9++vZmZmY2NTe4ySUlJiYmJaWlpOIIRQRCUdenI+tq1a7q6upUrV05OTjYxMfH3989RQE9Pr3bt
2qDytm3bGhkZoawRBEFZl4Ksvby8DA0N9+/fn5GRMWfOnBcvXuQoMGPGDNZ1D9i5cyfKGkEQlHUp
yDo4ONjDw4MtBwYGOjs75yhQr1696tWrN2/evFmzZtgMgiAIyrp0ZH38+HFQnhwXWNi9e3eOAoI5
rMHaKGsEQUQE5gYR5NatW0+ePGHLDg4ObIxiDi5dugQvwaPYHRjKGkEkGwMDoqPDm5tRymX9+vVr
ExOTWbNmzZ8/X01NbceOHTkK9O7de+zYsWZmZoMGDZo6dSrKGkEQ0fH1K/nwQXoONz+jQSjdv39/
Ly8vJyenpUuX5k76IZpETihrBEGQ/IyWmZmZkpICj0lJSVOmTNmzZ09uIb58+TI9Pf3u3bs1atRA
WSMIIjpcXMjZsySrQ5pUy9rGxgaUp6qq2rJly3nz5qXnSpjy+vXrjh07amhodOnS5dy5cyhrBEFE
BOYGEeTx48cf8moSgjjaBa5phCxdunT16tVr1qyxtrbGZhAEQUQKdt0TxNTUtBGXGTNmpKWlsZWh
oaHBwcFMiCBuZ2dnT09PlDWCICjr0pH1gQMHxo0bl5iYmJycPHny5NwTdwlOBQBlRLnfqampenp6
YOQc6aVQ1giCspY6WdvY2FhZWbHlnTt38peBZ8+e3bp1C4To5eXl4ODg7u6urKwsyv2+cuXK3r17
VVVVccJcBEFZS7us/f39NTU1jYyMZs6c2b17d7Az/6WLFy8aGxuDrFesWDF//vzZs2eLeFyMrq4u
hPwg67i4OMJNEGhgYGCcxZIlSzCyRhCUtbTI2sXFZfPmzXfv3nVycnr8+HHuAi9fvuQvDx8+vIR2
cceOHbVr127WrBk87tq1i3DHwR88eBAW/gcfFZc3b97Y29tfzcLb2xtljSAoa2mR9bFjx0B5Z8+e
FVbA1tYWCsjKysJjnTp1SmgXU1NT4+PjIY6GR1iGNY0bN4Z3rFSpEjxCQI3NIAgidWRmkn79MDcI
/2xkEm7fj0mTJh05ciT33F1t27blLwcGBop+7xUVFSHqz/vAMLJGEMlm6lQyeDDmBqG8ePECTO3m
5rZkyRITE5PcLSETJ04cNWrUggULFi9eLHo5Xr9+feHChfPnz0dZI4g0Eh5O3r+XnsPNz2iHDh2q
U6fO+vXrfXx8hAnR19cXYlsQOvazRhAEKR1ZHzlyZPny5WzZ09PT3d09n8KszQRljSCIiAAjXbiA
uUEonz596t+/P1ivQ4cODRs2dHBwyFHA0tJSTk5uz549RkZGa9asQVkjCCIiMDeIIFu3bgURV61a
FZYdHR1zT+sFQoT1LBsfNoMgCCJSsOsen6CgIC0treXLlysoKLRr1+7p06c5Cty+fVtJSalChQqN
GjW6e/cuyhpBEJS1SGWdmZkpmOuD38E5B2wOxoyMDBEnBkFZlxx2dnZr167F84CgrMuGrMF0urq6
4GhXV1dHR0dhf1yrVi1DQ0OIqX/9+oWyLruYmpqOHj06IzPz5OnTHC5r1qzJ8/KMIChr8ZK1vLw8
4Y4mL1++fL9+/fLfhJOT06JFi3LP0IiyFn8SEhJWrFjBBK2jpdWoVi22LCMre/v2bTw/CMpa3GUN
jmYLU6ZMYVGzt7d37nHnc+fO/fnzZ9++fZctWwYFUNZljnfv39dv1owJuiKHM4vDkecur54/PwUj
awRlLf6yrl27toyMjJycHA2yZGQg0IaF7du35xaikZHRx48fxfHAUNYF4962bYpcQV9etozExR0+
fHiVuTmeFkTcwdwgjIEDB+ZYc+fOndOnT+dYqaGhwV9+8OAByrrs4eICZ8q7Ro1LdnZ4MpAyJuvJ
k0FVmBukQOjr648aNWrx4sVmZmYVKlRAWZcxXr8m//1HqlQheeW/RRBx58sX8u6d9BzuPxkNhOjt
7X3lyhVXV1ccFFPGSEujo7/gLF27hicDQSRc1oKkp6eLbKfhvThZCOvijbLODzhpnTtTUx8/jicD
KavcvEns7TE3SIGwtrYuV67c3r17DQwMLC0tRbbTCQkJqqqqGFkXkehomgUYzs/OnXgykLIKyw3S
pAnmBiloU0Op5AaBaBrebunSpffv3xdWRkZGBr/PeXP3LjX19Ol4JpCyDXbdKzj29vZKSkoVK1Zs
1qyZl5dXCe3i7t27Gzdu3KZNG3jct28fWwkXiQsXLnTt2pU1gxw4cKBRo0ZtsujQoQNG1kKJjye+
viQpCc8EgrKWFln/4J6m9PT0Eh2anJiYGBkZGR0dDY9JXMXw28ebNm36+/dvWID1rAyDYDNInly4
QATmOEYQlLXky/rVq1e+vr4gxMePH3t4eMByq1atRLbTWlpaq1evPnHiRIsWLVJSUvI+MJR1Dk6d
oq0f6up4JhCUtRTJ+syZM1OnTgUhLly40MjIyNDQENaIbKdB0Obm5lOmTMknLyvK+g/gRFWsSGrX
JrlmPUYQlLUky5rx6NEj/rKurq54HRjKmg8Iulo1Ii9Pm6oRBGUthbI+efIkOFFWVrZcuXKKiooo
azGlTh3aAHLhAp4JRHLA3CCFokWLFvx5ct+L2ZzwKGtKXBzp2pWa+uhRPBmIpMlaT48G15GRKOu/
Y2BgMGHChGXLlpmbm+Nwc7EjJoaMGUNNvW4dVm1EAgkLIyEh0nO4/zoo5ubNm5cuXbp69WqlSpVQ
1uKFtzc19Zw5WKkRREplnZmZmcEdjy/YbY5NLoOyFiNSU0lQEE3YhCASye3bxMGBZLXEoqzz4MyZ
M/wh5k2aNGnIRVZWFmUtLjg7Ex8frMuIJAPxoro65gYpKJs2beIvr1q1CmUtFnh40NaPLl2wOiMS
Dnbdk5ADk05ZP31KFBWprAMCsC4jKGuUNcpaLElKIrVqUVOXWFItBEFZl0lZx8bGurm53bx509XV
VZSTD6Cs8yAzkzRoQE1tb4+1GEFZo6z/YMCAAf379585c6aGhsbs2bNR1qVGSgoZMYKaOtcM9AiC
skZZ/yFEHBRTaiQkELhSwvGamWH9RVDWKOu8hRgWFka4GVNR1qWGpyc19ejRWHkRKQJzgxSKu3fv
Kioq1qtXr0qVKhEi7O24ZcsWBQWFBg0aPHnyBGVN+fgRKy8idbKeNIloaWFukPx4/vz5y9KbcOT4
8eMODg5/LSYVczBevYq59BDp5fNnEhwsPYdbFFkfOXIEVNitW7fOnTvDo7a2dseOHQ8cOCCaPd62
bdvWrVu7du26Y8eOxMREtvLw4cOtWrXqmAXsleRH1jdv0tYPZWWsswiCss4b8LKpqWkcl6CgoAYN
GixbtiytZHJQuLu7c7Lo378/rOndu/fs2bMTEhLu3bsXHh7OisGewPK3LDIyMiRc1s+ekapVqaw/
fcIvMSKleHuTa9cwN0iBcHFx0dLSEpwvpuTvez5DOM+WfXx83r59K/TAJFjWoaGkZk1q6qdPscIi
UgrmBikg6enphw8fNhPoK7Zjxw4R7G5KSsqMGTMWLly4YcOGnTt3fhIeV0qsrJOTiaoqNfX581hh
EakGu+4VJLwdNGgQ2LBfv34aGhpqamrwKDI5xsTEnOMSGBiYKfwOSGJlPXo0NfXmzVhVEZQ1yvov
HDhwYPHixRDkRkREfOWSmpqK/axLnNRUYmhITb10KdZTBEFZS8qBSZ6sfX3Jf//h4BcEQVmjrMWe
Bw9omzWCIChrlLU4cucOOXcO6yaCoKxR1mLMy5ekcmU6pQCCIHxYbpC2bTE3CMpaPHj1itSrR39U
DAzE6okgf8h6wgSiqYm5QVDWYsDXr7wu1TifAILk5tMn8uaN9BwuylqM6dCBmnrbNqyVCIKgrMUV
NvPLwoX4HUWQvPHxIdevY24QlHXpkZ5OFiygpp41C+sjguQNyw3SuDHmBkFZlx4BAaR2bfpLN4Ig
+YBd91DWpUxqKrl/n0RHY2VEEJQ1ylosefqUuLtjHUQQlLWEyBpEXKNGjZo1a8JCspDh12VP1s+f
03ZqHPyCIChriZH1okWL2MKwYcOSkpIkQdavXpGmTamshU8BjCAIyrpM4urqunLlSmGvysrKlpkj
SUzkDX45eRIrIIKgrMuqrFevXs2fhnHt2rX89f9v735CIQ3jAI6/I3HYTZYMLjjsQdqEUps/iRJx
oUhCcUEppHdK7RzkT5zkolzc9mDb1qopf3LBwZgcNLIzZi7GyU7UGjtto9h333eHyYW1eNfz7nw/
B2ntYd53/b49y7zPI8vyx+tH+4aHh6UbYmJijLSyLirSSj01xfQB98XeIEZxfHzc29u7t7dn+JV1
U5NW6vFxpg/4u1g3NiplZewNIrqNjY2urq7z8/NbL0z8lXUopPT3a6W+cZQlgPvy+RS3O3ou16ix
Pjo6cjqdd12Y+LH2erW9T9++ZegA/Lex/vOFGeJn1mqvg0G+C4GHsNuVpSViTaz1tLOjzM0xa8DD
sTcIsdadx6M9+ZKczLgBj8Jb94i1jtRVQHiXaoeDWQOINbEWNdYVFZz8AhBrYi12rKuqtFLPzjJl
ALEm1qLGenBQK7XVyogBxJpYixrriQmt1B0d0XMEEUCsibXRYu10KvHxSm4uwwU8GXXdU16u7Q1C
rIn1U/J6WVMDTxzrhgaltFQ5OSHWxPrR1tb4dSKgF59Pcbmi53KJtZ6rabOZh18AEGuBY+33Xz38
cuduUwAezuFQVleJtdAuLi42Nzftdvu3248Af85Yn55enSewvs5AAbq4vNR2rGRvEMHJslxdXV1T
U9PS0iJOrIPB4Hb4BMX6eq3U09MMFKCf7fz8QEEBv2AU+0VfhzgnJycQCAgSa4vF8jIlZbauTiv1
wACzBOjn0/z8C0nqyczkrXtCm5mZycvLa21tHR0dFWRl3d3dHTkB8gPnCQB6WlhYiIxbe3s7sRbF
0NCQ+k8SFxenfhwZGVH/pK2tLfwlWZZDoZD6ydjYWPjvhMXGxmZkZPzLF9nX1xf57vlsszFOgH4W
FxdNJlN43NR1ErEWV2JiYviTwsLCs7MzQV7VO4slSZLeNzczS4DebDbbq6SkgZ6e6LlkQ8baarUW
FxeXlJSoS+yfwjwZ+GN3dzchQYma/5QBz0sduO/RdCqeUd+69+U3cZbVGrdbSUtTrn9EAwDRHmtB
uVzaI4vEGgCxJtYAiDUex+NR0tOJNQBiLbTDra0Jk0np7ORWACDWgtrf33+dnS1JUoXZzN0AQKwF
VVlZGXkoZnJykhsCgFiLaHl5OTU1VS31m6ysr34/NwQAsRbUyspKbW3t4cEBtwIAsQYAYg0AINYA
AGINAMQaAECsAQDEGgCINQBAZ78AOo9YA1pSNeUAAAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="non ser.png" FILE_TYPE="PNG" ID="FIG-11" MODIFIED="2017-08-03 16:40:29 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="11" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>
<B>Non-serious adverse events up to three months after randomisation.</B> Four trials provided data. The diversity-adjusted required information size (DARIS) was calculated based on non-serious adverse events of 5% in the control group; risk ratio reduction in the glucocorticosteroid group of 50%; type I error of 1%; and type II error of 20% (80% power). Trial diversity was 0%. The required information size was 2698 participants. The cumulative Z-curve (blue line) did not cross the trial sequential monitoring boundaries for benefit or harm (red inward sloping lines) and did not enter the trial sequential monitoring area for futility (inner-wedge with red outward sloping lines). The green dotted lines show the conventional boundaries of the naive alpha of 5% equal to Z-scores of +1.96 and -1.96.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAegAAAGMCAIAAACeV6YXAABJyElEQVR42u2dB1gURxvHqSoWrIkx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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2016-11-28 16:44:37 +0100" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2017-11-02 11:25:22 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<APPENDIX ID="APP-01" MODIFIED="2017-11-01 15:04:30 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1">
<TITLE MODIFIED="2015-06-24 15:08:14 +0200" MODIFIED_BY="Dimitrinka Nikolova">Search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2017-11-01 15:04:30 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<TABLE COLS="3" ROWS="6">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Database</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Search performed</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Search strategy</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cochrane Hepato-Biliary Controlled Trials Register</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>September 2016</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(glucocortico* or steroid* or dexamethasone or prednis* or hydrocortisone or corticosteroid* or cortiso* or budesonide* or beclomethasone*) AND (alcohol* and (liver or hepati*))<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2016, Issue 8</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 MeSH descriptor: [Adrenal Cortex Hormones] explode all trees</P>
<P>#2 (glucocortico* or steroid* or dexamethasone or prednis* or hydrocortisone or corticosteroid* or cortiso* or budesonide* or beclomethasone*)</P>
<P>#3 #1 or #2</P>
<P>#4 MeSH descriptor: [Hepatitis, Alcoholic] explode all trees</P>
<P>#5 (alcohol* and (liver or hepati*))</P>
<P>#6 #4 or #5</P>
<P>#7 #3 and #6</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MEDLINE Ovid</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1946 to September 2016</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1. exp Adrenal Cortex Hormones/</P>
<P>2. (glucocortico* or steroid* or dexamethasone or prednis* or hydrocortisone or corticosteroid* or cortiso* or budesonide* or beclomethasone*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</P>
<P>3. 1 or 2</P>
<P>4. exp Hepatitis, Alcoholic/</P>
<P>5. (alcohol* and (liver or hepati*)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</P>
<P>6. 4 or 5</P>
<P>7. 3 and 6</P>
<P>8. (random* or blind* or placebo* or meta-analys*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</P>
<P>9. 7 and 8<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Embase Ovid</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1974 to September 2016</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1. exp corticosteroid/</P>
<P>2. (glucocortico* or steroid* or dexamethasone or prednis* or hydrocortisone or corticosteroid* or cortiso* or budesonide* or beclomethasone*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>3. 1 or 2</P>
<P>4. exp alcohol liver disease/</P>
<P>5. (alcohol* and (liver or hepati*)).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>6. 4 or 5</P>
<P>7. 3 and 6</P>
<P>8. (random* or blind* or placebo* or meta-analys*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>9. 7 and 8<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Science Citation Index Expanded (Web of Science)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1900 to September 2016</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#5 217 #4 AND #3</P>
<P>#4 1,347,943 TS=(random* or blind* or placebo* or meta-analys*)</P>
<P>#3 1,060 #2 AND #1</P>
<P>#2 36,574 TS=(alcohol* and (liver or hepati*))</P>
<P>#1 425,242 TS=(glucocortico* or steroid* or dexamethasone or prednis* or hydrocortisone or corticosteroid* or cortiso* or budesonide* or beclomethasone*)</P>
<P/>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2017-11-01 15:04:19 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="2">
<TITLE MODIFIED="2017-02-01 15:35:53 +0100" MODIFIED_BY="Dimitrinka Nikolova">Level of liver enzymes (at the end of treatment)</TITLE>
<APPENDIX_BODY MODIFIED="2017-11-01 15:04:19 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<TABLE COLS="7" ROWS="7">
<TR>
<TH>
<P/>
</TH>
<TH COLSPAN="3">
<P>Glucocorticosteroids</P>
</TH>
<TH COLSPAN="3">
<P>Placebo/no intervention</P>
</TH>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Mean</P>
</TD>
<TD>
<P>SD</P>
</TD>
<TD>
<P>Number of participants</P>
</TD>
<TD>
<P>Mean</P>
</TD>
<TD>
<P>SD</P>
</TD>
<TD>
<P>Number of participants</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Campra-1973" TYPE="STUDY">Campra 1973</LINK>
</P>
</TD>
<TD>
<P>62.5</P>
</TD>
<TD>
<P>3.72</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>79.2</P>
</TD>
<TD>
<P>5.83</P>
</TD>
<TD>
<P>28</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Maddrey-1978" TYPE="STUDY">Maddrey 1978</LINK>
</P>
</TD>
<TD>
<P>34.5</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>23</P>
</TD>
<TD>
<P>41.7</P>
</TD>
<TD>
<P>4.1</P>
</TD>
<TD>
<P>27</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Theodossi-1982" TYPE="STUDY">Theodossi 1982</LINK>
</P>
</TD>
<TD>
<P>164.0</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>118</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>32</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Carithers-1989" TYPE="STUDY">Carithers 1989</LINK>
</P>
</TD>
<TD>
<P>74.9</P>
</TD>
<TD>
<P>4.19</P>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P>119.9</P>
</TD>
<TD>
<P>7.79</P>
</TD>
<TD>
<P>31</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>SD = standard deviation</P>
<P>- = SD data not reported</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2017-11-01 15:04:09 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="3">
<TITLE MODIFIED="2017-07-11 14:00:42 +0200" MODIFIED_BY="Dimitrinka Nikolova">Prothrombin index (s)</TITLE>
<APPENDIX_BODY MODIFIED="2017-11-01 15:04:09 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<TABLE COLS="7" ROWS="10">
<TR>
<TH>
<P/>
</TH>
<TH COLSPAN="3">
<P>Glucocorticosteroids</P>
</TH>
<TH COLSPAN="3">
<P>Placebo/no intervention</P>
</TH>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Mean</P>
</TD>
<TD>
<P>SD</P>
</TD>
<TD>
<P>Number of participants</P>
</TD>
<TD>
<P>Mean</P>
</TD>
<TD>
<P>SD</P>
</TD>
<TD>
<P>Number of participants</P>
</TD>
</TR>
<TR>
<TD>
<P>Percentage of normal</P>
</TD>
<TD COLSPAN="6">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Campra-1973" TYPE="STUDY">Campra 1973</LINK>
</P>
</TD>
<TD>
<P>77.5</P>
</TD>
<TD>
<P>2.5</P>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P>83.1</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>31</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ramond-1992" TYPE="STUDY">Ramond 1992</LINK>
</P>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>0.5</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P>0.5</P>
</TD>
<TD>
<P>29</P>
</TD>
</TR>
<TR>
<TD>
<P>At the end of treatment</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Maddrey-1978" TYPE="STUDY">Maddrey 1978</LINK>
</P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P>0.5</P>
</TD>
<TD>
<P>23</P>
</TD>
<TD>
<P>15.5</P>
</TD>
<TD>
<P>0.9</P>
</TD>
<TD>
<P>27</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Theodossi-1982" TYPE="STUDY">Theodossi 1982</LINK>
</P>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>32</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Carithers-1989" TYPE="STUDY">Carithers 1989</LINK>
</P>
</TD>
<TD>
<P>15.5</P>
</TD>
<TD>
<P>1.25</P>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P>16.25</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>31</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>SD = standard deviation</P>
<P>- = SD data not reported</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2017-11-01 15:04:13 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="4">
<TITLE MODIFIED="2017-10-31 20:00:02 +0100" MODIFIED_BY="[Empty name]">Level of serum albumin (g/L)</TITLE>
<APPENDIX_BODY MODIFIED="2017-11-01 15:04:13 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<TABLE COLS="7" ROWS="8">
<TR>
<TH>
<P/>
</TH>
<TH COLSPAN="3">
<P>Glucocorticosteroids</P>
</TH>
<TH COLSPAN="3">
<P>Placebo/no intervention</P>
</TH>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Mean</P>
</TD>
<TD>
<P>SD</P>
</TD>
<TD>
<P>Number of participants</P>
</TD>
<TD>
<P>Mean</P>
</TD>
<TD>
<P>SD</P>
</TD>
<TD>
<P>Number of participants</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Campra-1973" TYPE="STUDY">Campra 1973</LINK>
</P>
</TD>
<TD>
<P>33.3</P>
</TD>
<TD>
<P>1.48</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>30.08</P>
</TD>
<TD>
<P>0.66</P>
</TD>
<TD>
<P>28</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Maddrey-1978" TYPE="STUDY">Maddrey 1978</LINK>
</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>23</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>27</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Depew-1980" TYPE="STUDY">Depew 1980</LINK>
</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>0.17</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>25.8</P>
</TD>
<TD>
<P>0.13</P>
</TD>
<TD>
<P>13</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Carithers-1989" TYPE="STUDY">Carithers 1989</LINK>
</P>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>0.35</P>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P>29</P>
</TD>
<TD>
<P>0.4</P>
</TD>
<TD>
<P>31</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ramond-1992" TYPE="STUDY">Ramond 1992</LINK>
</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>0.17</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>0.37</P>
</TD>
<TD>
<P>29</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>SD = standard deviation</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2017-11-01 15:04:02 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="5">
<TITLE MODIFIED="2017-02-01 15:41:38 +0100" MODIFIED_BY="Dimitrinka Nikolova">Level of bilirubin (&#956;mol/L) (at the end of treatment)</TITLE>
<APPENDIX_BODY MODIFIED="2017-11-01 15:04:02 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<TABLE COLS="7" ROWS="8">
<TR>
<TH>
<P/>
</TH>
<TH COLSPAN="3">
<P>Glucocorticosteroids</P>
</TH>
<TH COLSPAN="3">
<P>Placebo/no intervention</P>
</TH>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Mean</P>
</TD>
<TD>
<P>SD</P>
</TD>
<TD>
<P>Number of participants</P>
</TD>
<TD>
<P>Mean</P>
</TD>
<TD>
<P>SD</P>
</TD>
<TD>
<P>Number of participants</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Campra-1973" TYPE="STUDY">Campra 1973</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>43.2</P>
</TD>
<TD VALIGN="TOP">
<P>2.9</P>
</TD>
<TD VALIGN="TOP">
<P>22</P>
</TD>
<TD VALIGN="TOP">
<P>63.95</P>
</TD>
<TD VALIGN="TOP">
<P>6.84</P>
</TD>
<TD VALIGN="TOP">
<P>28</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Maddrey-1978" TYPE="STUDY">Maddrey 1978</LINK>
</P>
</TD>
<TD>
<P>64.98</P>
</TD>
<TD>
<P>4.97</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>66.69</P>
</TD>
<TD>
<P>3.69</P>
</TD>
<TD>
<P>31</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Depew-1980" TYPE="STUDY">Depew 1980</LINK>
</P>
</TD>
<TD>
<P>68.4</P>
</TD>
<TD>
<P>6.5</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>136.8</P>
</TD>
<TD>
<P>11.79</P>
</TD>
<TD>
<P>13</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Carithers-1989" TYPE="STUDY">Carithers 1989</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>125</P>
</TD>
<TD VALIGN="TOP">
<P>8.12</P>
</TD>
<TD VALIGN="TOP">
<P>36</P>
</TD>
<TD VALIGN="TOP">
<P>190</P>
</TD>
<TD VALIGN="TOP">
<P>17.9</P>
</TD>
<TD VALIGN="TOP">
<P>31</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Ramond-1992" TYPE="STUDY">Ramond 1992</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
<TD VALIGN="TOP">
<P>7.1</P>
</TD>
<TD VALIGN="TOP">
<P>32</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>18.8</P>
</TD>
<TD VALIGN="TOP">
<P>29</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>SD = standard deviation</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2017-11-02 11:25:22 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="6">
<TITLE MODIFIED="2017-03-01 17:17:53 +0100" MODIFIED_BY="Dimitrinka Nikolova">Age</TITLE>
<APPENDIX_BODY MODIFIED="2017-11-02 11:25:22 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<TABLE COLS="7" ROWS="16">
<TR>
<TH>
<P/>
</TH>
<TH COLSPAN="3">
<P>Glucocorticosteroids</P>
</TH>
<TH COLSPAN="3">
<P>Placebo/no intervention</P>
</TH>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Mean</P>
</TD>
<TD>
<P>SD</P>
</TD>
<TD>
<P>Number of participants</P>
</TD>
<TD>
<P>Mean</P>
</TD>
<TD>
<P>SD</P>
</TD>
<TD>
<P>Number of participants</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Porter-1971" TYPE="STUDY">Porter 1971</LINK>
</P>
</TD>
<TD>
<P>44.6</P>
</TD>
<TD>
<P>4.4</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>49.5</P>
</TD>
<TD>
<P>8.9</P>
</TD>
<TD>
<P>9</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Campra-1973" TYPE="STUDY">Campra 1973</LINK>
</P>
</TD>
<TD>
<P>43.1</P>
</TD>
<TD>
<P>11.1</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>42.7</P>
</TD>
<TD>
<P>8.1</P>
</TD>
<TD>
<P>28</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Blitzer-1977" TYPE="STUDY">Blitzer 1977</LINK>
</P>
</TD>
<TD>
<P>47.2</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>48.4</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>16</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Maddrey-1978" TYPE="STUDY">Maddrey 1978</LINK>
</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>8.5</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>42.3</P>
</TD>
<TD>
<P>11.1</P>
</TD>
<TD>
<P>32</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Shumaker-1978" TYPE="STUDY">Shumaker 1978</LINK>
</P>
</TD>
<TD>
<P>45.5</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>44.5</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>13</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Depew-1980" TYPE="STUDY">Depew 1980</LINK>
</P>
</TD>
<TD>
<P>49.8</P>
</TD>
<TD>
<P>2.1</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>48.2</P>
</TD>
<TD>
<P>2.3</P>
</TD>
<TD>
<P>13</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Mendenhall-1984" TYPE="STUDY">Mendenhall 1984</LINK>
</P>
</TD>
<TD>
<P>51.5</P>
</TD>
<TD>
<P>8.2</P>
</TD>
<TD>
<P>90</P>
</TD>
<TD>
<P>50.4</P>
</TD>
<TD>
<P>9.2</P>
</TD>
<TD>
<P>88</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Bories-1987" TYPE="STUDY">Bories 1987</LINK>
</P>
</TD>
<TD>
<P>41</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>49</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>21</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Carithers-1989" TYPE="STUDY">Carithers 1989</LINK>
</P>
</TD>
<TD>
<P>43.1</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P>44.4</P>
</TD>
<TD>
<P>1.7</P>
</TD>
<TD>
<P>31</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ramond-1992" TYPE="STUDY">Ramond 1992</LINK>
</P>
</TD>
<TD>
<P>48.1</P>
</TD>
<TD>
<P>1.3</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>48.2</P>
</TD>
<TD>
<P>1.6</P>
</TD>
<TD>
<P>32</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-De-2014" TYPE="STUDY">De 2014</LINK>
</P>
</TD>
<TD>
<P>42.7</P>
</TD>
<TD>
<P>0.4</P>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>41.3</P>
</TD>
<TD>
<P>7.8</P>
</TD>
<TD>
<P>31</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Thursz-2015" TYPE="STUDY">Thursz 2015</LINK>
</P>
</TD>
<TD>
<P>48.6</P>
</TD>
<TD>
<P>9.8</P>
</TD>
<TD>
<P>277</P>
</TD>
<TD>
<P>47.9</P>
</TD>
<TD>
<P>9.2</P>
</TD>
<TD>
<P>276</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Thursz-2015" TYPE="STUDY">Thursz 2015</LINK>
</P>
</TD>
<TD>
<P>49.3</P>
</TD>
<TD>
<P>10.6</P>
</TD>
<TD>
<P>274</P>
</TD>
<TD>
<P>48.8</P>
</TD>
<TD>
<P>10.3</P>
</TD>
<TD>
<P>276</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>SD = standard deviation</P>
<P>- = SD data not reported</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2016-11-28 16:44:37 +0100" MODIFIED_BY="[Empty name]">
<EXTENSION ID="AFF_9708AA4382E26AA20165AC2EE764A66D_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="9708AA4382E26AA20165AC2EE764A66D">
<ADDRESS>
<DEPARTMENT>The Cochrane Hepato-Biliary Group</DEPARTMENT>
<ORGANISATION>Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital</ORGANISATION>
<ADDRESS_1>Blegdamsvej 9</ADDRESS_1>
<ADDRESS_2/>
<CITY>Copenhagen</CITY>
<ZIP>DK-2100</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_79143FAF82E26AA200C1C7C4F47593CE_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="79143FAF82E26AA200C1C7C4F47593CE">
<ADDRESS>
<DEPARTMENT>Clinic of Internal Diseases Propedeutics</DEPARTMENT>
<ORGANISATION>I.M. Sechenov First Moscow State Medical University</ORGANISATION>
<ADDRESS_1>Pogodinskaja 1/1</ADDRESS_1>
<ADDRESS_2/>
<CITY>Moscow</CITY>
<ZIP>119991</ZIP>
<REGION/>
<COUNTRY CODE="RU">Russian Federation</COUNTRY>
<PHONE_1>+7916 682 99 54</PHONE_1>
<PHONE_2>+7495 417 13 72</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;15 trials included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;16 trials (37 records) included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;42 studies (67 records) assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;932 study records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;413 duplicate records removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;1345 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;865 study records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;26 full-text studies (30 records) excluded, with reasons&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>